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ABSTRACT
Tumour-associated arteries are a potential target for therapeutic strategies aimed at reducing or 
stopping tumour growth and metastases. However, the tumour vasculature exists in a state of 
‘near maximal vasodilation’ and is markedly hyporesponsive to vasoactive agents generally. The 
role of nitric oxide (NO) in the growth and maintenance of solid tumours is unclear. Recent 
evidence suggests that it may be responsible for some of the characteristics of angiogenically- 
derived vessels found within the tumour and also for those of ‘normal’ vessels which become 
incorporated into the surrounding host tissue. A marked hyporesponsiveness to vasoactive agents 
also characterises vessels from animals in endotoxin-induced shock. One aim of the present study 
then was to compare the properties of arteries which formerly supplied an implanted solid 
tumour (tumour epigastric artery, or TEA) with arteries taken from experimental animals (rat tail 
artery, or RTA) injected with bacterial lipopolysaccaride (LPS).
The extent of endotoxaemia resulting from LPS treatment was assessed by (a) monitoring 
arterial blood pressure, using the tail cuff method; (b) measuring accumulated plasma nitrite and 
nitrate; (c) monitoring the development of hyporesponsiveness of RTAs to phenylephrine (PE); 
(d) detecting expression of inducible nitric oxide synthase (iNOS) by Western blot and 
immunocytochemical analysis; and (e) monitoring the loss of sensitivity of pre-contracted 
vessels from LPS-treated rats exposed to the vasodilator S-nitroso-N-acetylpenicillamine.
RTAs from LPS-treated rats and TEAs were less sensitive to PE than control arteries. This 
difference was abolished by non-selective NOS inhibitors (L-NAME and L-NMMA) and by the 
isoform-selective inhibitor aminoguanidine (AG). Furthermore, the protein synthesis inhibitor 
cycloheximide also reversed the hyporesponsiveness to PE of both types of vessel. The 
‘restoring’ effect of cycloheximide was abolished when given after indomethacin, a specific 
cyclooxygenase inhibitor.
Chronic, oral administration of L-NAME or AG to tumour-bearing rats (via the drinking water) 
significantly slowed tumour growth. When L-NAME treatment was halted, tumour growth 
resumed at pre-L-NAME (control) rates. A single i.p. injection of LPS also impaired tumour 
growth: this was dependent upon the time of injection, with no effect seen 24hrs prior to tumour 
implantation and the maximum delaying effect at 11 days post-implantation. LPS potentiated the 
growth retarding effects of L-NAME but abolished those of AG.
These results provide evidence for the involvement of iNOS-derived NO in regulating the tone of 
arteries supplying a solid tumour and also of those from animals in septic shock. They suggest 
that NO may assist tumour growth by helping to maintain an adequate flow of blood into the 
tumour and they highlight the L-arginine/NO pathway as a potential target for the design of 
improved therapeutic interventions.
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Chapter 1 - Introduction
Part A
Biology of Nitric Oxide
1.1 Introduction
Nitric oxide (NO) was quietly ‘going about its business’ long before humans 
evolved. Yet, only within the last 10 years or so have we belatedly recognised 
that it appears to be everywhere in the body and relevant to many, if not all, 
physiological functions. One of the smallest biological molecules known, NO 
has finally energed from obscurity to become one of the most talked about topics 
in modern biology. It is ironic that having long been studied by industrial 
chemists as an environmental pollutant, contributing to smog and acid rain, it 
should turn out to be one of the most important mediators of physiological 
function in mammals.
In order to readily appreciate the key findings which have helped determine the 
course of NO research, and provide us with discernible evidence for its role, a 
chronological diary of publications is listed below.
1 The first indication that mammals (including humans) could generate nitrate 
(NO3') was in 1916 (Mitchell et al., 1916). This study measured NO3- levels in 
urine and concluded that more NO3' was being excreted than ingested in the diet.
2 More than sixty years elapsed before Mitchell’s observation was confirmed, at 
which time Tannenbaum et al., (1978) established that humans could synthesise 
NO3- and nitrite (NO2’).
3 In 1980, Furchgott and Zawadzki coined the term ‘endothelium-derived 
relaxing factor’ (EDRF) to describe the substance, released by endothelial cells 
in response to acetylcholine (Ach), which could relax vascular smooth muscle.
1
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4 Injected bacteria were found to stimulate mammalian macrophages to release 
high levels of NO2" and NC>3“ (Steuhr & Marietta, 1985).
5 It was established that neither NO2' nor NO3" is responsible for the cytotoxic 
effect of activated macrophages on tumour cells (Hibbs Jr. et al., 1987).
6 The production of NO2" and NO3" requires oxidation of a guanidino nitrogen 
of L-arginine which produces an intermediate oxide of nitrogen more reactive 
than either NO2" or NO3" (Miwa et al., 1987).
7 EDRF released by Ach-stimulated endothelial cells is neither NO3' nor NO2' 
but more likely NO- (Palmer et al., 1987; Ignarro et al., 1987).
8 The ability of activated macrophages to kill tumour cells resides in the 
conversion of L-arginine to L-citrulline and NO. The production of NO and the 
cytotoxic effect were both inhibited by NG-methyl-L-arginine (Hibbs Jr. et al., 
1988).
9 L-arginine is identified as the precursor for NO synthesis in vascular 
endothelial cells (Palmer et al., 1988).
10 Neuronal cells of the brain can be stimulated to release a factor similar to that 
released from endothelial cells and macrophages (Garthwaite et al., 1988).
So in the ten years since the initial discovery that humans produce NO2" and 
NO3- it emerged that three major cell types, (macrophages, endothelium and 
neurons), spanning diverse areas of physiological function (cytotoxicity, 
vasorelaxation and neurotransmission), are stimulated to synthesise the same 
labile mediator from L-arginine. The identity of this mediator is most likely NO 
although this has not been proven as yet and so remains an area of intense 
research and debate.
2
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The studies listed above paved the way for an avalanche of research which was 
to follow and ultimately resulted in NO being named ‘Molecule of the year’ in 
1992 by the American Association for the Advancement of Science. Now that 
the presence of NO has been established considerable research now focuses on 
trying to decipher the biosynthetic mechanism(s) responsible for its production. 
In what must be considered a relatively short period of time since the discovery 
of NO in mammals, a tremendous amount has already been learned about the 
enzymes involved in its synthesis. The details concerning the synthesis of NO 
are dissussed in the ‘NOS’ section of this introduction.
1.2 NO is an Endothelium-Derived Relaxing Factor
It was first shown in 1980 by Furchgott and Zawadzki that acetylcholine could 
stimulate the release of a factor from the endothelium which relaxed 
precontracted rabbit aortic rings. This was termed an endothelium-derived 
relaxing factor (EDRF) and has been identified as NO by two research groups 
working independently of each other, one led by Moncada at the Wellcome 
laboratories in England and the other in Los Angeles by Louis Ignarro (Ignarro 
etal., 1987).
Moncada’s group, Palmer et al., (1987), showed that authentic NO and 
endogenous EDRF release from cultured porcine aortic endothelial cells both 
had virtually identical effects on precontracted strips of denuded rabbit aorta. 
Furthermore, the levels of NO released by bradykinin, determined using a 
chemiluminescence method, could account for vasorelaxation of the bioassay 
strip produced by EDRF.
Similar perfusion bioassay systems, in which the transit time of the effluent from 
endothelial cells to the denuded preparations can be varied, have been used to 
study the rate of decay of EDRF. Decay is responsible for the diminished 
relaxation caused by EDRF and NO as they pass down the cascade (Palmer et
3
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al., 1987; Khan & Furchgott, 1987). EDRF and NO display similar diminished 
relaxation suggesting that they have similar chemical instability.
A considerable range of half-life values (3 to 50 sec.) for EDRF has been 
reported (Rubanyi et al., 1985; Gryglewski et al., 1986; Griffith et al., 1984; 
Cocks et al., 1985; Feelisch et al., 1994), raising some doubt as to its chemical 
identity. Discrepancies concerning instability are largely due to the presence of 
superoxide free radicals (O2') within the experimental solutions (Gryglewski et 
al., 1986). Different laboratories with different experimental design for 
perfusion, superfusion and oxygenation will ultimately have different levels of 
O2‘ in their medium. NO reacts with O2' to produce peroxynitrite (ONOO"), a 
powerful oxidant which may be responsible for many cytotoxic effects attributed 
to NO (Beckman et al., 1990). The endogenous enzyme, superoxide dismutase 
(SOD), can be added to the superfusate to prolong the half-life of EDRF by 
catalysing the conversion of O2‘ to hydrogen peroxide.
The vascular smooth muscle (VSM) relaxation associated with EDRF 
(unstimulated or Ach-stimulated) is mediated by cyclic 3’, 5’,-monophosphate 
(cGMP; Rapoport & Murad, 1983) and is inhibited by haemoglobin or 
methylene blue (Griffith et al., 1984; Martin et al., 1985) in much the same way 
as NO (Murad et al., 1978), although it has been suggested more recently that 
these inhibitors of EDRF/NO- also generate O2' (Marczin et al., 1992).
In 1990 it was proposed that while spontaneous, de novo NO synthesis in 
endothelial cells accounts for basal EDRF activity, stimulated EDRF release 
occurs from 5-nitrosothiol stores which decompose releasing NO- by exocytosis 
(Ignarro, 1990). Indeed, light sensitive S-nitrosothiol stores are thought to exist 
in VSM cells (Venturini et al., 1993) which can be depleted and later replenished 
by endothelium-derived NO in an NG-monomethyl-L-arginine-sensitive manner 
(Megson et al., 1995). The physiological relevance of a photosensitive store of 
NO in VSM is still unclear. Iron-sulphur cluster nitrosyls eg. Roussins black salt
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([Fe4S3(NC>7)]) can enter endothelial cells and decompose to release NO and 
may represent another potential store in vascular tissues (Flitney et al., 1992).
A comparison of NO, S-nitrosothiol and EDRF effects using rabbit aortic rings 
(Furchgott et al., 1992) revealed that although relaxations induced by s- 
nitrosothiol and Ach-stimulated EDRF were mediated by NO, they were only 
slightly inhibited by xanthine + xanthine oxidase (O2' generators), while the 
relaxation induced by authentic NO was completely inhibited. This seemed to 
suggest that the behaviour of abluminal EDRF more closely resembles that of an 
s-nitrosothiol which can enter VSM cells before releasing NO, than NO itself.
In contrast, perfusion bioassay experiments suggest that EDRF release into the 
lumen of vessels is most probably NO, since both display a similar diminished 
relaxation with increasing transit time to the bioassay ring (Furchgott ef al., 
1991). This was supported by Feelisch et al., (1994), who concluded that s- 
nitrosylated compounds (including s-nitrosoglutathione and s-nitrosocysteine) 
are up to 10-fold more potent than EDRF and, together with a number of other 
potential candidates for EDRF, (ie sodium nitroxyl, hydroxylamine and 
dinitrosyl-iron-cysteine complex), are more stable than EDRF and less 
susceptible to inhibition by oxyhaemoglobin.
Further indications that EDRF may not be NO are evident using a perfusion 
bioassay system in which infused NO relaxes certain nonvascular smooth muscle 
preparations while EDRF released from cultured bovine endothelial cells does 
not (Dustin et al., 1987). EDRF also binds to anionic exchange resins while NO 
does not (Shikano et al., 1988). EDRF and NO in solution at room temperature 
(R.T.) are undetectable using conventional electron paramagnetic resonance 
(EPR) spectroscopy (Henry et al., 1993). However, because NO is paramagnetic 
EPR can detect NO adducts. The complexity surrounding spin-adducts 
compromises the efficiency of EPR, and with the potential for so many NO
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interactions in vivo, there is a growing concensus that EDRF is not NO but more 
likely a precursor (Greenberg et al., 1990).
1.3 Biochemical Properties and Interactions of NO
NO is a colourless gas at R.T. and due to its solubility in water is physiologically 
present as an aqueous solution. Its uncharged, hydrophobic properties promote 
its ability to diffuse readily across different cell membranes. NO has an unpaired 
electron in its antibonding k orbital and as such is paramagnetic with a reduced 
bond order of ~ 2.5 and an N-O bond length of -1.5 angstroms (i.e. between 
triple and a typical double bond length) (Butler & Williams, 1993).
The nitrogen oxide species normally present in physiological systems are likely 
to be tightly regulated by cellular redox reactions influencing their oxidative 
state, the formation of reactive oxygen species and ultimately their interaction 
with thiols, metals and metalloproteins.
1.3.1 Interaction with Thiols
The highly reactive nature of NO stems from the redox couples it forms with the 
nitrosonium cation (NO+) and the nitroxyl anion (NO~) or its acid, HNO. NO is 
a poor nitrosating agent, but when oxidised to NO+, 5-nitrosothiols can be 
readily formed(eclu- *) which may transfer NO+ to a second thiol (R2S)(eclu- 2) in a 
process called transnitrosation (refer to Butler et al., 1995).
(1) RSH + NO+ -> RlSNO + H+
(2) RlSNO + R2S" -» RlS- + R2SNO
5-nitrosothiols may therefore provide a mechanism for transporting and 
supplying NO+, which would otherwise immediately form nitrous acid in 
aqueous solution.
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It has been shown that NO’ can be reconverted to NO by SOD (Fukuto et al., 
1993). The physiological relevance of this has yet to be resolved although 
theoretically NO" could react directly with molecular oxygen to produce 
peroxynitrite. The abundance of proteins with which NO may interact in vivo 
lessens the likelyhood of this happening.
1.3.2 Peroxy nitrite Formation
The activated immune response results in overproduction of NO which can react 
with O2" and increase the formation of other potentially more toxic products, 
including peroxynitrite (ONOO")(eclu- 3). ONOO" is almost instantly (half-life 
~lsec.) protonated to peroxynitrous acid (ONOOH) which subsequently 
decomposes to nitrogen dioxide and hydroxyl radicaKeclu- 4) (Beckman et al., 
1990).
(3) NO- + O2" ONOO"
(4) ONOO’ + H+ ONOOH -> NO2 + -OH
The hydroxyl radical is an extremely reactive species and may be responsible for 
much of the damage caused by peroxynitrite, such as lipid peroxidation (Radi et 
al., 1991) and nitration of several functional groups of amino acids including 
tyrosine (Ischiropoulos et al., 1992). The nitrated tyrosine in proteins appears to 
be a specific biological marker of peroxynitrite and may offer significant insight 
into the role of peroxynitrite in the pathology associated with a number of 
inflammatory conditions, including sepsis, adult respiratory distress syndrome 
and atherosclerosis (Crow & Beckman, 1995).
New evidence suggests that peroxynitrite may also assist in detoxification by 
reacting with certain sugars (eg. glucose) commonly found in physiological 
buffers to form an NO-donor with characteristics of an organic nitrite/nitrate
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(Moro et al., 1995). This will undoubtedly be relevant to in vitro and ex vivo 
studies and it remains to be clarified whether similar reactions also occur in vivo.
1.3.3 NO in Aqueous Solution
The reaction between NO and O2 is not favourable at physiologically relevant 
levels of NO (ie. l-100nM) and will more readily occur at supraphysiological 
[NO]. Lipopolysaccharide-induced high levels of NO in vivo may favour the 
reaction between NO and O2.
In this respect it has been observed that in aqueous solution NO reacts much 
more slowly with O2 (half-life of several hours) than predicted using in vitro 
bioassay systems (half-life of 3-50sec.; Kharitonov et al., 1994). Interactions 
with O2' and redox metals, which typically contaminate bioassay buffers, will 
inactivate NO zn vitro. The inactivation by O2" is less evident in vivo with no 
significant alteration in NO-mediated vasorelaxation in the presence of added 
SOD (Wolin etal., 1990).
NO is oxidised by O2 to nitrogen dioxide(eclu- 5) which, under physiological 
conditions of temperature, oxygen tension and pH, usually reacts with more NO 
to form the anhydride of nitrous acid(e9u- 6) and finally nitrous acid or nitrite ion, 
depending on pH(e9u- 7). Alternatively nitrogen dioxide may react with water to 
produce a mixture of nitrate and nitrite(eclu- 8), although this reaction is thought to 
be much slower (ca. lOx) than its reaction with NO (Feelisch et al., 1991).
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(5) 2NO + O2 2NO2
(6) NO2 + NO- —> N2O3
(7) N2O3 + H2O -> 2HNO2 -> 2H+ + 2NO2“
(8) 2NO2 + H2O -> HNO2 + HNO3
1.3.4 Interaction with Haemoglobin
The high oxygen tensions in arterial blood favour nitrate as the main breakdown 
product of NO’s reaction with oxygen, rather than nitrite (NO2‘) which is the 
main product in oxygenated aqueous solution. The interactions of NO and its 
metabolites (ie. NO2“) with haemoglobin (Hb) (and myoglobin) appear to be 
responsible for nitrate formation in vivo (Wennmalm et al., 1993).
The relative amounts of methaemoglobin (metHb, Hb (Fe111)), nitrosylated Hb 
(HbNO) and nitrate formed is dependent on the oxygenation state of Hb within 
the erythrocytes. In arterial blood (O2 saturation 94-99%) nearly all of the 
oxygenated Hb (oxyHb, Hb(Fen)O2) which binds NO is converted to metHb + 
nitrate (e9u- 9) with little HbNO. In venous blood (O2 saturation 36-85%) 
deoxygenated Hb (deoxyHb, Hb(Fen)) reacts with NO to form mainly 
(Hb(Fen)NO), with less nitrate(e9u-10).
(9) NO + (Hb(Fen)O2) -> (Hb(FeIn)) + NO3-
(10) NO + (Hb(Fen)) -> (Hb(Fen)NO)
NO, like carbon monoxide, binds to the iron centre of oxyHb impeding the 
ability of erythrocytes to transport oxygen. MetHb does not accumulate in these 
cells as it is efficiently converted back to Hb(Fen) by the NADPH-dependent 
enzyme, methaemoglobin reductase (Wennmalm et al., 1993). The nitrate 
produced is transferred into the blood serum and excreted via the kidneys into 
the urine, with a small amount being taken up into the saliva.
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The interaction between NO and deoxy Hb is similar to that of oxyHb however, 
NO can remain complexed with deoxy Hb for up to 4hrs with a 106-fold greater 
affinity than O2 (Henry, et al., 1993). The mechanism responsible for releasing 
NO- from deoxyHb is not clear but may involve the oxidation of NO to nitrite.
Jia et al., (1996) recently suggested that certain nitrosothiols can enter 
erythrocytes and complex with oxyHb in the lungs to form s-nitrosylated oxyHb 
(SNO-Hb(Fen)O2) without compromising O2 transport. 5-nitrosothiols are not 
subject to diffusional constraints imposed by Hb so can transport NO out of the 
lungs to the tissues. The idea that NO can mediate vasoactive effects away from 
its release site is controversial and will undoubtedly generate considerable 
interest.
1.4 Detecting NO
Accurate methods of detection have to be devised in order that the distribution 
and reactivity of NO in vivo be more fully appreciated. There is a growing 
number of such methods, although several do not measure NO directly.
1.4.1 Griess Reaction
The assay based on the Griess reaction does not measure NO directly, but relies 
instead on the propensity for NO to be oxidised to nitrite and nitrate under 
physiological conditions. The reagents detect nitrite so all nitrate is first reduced, 
using either a copper-coated cadmium column or a bacterial enzyme, nitrate 
reductase. The purple azo derivative which is formed in the reaction is monitored 
spectrophotometric ally at 540nm (Green et al., 1982).
This assay only infers NO production and offers little qualitative information as 
to whether the nitrite or nitrate is derived via NO metabolism or the diet. The 
technique is however quick and easy to use, with considerable sensitivity. The 
stability of nitrate in mammalian systems means that lipopolysaccharide (LPS)-
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induced increases in NO production can be measured from blood serum samples 
(Schmidt & Keim, 1996).
1.4.2 The Oxyhaemoglobin Assay
Another assay relying on spectrophotometry involves a shift in the visible 
spectrum peak absorbance from 415nm to 406nm as NO rapidly converts oxyHb 
to metHb and nitrate ion^11-12\
(12) (Hb(Fen)O2) +NO- Hb(FeIn) + NO3"
The oxyHb assay is a useful method for obtaining kinetic information 
concerning NO production under physiological conditions although with so 
many redox-active species within the biological milieu (ie. thiols, hydrogen 
peroxide, O2', ONOO-) inaccuracies in measurement must be anticipated. 
(Feelisch etal., 1996).
1.4.3 Electron Paramagnetic Resonance (EPR)
Although NO is paramagnetic, in its unexcited state it is undetectable using EPR 
in solutions at room temperature. The intervention of EPR as a means of 
monitoring NO production relies on the formation of NO adducts. NO-specific 
adducts include organic spin-traps like Fen-diethyldithiocarbamate (DETC)2 
which complexes with NO to form FeNO(DETC)2- This adduct has been used 
successively to detect NO in organs from animals pre-exposed to LPS. EPR can 
detect minute amounts of NO in specific cells, tissues and living animals and as 
such represents a powerful tool for measuring NO in various pathological 
conditions such as septic shock or diabetes mellitus (Henry et al., 1993; Singel & 
Lancaster Jr., 1996).
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1.4.4 Chemiluminescence Reaction with Ozone
NO reacts with ozone (O3) in the gaseous phase to produce nitrogen dioxide in 
an excited state (NO2*/eclu-13\
(13) NO + O3 —» NO2* + O2
As NO2* relaxes to its normal, unexcited state it emits light of a characteristic 
energy^qu-14) which is detectable using a photomultiplier tube.
(14) NO2*NO2 +/*v
Chemiluminescence is one of the most accurate assays available and, in addition 
to measuring NO itself, it can also be used to measure the intermediates and end- 
products of NO oxidation. However, due to the diversity and variability of NO 
interactions in vivo, this procedure can only be used outwith the biological 
milieu. (Hampl et al., 1996).
1.4.5 Electrochemical NO Probes
Electrochemical probes for NO rely on the propensity of NO to oxidise at the 
anode. The current generated is proportional to the amount of NO oxidised. 
Porphyrinic sensors have been used to detect the release of NO from a single cell 
in situ (Malinski & Taha, 1992) and more recently, the NO release associated 
with infused Ach and brady kinin in the human vein (Vallance et al., 1995). 
Therefore NO probes provide further evidence that EDRF in humans is NO and 
will undoubtedly prove invaluable in assessing the roles of NO in physiological 
systems on a moment to moment basis. More recently other types of NO sensor 
have been reported to detect endogenous NO release in vivo (Leung et al., 1996).
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1.5 Physiological Roles of NO
1.5.1 Modulation of Arterial Tone
NO is an important mediator of vascular tone, maintaining local and systemic 
vascular resistance, blood flow and oxygen delivery. An imbalance in NO 
synthesis is implicated in a number of life threatening conditions eg. septic 
shock, resulting from excess NO production, or diabetes, ischaemia and systemic 
hypertension, all of which are associated with impaired NO production.
The monolayer of endothelial cells lining the inner surface of blood vessels is the 
source of numerous factors which modify VSM activity, either spontaneously 
(ie. basal release) or in response to stimulation (eg. shear stress or endothelium- 
dependent agonists). NO is just one of a number of endothelium-derived relaxing 
factors. Other EDRFs include prostaglandin I2 (PGI2) and endothelium-derived 
hyperpolarising factor (EDHF; Tare et al., 1990). Constricting factors (EDCF) 
are also released from endothelium and include endothelin-1 (ET-1) and 
thromboxane A2 (TXA2).
Most of these factors generate second messengers within VSM which ultimately 
regulate vascular tone (ie. PGI2 increases cAMP; NO increases cGMP; ET-1 and 
TXA2 increase INP3 and 1,2 DAG). Basal NO can be considered a tonic 
suppressor of vascular contractility whereby the true state of contraction is only 
unmasked when NO is inhibited eg. by haemoglobin. Agonist-stimulated (eg. 
phenylephrine; cci adrenoceptor agonist) contractions are also antagonised by 
basal NO release (Martin et al., 1986).
Therefore, although the mechanisms employed to regulate vascular tone are 
varied, they principally deal with two opposing responses, vasorelaxation and 
vasoconstriction.
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1.5.1a Blood Flow - Basal Tone
In the absence of any mechanism regulating vascular tone (ie. innervation, 
circulating and locally synthesised substances) small arteries reside in a partially 
constricted state in vivo due to the flow of blood through them. Blood flow 
exerts physical forces on vessel walls resulting in a persistant contraction, often 
referred to as basal tone. Although frequently overlooked, basal tone is essential 
to ensure adequate circulation and so prevent peripheral vascular collapse (Segal 
& Duling, 1987). Specific inhibitors of NOS eg. NG-monomethyl-L-arginine 
(L-NMMA) increase arterial tone, both in vitro and in vivo (Moncada et al., 
1991) indicating that basal release of EDRF in unstimulated vessels regulates 
basal tone.
The synthesis of EDRF can also be enhanced in endothelial cells by a variety of 
mechanisms.
1.5.1b - Stretch and Shear Stress
Vessel walls are also subject to shear stress (a tangential force generated by 
friction between cells in the blood and endothelial lining) and stretch (pressure 
perpendicular to the endothelial layer associated with blood flow, volume, 
viscosity and velocity). As well as contributing to basal tone these physical 
forces also establish active tone (myogenic activity) within the vessels by 
elevating intracellular calcium concentration [Ca2+]i (Bevan, 1991; Falcone et 
al., 1993). Endothelial basal activity is principally determined by shear stress 
while stretch regulates arterial diameter in a smooth muscle-dependent manner 
(Johnson, 1991). This was demonstrated by altering fluid viscosity, which is 
proportional to shear stress, in isolated segments of artery and maintaining a 
constant pressure (Koller et al., 1993).
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Shear stress on endothelial cells may be detected by sialic acid residues built into 
its surface (Heckler et al., 1993). This may provide a Ca2+-independent 
activation of membrane bound eNOS. (See fig. 1.1).
Mechanosensitive ion channels (Ca2+, K+ and Cl") also exist on endethelial cells 
and are activated in response to shear stress (Oleson et al., 1988). Tone is altered 
by changes in intracellular ionic concentrations, for instance K+ selective 
channels can hyperpolarise endothelial cell membranes to cause an EDRF- 
independent relaxation (Oleson et al., 1988), while stretch-induced Ca2+ influx 
(via stretch-activated Ca2+ channels) (Kirber et al., 1988) and activated voltage- 
dependent channels (Harder et al., 1987) can cause constriction (Laher & Bavan, 
1987).
Shear stress is also thought to influence the release of ET-1, a potent endothelial- 
derived vasoconstrictor. Whether ET-1 release is suppressed (Malek & Izumo, 
1992) or stimulated (Yoshizumi et al., 1989) is thought to be determined by 
differences in the level of shear stress imposed on the endothelial cells (Morita et 
al., 1993). It is also possible that NO inhibits ET-1 release (Boulanger & 
Luscher, 1990).
NO (Hutcheson & Griffith, 1991, 1994) and PGI2 release (Frangos et al., 1985) 
are enhanced in isolated preparations by increased flow and perfusate viscosity. 
The expression of endothelium-derived NOS (eNOS; Section 1.9) mRNA and 
protein are also upregulated following exposure of endothelial cell cultures to 
shear stress (Busse et al., 1994). Indeed, a shear stress regulated component has 
been identified in human eNOS, allowing for a transcriptional regulation of NOS 
activation in vivo (Marsden et al., 1992). Significantly, both EDRFs are 
implicated in endothelium-dependent hyperpolarisation (Tare et al., 1990; 
Parkington et al., 1993). NO (Kitamura, 1993) and NO-donor drugs (Haeusleu & 
Thorens 1976) have been shown to hyperpolarise arterial preparations.
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Flow-induced hyperpolarisation can also occur in response to agonists which 
induce EDRF synthesis (Bolton & Clapp, 1986). This endothelium-dependent 
hyperpolarisation is thought to reflect a cGMP-dependent protein kinase- 
mediated phosphorylation of Ca2+-activated K+ (Kca) channels (Bolotina et al., 
1994) or ATP-sensitive K+ (Katp) channels, although the exact mechanism 
varies between tissues and species (Parkington et al., 1993). Species differences 
are further suggested by studies using the endothelium-dependent agonist 
acetylcholine (Ach). In rabbit aortic endothelial cells Ach is thought to cause 
hyperpolarisation by activating Kca channels, increasing cytosolic [Ca2+] and 
stimulating EDRF release (Sakai, 1990). Conversely Ach-induced 
hyperpolarisation in rat mesenteric artery is not inhibited by oxyhaemoglobin or 
methylene blue, suggesting an EDRF-independent mechanism (Chen & Suzuki, 
1989).
Ach and ATP are synthesised in endothelial cells (Parnevalas et al., 1985) and a 
number of other EDRF-stimulating agonists are stored, including vasopressin, 
angiotensin II, substance P and bradykinin (Ralevic et al., 1992). Flow can 
induce agonist release from endothelial cells (Ralevic et al., 1990) which will 
potentiate an increase in [Ca2+]j and the subsequent release of EDRF. By 
altering membrane potential (ie. hyperpolarisation), agonists upregulate 
L-arginine transport into endothelial cells which may permit a sustained increase 
in EDRF synthesis (Bussolati et al., 1993).
Therefore, in summary, the mechanisms employed to sustain Ca2+ influx evoked 
by flow include (1) activation of mechanosensitive Ca2+ channels, (2) activation 
of non-selective cationic channels, (3) activation of an inward rectifying K+ 
current involving both Kca and Katp channels which may cause 
hyperpolarisation. Endothelial cells lack voltage-operated Ca2+ channels so 
hyperpolarisation increases the electrochemical gradient for Ca2+ entry into 
endothelial cells (Luckoff & Busse, 1990). Shear stress and endothelium-
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dependent agonists initiate a guanine nucleotide (G)-protein-phospholipase C 
(PPLC) interaction resulting in 1,4,5-trisphosphate (IP3) formation from 
phosphoinositides. IP3 stimulates Ca2+ release from internal stores (Prasad et al., 
1992). (4) As a byproduct of PPLC activation, 1,3,4,5-tetrakiphosphate (IP4) 
may upregulate Ca2+ influx by opening Ca2+ permeable channels (Ltickoff & 
Clapham, 1992). (5) Adjacent endothelial cells are in intimate contact via gap 
junctions (Beny & Pacicca, 1994) such that increases in [Ca2+]j can be 
propagated from one cell to the next. Similarly this could result in a propagated 
EDRF release as eNOS is activated in sequence. (6) eNOS is well suited to a 
Ca2+-dependent activation. Its location in the plasma membrane will favour 
stress related mechanotransduction and its activity is potentiated by the high 
intracellular pH induced by agonists such as bradykinin (Fleming et al., 1993).
These mechanisms act to reinforce the Ca2+ dependent activation of eNOS and 
subsequent release of EDRF. Although they may be relevant to both shear stress- 
and agonist-induced EDRF synthesis, fundamental differences in their use of 
Ca2+ exist. Agonist-induced EDRF synthesis relies on Ca2+ derived from 
internal stores while, in contrast, shear stress primarily utilises cytosolic Ca2+ 
(MacArthur et al., 1993). This is demonstrated using inhibitors of Ca2+-ATPase 
(the enzyme responsible for Ca2+ re-uptake into internal stores) which attenuate 
agonist-induced EDRF but stimulate shear stress-induced EDRF.
1.5.2 Activation of Guanylate Cyclase
Guanylate cyclase (GC) exists in most cells as a polymorphic enzyme with both 
cytosolic (soluble) and membrane-bound (particulate) isoforms. NO generally 
targets the soluble isoenzyme which is a haem-containing heterodimer with a 
and P subunits of Mr s in the range of 73-88KDa and 70KDa respectively 
(Waldman & Murad, 1987).
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NO released from the endothelial lining of blood vessels permeates through into 
the neighbouring VSM where it causes vasodilation. This constant or 
constitutive release of NO from the endothelium is initiated by and helps to 
counter the vasoconstriction created by Ca2+ released both intra- and 
intercellularly. The biochemical pathway responsible for this vasodilation is 
initiated by the binding of NO to the haem iron in soluble guanylate cyclase 
(sGC). This activates sGC which subsequently catalyses the hydrolysis and 
cyclization of guanosine 5’ triphosphate (GTP), forming guanosine 3’,5’ cyclic 
monophosphate (cGMP) and pyrophosphate. In its capacity as an intracellular 
‘second messenger’, cGMP functions to alter cellular processes directly, eg. by 
regulating nucleotide phosphodiesterases or stimulating cGMP-gated ion 
channels; or indirectly, by activating cGMP-dependent protein kinase. This 
kinase is then able to phosphorylate key protein substrates which modify cellular 
function and initiate relaxation (Knowles & Moncada, 1992).
The first conclusive evidence that NO is involved in sGC activation came from 
studies by Murad et al., (1978). They showed that sodium azide could increase 
the levels of cGMP in crude tissue extracts via the production of NO. This 
process required certain haemoproteins to be present and was inhibited by other 
haemoproteins eg. haemoglobin and myoglobin (Mital et al., 1975). A 
constituent of the sGC was able to convert the azide, in the presence of oxygen, 
to NO and so activate the enzyme. This constituent was subsequently identified 
as haem which forms a very stable bond with NO.
A number of other compounds which are known to release NO including, 
glycerol trinitrate, sodium nitroprusside (SNP) and amyl nitrite, can also activate 
sGC from crude extracts (Waldman & Murad, 1987). Because of their ability to 
release NO and cause relaxation in vascular (and nonvascular) smooth muscle, 
these compounds are often referred to as ‘nitrovasodilators’.
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Exposure of sGC (from crude extract) to NO alone also causes activation and 
results in a characteristic shift in Soret absorption peak from 431 to 398nm. Thus 
NO appears to be the main mediator of sGC activation (Braughler et al., 1979).
The ability of NO and certain nitro vasodilators to activate sGC is lost in partially 
purified enzyme preparations but can be restored by adding free haem-containing 
metalloproteins such as catalase, haematin, cytochrome C or peroxidase (Craven 
et al., 1978). This suggests two things: Firstly that purification of sGC can result 
in dissociation of the loosely-bound haem moiety, rendering the haem-deficient 
enzyme unresponsive to NO. This implies that activation of mammalian sGC by 
NO (and certain nitroso-compounds) is haem-dependent. Secondly, the haem 
contained in other proteins can be used by sGC to bind NO and facilitate 
activation (Craven & DeRubertis, 1978). The formation of the nitrosyl (NO)- 
haem complex is therefore crucial to the activation of sGC. This is further 
substantiated using agents which bind haem, eg. sodium cyanide. Cyanide 
inhibits the activation of sGC by azide, SNP and NO in crude and purified 
preparations (Kimura et al., 1975).
Preformed NO-haemoproteins (eg. NO-catalase, NO-haemoglobin, NO­
cytochrome P450 and NO-myoglobin) can maximally activate haem-containing 
sGC, as well as partially purified, haem-deficient sGC, more effectively than 
some nitrovasodilators, although experimental conditions will undoubtedly 
influence the results as some nitrovasodilators are oxygen dependent (eg. sodium 
azide) while others are not (eg. SNP) (Waldman & Murad, 1987). 
Spectrophotometric analysis suggests that an exchange occurs between the NO- 
haemoprotein and the sGC whereby the NO-haem moiety is transferred from the 
NO-haemoprotein to the haem-deficient sGC (Ignarro et al., 1986). The sGC is 
therefore reconstituted with its NO-haem complex. Furthermore, haem transfer 
does not occur between haem-deficient sGC and haemoprotein suggesting that 
either NO-haem binds less tightly to haemoglobin, myoglobin and catalase than
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haem, so is more easily released, or alternatively, that sGC has a greater binding 
affinity for NO-haem than haem alone.
Electron paramagnetic resonance (EPR) studies indicate that binding of NO to 
the haem (ferroprotoporphyrin IX) in sGC weakens the co-ordinate bonds 
holding iron in the plane of the protoporphyrin ring. This causes the iron to 
protrude out away from the hydrophobic pocket of the haemoprotein (Ignarro et 
at., 1992; Morse & Chan, 1980), effectively rearranging the structure of the NO­
haem complex to one resembling protoporphyrin IX, activating the enzyme 
(Wolin et al., 1982). Protoporphyrin IX, the demetalated (ie. without iron) 
precursor of haem, can activate reconstituted, haem-deficient and haem 
containing sGC, all in the absence of NO. This, and the fact that by adding iron 
into protoporphyrin IX inhibits NO mediated activation of sGC (Murad et al., 
1979), suggests that formation of this protoporphyrin-like molecule is necessary 
for sGC activation.
The activation of partially purified enzyme preparations is potentiated by adding 
reducing agents which generate NO-haem complexes from haemoproteins (but 
not preformed NO-haemoproteins). This occurs as the haem-iron is maintained 
in the ferrous (Fe2+) form so its affinity for NO is increased. Oxidising agents 
also influence sGC activation.
In general thiol-reducing agents (glutathione, ascorbate, dithiothreitol and 
cysteine) potentiate activation by NO or NO donors and thiol-oxidising agents 
(hydrogen peroxide, methylene blue and superoxide) inhibit it (Lewicki et al., 
1982). Inhibition may be due to the conversion of NO to higher oxides of 
nitrogen (NO2) before reaching the active site, or alternatively, oxidation of the 
recipient haem to its ferric form. Reducing agents will favour activation by 
preventing these oxidations.
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Interestingly, SOD, which protects NO by converting 02" to hydrogen peroxide 
(H2O2), can activate partially purified sGC (Mittal & Murad, 1979) an effect 
which is potentiated by increasing O2' concentration (Mittal & Murad, 1977). 
This suggests that superoxide anions are required for the activation of sGC 
which seems contradictory to the understanding that they inhibit activation by 
degrading NO. This may be explained by one of two possibilities, firstly 02“ and 
H2O2 may act indirectly on sGC by forming hydroxyl free radicals which are 
known to activate sGC in vivo (Murad et al., 1978), or 02“ may act directly on 
sGC. The second possibility is that the oxidation of sulfhydryl (SH) groups will 
promote activation but conversely, ‘overoxidation’ will inhibit it.
Agents that oxidise or reduce SH groups significantly alter both basal and 
stimulated sGC activity. Alkylating agents (eg. ethacrynic acid) can covalently 
modify free thiol groups to inhibit activity (Katuski et al., 1977). Similarly, 
oxidising agents (eg. oxidised glutathione) which convert free thiols to 
disulfides, and enhanced mixed disulfide formation with agents such as cystine 
or cystamine, can also inhibit sGC activity (Katsuki et al., 1977). Inhibition by 
cystamine is reversible with dithiothreitol in purified rat lung extracts, although 
this ability very much depends on the oxidation state of sGC (Ignarro et al., 
1981). The concentration-dependent nature of these inhibitory agents (Craven & 
DeRubertis, 1978) implies that the catalytic site of sGC is regulated by one or 
more SH groups (Braughler Jr., 1983), one dealing with basal (ie. preincubation 
in oxygen atmosphere) activity and the other with agonist (NO- activated)- 
stimulated activity.
1.5.3 VSM Contraction
Basal [Ca2+]j is estimated to be ~100nM in VSM cells, although this varies 
significantly depending on experimental conditions (eg. stretch, temperature) 
(Morgan & Sue-Matsu, 1990). An increase in free [Ca2+]j is a prerequisite for
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VSM contraction. This can be established via receptor-or voltage-dependent 
channels which allow influx of extracellular Ca2+ through the sarcolemma (SL) 
or by Ca2+ release from the sarcoplasmic reticulum (SR). The release of Ca2+ 
from the SR is mediated via certain G-protein receptors such as a i-adrenoceptor 
and angiotensin II that stimulate phospholipase (PLC) to hydrolyse 
phosphatidylinositol 4,5, bisphosphate (PI-P2) to inositol trisphosphate (IP3; 
usually the 1,4,5 isomer) and 1,2, diacylglycerol (DG). DG is a potent activator 
of phosphokinase C (PKC) (Weinheimer et al., 1986) although the consequence 
of this is poorly understood. It has been suggested that PKC can inhibit EDRF 
release and also phosphorylate structural components within myosin light chains 
(Ohanian et al., 1990). This may be important for sustained vasoconstriction.
Ca2+ can be pumped into the cell by Ca2+-stimulated ATPases (Ca2+-ATPase) 
distributed in the SL and SR. IP3 binds to specific receptors on the SR, releasing 
Ca2+ into the cytosol without influencing SL channel activity (Somlyo et al., 
1985).
1.5.3a Contractile Proteins
The trigger for muscle contraction in VSM is the Ca2+-binding protein, 
calmodulin (CaM), as opposed to troponin C in skeletal and cardiac muscle. 
Four Ca2+ ions complex wth CaM, activating myosin light chain kinase (MLCK; 
Walter, 1989) to phosphorylate 20KDa myosin regulating light chains (MLC). 
The phosphorylation of MLC triggers actin-myosin crossbridge cycling and 
hydrolysis of ATP -* ADP+Pi (Moreland, 1990). Ca2+/CaM-stimulated 
phosphorylation of MLC is associated with the initial phase of VSM contraction 
(Rasmussen etal., 1987).
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1.5.4 Regulation of Myosin Phosphorylation by cGMP- Relaxation
Myosin phosphorylation is mediated by a number of factors including cyclic 
nucleotides, cAMP and cGMP. However, endothelium-dependent VSM 
relaxation is preceded by an increase in cGMP but not cAMP (Furchgott et al., 
1984). Increases in VSM [cGMP] results in a wide range of target intracellular 
proteins being phosphorylated by cGMP-dependent kinases (PKGs) (Fiscus et 
al., 1984) which, under physiological conditions are thought to relax VSM by 
decreasing [Ca2+ ]i (McDaniel et al., 1992). The mechanisms participating in 
reducing [Ca2+ ]i are outlined below.
1) Increased [cGMP] stimulates ATPase-mediated extrusion of Ca2+j and 
Na+/Ca2+ exchange (ie. Na+ influx and Ca2+ efflux) through the SL (Popescu et 
al., 1985; Furukawa et al., 1991). Accelerated Ca2+ extrusion can be initiated by 
SNP in the rat aorta (Magliola & Jones, 1990).
2) The level of agonist-stimulated phosphoinositide turnover can be decreased 
by a downregulation of G-protein activity and uncoupling of activated G-protein 
to PLC (Hirata et al., 1990).
3) The Ca2+ pump in the SR of VSM cells is regulated by protein kinases ie. 
cAMP-dependent kinase (PKA) and cGMP-dependent kinase (PKG) which 
phosphorylate certain proteins including phospholamban (Cornwell et al., 1991). 
Phospholamban is thought to decrease [Ca2+ ]j by activating the SR Ca2+ pump 
and sequestering cytosolic Ca2+ (Twort & Van Breeman, 1988).
4) Upregulated cGMP, or application of the cGMP derivative 8-bromo-cGMP, 
inhibits voltage-dependent long-lasting (L)-type Ca2+ channels without 
influencing transient (T)-type Ca2+ channels (Bkailey et al., 1988). Receptor­
operated channels (ROC) are also inhibited by PKG (Collins et al., 1986). In 
contrast, Ca2+-dependent K+ channels are opened by PKG and may explain the 
resulting membrane hyperpolarisation which often occurs in VSM cells.
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5) Changes in membrane potential can interfere with Ca2+ motility. 
Hyperpolarisation closes voltage-operated Ca2+ channels (Nelson et al., 1990) 
and reduces IP3 formation and the subsequent mobilization of Ca2+ from SR
stores (Itoh et al., 1992).
Fig. 1.1 Diagram of the mechanisms relating to relaxation/contraction in 
vascular tissues.
The hydrolysis and inactivation of cGMP and cAMP is performed by specific 
cyclic nucleotide phosphodiesterases (PDEs). Increased [cGMP]| leads to 
inhibition of a cGMP-dependent cAMP-PDE (CGI-PDE), elevating [cAMP]i in 
platelets (Maurice & Haslam, 1990) and rat aorta (Lindgren et al., 1990). SNP 
acts synergistically to isoprenaline-induced increases in cAMP in VSM cells.
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CGI-PDE inhibition by increased cGMP is thought to be responsible for this 
effect (Maurice & Haslam, 1991).
1.6 Other Physiological Roles of NO
NO is involved in numerous processes other than regulation of cardiovascular 
tone. For the purposes of this introduction only a select few are mentioned.
1.6.1 NO in the Central Nervous System (CNS)
The widespread distribution of NOS within the brain indicates that NO may be 
involved in most aspects of CNS function. Perhaps of most interest in recent 
years has been the notion that NO regulates synaptic plasticity. Stimulation of 
excitatory amino acid receptors eg. NMDA, (the glutamate subtype, N-methyl- 
D-aspartate) Ca2+-dependently increases NO release to mediate long term 
potentiation of synaptic transmission (LTP; Schuman & Madison, 1991) or long 
term synaptic depression (LTD) by supressing the sensitivity of AMPA receptors 
(the glutamate subtype, <x-amino-3-hydroxy-5-methyl-4-isoxazolepropionate) 
(Shibuki & Okada, 1991). LTP and LTD are considered elements of experience- 
driven synaptic network remodelling that may underlie learning and memory.
Under pathological conditions of ischaemia, NOS is no longer exclusive to 
neurons but can be detected in astrocytes (Wallace & Bisland, 1994) and 
microglial cells which may promote neuronal cell death (Boje & Arora, 1992). 
This idea is strengthened by evidence that N°>-substituted L-arginine analogues 
have been shown to reduce neuronal damage associated with cerebral ischaemic 
models in the rat (Buisson et al.. 1992; Nagafugi et al., 1992; Garthwaite & 
Boulton, 1995).
1.6.2 NO in the Peripheral Nervous System (PNS)
Two major neurotransmitters in the PNS are acetylcholine and noradrenaline 
although certain peripheral nerves use neither and are termed nonadrenergic
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(NA) noncholinergic (NC) or NANC nerves. NO was discovered to be the 
neurotransmitter in NANC nerves influencing peristaltic function of the 
stomach, gastrointestinal tract, respiratory tract and relaxation of the corpus 
cavernosum to facilitate penile erection. (Rand & Li, 1995).
1.6.3 Immune and Inflammatory Systems
Almost every cell in our body is able to express calcium independent NOS 
(iNOS) during cell-mediated immune responses (Nathan & Hibbs, 1991). The 
high levels of NO produced offer a non-specific line of defence against bacteria, 
parasites and viruses. NO is also thought to suppress T lymphocyte-mediated 
antigen-specific immune responses (Lepoivre et al., 1995). NO can therefore be 
regarded as a modulator of the immune response in humans.
NO formation is increased during inflammation (arthritis, colitis, Crohn’s 
disease), although endogenous release appears to have both pro- and 
antiinflammatory effects. Proinflammatory functions relate to the self-destructive 
nature of high NO production as demonstrated in autoimmune disease, immune 
rejection of allografted organs and sepsis. These are off-set by the 
antiinflammatory effects of NO such as inhibited neutrophil adhesion to vessel 
walls (Kubes et al., 1991) and cytokine formation.
The role of NO in fighting cancer is discussed in Part C and its role in sepsis is 
further discussed in Part D.
1.7 Cellular Interactions of NO. Cytotoxic Implications
The interactions of NO with non-haem iron accounts for many of the cytotoxic 
effects of activated macrophages on tumour cells (Hibbs Jr. et al., 1990) and 
microbes (Nathan & Hibbs Jr., 1991). Indeed, the non-specific cytotoxicity of
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NO can also inhibit the activated macrophages themselves (Drapier & Hibbs Jr., 
1988).
High levels of NO potently inhibit mitochondrial respiration and energy 
metabolism by interacting with non-haem iron in certain vital enzymes, 
including mitochondrial aconitase (a key enzyme of the Krebs cycle), NADH: 
ubiquinone oxidoreductase (complex I) and succinate: ubiquinone 
oxidoreductase (complex II; involved in mitochondrial respiration; Hibbs Jr. et 
al., 1990). The removal of intracellular iron is critical to this inhibitory effect 
and is reversible by replacing the lost iron (Drapier & Hibbs Jr., 1986). The 
profound disruption of iron metabolism stems from NO’s ability to complex with 
transferrin and promote iron exocytosis from the ferritin store (Reif & Simmons, 
1990). The resultant loss of intracellular iron causes cytostasis (inhibited cell 
growth and proliferation) and cytotoxicity.
NO mediated activation of adenosine diphosphate (ADP)-ribosylation may also 
influence energy metabolism (Zhang et al., 1994). ADP-ribosylation is initiated 
by the activation of intracellular polyADP-ribosyltransferase which may 
contribute to NO mediated neurotoxicity in vitro by inhibiting the important 
glycolytic protein glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Zhang 
et al., 1992). The inhibition of GAPDH decreases ATP formation by glycolysis 
and reduces the flow of substrates to the electron transport chain, ultimately 
resulting in cell death. The cytotoxic effects of NO in pancreatic islet cells can 
be blocked using inhibitors of polyADP-ribosyltransferase such as nicotinamide 
(NA; Kallmann et al., 1994). NA is also a precursor of NAD+ (the required 
substrate of the PolyADP-ribosylation reaction). PolyADP-ribosyltransferase 
repairs DNA using NADH which is converted to NAD+. The subsequent 
depletion of available substrate (NAD+) severely limits ATP synthesis. Whether 
NA inhibits NO mediated cytotoxicity by replenishing NAD+ or preventing ATP
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inhibition is not clear. It is also unclear whether GAPDH inhibition is 
responsible for cytotoxic effects outside the brain.
Ribonucleotide reductase (RNR), the rate limiting enzyme catalysing the 
synthesis of DNA, is reversibly inhibited by NO in murine adenocarcinoma cells 
(Lepoivre et al., 1992). Whether other cells apart from macrophages can release 
sufficient NO to inhibit DNA synthesis is questionable, although VSM cells can 
be stimulated to release high levels of NO which inhibit mitochondrial 
respiration (Geng et al., 1992). It has also been suggested that an endothelium- 
derived factor which is not NO can suppress intra-arterial DNA synthesis 
(DeMey et al., 1991). This will be important when considering contractile 
properties of intact and denuded arterial preparations. It is also important to 
realise that cytotoxicity will also be mediated by other oxides including 02" and 
ONOO- (Section 1.3.2). This is evident from reports which show that aconitase 
inactivation is mediated by the above and not by NO (Hausladen & Fridovich, 
1994).
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Part B
Nitric Oxide Synthase
1.8. Introduction
NO radical is generated by a family of isozymes called nitric oxide synthases 
(NOSs) which are expressed throughout a diverse range of mammalian cells, 
including the endothelium (Palmer & Moncada, 1989) and vascular smooth 
muscle (Busse and Mulsch, 1990), cells in the brain (Bredt et al., 1990a), the 
liver (Geller et al., 1993), kidneys (Tracey et al., 1994), lungs (Tracey et al., 
1994), heart (Schulz et al.., 1992 ), digestive system (Timmermans et al., 1994) 
and also various cells associated with the immune response, including 
macrophages (Nathan et al., 1991), Kupffer cells (Billiar et al., 1989), and 
neutrophils (McCall et al., 1989). In fact NO has been found in nearly every rat 
or murine tissue so far studied.
The catalytic conversion of L-arginine amino acid to NO and L-citrulline by 
NOS is thus far thought to predominate amongst mammals. However, within the 
next few years it is possible that other NOSs will be identified in species further 
down the evolutionary chain. Animals other than mammals can produce NO but 
usually do so without the use of NOS: for instance, microbes reduce nitrite or 
oxidise ammonia to produce NO (Feldman et al., 1993). The many physiological 
roles governed by NO in mammals may explain why evolution has seen fit to 
select for the ability to synthesise NO from NOS, which offers a highly flexible 
and very powerful mechanism for generating NO on demand.
In 1985 mice with particular genetic abnormalities were found to possess 
macrophages which produced high levels of nitrite and nitrate (Steuhr & 
Marietta, 1985) and by 1988 it was realised that macrophages could be 
stimulated to produce NO (Marietta et al., 1988).
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Only in the past few years, following the initial purification of NOS from the rat 
cerebellum by Bredt et al. (1990b), has an appreciable understanding and 
characterization of the enzyme begun to emerge. With improved molecular 
techniques, more isoforms of NOS have been purified, cloned and in some cases 
functionally expressed. The purification and cloning procedures applied to these 
enzymes reveal much about their biochemical composition with regard to the 
presence of distinct regulatory sites that include 3 cAMP-dependent 
phosphorylation sites, as well as those for the necessary cofactors: nicotinamide- 
adenine dinucleotide phosphate (NADPH), flavin adenine dinucleotide (FAD), 
flavin mononucleotide (FMN) and (6R)-5,6,7,8-tetrahydrobiopterin (BH4). 
Molecular cloning of brain (Bredt et al., 1991), macrophage (Lowenstein et al., 
1992) and endothelial (Lamas et al., 1992) NOS’s has permitted the localization 
of their respective mRNAs by in situ hybridization. Analysis of the precise 
amino acid sequence in NOS reveals the compartmentalisation that exists in 
every isoform with the reductase domain at the carboxy-terminal and the 
oxygenase domain at the amino-terminal. Ultimately, studies detailing the 
quaternary structure of NOS will help to uncover exactly how it interacts with its 
substrate and the various prosthetic groups which make up the complete dimeric 
molecule.
In conjunction with the ability to purify NOS, new technology allowed 
polyclonal and monoclonal antibodies to be made which are specific to particular 
isoforms. These antigen-antibody complexes can be visualised immunologically, 
either histochemically with antibodies conjugated to fluorescent markers, eg. 
fluorescein isothiocyanate (FITC), or biotinylated to a 2° antibody which is 
itself labelled, ie. the avidin-biotin complex (Kobzik & Schmidt, 1996). A more 
definitive confirmation of antigenic sites can be obtained with Western analysis 
of protein extracts following electrophoresis (sodium dodecyl sulphate- 
polyacrylamide gel electrophoresis; SDS-PAGE) onto nitrocellulose membranes 
(Mayer et al., 1990). A positive band on the membrane can be detected using a
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number of methods, including enhanced chemiluminescence (ECL). The activity 
of NOS can also be assayed directly. This involves using radiolabelled 
substances, eg. by monitoring the production rate of L-[14C] citrulline from 
L-[14C] arginine and determining the concentration of L-[14C] citrulline at a 
given time (Galea et al., 1992). An alternative method for measuring the activity 
of NOS indirectly involves analysing the levels of nitrite/nitrate production using 
the Griess reaction (Green et al., 1982).
The ability to purify the different isoforms of NOS has revolutionised the study 
of NO producing cells and tissues and it is now clear that the use of specific 
antibodies is far superior to many techniques previously used. Histochemical 
techniques of detecting NOS activity are still widely used, the most common of 
which detects NADPH-diaphorase. NADPH-diaphorase staining is a cheaper 
alternative to antibodies for the detection of NOS activity (Weinberg et al., 
1994; Weinberg et al., 1996), although the specificity of NADPH-diaphorase has 
come under considerable scrutiny since its introduction by Thomas and Pearse in 
1961. Much of this scrutiny has been dismissed since the discovery that neuronal 
NOS (nNOS) is an NADPH-diaphorase (Dawson et al., 1991). Although it is 
clear that NOS possesses NADPH-diaphorase activity in the presence of the 
electron acceptor, nitroblue-tetrazolium (NBT), it should be noted that not all 
NOS isoforms coincide with NADPH-diaphorase staining (Tracey et al., 1993), 
suggesting that not all diaphorase staining represents NOS activity.
1.9 Isoforms of NO Synthase
Recent biochemical studies and analysis of cDNA amino acid sequences reveal 
that NOS isoforms are highly conserved (80-94% homology) from one species to 
the next (Sessa, 1994), a feature that implies the existence of a NOS gene family 
which, although conserved, are also diverse in both distribution and roles: 
(vascular signalling:-endothelium, cytotoxicity:- macrophage and 
neurotransmission:-brain; see Section 1.1-1.7). These regions encode the binding
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sites for the oxidative cofactors involved in regulating activity of NOS. All 
isoforms of NOS so far discovered display binding sites for NADPH, flavin 
adenine dinucleotide, flavin mononucleotide and (6R)-5,6,7,8-
tetrahydrobiopterin (BH4) (Katusic & Cosentino, 1994).
Type Comparative
Homology
Required
Cofactors
Regulators Potent
Inhibitors
Mr
(KDa)
Loci Ref
Constitutive 
(cytosolic) 
bNOS-1 a
Significant homology 
to cytochrome P-450 
reductase.
NADPIITAD, 
FMN.O2.BH4, 
reduced thiols
Ca2+/CaM, 
protein kinases
L-NAME,
L-NMMA.
L-NARG
155-160
Brain, cerebellum, 
neuroblastoma cells 
human epithelial- 
type tumour cells
1
Constitutive 
(cytosolic) 
eNOS- lb
50-60% sequence 
identity widi rat brain 
and murine 
macrophage isofomts
NADPH.FAD, 
FMN.O2JJH4, 
reduced thiols
Ca2+/CaM L-NAME - Vascular endothelial 
cells (VECs)
2
Constitutive
(cytosolic)
cNOS-Ic
- NADPHTAD,
O2J3H4
Mg2+,Ca2+. 
Stimulated by 
receptor agonists eg. 
Icukotricne B4
L-NAME 150 Neutrophils
3
Inducible 
(cytosolic) 
INOS- II
50-60% sequence 
identity with bNOS.
NADPH.FAD, 
FMN.O2.BH4. 
reduced thiols
LPS, NO, cytokines, 
IRF-l.NA-p. 
Sensitive (0 CaM 
antagonists
Dcjsamcthasone, 
ami noguanidine, 
L-NMMA
125-135
150
macrophages, VSM, 
tumour cells, neurons 
nstrocytes, microglia, 
kupfTcr cells, 
endothelial cells
4
Constitutive 
(membrane - 
bound) 
eNOS- III
95% sequence 
identity with human 
VEC eNOS- lb
NADPH.FAD.
FMN,O2,BH4
Ca2+/CaM, 
myristylalion for 
membrane 
association
L-NAME.
L-NMMA,
L-NARG
135 VECs
5
Inducible
(membrane - 
bound) 
iNOS-IV
-
BH.,. NADPH
- L-NMMA - macroplingcs
6
Inducible
(cytosolic)
iNOS-V
- -
IL-1 p, Ca2>-
depeudent
L-NMMA,
EGTA -
Chondrocytes,
cartilage
7
Abbreviations; 5,6,7,8-tctrahydrobioptcrin (BH4), flavin-mononucleotide (FMN), uicotinamide-adeniuc-dinuclcotide (NADPH), 
flavin-adenine diuuclcotide (FAD), interleukin-ip (IL-IP), nuclear transcription factor (NAP). References; 1 Schmidt et al., 1991, 
2F6retermnnn et al., 1991, ^Yui et al., 1991,^Lowcnslcin el al., 1992,^Lamas et al., 1992, ^Forstermannefa/., 1991, TPalmcr etal., 1992.
Table 1.1 NOS Isoforms
Three separate genes exist encoding three isoforms of NOS. These genes are 
distinct from one another. This is manifested by their rather modest (50-60%) 
comparative homology (Nathan & Xie, 1994). In humans the genes for 
neuronal/epithelial NOS, cytokine-inducible NOS and endothelial NOS are 
located on chromosomes 12, 17 and 7 respectively (Forstermann et al., 1994). 
These three isoforms can broadly be categorised into 2 main groups; a 
constitutive group (eNOS), containing the neuronal NOS (nNOS) located in the 
brain together with an endothelial located NOS (eNOS). The second group 
contains the inducible isoform of NOS (iNOS) which is expressed in 
macrophages (macNOS).
eNOS isoforms are strictly regulated by binding of the calcium/calmodulin 
complex (Busse & Mulsch, 1990) and is usually associated with the sustained
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release of small (basal) amounts of NO during normal physiological activity 
(Griffith et al., 1984). Under pathophysiological conditions, such as a stroke, the 
cNOS isoforms may produce significantly higher levels of NO, enough to 
become cytotoxic to nearby cells (Nowicki et al., 1991). This increase in cNOS 
activity is dependent on a stimulus which acts either via a receptor, ie. a 
receptor-dependent agonist eg. acetylcholine, bradykinin, 5-hydroxy tryptamine 
(serotonin), substance P or thrombin, or alternatively via a receptor-independent 
mechanism. (Furchgott & Vanhoutte, 1989). These receptor mediated agoinsts 
bind to the endothelial cell surface causing a rapid increase in intracellular 
calcium concentration and subsequent NO release. Interestingly the increase in 
calcium is far more transient than the resultant increase in NOS activity. This 
may be due to the activation of secondary-mechanisms such as activation of 
sodium/hydrogen exchange channels which increase intracellular pH levels 
(Fleming etal., 1994).
Stimulated release of cNOS-derived NO is most commonly associated with the 
eNOS isoform, where receptor-independent, physical stimuli such as fluid shear 
stress have been shown to upregulate the expression of NOS activity in cultured 
endothelial cells (Busse et al., 1994; see Section 1.5.1b). Indeed, the part of the 
gene involved in this stress-related release of NO has been discovered and 
clearly shows that shear stress can regulate the transcriptional expression of 
eNOS in vivo (Marsden et al., 1992).
The physical attributes of eNOS which implement shear stress-induced 
regulation of NO release may be related to the fact that 95% of eNOS is 
particulate, whilst only 5% is present in the cytosol (Forstermann et al., 1991). 
Note that although eNOS is found in the vascular endothelium of most organs 
and tissues (Forstermann et al., 1993), eNOS has also been located outside the 
vascular endothelium, in CA1 neurons (O’Dell et al., 1994) and kidney tubular 
epithelial cells (Tracey et al., 1994). The 133KDa eNOS isolated and cloned
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from bovine aortic endothelial cells possesses a saturated fatty acid myristate 
located in its amino terminal (Pollock et al., 1992), either binding to a cellular 
membrane directly or indirectly via a myristyl protein receptor (Lamas et al., 
1992; Sessa et al., 1992). Theoretically, due to the lack of evidence for any 
transmembrane domain regions, this myristylation binding site may anchor the 
enzyme to the plasma membrane (Busconi & Michel, 1993) and provide a means 
for the endothelium to react to small changes in blood flow (ie. fluid shear 
stress). Subsequent activation of eNOS to release NO into the underlying smooth 
muscle would enlarge the diameter of vessels and thus reduce the stress induced 
by blood flow.
Membrane attachment may also improve the coordination between agonists 
binding to their endothelial receptors and the subsequent agonist-induced release 
of NO. By minimising the distance between the membrane bound receptors and 
eNOS the time to react would be reduced. The precise reason for attachment of 
eNOS to the cell membrane is unclear. It will however, undoubtedly provide an 
ideal communication between intraluminal and extraluminal environments.
Neuronal NOS and iNOS are completely devoid of any membrane-associating 
elements and are therefore cytosolic in nature and usually found in the soluble 
fraction of cell or tissue homogenates (Nathan & Xie, 1994; Stuehr & Griffith, 
1992). nNOS was the first enzyme to be purified and fully characterised from rat 
and purine cerebellum (Bredt et al., 1991). Since then this same isoform has 
been localised to several cell types including, kidney macula densa cells, 
peripheral non-adrenergic non-cholinergic neurons, skeletal muscle, pancreatic 
cells (Bredt & Snyder, 1990; Forstermann et al., 1993; Nathan, 1992) and some 
forms of epithelial cell (Kobzik et al., 1993). Using sequential affinity 
chromatographic techniques on 2’5’-ADP sepharose and calmodulin agarose, the 
denatured monomeric protein displayed a molecular mass (Mr) of 150 to 160 
KDa, whilst a molecular mass of around 279 was calculated for the native
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protein (Schmidt et al., 1991). This was the first indication that the nNOS 
enzyme was a homodimer consisting of two equally sized subunits each of 
~155KDa. Recently it has been proposed that nNOS may exist as a monomer- 
dimer equilibrium polypeptide (Masters, 1994).
All NOS isoforms are now thought to be homodimeric in nature, including the 
inducible isoform which was purified from murine macrophages with a 
monomeric Mr of 130KDa and was dimeric under native conditions (Hevel et 
al., 1991; Stuehr et al., 1991a). Subunit dimerization is required to generate 
active iNOS. Individual subunits cannot synthesise NO but can initiate electron 
transfer from NADPH to acceptors eg. ferricyanide or cytochrome C (Baek et 
al., 1993).
The potential to express iNOS is considered ubiquitus among all nucleated cells 
in the mammal and so fulfills a very general role in non-specific host defense 
(Karupiah et al., 1993; Nathan & Hibbs Jr., 1991). Thus, a growing number of 
cells have been shown to express iNOS including human hepatocytes (Geller et 
al., 1993) human cancerous cells of the brain (Fujisawa et al., 1995) and cervix 
(Werner-Felmayer et al., 1993), myocardium (Schulz et al., 1992), neurons 
(Minc-Golomb et al., 1994), glial cells (Simmons & Murphy, 1992; Wallace & 
Bisland, 1994), human (Sherman et al., 1993) and murine tumour (Bastian et al., 
1994) cell lines, human bronchial epithelial cells (Felley-Bosco et al., 1994), 
human (Janssens et al., 1992) and rodent (Kilbourn & Belloni, 1990) vascular 
endothelium, human chondrocytes (Charles et al., 1993), Kupffer cells (Billiar et 
al., 1989), mesangial cells (Pfeilschifter & Vosbeck, 1991), smooth muscle cells 
(Geng et al., 1994) and neutrophils (McCall et al., 1991).
In contrast to rodent macrophages, the induction of NO from cultured human 
macrophages is proving curiously difficult, although recently these cells have 
been shown to express iNOS (Kobzik et al., 1993). As the most prolific producer 
of NO during certain immunostimulated conditions in the human body (Iyengar
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et al., 1987), iNOS is able to kill tumour cells and pathogens (section 1.7). The 
lack of discrimination by NO means that sometimes, when levels are high 
enough, more harm than good is done, as vessel walls become excessively 
dilated, systemic blood pressure drops, and patients can often die. This is thought 
to underlie the lethality associated with sepsis syndrome (Rees et al., 1990). The 
expression of iNOS usually occurs in response to various inflammatory 
cytokines eg. IL-1|3, TNF-a, IFN-y, IL-2 and bacterial lipopolysaccharides 
(LPS; Chesrown et al., 1994), different combinations of which may result in 
synergistic enhancement of iNOS expression (Kilboum & Belloni, 1990). iNOS 
can also be expressed in some healthy tissues including fetal or adult lung 
(Kobzik et al., 1993) and during pregnancy (Sladek et al., 1993).
Like all forms of NOS, iNOS also requires the binding of calmodulin (CaM) for 
activity; however, iNOS CaM is normally tightly bound in a Ca2+-independent 
and noncovalent manner (Cho et al., 1992). This means the C-terminal domain 
and the N-terminal domain are always aligned and the enzyme is continually 
primed for full catalytic activity. Exceptions to the rule do exist with a CaM-free 
iNOS found in rat liver (Evans et al., 1992) and a calcium-dependent iNOS in 
rabbit chondrocytes (Palmer et al., 1992).
The activity of iNOS is regulated at many different levels, whether it be 
transcriptionally eg. nuclear factor (NF)-AB (Schreck et al., 1992) which can be 
stimulated by NO itself (Lander et al., 1993), or post-transcriptionally eg. with 
protein synthesis inhibitors like cycloheximide which can super-induce a 2.5 to 5 
fold increase in iNOS mRNA expression in cultured cells and prolong the life of 
newly made iNOS mRNA (Oguchi et al., 1994). Alternatively, non­
transcriptional factors can regulate iNOS expression eg. cAMP-elevating agents 
(Gross et al., 1994) or UV-B radiation (Warren, 1994).
The capacity of cycloheximide to super-induce and sustain the expression of 
iNOS mRNA appears to be unrelated to its ability to inhibit protein synthesis. It
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is more likely to be associated with its ability to simultaneously super-induce 
the NF-XB transcription factor and/or the immediate-early genes; c-fos and c- 
jun . (Edwards & Mahadevan, 1992). The respective mRNA sequences of these 
genes, like iNOS mRNA, contain multiple AUUUA destabilizing elements 
(Asson-Batres et al., 1994). The possibility that cycloheximide interferes with 
these sequences is becoming increasingly apparent. Conversely, the transforming 
growth factor (TGF)-{3 has been shown to infer mRNA instability (Vodovitz et 
al., 1993) and so inhibits the expression of iNOS in cultured, immunostimulated 
V.S.M. cells (Durante et al., 1994). It is therefore obvious that mRNA stability 
maybe the major site for regulating iNOS expression by cytokines. IFN-y and 
LPS, like cycloheximide, can also regulate iNOS expression in macrophages 
both transcriptionally and post-transcriptionally, by increasing the expression of 
iNOS individually and by prolonging the half-life of iNOS mRNA from 1-1.5 
hrs to 4-6hrs synergistically (Weisz et al., 1994). However, the ability to 
stimulate iNOS expression appears to differ depending on whether the cells are 
in culture or in ex vivo preparation (Sirsjo et al., 1994) and may require the 
presence of other factors involved in regulating the expression of the iNOS gene. 
One such factor, termed interferon regulatory factor-1 (IRF-1) is required for 
iNOS activation in murine macrophages (Kamijo et al., 1994). The associated 
cytokine, IFN-y, has also been shown to stabilize iNOS mRNA (Vodovitz et al., 
1993) and enhance transcription of the iNOS promotor construct (Xie et al., 
1993). Post-transcriptional modification, such as phosphorylation (Michel et al., 
1993) and myristylation (Pollock et al., 1992), are likely to influence enzyme 
activity. However, iNOS is cytosolic in nature and there are no reports of 
phosphorylation of iNOS either in vitro or in vivo. It therefore appears that the 
regulation of NOS activity by phosphorylating calcium/CaM-dependent kinases 
is solely a property associated with the constitutive isoforms (Bredt et al., 1991). 
Tyrosine kinases are however thought to be involved in regulating the activation 
of iNOS (Marczin et al., 1993).
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The most important post-translational modification allowing for the activation of 
iNOS is subunit assembly and the binding of cofactors. Essentially, for full 
enzymatic activity, iNOS, like the other isoforms, must have the necessary redox 
cofactors to ensure proper alignment of the monomeric subunits into dimeric 
formation, which in turn allow the correct electron exchange to occur between 
the oxidase (amino) and reductase (carboxyl) domains (Stuehr et al., 1991a). 
Whether the exchange of electrons is between monomeric subunits of the same 
polypeptide, or between neighbouring proteins in a head to tail arrangement, is 
still under debate (Feldman et al., 1993). However a recent study characterising 
macNOS presented evidence for a head to head subunit interaction between 
oxygenase domains (Ghosh & Stuehr, 1995). The presence of oxygen and 
adequate L-arginine are also required without which NO cannot be made 
properly and may result in uncoupled NADPH oxidation (electron loss). The 
uncoupling of electrons is far more prevelant in nNOS than in iNOS (Abu-Soud 
& Stuehr, 1993). This may reflect a protective mechanism to reduce the 
incidence of O2" production by iNOS which is more likely to happen with the 
large amounts of NO it produces compared to eNOS. Studies on substrate levels 
in plasma samples reveal the concentration of L-arginine to be in the range of 
150-200pM (Stuehr & Grffith, 1992), which may appear to be ample, but added 
exogenous L-arginine can still increase vasodilation suggesting that L-arginine is 
limiting (Creager et al., 1992). Measures to improve the availability of L- 
arginine for iNOS-activated NO release are present, as both the L-arginine Y+ 
transporter system (Bogle et al., 1992) and argininosuccinate synthetase activity 
(Hattori et al., 1994) are upregulated with cytokine-induced increases in NO 
production. The enzyme responsible for the de novo synthesis of BH4, guanosine 
triphosphate cyclohydrolase 1, is not normally expressed in unstimulated cells 
but is detectable in endothelial cells and vascular smooth muscle cells following 
exposure to LPS and IFN-y (Gross & Levi, 1992) in a time course similar to 
iNOS expression (Hattori & Gross, 1993). Thus it is becoming increasingly
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apparent that several other enzymes are induced simultaneously in a cell after an 
exposure to cytokines, in order to provide the cofactors required to sustain the 
high levels of NO associated with iNOS.
The well known affinity of haemoproteins for NO has prompted speculations 
that a negative-feedback effect of NO on iNOS activity occurs by binding as a 
sixth ligand to the iron of the heme cofactor (Griscavage et al., 1993). Whether 
this occurs in vivo is still a matter of debate. Further characterisation of the 
stability of NOS-NO complexes is required before this question can be 
answered. The binding of L-arginine seems to weaken affinity of NO for the 
ferric heme in NOS but not the ferrous heme (Hurshman & Marietta, 1995).
In general the intra-isoform homology is appreciablely high from one species to 
the next eg. bovine eNOS displays 95% identity with human eNOS (Lamas et 
al., 1992), although comparisons between iNOS isoforms from rodents with 
those from humans reveal significantly lower homology (Marietta, 1994). 
Surprisingly, several human inducible isoforms of NOS have been cloned, 
including one from hepatocytes (Geller et al., 1993) and one from a colorectal 
adencarcinoma cell line (Sherman et al., 1993) and were found to be essentially 
identical. It seems, therefore, that in general all human isoforms of iNOS are 
identical regardless of their origin, while significant differences exist when 
compared with the inducible isoforms of NOS in rodents. This may suggest that 
the human iNOS gene evolved completely independently from the iNOS gene in 
other animals. The difficulty in detecting iNOS in human macrophages and 
monocytes may indicate a reduced tendency to express this isoform in these cells 
and calls into question the validity of studying iNOS in rodents as a model for 
iNOS expression in humans.
39
Chapter 1 - Introduction
1.10 Homology
Cloning and expression of the complementary DNA sequence for NOS from rat 
cerebellum and macrophages reveals a similarity (36% sequence identity) 
between them and the cytochrome P-450 reductase (CPR) enzymes (Bredt et al., 
1991. Indeed bNOS expresses CPR activity (Klatt et al., 1993). The greatest 
similarity in amino-acid sequence is at the binding sites for NADPH, FAD and 
FMN, located in the carboxyl (C) terminal. The only other protein displaying 
this unique binding sequence is the bacterial enzyme, sulfite reductase (32% 
identity to NOS). The amino (N) terminal of NOS, which contains the heme 
binding site, shows no significant homology to any other known protein. NOS 
has a CPR type iron protoporphyric IX heme (White & Marietta, 1992; Stuehr & 
Ikeda-Saito, 1992; McMillan et al., 1992) and therefore reacts with carbon 
monoxide in the presence of NADPH to give an absorbance peak characteristic 
of CPR enzymes (Xmax of ~450nm) (White & Marietta, 1992). This spectral 
signature relegated to substrate-bound, high-spin CPR enzymes (Poules et al., 
1985) is conferred by ligation of a cysteine thiolate to the iron (Fe3+) of the 
heme complex (Renaud et al., 1993). The ten residue consensus sequence 
encoding for cysteine in CPR is apparently absent in NOS (Marietta, 1993), with 
the best correspondence seen at residues 409-417 for nNOS and 188-196 for 
murine macNOS (Poulas et al., 1987). A cysteine thiolate ligand does however 
exist in native dimeric macNOS (Steuhr & Ikeda-Saito, 1992). The ability of 
Ebselen to inhibit eNOS (Zembowicz et al., 1993) is thought to relate to its 
inhibitory effect on the transfer of elecrons from NADPH to FMN and its ability 
to break a cysteine-thiolate Fe3+ bond in some P-450 enzymes (Nagi et al., 
1989). This suggests that the presence of the cysteine-thiolate ligand in CPR and 
NOS is crucial for catalytic activity.
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Fig. 1.2 A schematic model showing the spatial relationships of the cofactor 
recognition site within NOS and CPR. In humans the genes for iNOS, nNOS and 
eNOS are found on chromosomes 17, 12 & 7 respectively. Abbreviations: 
N-terminal myristolation site (Myrist.), protein kinase A phosphorylation site 
(PKAP), transmembrane domain (TMD).
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The mechanistic roles of NOS and CPR are similar; both enzymes use the same 
two distinct heme-based oxidants during the course of NO formation and 
oxygen-activation respectively (Feldman et al., 1993). Both enzymes are 
involved in single electron transfer during catalysis (Vermilion et al., 1981) and 
can form superoxide anions under certain conditions. Due to the presence of 
similar iron-heme centres in NOS and CPR, and considering the high affinity 
between NO and the iron-heme, it is not surprising that NO can inactivate NOS 
and CPR to a similar degree (Griscavage et al., 1993; Rogers & Ignarro, 1992; 
Stadler et al., 1994; Khatsenko et al., 1993). Furthermore, the heme prosthetic 
group of NOS, like the thiolate-ligated heme of CPR, is presumed to bind and 
activate molecular oxygen in order to hydroxylate substrates (Kwon et al., 
1990), although their respective substrates do differ; CPR substrates tend to be 
very hydrophobic and their active sites are designed accordingly. L-arginine, on 
the other hand, is very hydrophilic (Marietta, 1993).
Most CPR are not ‘self-sufficient’, requiring a flavoprotein reductase and an 
iron-sulfur protein to allow electron transfer to the heme group (Marietta, 1994). 
Bacillus megaterum (P-450bm3), a fatty acid monooxygenase, is unusual in this 
respect by having a flavoprotein reductase and a heme group constitutively 
present (Narhi & Fulco, 1986). P-450gM3 is therefore fully functional as a 
monomer and as such is an example of a ‘self-sufficient’ P-450 enzyme. The 
NOS monomeric subunit is not capable of catalytic self-sufficiency as the 
cofactor binding sites are shared between subunits. NOS must undergo 
dimerization to become active (Ghosh & Stuehr, 1995). Dimeric NOS contains 
dual flavoproteins and a heme group and thus could be considered as the first 
self-sufficient, mammalian, P-450-type enzyme.
The similarities between CPR and NOS led to suggestions that NADPH- 
diaphorase (N-dia) may be similar to cytochrome P-450 oxidase (Snyder, 1992). 
Neuronal NOS is identical to neuronal N-dia (Hope et al., 1991), the activity of
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which is represented histochemically by a blue/purple colour formed as 
nitroblue-tetrazolium salt (NBT) is reduced to NBT-formazan (NBTF). Because 
NOS and diaphorase are identical the substrate NBT can competitively inhibit 
bNOS activity. Surprisingly, N-dia activity in bNOS is not regulated by 
calcium/CaM binding (Schmidt et al., 1992), suggesting that the diaphorase 
activity is not specific to NOS. The same appears to be true for CPR, which as 
part of the microsomal monooxygenase system in liver, is often associated with 
mitochondria (Bredt et al., 1991). N-dia is not seen in mitochondria (Mizukawa 
et al., 1988). NOS contains dihydropterin reductase which converts half 
quinone-dihydrobiopterin to half tetrahydrobiopterin (BH4) and may represent 
the N-dia activity in NOS (Schmidt et al., 1992b). The formation of BH4 can 
partially reverse the inhibitory effect of NBT on NOS activity and may explain 
why iNOS activity, together with the associated increase in BH4 production 
(Gross et al., 1994), shows increased N-dia staining compared to eNOS. Rather 
than the N-dia staining (ie. NBTF formation) being due to the NOS actvity 
directly, it may be due to the upregulation of dihydropterin reductase and the 
increased BH4 production which results. Unfortunately due to the diversity of 
oxidative-reductive activities that can provide a reduction of NBT, the activity of 
N-dia is difficult to characterise (Bredt et al., 1991; Snyder, 1992).
In conclusion, much of our understanding regarding the biochemistry of NOS 
has come from studies involving CPR enzymes. Their roles as electron 
transferase enzymes are similar and their close homology (-60%) in the C 
terminal could suggest that in phylogeny CPR may have provided the electron 
transport necessary for NO activity. Alternatively, considering that the highly 
conserved motif that denotes a CPR is lacking in NOS (Marietta, 1993) it 
appears that rather than possessing all the necessary attributes which define a 
P-450 family member, as well as additional divergent characteristics which make 
it distinct, NOS may be converging in evolutionary terms towards the P-450 
enzyme (Nelson et al., 1993). NOS joins a number of other enzymes, including
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thromboxane synthase, chloroperoxidase and allene oxide synthase, as proteins 
which display similar optical properties to P450-enzymes but are otherwise only 
distantly related.
1.11 The L-Arginine/NO Pathway
NOS catalyses the five-electron oxidation of one of two equivalent guanidino 
nitrogens of the amino acid, L-arginine. This ultimately results in the conversion 
of L-arginine into equimolar amounts of L-citrulline and NO product (Nathan & 
Hibbs Jr., 1991; Steuhr & Griffith, 1992). The exact mechanisms of this reaction 
are not clear, though there are at least two definitive steps involved (see figure 
1.3).
The first step involves the hydroxylation of L-arginine into N^-hydroxy-L- 
arginine. N^-hydroxy-L-arginine represents the enzyme-bound intermediate of 
this reaction (Campos et al., 1995; Stuehr et al., 1991b). This initial step is a two 
electron oxidation, converting 1 mole of the oxidative cofactor NADPH to 
NADP+ and the removal of one oxygen atom from molecular oxygen (i.e 
dioxygen) to form water. The same oxygen atom involved in forming the water 
molecule is subsequently incorporated into one of the guanidino nitrogens of 
L-arginine, transforming L-arginine into N^-hydroxy-L-arginine. This step can 
therefore be described as an NADPH-dependent, monooxygenase hydroxylation 
reaction and the dioxygen can in essence be considered a cosubstrate here. 
(Kwon et al., 1990). The use of N®-hydroxy-L-arginine intermediate by NOS is 
an enantiomer-specific reaction, as N®-hydroxy-D-arginine cannot be substituted 
as an intermediatory substrate (Campos et al., 1995). Interestingly, N^-hyroxy- 
L-arginine is thought to be a potent inhibitor of arginase activity and this may 
prove crucial in regulating NO synthesis (Daghigh et al., 1994; Boucher et al., 
1994). The inhibition of arginase activity would presumably allow more 
L-arginine for making NO rather than being converted to L-ornithine and urea 
(see figure 1.5).
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The second step involves conversion of N®-hydroxy-L-arginine to equimolar 
amounts of L-citrulline and NO. The sequence of reactions is more complicated 
than the first step and involves a three-electron oxidation, with only 0.5 moles of 
NADPH being oxidized to NADP+, insertion of oxygen into the ureido group of 
L-citrulline and finally scission of the carbon-nitrogen bond in N^-hyroxy-L- 
arginine. Homolytic cleavage between the oxidized guanidino nitrogen and 
carbon is thought to result in the release of the previously inserted oxygen atom 
(step one), together with the hydroxylated nitrogen atom. (Feldman & Griffith, 
1993). The nitrogen and oxygen atoms ultimately form the nitric oxide molecule. 
Therefore L-citrulline and NO derive their respective oxygen atoms from two 
distinct molecules of oxygen, so the NOS enzyme requires two molecules of 
molecular oxygen for every catalytic cycle synthesising NO from L-arginine. 
This explains why the synthesis of NO is severely limited under anaerobic 
conditions, (>90%) (Steuhr etal., 1991b).
Only recently have the finer details relating to the L-arginine/NO pathway come 
to light and predictably the intermediatory reactions (steps 1&2) of the pathway 
are becoming more complicated with time. Indeed, another intermediate is 
thought to exist called carbodiimide. This amino acid is hydrated to form 
L-citrulline (Marietta et al., 1988).
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Fig. 1.3 The proposed enzymatic pathway for nitric oxide synthesis from 
L-arginine.
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1.12 Prosthetic Groups
The mechanisms of NO synthase in catalysis are still not fully understood. 
However, over the past ten years, considerable knowledge as been acquired 
regarding the role of the various cofactors which ultimately govern the activity 
of the enzyme.
1.12.1 Flavins
Purified inducible and constitutive isoforms of NOS have been found to contain 
tightly bound FAD and FMN associated with specific recognition sites encoded 
in the reductase domain of NOS (i.e. in the carboxyl half of the NOS molecule) 
(Feldman & Griffith, 1993). Molecular cloning studies reveal that each subunit 
of the enzyme contains 1 molecule of each of the flavin nucleotides (Stuehr & 
Griffith, 1992).
Reductase Oxygenase domain Oxygenase domain
domain
Fig. 1.4 Schematic diagram of the quaternary structure of activated NOS. The 
binding of calmodulin (CaM) to eNOS is thought to align the domains, allowing 
electron transfer from FMN to haem. N.B. CaM is constitutively bound to iNOS.
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By comparing the functions of these flavins in other enzymes which show a 
striking similarity to NOS (eg. cytochrome P-450 reductase) it is postulated that 
FAD has the role of storing up to four electrons derived from NADPH (Bredt et 
al., 1991). From there they are transferred to FMN and subsequently to the 
catalytic heme centre located within the oxygenase domain. Electrons are 
delivered one at a time to the heme centre and the flavins can accept one or two 
electrons from NADPH. The extra NADPH electron is stored from the first
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catalytic cycle and is available for the second cycle (Campos et al., 1995). By 
this process the active NOS enzyme contains a flavin radical (Stuehr & Ikeda- 
Saito, 1992) undergoing repeated redox cycles (3 cycles/mol. of NO): [FAD, 
FMNH-] [FADH-, FMNH2J -> [FAD, FMNH2] -> [FAD, FMNH-]. Binding 
FMN and FAD in a single protein is a unique property of NOS and cytochrome 
P-450 reductase enzymes. This may facilitate the transfer of single electrons 
between the flavin rings, a requirement in NOS and cytochrome P-450 reductase 
radical catalysis.
It is worth noting that the consensus recognition sites for the oxidation cofactors 
are virtually identical in neuronal and macrophage type NOS, and so FAD and 
FMN may serve similar functions in both isoforms.
1.12.2 Tetrahydrobiopterin (BH4)
Each subunit of active NOS contains one molecule of (6R)-5,6,7,8- 
tetrahydrobiopterin (BH4) and sequence studies suggest that the BH4-dependent 
site in NOS, derived from rat brain, is located between the FMN and calmodulin 
binding sites (amino acid residues 750-769; Uvarov & Lyashenko, 1995). This 
differs slightly from inducible NOS in which the BH4 binding site is thought to 
be nearer the heme binding site, between the N-terminus and the calmodulin 
(Cho etal., 1995).
Although the exact function of this cofactor remains unclear, both inducible and 
constitutive NOS have an absolute requirement for BH4 in order to achieve full 
activation (Baek et al., 1993). Intact cells use BH4 to regulate NOS activity and 
therefore the levels of NO being produced (Werner-Felmayer et al., 1993). This 
opens up the possibility of using BH4 inhibitors to regulate NO production. 
Indeed, NO synthesis by the immune activated NOS can be inhibited dose- 
dependently by 2,4, diamino-6-hydroxypyrimidine (DAHP), a selective inhibitor 
of GTP-cyclohydrolase 1, the rate-limiting enzyme for de novo BH4 synthesis
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(Gross & Levi, 1992). The latter study also showed that BH4 was limiting the 
rate of NO synthesis in V.S.M: by adding excess BH4 the rate and onset of NO 
production could be considerably increased. Similarly, cytokine-activated 
murine brain endothelial cells require de novo protein synthesis for BH4 
production and increased NO synthesis (Gross et al., 1991). The same appears to 
be true of constitutive NOS (Werner-Felmayer et al., 1993). Not surprisingly, the 
induction of NO synthesis in these cells was inhibited by the protein synthesis 
inhibitor, cycloheximide. This suggests that guanosine triphosphate (GTP) is the 
main biosynthetic precursor to BH4 involved in basal and inducible NO 
production in both endothelium and V.S.M. (Gross et al., 1994). Cytokines, 
including IFN-y and TNF-a, together with LPS can induce up to a 100 fold 
increase in the levels of GTP-cyclohydrolase 1 (Werner-Felmayer et al., 1993). 
This LPS-induced increase in GTP-cyclohydrolase 1 and BH4 in rat tissues 
correlate directly with increased levels of plasma nitrogen oxides and systemic 
vascular hypotension, indicative of increased NO production.
Cytokine-induced production of NO is suppressed by selective inhibitors of 
sepiapterin reductase, although the constitutive NO production associated with 
endothelial cells remains unaffected (Schoedon et al., 1994). This implies that 
constitutive production of NO by endothelial cells derives much of its BH4 from 
the GTP precursor, while iNOS requires both the pterin-salvage pathway and the 
GTP precursor. This may provide a means of selectively inhibiting the high 
levels of inducible NOS often associated with certain pathophysiologial 
conditions, without compromising constitutive NOS necessary for normal 
physiological function.
Although cytokines can induce BH4 biosynthesis in human vascular endothelial 
cells most (up to 90%) of the BH4 produced by the endothelium is not used 
locally but is directed at the underlying V.S.M. (Schoedon et al., 1993). The 
resultant increase in cytokine-inducible NOS activity and NO release in the
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V.S.M. facilitates vasodilatation. This means that in human studies of inducible 
NO release by V.S.M. the endothelium is required to be intact inorder for full 
iNOS activity in V.S.M. to be expressed. The same may not be true of non­
human endothelial cells, but may reflect an inherent inability of human type 
endothelial cells to express an inducible, high output NOS (Schoedon et al., 
1993). If it is discovered that a similar situation exists in non-human vasculature 
(eg. rodent), then subsequent studies of NO release by V.S.M. would require the 
use of intact vessels.
Much of the work concerning BH4 production has been carried out in animals, 
most commonly the rat or mouse, so it is important to realise that results 
obtained from these studies may not always correlate with those found in human 
studies.
Cultured rat aortic smooth muscle cells exposed to LPS can produce BH4 via de 
novo synthesis of GTP (Gross et al., 1994), although NOS activity is 
superinduced in these cells following inhibition of the GTP converting enzyme, 
GTP cyclohydrolase 1. This apparent contradiction may relate to a balance or 
interplay between two transcriptional processes associated with LPS induced NO 
production. The first involves the induction of NOS and GTP cyclohydrolase 1: 
If BH4 synthesis is prevented by inhibiting the GTP de novo synthetic pathway 
(using DAHP), together with the pterin salvage pathway (using methotrexate), 
then NO synthesis is almost completely inhibited. Neither of these inhibitors 
interferes with the induction of iNOS. This situation results in a pool of newly 
formed iNOS which is unable to produce NO due to the lack of BH4 and can be 
rectified by replacing BH4.
A second process may exist by which GTP regulates NOS activity directly. This 
would conform with both situations. The ability to induce NOS activity in a 
given cell and limit BH4 availability to determine when and how much NO is
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produced will undoubtedly offer scope for clinical application. NO could be 
released as a cytotoxic agent against tumour cells where and when it was needed.
Exactly how BH4 determines NOS activity, and to what extent this is due to a 
limited catalysis or a change in its structural configuration, remains elusive. NOS 
is unique in forming a stable bond with BH4 (Schmidt et al., 1995). In most 
other enzymes which require BH4, like aromatic amino acid hydroxylases (eg. 
phenylalanine hydroxylase, where it serves to provide the 2 electrons necessary 
for oxygen reduction), the prosthetic group is freely diffusible in and out of the 
enzyme, allowing its interaction with any number of enzymes (Giovanelli et al., 
1991). Whether this property of BH4 in NOS bears any relevance to its 
mechanism is still unclear, but a more stable bond between BH4 and NOS may 
allow for a more permanent and definitive change in the shape of NOS. This 
would seem less likely if the BH4 was diffusing freely between other enzymes. 
BH4 may therefore serve to regulate NOS activity by rearranging the enzyme 
from its inactive monomeric state to its dimeric active state (Baek et al., 1993). 
Indeed spectral analysis has revealed a significant shift in peak Soret absorbance 
when comparing BH4-deficient NOS (Xmax = ~418nm) with B ^-saturated 
NOS (Xmax ~ ~400nm) (Hevel & Marietta, 1992). This suggests a structural 
effect that is mediated by BH4. It was subsequently found that the majority of 
pterin-deficient NOS exists in the inactive monomeric state, while NOS with 
added BH4 is shifted to the dimeric state (Hevel & Marietta, 1992). However, 
the process of dimerization cannot be accredited to BH4 alone, since it also 
requires the binding of L-arginine and heme (Baek et al., 1993). Interestingly, 
NOS deficient of BH4 is unable to couple the electrons continuing to be released 
by NADPH (Heinzei et al., 1992). This suggests that electrons cannot flow 
through NOS without BH4,
As previously mentioned, aromatic hydroxylases require BH4 to carry out redox 
reactions. It has recently been suggested that BH4 in NOS may also participate in
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redox reactions (Mayer et al., 1995), this theory is however controversial 
(Giovanelli et al., 1991).
1.12.3 Heme Group
Heme (iron-protoporphyrin IX), like other prosthetic groups, is an integral part of 
the enzyme and perhaps the role most commonly attributed to this cofactor is the 
final electron acceptor during NO synthesis (Abu-Soud & Stuehr, 1993). The 
heme centre receives NADPH-derived electrons from FMN and so completes the 
transfer of electrons from the COO" terminal (reductase domain) to the NH2- 
terminal (oxidase domain). This transfer of electrons results in the reduction of 
heme: Fe3+(ferric) —> Fe2+(ferrous) and is regulated by calmodulin (Abu-Soud 
& Steuhr, 1993). The flavin-to-heme electron transfer also requires NOS to be 
assembled into a dimeric conformation, which for the macrophage derived NOS 
(mac-NOS) may involve two monomeric subunits interacting at their NH2, 
catalytic terminals (Ghosh & Stuehr, 1995). This process requires L-arginine, 
BH4 and heme, with stoichiometric amounts of BH4 and heme remaining bound 
after dimerization in order to bind the subunits together (Baek et al., 1993).
Deficiences in any one of the cofactors necessary for dimerization may lead to 
electron uncoupling (Pou et al., 1992). In such cases, electrons are not 
transported to the heme centre, but may instead be sequestered by electron 
acceptors eg. cytochrome C, ferricyanide or more commonly oxygen (Schmidt et 
al., 1992a). The acceptance of stray electrons by oxygen can result in the 
production of superoxide anions (Saran et al., 1990) which can then react with 
NO to form peroxynitrite.
With sufficient cofactors, the activated heme iron is able to bind and reduce O2 
(at the sixth ligand), facilitating both the oxidation of L-arginine to hydroxylated 
L-arginine (NOH-Arg) and ultimately the conversion of NOH-Arg to citrulline and 
NO (Pufahl & Marietta, 1993, Marietta, 1993). Corroborative evidence for this
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comes from studies using carbon monoxide, which binds the active heme giving 
an absorbance maximum of ~446nm. This is also a feature of reduced CO 
complex formation found in cytochrome P-450 type hemes (Stuehr & Ikeda- 
Saito, 1992). Also, in common with P-450 enzymes, NOS hemes are bound to a 
cysteine (Cys) thiolate and recently the putative binding sites of heme in the 
N-terminal region have been identified with the fifth ligand attaching to Cys 194 
(mouse iNOS), Cys 415 (rat nNOS) and Cys 186 (bovine eNOS) (Renaud et al., 
1993).
The affinity of hemoproteins to bind NO is well established (eg. the high affinity 
associated with the NO-mediated activation of gyanylate cyclase), so the 
possibility that NO may bind to heme and regulate NOS activity is not altogether 
surprising. What is surprising, however, is the lack of rapid self-in-activation 
related to NOS. NO can potentially form unstable nitrosyl complexes with both 
ferric and ferrous NOS hemes in the presence of O2 (Marietta, 1994) and in this 
way inactivate NOS. The presence of the cysteine ligand in NOS may confer 
instability in these complexes, as hemoproteins with ligands other than cysteine 
(eg. haemoglobin, which has a histidine ligand), form stable heme-NO 
complexes under aerobic conditions. Exactly how this works is not known. In 
vitro assays reveal that substrate binding also influences the affinity of NO for 
NOS heme. L-arginine binding in iNOS, although not necessary for nitrosyl 
complex formation, reduces the affinity of NO for the ferric heme but not ferrous 
heme (Hurshman & Marietta, 1995). Similar results have been found for eNOS 
(Wang et al., 1994). This suggests that L-arginine offers a measure of protection 
from NO binding in place of O2, with less protection after the enzyme has been 
activated. Further analysis of the intermediate steps involved in NO synthesis 
will undoubtedly reveal other mechanisms designed to protect NOS activity 
from NO-mediated inactivation.
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1.12.4 Calmodulin
Recognition sites for calmodulin (CaM) are present in neuronal NOS (nNOS) 
(Zhang & Vogel, 1994), endothelial NOS (eNOS) (Lamas et al., 1992), and the 
inducible NOS in actived macrophages (macNOS) (Lyons et al., 1992; Xie et 
al., 1992). However, there are several differences in the consensus binding sites 
and proposed functions of CaM in these isoforms of NOS (Abu-Soud & Stuehr, 
1993).
CaM is a single polypeptide with a molecular weight of 16,700 and is thought to 
be present in all eukaryotic cells so far studied. In mammalian tissues the 
concentration of CaM is thought to vary between 2 and 30pM (Carafoli, 1987). 
CaM has been found in a wide range of phylogenetically diverse species, yet the 
primary structure of CaM is so highly conserved that antibodies from bovine 
brain can cross-react with CaM in cotton seed (Wallace & Cheung, 1979). This 
suggests that CaM is one of the oldest members of the calcium-binding protein 
family. As a Ca2+ receptor, CaM is an integral part of many intra- and 
intercellular mechanisms that exist within any given tissue.
In NOS, CaM serves to regulate NO synthesis and does so through a variety of 
means (Schmidt et al., 1991). The eNOS isoforms in endothelial cells (Busse & 
Miilsch, 1990) and neuronal cells (Bredt & Snyder, 1990), have an absolute 
requirement for Ca2+ and CaM. In contrast, inducible macNOS is apparently not 
regulated by intracellular Ca2+ although it does contain CaM (Cho et al., 1992), 
and is regulated instead at the level of gene transcription (Xie et al., 1992). The 
activity of purified macNOS is therefore neither enhanced by exogenous Ca2+ 
and CaM, nor inhibited by chelators of divalent cations or drugs that block the 
binding of CaM to its targets (Stuehr et al., 1991; Yui etal., 1991a). Constitutive 
NOS is inhibited by such inhibitors (Bredt & Snyder, 1990; Busse & Miilsch, 
1990). Not all inducible forms of NOS conform to this rule; Ca2+-dependent
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(Palmer et al., 1992) and CaM-dependent (Iidas, 1992) isoforms of inducible 
NOS also exist.
Polyacrylamide gel electrophoresis has revealed that all cNOS peptides bind to 
CaM with 1:1 stoichiometry (Zhang & Vogel, 1994). On binding the CaM takes 
on an amphipathic helical conformation, similar to the CaM involved in binding 
to the domains of myosin light chain kinases (Olwin et al., 1984), ensuring an 
adequate interaction with its receptor proteins. The ability of CaM to assume a 
tertiary structure and display high flexibility may relate to the fact that NOS 
associated CaM does not contain cysteine or hydroxyproline (Cheung, 1980). 
Cysteine would restrict these conformational changes. Whether this binding 
pattern also exists for inducible NOS has not been addressed.
Urea gel electrophoresis and fluorescence spectroscopy have been used to 
identify the putative high affinity CaM binding sites associated with the NOS 
enzymes. The CaM binding domain is conserved in cNOS enzymes as a stretch 
of basic and hydrophobic amino acids and for nNOS this sequence exists 
between the 725-754 peptide residues (Vorherr et al., 1993). The eNOS 
consensus binding site is situated between the peptide residues 493-513 
(Lamas et al., 1992). The eNOS consensus binding site is located at a similar 
amino acid sequence number to macNOS; the macNOS consensus binding site is 
at residues 503/4-532 (Lowenstein et al., 1992) however 16 out of the 29 
residues in the eNOS CaM binding site are different to macNOS. This suggests 
that the CaM binding sequences are genetically distinct from one another and 
will most probably display different binding affinities for CaM. The cNOS 
binding site is thought to share the same or similar region on CaM as a CaM- 
dependent phosphodiesterase (Zhang & Vogel, 1994). This is evident by the 
competitive inhibition that exists between these two enzymes.
nNOS does not exist as an enzyme bound to CaM. It is therefore inactive, but 
can be constitutively activated following binding of CaM with transient
55
Chapter 1 - Introduction
increases in intracellular Ca2+ levels. Spectral anaysis indicate that this binding 
is not a prerequisite for L-arginine binding to nNOS (Abu-Soud & Stuehr, 1993). 
In contrast CaM is very tightly bound to macNOS (Stuehr et al., 1991a). 
macNOS is one of the only four enzymes known to date to bind CaM in an 
apparently Ca2+-independent manner (Vorherr et al., 1993) and does not require 
the elevation of [Ca2+] above levels found in resting cells (400-1100 nM) (Olwin 
& Storm, 1985). Indeed, CaM is so tightly bound to macNOS that they copurify 
(Cho et al., 1992), which would explain why inhibitors of CaM are unable to 
detach or interrupt CaM’s interplay with macNOS. Three other enzymes which 
also display this characteristic are the K-subunit of phosphorylase kinase (Picton 
et al., 1980), a cyclic nucleotide phosphodiesterase (Laemmli, 1970) and the 
adenylyl cyclase of Bordetella pertussis (Ladant, 1988).
Cho et al., (1992) were the first to suggest a role for CaM in regulating electron 
transfer and this was confirmed the following year by Abu-Soud & Stuehr, 
(1993). The idea is not altogether a novel one, nor is it unique to NOS. Evidence 
implies that the multimeric heme protein, sulfite reductase, may also use CaM to 
regulate electron transfer. As CaM is constitutively bound to macNOS it is 
continually primed to transfer NADPH-derived electrons onto its heme, 
requiring only the addition of NADPH to enable spontaneous reduction of the 
macNOS ferric-state heme (Abu-Soud & Stuehr, 1993). The addition of L- 
arginine to macNOS significantly increases the NADPH oxidation, however, in 
nNOS L-arginine binding slightly decreases NADPH oxidation. This suggests 
that electron transfer from NADPH in macNOS is dependent on substrate, in 
contrast to that of nNOS. This may enable nNOS to limit the amount of 
superoxide production in the absence of substrate. The substrate-dependent heme 
reduction in macNOS is also seen in cytochrome P450 enzymes (Gonzalez, 
1989).
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When considering the respective interactions of CaM with the different isoforms 
of NOS it is clear that the constitutive nature of CaM in macNOS is suited to 
release high levels of NO over prolonged periods of time, while the Ca2+/CaM 
regulated eNOS is better suited to release short bursts of NO in response to 
humoral signals mediated by Ca2+ transients.
CaM will undoubtedly influence pathways related to NO synthesis. For instance, 
it can stimulate phospholipase A2 activity in human platelets and may also 
regulate both the synthesis and degradation of 3’,5’-cyclic adenosine 
monophosphate (cAMP) in the brain (Cheung, 1980). Agonist-induced increases 
in cAMP can inhibit LPS-induced NO synthesis (Hon et al., 1995). CaM may 
also have an important role in cellular proliferation, as preventing it from 
binding and activating its target enzymes can attenuate the growth of malignant 
cells (Hait et al., 1995).
1.13 L-Arginine and its Analogues
1.13.1 L-Arginine
L-arginine is an essential amino acid involved in a number of pathways relating 
to the metabolism of nitrogen, including the urea cycle and amino acid 
metabolism. L-arginine is required for polyamine biosynthesis, a process 
required for cell replication, and it also regulates a number of hormones in the 
body including insulin (Dupre et al., 1968), pancreatic somatostatin (Utsumi et 
al., 1979), adrenal catecholamines (Imms et al., 1969) and growth hormones 
(Merimee et al., 1965). L-arginine is therefore important for growth and 
development of the body, so requires rapid synthesis and recycling to satisfy 
demand.
In mammals the synthesis of L-arginine occurs predominantly in the liver from 
L-glutamate, although synthesis also occurs in proximal tubules of the kidney 
and is supplemented by an exogenous supply of L-arginine in the diet.
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Fig. 1.5 Schematic diagram of L-arginine metabolism.
The biosynthesis of L-arginine in the liver is catalysed by two cytosolic 
enzymes: argininosuccinate synthetase (AS) and argininosuccinate lyase (AL) 
and due to the high levels of arginase most of the arginine is quickly converted 
to urea and ornithine and so is not released into the circulation (Meijer et al., 
1990) (see figure 1.5 above). The complete urea cycle exists solely in the liver, 
and though the kidney also synthesises L-arginine from AS and AL, its 
incomplete urea cycle allows L-arginine to be released into the circulation for 
use elsewhere (Morris et al., 1994).
AS and AL also function to recycle arginine from citrulline for the sustained 
high level NO production associated with inducible NOS. Immunostimulants can 
induce AS activity and mRNA expression in cultured vascular smooth muscle 
cells, macrophages (Hattori et al., 1994) and vascular endothelial cells (Morris et 
al., 1994). These cells also express iNOS and the timecourse for AS induction is 
similar to that for NOS (Morris et al., 1994), with peak activity occuring around 
24hrs after the initial stimulation. The ability to regenerate L-arginine offers an 
important means for providing adequate substrate during immune-activated high 
NO production. The potential for supressing ‘overproduction’ of NO, in
58
Chapter 1 - Introduction
conditions such as septic/cytokine-induced shock, by regulating AS activity is 
still an avenue to be explored. However, the development of a specific inhibitor 
to inducible AS (iAS) may prove invaluable in discerning the relative 
importance of this specialised arginine-citrulline cycle in disease. NG- 
monomethyl-L-arginine (L-NMMA) does not inhibit the LPS and/or IFN-y- 
mediated expression of iAS in cultured aortic smooth muscle cells (Hattori et al., 
1994), suggesting that depletion of L-arginine is not a prerequisite for iAS 
expression. Indeed, excess L-arginine was found to potentiate iAS activity. It 
appears therefore, that AS joins an ever increasing group of enzymes which 
become active during the immune response.
Cycloheximide potentiates the induction of iNOS mRNA, but attenuates the 
induction of AS mRNA (Hattori et al., 1994) which may result in a pronounced 
substrate deficiency and perhaps invoke an upregulated transport of L-arginine 
into the cells from the surrounding milieux to compensate.
A number of cell types when activated express iAS and AL in vitro and are also 
capable of transporting extracellular L-arginine, including murine macrophages 
(Bogle et al., 1992), vascular endothelial cells and vascular smooth muscle cells 
(Stoclet et al., 1994). The uptake of L-arginine is thought to be facilitated by the 
cationic amino acid transporter, system y+, which is characterised by being a 
single/saturable receptor (km= 0.11-0.14mM; Sato et al., 1992). Cytokines and 
endotoxin also potentiate the uptake of L-NMMA NOS inhibitor into human 
vascular endothelial cells (Bogle et al., 1993). L-arginine competitively inhibits 
this uptake, suggesting that L-NMMA may enter cells via system y+. In contrast 
N03-nitro-L-arginine methyl ester (L-NAME) probably enters via another route 
as its uptake is only slighty inhibited by L-arginine.
Why these cells should require increased uptake of L-arginine together with an 
increased synthesis of L-arginine is not clear. In macrophages, the L-arginine 
may be rapidly converted to urea and ornithine by arginase, thus limiting its use
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for NO production (Chen & Broome, 1980). Whether extracellular L-arginine is 
required to replace recycled L-arginine, or whether the cycled L-arginine is part 
of a closed pathway is not known. Either way, the fact that two systems are 
adapted to provide L-arginine during cytokine or bacterial-induced activation 
highlights its importance and potentially limiting effect on the high output NO 
pathway.
The notion that arginine may influence the progression of cancer is by no means 
new. Since the beginning of this century investigators have looked at the effects 
of altered arginine uptake on the growth of experimental tumours in animals and 
found that arginine could either stimulate (Gilroy, 1930) or inhibit (Beard, 1942) 
growth, depending on experimental protocol. Further studies suggested that 
perhaps the inhibitory effects of arginine were specific to certain types of 
carcinogenically-induced tumour (Weisburger et al., 1969; Takeda et al., 1975). 
With a better understanding of the many physiological roles involving arginine it 
is becoming increasingly apparent that this ‘double-edged sword’ may reflect an 
imbalance in two metabolic pathways in which arginine is an intermediate (ie. 
the urea cycle and the L-arginine/NO pathway). The urea cycle involves the 
enzymatic conversion of arginine to ornithine and urea by arginase, while NOS 
converts L-arginine to L-citrulline and NO. The competition for arginine which 
exists between these pathways is evident by the increased urea synthesis which 
occurs in the presence of NG-monomethyl-L-arginine (NOS inhibitor). High 
levels of NO are known to have cytotoxic/cytostatic effects on tumour cells 
(Hibbs et al., 1987) and will therefore suppress tumour growth, while ornithine 
promotes cellular proliferation, DNA synthesis and tissue regeneration, so will 
favour tumour growth. (Haddox & Russell, 1981). Consequently, it is thought 
that malignant cells require a higher concentration of arginine than normal cells 
to maintain their high cellular turnover (Currie & Basham, 1978).
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Immune-activated macrophages, which are known to express iNOS and arginase 
activity (Albinar et al., 1988), also require high levels of arginine, and are 
thought to be instrumental in modifying tumour growth (Mills et al., 1992). It 
appears a rather unfortunate quirk of nature perhaps, that arginine should be 
required by tumour cells as well as by the macrophages which are designed to 
kill them.
1.13.2 L-Arginine Binding to NOS
On binding to the NH-terminal of NOS, L-arginine facilitates a stiochiometric 
activation of the enzyme by assembling the dimeric structure and allowing 
electrons to flow through the reductase terminal onto the heme group (McMillan 
& Masters, 1993). As with BH4, the binding site for L-arginine within NOS 
remains unidentified, although both appear to be close to the ferric iron of the 
heme group (Wang, 1994) between the NH-terminal and calmodulin. This may 
include residues 194 to 503 in the macrophage associated NOS (Ghosh & 
Stuehr, 1995) although this varies between isoforms. The region thought to 
contain the binding sites for L-arginine, BH4 and heme is, however, highly 
conserved, with 65-71% sequence identity between the three main isoforms of 
NOS (Hurshman & Marietta, 1995).
Similarly, all isoforms of NOS display enantiomer-specific binding of arginine, 
such that L-configuration at the a-carbon is required for substrate activation 
(Moncada, 1989). D-arginine is therefore not a substrate for NOS. Although 
L-arginine is the only ‘true’ physiological substrate for NOS, the enzyme 
displays considerable flexibility to accomodate a number of different L-arginine- 
containing peptides which can substitute for L-arginine. These include 
L-homoarginine, L-arginamide and L-arginyl-L-aspartate (Hibbs et al., 1987). 
With plasma levels ranging from 150 to 200|lM, L-arginine is by far the most 
abundant of these molecules (Stuehr & Griffith, 1992). If L-arginine is deficient,
61
Chapter 1 - Introduction
the biosynthetic intermediate NG-hydroxyl-L-arginine can also act as substrate 
for both iNOS and eNOS (Hecker et al., 1991).
1.13.3 Analogues of L-Arginine. NOS Inhibitors
The discovery in 1988 that NO is synthesized in porcine vascular endothelial 
cells from the terminal guanidino nitrogen atom(s) of L-arginine (Palmer et al., 
1988) led to the idea of using substituted analogues of L-arginine to regulate NO 
production. •
L-ARGININE
NH
AL-NAME COCH3NH NH
H™ ^NH2
L-NA
NO2
AG
NH2+ X’
(X = HC03-, H2SO4- or C1-)
Fig. 1.6 Some analogues of L-arginine.
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The biological actions of NO can be regulated either directly, by interfering with 
the synthesis of NO from the NO-generating cell itself, or indirectly by 
inhibiting the influence of NO on its target cell. Direct inhibition of NO 
synthesis by the generator cell is usually achieved by disabling NOS, while 
indirect inhibition involves binding the NO released to a compound. For 
example haemoglobin (Hb) scavenges NO from the surrounding milieu to form 
nitrosylated-haemoglobin (HbNO) and thus prevents it from interacting with its 
target cell.
Examples of generator-target cell ‘couples’ include endothelium with VSM and 
macrophages with tumour cells. In the first, endothelial-derived NO diffuses into 
the VSM where its molecular target is gyanylate cyclase (GC) and by binding to 
GC, initiates VSM relaxation. In the second, activated macrophages release high 
levels of NO which can enter tumour cells and cause an array of metabolic 
dysfunction eg. inhibition of mitochondrial respiration, cellular iron loss, 
inhibition of DNA synthesis (Hibbs et al., 1988). In cases where the tumour cells 
are unable to synthesise NO, nitrosylation of iron proteins by macrophages 
illustrates a paracrine interaction between the two cell types.
With the increasing number of inhibitors available which display modest 
selectivity towards either the constitutive or inducible isoforms of NOS 
(Marietta, 1994), regulation of NO activity by inhibiting its synthetic enzyme 
promises to be of considerable therapeutic advantage. High output NO derived 
from iNOS is implicated in a number of pathological conditions such as arthritis 
(Stefanovic-Racic et al., 1993; Ialenti et al., 1993), diabetes (Kolb & Kolb- 
Bachofer, 1992) and septic shock (Ochoa et al., 1991). In such conditions 
selective inhibition of iNOS-derived NO, without interfering with basal EDNO, 
would eliminate the compromise which usually results from treatment using 
non-selective inhibitors (Robertson et al., 1994). Isoform-selective inhibition of 
NO is not usually a characteristic of NO scavengers. In a condition such as septic
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shock, the aim would be to administer a drug which rapidly removes the 
potentially cytotoxic, high output NO released by immune-activated cells and 
discharges it equally rapidly from the body with no harmful side effects. 
Recently Johnson Matthey have developed a number of compounds which may 
be suitable in treating septic shock (Fricker et al., 1995; see chapter 6).
Direct inhibition of NO synthesis results from using L-arginine analogues as they 
compete with L-arginine for the same binding site on NOS. N-alkyl derivatives 
were first used as NOS inhibitors by Hibbs et al., (1987). Since then, numerous 
derivatives of L-arginine have been tested which offer varying degrees of 
selectivity, potency and reversibility: two of the most widely used are the methyl 
ester analogue of NG-nitro-L-arginine, NG-nitro-L-arginine methyl ester 
(L-NAME) and NG-monomethyl-L-arginine (L-NMMA). Both dose-dependently 
inhibit endothelial-derived NO (EDNO) in vitro and in vivo, although L-NAME 
takes almost twice as long to to have its effect (Rees et al., 1990). The latter 
study also suggested that L-NAME is ca. lOOx more potent against acetylcholine 
(Ach)-induced EDNO release as compared to L-NMMA in vitro, while a more 
recent study, also carried out in the rat, found that L-NMMA (up to ImM) 
cannot inhibit agonist-stimulated NO production (Frew et al., 1993). The 
situation is further confused by evidence that L-NMMA can inhibit agonist- 
stimulated relaxations in a number of unrelated tissues (Crack & Cocks, 1992; 
Liu etal., 1991). It appears therefore that L-NMMA inhibits basal EDNO release 
independent of the tissue type but only inhibits agonist-induced NO in certain 
types of tissue. The same is also true for L-NAME which displays tissue-specific 
inhibition and tissue-specific reversibility of agonist-stimulated NO in vitro 
(Randall & Griffith, 1991; Martin et al., 1992). This infers mechanistic 
differences in basal and agonist mediated NO release between tissue types and/or 
differences in analogue binding sites between tissues.
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The hypertensive response induced by L-NAME in vivo indicates that it is 
approximately lOx more effective at inhibiting basal NO synthesis in the rat than 
L-NMMA (Rees et al., 1990), although the metabolite of L-NAME, NG-nitro-L- 
arginine, is reported to be ca. 87x more potent than L-NMMA (Aisaka et al., 
1989). At a supramaximal dose (4.8 x IO-5 mol/Kg, i.v.), the effects of 
L-NMMA and L-NAME are comparable; however at this dose L-NAME only 
inhibited Ach-induced depressor response by ca. 50% in vivo (Wang et al., 
1993). Again, this reveals differences between basal and agonist NO inhibition, 
and suggests a difference in L-NAME’s ability to supress Ach-induced 
vasodilation in vitro and in vivo. In vivo, L-NAME and L-NMMA both cause an 
L-arginine-reversible bradycardia (dose; < 300mg/Kg i.v.) (Rees et al., 1990) 
and since NO is involved in C.N.S. neurotransmission (Knowles et al., 1989), 
NO levels may also regulate heartrate. Regional differences in NO-mediated 
neurotransmission may also reflect differences in pressor responses to L-NAME 
and L-NMMA amongst different vascular beds in the rat (Gardiner et al., 1989).
In addition to the constitutive enzyme (eNOS) associated with basal and agonist- 
induced NO release, a calcium/calmodulin independent isoform of nitric oxide 
synthase (iNOS) can be induced following exposure to bacterial endotoxins 
(Rees et al., 1990; see Part D of Introduction). The subsequent expression of 
iNOS in cultured endothelial cells (Radomski et al., 1990) and homogenised 
vascular smooth muscle cells (Knowles et al., 1990) of the systemic vasculature 
results in vasodilatation, hyporesponsiveness to constrictors and, in extreme 
cases, cardiovascular collapse and septic shock. It is perhaps surprising that 
expression of iNOS in systemic vessel walls has so far not been shown 
convincingly using histological techniques. A sustained period of excess NO 
release is implicated in the pathogenesis of septic shock by the fact that NOS 
inhibitors can restore vascular responsiveness in vitro (Schott et al., 1993) and in 
vivo (Thiermermann & Vane, 1990). Results from in vitro studies suggest that L-
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NAME and L-NMMA are equipotent in reversing the endotoxin-induced 
vascular hyporesponsiveness to phenylephrine in rat aorta (Joly, et al., 1994).
The effects of L-NMMA and L-NAME on immunologically-activated NO 
production is discussed in chapter 4.
1.13.4 Non-Specificity of NOS Inhibitors.
Much of our knowledge regarding the physiological and pathophysiological 
roles of NO is based on experimental observations using L-NAME or L-NMMA. 
The term ‘specific’ NOS inhibitor is often used to define them, implying that any 
haemodynamic effects caused by these arginine analogues results from 
inhibition of NO synthesis. Increasing evidence suggests that this may not be the
case.
Homeostasis requires that any alteration in physiological state will be 
compensated by changing some other physiological parameter. This will also 
apply to altered NO production following treatment with NOS inhibitors and 
may partly explain , why the levels of prostaglandin (PG), a potent vasodilator, 
are increased following NO inhibition. (Salvemini et al., 1995). The increased 
levels of PG may in effect compensate for the reduced NO levels. Endogenous 
inhibitors of NOS, like NG, NG-dimethylarginine (DMA), could theoretically be 
regulated in accordance with NO levels in human plasma (Moncada et al., 1991). 
If NO levels increase, DMA could convert from its inactive isomeric form to its 
active form and temporarily inhibit NOS activity. L-NMMA is also present in 
the body, although in smaller quantities (Vallance et al., 1992) and studies 
carried out on isolated rings of vasculature suggest that L-NMMA can be 
metabolized to L-citrulline and ultimately L-arginine (Archer & Hampl, 1992). 
Indeed, cultured bovine aortic endothelial cells deprived of L-arginine express an 
enhanced ability to metabolize L-NMMA to L-arginine (Hecker et al., 1990). It 
is not known whether this also occurs in vivo.
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The structural properties of L-NAME and L-NMMA can also result in various 
non-specific effects, unrelated to the competitive inhibition of L-arginine 
binding. For instance, L-NAME and L-NMMA both contain iron binding groups 
(eg. alcohols, amines and carboxylates) which could interfere with electron 
transfer through iron centres in a number of enzymes directly relevant to NO- 
mediated relaxation (Peterson et al., 1992). Soluble gyanylate cyclase (sGC) and 
NOS both contain iron, so it could be said that the ability for L-NMMA and 
L-NAME to inhibit NO-mediated relaxation may result from inhibited NO 
synthesis and/or the inactivation of sGC.
Similarly the ability for L-arginine derivatives to modulate adrenergic 
neurotransmission may reflect this non-stereospecific interaction with iron 
(Peterson et al., 1992) or equally may be due to the decreased NO levels 
resulting in altered release of noradrenaline (Yamamoto et al., 1993).
Analogues of L-arginine often have altered carboxyl groups which in itself can 
impart distinct nonspecific interactions. Analogues with alkyl or aryl 
esterification of the carboxyl group eg. L-NAME and Na-benzoyl L-arginine 
ethyl ester (BAEE) respectively, are competitive antagonists of muscarinic 
receptors, an effect which is not reversed by added L-arginine (Buxton et al.,
1993). This suggests that antagonism is not related to the inhibition of NOS. 
Analogues with free a-carboxyl groups (eg. NG-nitro-L-arginine) can also bind 
to arginase (Robertson et al., 1993). This may result in elevated extracellular [L- 
arginine], as L-arginine transport into cells may be inhibited (Westergaard et al., 
1993), NOS activity is inhibited and arginase activity is inhibited.
As more structural analogues of L-arginine are introduced into experiments, so 
there will be a growing number of nonspecific anomalies associated with them. 
It is important to be aware of these when interpreting and evaluating NOS 
inhibitors in vitro and in vivo.
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IN VITRO IN VIVO SPECIFICITY OTHER Effects
Table 1.2 Analogue inhibitors of
 NO
S: com
parative effects in rats.
L-NMMA Reversibly inhibits basal EDNO release, maximally 
effective at >50^M, 15minutes incubation. Does not 
inhibit agonist-stimulated EDNO release from the rat 
aorta (300^M) but does in the rabbit aortafby 64%). This 
effect is reversible with a 5 fold [L-arginine). Is a potent 
reversible inhibitor of LPS-induced NO production. 
Uptake in human V.E.C’s is potentiated by LPS.
At3mg/Kg i.v. produces a small (13+/-5mmHg), transient 
(<20 mins.) increase in MA.P. At 300mg/Kg the increase 
in M.A.P. is maximal (45.6+/~4.4mmHg) with rapid 
onset, <5 mins, and returns to control levels within lhr. 
At >100mg/kg inhibits the hypotensive response to Ach 
and Bradykinin. Moderate dose of 30mgZKg is most 
effective against endotoxin-induced hypotension. Also 
decreases heart rate (~25 b.p.m.). Equimolar [L-arginine] 
required to reverse effects.
L-NMMA metabolized to L- 
citrulline by E.Cs may 
enhance NO production (rat 
aorta).
Maximal inhibition of 
NANC relaxation is 
50%. Has ability to 
modify electron 
transfer through iron 
centres which may 
extent its inhibitory 
effects beyond NOS.
L-NAME Is 2-3x more potent at inhibiting basal and >100x more 
potent at inhibiting Ach-induced EDNO release compared 
to L-NMMA. Ach relaxations in the rat aorta are 
completely abolished by 10^M L-NAME, an effect which 
is reversible with 300^M. Is less potent than L-NMMA at 
inhibiting LPS-induced NO release at low concentrations 
but equipotent at >50/zM. Is an irreversible inhibitor of 
bNOS.
lOx more potent than L-NMMA at increasing blood 
pressure but response slower to plateau (~10 mins) and 
longer (>2hrs). A bolus injection lOmg/Kg (i.v.) 
increased b.p. by 43.4%, decreased heart rate and cardiac 
output by 28% and 39% respectively (all within 10 
mins.). >1000mg/Kg causes partial inhibition of Ach- 
induced responses (by ~53+/-4%). Partially reverses the 
hypotension in LPS -treated rats. A 10 fold dose of L- 
arginine is required to fully reverse effects.
L-NAME is thought to be 
metabolised to L-NARG (~10 
mins, in vivo, 30mins.w 
vitro). Differential effects on 
regional vascular
conductances reflects varying 
degrees of neural
intervention, or different 
interactions between L- 
NAME and the NO pathway.
Has the ability to 
modify electron 
transfer through iron 
centres. Is a
muscarinic receptor 
antagonist
L-NARG A reversible inhibitor of basal and agonist (Ach)- 
stimulated EDNO release (approx. 5 and 30x more potent 
than L-NMMA respectively). Reversibily inhibits bNOS 
(>5x more potent than L-NMMA). Equipotent with L- 
NMMA and AG at inhibiting LPS-induced NO 
production in rat aorta. Maximally effective at >10//M, 15 
mins, incubation and requires a 10 fold [L-arginine) to 
ensure full reversal within lhr. D-NARG also inhibits 
Ach-induced relaxations in aortic rings.
Approx. 87x more potent than L-NMMA (i.v.). Maximal 
change in M.AJP. within 6-8 mins. Sustained elevations in 
M.A.P. at a 0.6mg/Kg (i.v.) and at 2mg/Kg significantly 
inhibits Ach-induced vasodilations. No significant effect 
on heart rate (<21.9mg/Kg i.v.). A 3-4 fold dose of L- 
arginine is required to reverse effects; (6.5mg/Kg (i.v.) L- 
NARG: +40-45mmHg MAP.).
One of the most potent 
inhibitors of EDNO 
production. Due to its relative 
insolubility in water is less 
frequently used than other 
analogues.
Decreases N.A. 
outflow in rat isolated 
perfused mesenteric 
vasculature. 30x more 
potent than L-NMMA 
at inhibiting NANC 
transmission. Inhibits 
rat liver arginase 
(Ic50= 27+/-4 mM).
AG Approx. 15x less potent than L-NMMA on bNOS and 
does not inhibit basal or agonist-induced EDNO release. 
Is a potent reversible inhibitor of LPS-induced NO 
production. AG is maximally effective at >100/zM, lhr 
incubation and requires equimolar [L-arginine) for full 
reversal within lhr.
40x less potent at increasing MA.P. than L-NMMA in 
anaesthetized rat. Effective doseage,100-300mg/Kg/day 
(orally), >300mg/Kg/day may lead to behavioural side 
effects.
Is approx. 10-100x more 
potent as an inhibitor of 
iNOS activity compared to 
eNOS activity.
Inhibits histamine 
catabolism. Affects 
polyamine
degradation. Inhibits 
oxidative modification 
of LDL proteins. 
Inhibits RNR and 
nonenzymatic 
glycosylation.
Abbreviations : LNMMA = L-NG-monomethylarginine L-NAME= L-NG-nitro-arginine methyl ester L-NARG= L-NG-nitro-arginine AG= Aminoguanidine
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Part C
NO and the Growth and Maintenance of 
Solid Tumours.
1.14 Introduction
Mortality caused by the four most common solid tumours found in humans, (ie. 
lung, colorectal, breast and prostate) has not significantly decreased in recent 
years (Boring et al., 1992). The reason for this disappointing statistic is due to 
the relative insensitivity of these tumours to many of the therapeutic strategies 
presently used, including radiation therapy, chemotherapy, hormone therapy and 
certain immune therapies (Jain, 1994; Denekamp, 1993). This section of the 
introducion deals with newly-acquired knowledge concerning the role of NO in 
regulating tumour growth.
1.14.1 The Solid Tumour Solid tumours are composed of two distinct but 
interdependent compartments: maligant cells and the stromal matrix that they 
induce and in which they are dispersed (Dvorak, 1994). It is now clear that much 
of the inefficiency of current treatments is due to the inability of systemically 
administered drugs, or in the case of immune therapy, cytotoxic antibodies and 
circulating cytotoxic inflammatory cells, to penetrate the stroma and reach the 
tumour cells in sufficient quantities to be effective (Jain, 1994). The stroma 
commonly consists of laminin, a dense lattice of collagens and interstitial 
connective tissue containing a fibrin-fibronectin gel, new blood vessels and cells 
derived from tissue (eg. fibroblasts and mast cells) and blood (eg. monocyte- 
derived macrophages, platelets and lymphocytes). Therefore, although stroma 
represents the ‘lifeline’ to solid tumours, providing a vascular supply carrying 
nutrients, allowing gas exchange and waste disposal, it also forms an effective 
barrier between the tumour cells and the surrounding host tissue.
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1.14.2 Angiogenesis Tumour vascularization involves two types of vessels: 
those recruited from normal host tissue and newly formed vessels 
(neovasculature). The term ‘angiogenesis’ was first used by Hertig (1935) to 
describe the development of new blood vessels in the placenta. However, the 
mechanisms of angiogenesis have been described most extensively in studies 
involving solid tumours. Tumour angiogenesis refers to the directional sprouting 
of new vessels toward a solid tumour (Baillie et al., 1995) and an increasing 
number of factors which stimulate or inhibit this process have been identified 
both in vitro and in vivo (Klagsbrun & D’Amore, 1991; Folkman, 1985). By 
targetting these factors it is hoped to render the prevascular solid tumour 
dormant, both in terms of growth and metastases. The potential for this so called 
‘anti-angiogenic strategy’ was highlighted by the discovery that solid tumours 
are dependent on angiogenesis to grow beyond a diameter of ~2-3mm (Folkman, 
1972). However, the ability to arrest tumour growth, by interfering with the 
angiogenic processes, is complicated by the multitude of factors released within 
a single tumour. Inhibition of a single factor is unlikely to be effective and only 
through a better understanding of the synergism that may or may not exist 
amongst them, will the key ones be identified and targetted.
1.14.3 Metastasis The formation of secondary tumours at anatomical sites 
away from the primary tumour requires that tumour cells successfully negotiate a 
number of barriers, including extracellular matrix, intravasation and 
dissemination through the bloodstream or lymphatic channels and finally 
extravasation through the vessels and surrounding interstitial connective tissue. 
This process is referred to as metastasis and underpins the deadly nature of 
cancer. A tumour cell undergoing metastasis can release degradative enzymes to 
aid its passage through extracellular matrix (Tryggvason et al., 1987). 
Furthermore, tumour-activated host cells are also thought to release similar 
enzymes (Gabbert, 1985). Specific adhesion molecules have been identified 
mediating the adherence of tumour cells to the vascular endothelium (Alby &
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Auerbach, 1984) and underlying basement membrane (Haberern & Kapchik, 
1985). These can also be induced by immune-activated cytokines (Rice et al., 
1988). It appeal’s, therefore, that the immune system may in some cases promote 
metastasis rather than inhibit it.
1.14.4 Tumour Vasculature In practice, the ability to identify and treat solid 
tumours before they establish their blood supply (2-3mm diameter) is not always 
possible and they often remain undiagnosed until such time as they have 
undergone metastases. This fact led to research into ‘vascular targeting’ as a 
potential therapy with the premise that destruction, occlusion or altered blood 
flow of vessels would result in the death of tens of thousands of tumour cells that 
were totally dependent on them (Denekamp, 1982, 1984, 1986). So, in contrast 
to anti-angiogenesis, which aims to induce tumour stasis, vascular targeting aims 
to provide partial or complete regression of the solid tumour (Denekamp, 1993). 
The rationale for targeting tumour vasculature has been further strengthened by 
the discovery that they possess distinct anatomical, physiological and 
immunological characteristics that distinguish them from normal vessels of the 
host (Baillie et al., 1995; Buttery et al., 1993; Chaplin, 1991; Kennovin et al.,
1994).
The hallmarks of tumour neovasculture include their chaotic, tortuous nature, 
often twisting into corkscrew-like coils (Peterson, 1991), their sustained 
hyperpermeability to plasma proteins and their propensity to collapse as the 
interstitial pressure increases within the growing tumour (Jain, 1994). These 
characteristics are due to the frail architecture of the vasculature which consists 
of only a single, often incomplete, endothelial lining (Peterson, 1991) with 
tumour cells sporadically integrated between them (Konerding et al., 1989). 
They lack adrenergic innervation and contractile elements associated with the 
VSM (Peterson, 1991). These features are usually retained in normal vessels 
incorporated into the tumour (Peterson, 1991). The incomplete structure inherent
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to tumour neovasculature has been exploited recently with the introduction of 
specific antibodies which target the exposed subendothelial matrix (Epstein et 
al., 1995). Studies have shown that by conjugating these antibodies to vasoactive 
agents (ie. IL-2, TNF and IL-IB), a more specific and efficient uptake of tumour- 
specific radiolabeled antibodies can be afforded. It is hoped that the same 
principal may also extend to the delivery of cytotoxic reagents in highly 
vascularised tumours.
A vascular permeability factor (VPF) has been isolated from tumourigenic cells 
(Senger et al., 1990) and may be responsible for the hyperpermeability of 
tumour vessels (Dvorak et al., 1991). Furthermore hypoxia, due to central 
vascular collapse, induces VPF which can promote angiogenesis (Schwelki et 
al., 1992) and antibodies directed against VPF have been shown to significantly 
reduce tumour growth (Kondo et al., 1993). VPF gene expression in response to 
hypoxia is thought to be regulated by NO (Tuder et al., 1995) yet the vascular 
hyperpermeability in solid tumours is inhibited by NOS inhibitors and NO­
scavengers (Maeda et al., 1994). This evidence suggests that while both NO and 
VPF enhance vascular permeability, NO may act to counter the angiogenic 
stimulus of VPF. The continued expression of VPF may be crucial when 
defining the difference between the processes underlying tumour growth and 
wound healing. Vascular' permeability in wound healing is transient; after about 
a week any remaining blood vessels are reabsorbed and a scar is formed. In 
contrast, the persistant hyperpermeability associated with tumour vessels allows 
new provisional stroma to be laid down at the periphery. It is for this reason that 
solid tumours are often referred to as ‘wounds that don’t heal’ (Dvorak, 1994).
1.14.5 Tumour Blood Flow Recent approaches to tumour therapy are based on 
the concept that tumours can be starved of nutrients and oxygen, which are 
necessary for growth, by restricting their blood flow (Denekamp et al., 1983). A 
novel pharmacological approach has potential value only if a difference exists
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between the responses to vasoactive drugs by normal vessels and by tumour- 
supplying vessels. This difference has been established using a number of 
vasoactive agents (Hirst & Wood, 1989).
Fully-differentiated tumour vessels, which possess VSM, constrict with 
systemically administered vascontractile agents (eg. phenylephrine), but are 
unresponsive to vasodilatory drugs (eg. hydrazaline; Chan et al., 1984; Mattisson 
& Peterson, 1981), while poorly-differentiated vessels, which lack VSM, are 
relatively unreactive to drugs which act on smooth muscle, and so tumour blood 
flow varies in concert with local blood flow. LPS-induced systemic hypotension 
in a tumour-bearing animal would therefore be expected to reduce blood flow 
through a tumour. This phenomenon where blood is diverted from the tumour to 
normal tissue is often referred to as the steal effect. The diminished response to 
vasodilatory drugs prompted the idea that tumour vessels reside in a state of near 
maximal dilatation, although the factor mediating this effect has yet to be 
identified.
More recently, a study by Stiicker et al., (1991) found that host-derived 
arterioles, feeding into a chemically-induced (Meth-A) tumour in mice, were 
significantly more sensitive to i.v. injections of serotonin when compared to 
control arterioles not associated with the tumour. Furthermore, the feeding 
arterioles were also of a larger diameter than the controls, although the 
vasocontractile effect of serotonin was sufficient to reduce tumour growth and 
prolong survival in these animals. The effects of these agents are transitory and 
may prove to be more effective when used in combination with other more 
conventional therapies. Vasodilators could improve the delivery of drugs for 
chemotherapy or increase oxygen supply to radioresistant, hypoxic cells, or in 
some instances, actually increase the hypoxic cell fraction due the steal effect, 
which can then be targeted using bioreductive agents (Brown, 1991).
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More ‘long-term’ effects on tumour blood flow are possible using other agents 
including, flavone acetic acid (FAA) and TNF, although as with other therapies 
which mediate their effects by induction of ischaemia (eg. photodynamic 
therapy; PDT), their mechanism of action remains unclear. Recently, however, 
NO has been implicated as a mediator in PDT (Gilissen et al., 1993) and FAA 
therapy (Li et al., 1991; Thomsen et al., 1990). Indeed the haemorrhagic necrosis 
produced in subcutaneous tumours by FAA is similar to that produced by 
endotoxin, which is known to induce NO production (Parr et al., 1973).
For a number of years now, the pulsatile pressure of arterioles within tumours 
and feeding vessels located in the surrounding host tissue has been documented 
(Peters et al., 1980; Intaglietta et al., 1977; Kennovin et al., 1994), but again, the 
mechanisms underlying this are not altogether clear. Fluctuations in pressure are 
thought to reflect spontaneous vasomotion within these vessels, resulting in 
intermittent blood flow through them. Large subcutaneous tumours are more 
prone to intermittent blood flow than small tumours (Chaplin et al., 1987) which 
may indicate that increased interstitial pressures can potentiate intermittency as 
vessels that constrict become crushed by the surrounding tumour cells (Jain, 
1994). Interestingly, the radiosensitizer, nicotinamide, has been shown to reduce 
pulsatile pressure in host-derived tumour vessels (Hirst et al., 1995) which may 
indicate that its ability to re-oxygenate hypoxic cells reflects an improved blood 
flow through these vessels.
1.14.6 The Role of NO in Solid Tumour Growth Human and animal cancer 
cells grown in culture are capable of expressing NOS genes at the mRNA level 
(Amber et al., 1988; Radomski et al., 1991) and of generating NO (Jenkins et 
al., 1994). Furthermore, in situ studies indicate a correlation between the levels 
of NOS protein within tumour cells and the grade of malignancy of the tumour 
(Thomsen et al., 1994; Cobbs et al., 1995). Tumour-infiltrating macrophages can 
also be activated to release high levels of NO, as well as IL-1 and TNF (Brunda
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et al., 1991), although Thomsen et al. (1994) determined that they did not 
provide a significant contribution to tumour NOS activity in human 
gynecological tumours.
The production of NO within tumour vasculature and its role in tumour biology 
remains ill-defined, however, increasing evidence indicates that the 
neovasculature and incorporated host vessels of some tumours express iNOS 
activity (Buttery et al., 1993; Kennovin et al., 1994). Specific inhibitors of NOS 
have been widely used to assess the consequence of a sustained, high level NO 
release within these vessels which has led to the conclusion that it is involved at 
all stages of tumour growth; by regulating angiogenesis (Pipili-Synetos et al., 
1993, 1994), and the subsequent blood flow through these newly formed blood 
vessels (Andrade et al., 1992; Tozer et al., 1995) and also in the processes 
associated with metastasis (Dong et al., 1994).
Ultimately, a growing number of NOS inhibitors have been shown to suppress 
tumour growth (Thomas et al., 1986; Freemantle et al., 1994; Kennovin et al.,
1994) although, the multiple roles of NO, ie. as a vasodilator, an inhibitor of 
platelet adhesion and aggregation (Hogan et al., 1988), a cytotoxic agent or as an 
inducer of apoptosis in tumour cells (Jonathan et al., 1994), has made it difficult 
for such studies to clearly identify which inhibited effect(s) of NO is responsible 
for reduced growth. Clearly any one of these effects could be instrumental in 
determining the growth of a tumour; enhanced platelet aggregation associated 
with NO inhibition could promote microthrombus formation in tumour feeding 
vessels and so contribute to tumour vascular stasis. A reduced vasodilation of 
these vessels may also increase the likelihood of vascular stasis as they constrict 
and obstruct blood flow. Regardless of the mechanism involved, the main effect 
of NOS inhibitors is a reduced blood flow (Andrade et al., 1992; Tozer et al.,
1995) . Using sponge implants in mice, Andrade et al. found that L-NAME was 
~2 fold more potent than L-NMMA at reducing blood flow and that this effect
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was not seen until after day 7 post-implantation. This suggests that NOS is not 
active by day 7. This was confirmed in a more recent study using sponge 
implants in mice (Buttery et al., 1993). Visual analysis of altered blood flow in 
tumour-associated vasculature has been carried out using tumours (R3230Ac 
mammary carcinomas) implanted into subcutaneous window chambers (Meyer 
et al., 1995). The diameter of post capillary venules and red blood cell flux were 
measured using video microscopy and the effects of L-NMMA (50pM) and L- 
arginine (200p,M) determined. L-NMMA decreased tumour blood flow by 43% 
and by 17% in normal vessels close to the tumour. Control (non-tumour) vessels 
displayed an 83% decrease in blood flow which was subsequently restored by 
L-arginine. Interestingly, L-arginine had little effect in tumour containing 
chambers, suggesting that a reduction of tumour NO, combined with normal 
tissue rescue with L-arginine, may provide a means for selective tumour therapy. 
The ability of L-NMMA to reduce blood flow in tumour vessels correlated with 
an increase in the number of vessels showing intermittent flow, which suggests 
that L-NMMA potentiates spontaneous pulsatile pressure by inhibiting NO 
synthesis. This study also highlighted the fact that normal vessels in the vicinity 
of a tumour respond to NO inhibition in a similar manner as tumour vessels. This 
implies that a growing tumour continually releases factors into the surrounding 
milieu which can alter the physiological characteristrics of nearby host vessels. 
The extent of this ‘sphere of influence’ is not known.
The consequences of NO inhibition have also been studied using magnetic 
resonance spectroscopy which allows the ratios of high to low energy phosphates 
within the growing tumour to be assessed in response to the altered nutrient 
availability which results (Wood et al., 1993). When administered to tumour and 
normal tissue, nitro-L-arginine (lOmg/Kg; i.v.) caused a tumour selective 2-4 
fold increase in the ratio of inorganic phosphate to total phosphate, implying that 
the tumour was being starved of essential metabolic substrates eg. oxygen. From 
this study and those mentioned above it is clear that NOS inhibitors promote
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hypoxia in solid tumours. It follows that NOS inhibitors may prove beneficial 
when applied in combination with bioreductive alkylating agents, eg. mitomycin 
C, which target oxygen-deficient cells (Sartorelli, 1988). Considerable research 
now focuses on this area of tumour therapy.
Recently, the increase in NO concentration within peritoneal carcinomas, 
induced in syngeneic BD 9 rats, has been shown to parallel tumour growth 
(Lejeune et al., 1994). This study also found that NO production was effective at 
supressing the proliferation of tumour-infiltrating T-lymphocytes, an effect 
which was reversible with L-NMMA. It could be suggested from this evidence 
that NO may potentiate the growth of certain solid tumours by supressing the 
host’s immune response, which counteracts the cytotoxic function normally 
associated with high level NO release (Stuehr et al., 1989). The 
immunosuppressive effect of NO is further implicated by the work of Orucevic 
& Lala (1995), who showed that NO interferes with lymphocyte-activated killer 
cell activation in vivo, an effect which could be abolished by L-NAME. This 
study also showed that although the high output NO induced by IL-2 is inhibited 
by L-NAME, the anti-tumour effect of IL-2 in vivo is potentiated. This suggests 
that NOS inhibitors may be effective when used in combination with certain 
immunostimulants, for instance LPS. LPS is known to induce the expression and 
synthesis of a great many factors which will undoubtedly influence tumour 
growth (including TNF, IL-16 and IFN-gamma) and because the effect of LPS 
on vascular resistance in tumours is not inhibited by specific scavengers of NO 
(Tozer et al., 1995), it appears that NO itself is not responsible. It is conceivable 
that bioadducts of NO (ie nitrosothiols) are involved, although this view is still 
controversial (Feelisch et al., 1994). The potential for combined therapy of LPS 
+ selective iNOS inhibitors is particularly relevant in view of recent clinical 
trials which show that the efficacy of LPS against cancer is limited by its toxic 
side effect, most noteably the sustained hypotension associated with high NO 
production (Engelhardt et a/., 1991).
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It has yet to be determined if the presence of NO within tumour vasculature 
represents a homeostatic response by the tumour to an inadequate supply of 
nutrients, in an attempt to increase blood flow through the few unoccluded 
vessels which remain, or whether it is simply due to the large number of 
immune-activated host cells releasing high levels of NO inside the tumour. Until 
this ambiguity is resolved, the true function of NO in tumours, whether it is 
induced by the tumour to assist in its growth or as part of the immune response 
to attack it, will remain undefined and the intervention of therapies which 
modify NO levels may not attain their full potential.
The opposing effects of NO on the immune system, and hence tumour growth, is 
determined largely by the amount of NO indigenously present (Jenkins et al., 
1995), with higher concentrations of NO providing anti-tumour activity and 
lower concentrations promoting tumour growth. Hopefully, a better 
understanding of the host’s immune response to solid tumours will make it 
possible to manipulate factors, including NO, within tumours to be released at 
the right concentration, in the right place and at the right time, and by applying 
this strategy in combination with therapies which already exist, ultimately 
achieve complete regression of the tumour.
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Part D
1.15 Endotoxic Shock
Septic shock is a life-threatening condition manifested by cardiovascular 
collapse and is estimated to affect up to a quarter of a million people in the 
U.S.A. every year (Kilbourn et al., 1990b). It is defined as a bacterial infection 
resulting in a potentially fatal condition. The syndrome is associated with 
haemodynamic dysfunction, most noteably a sustained drop (> 40mmHg) in 
systolic blood pressure (Glauser et al., 1991). It is only since the 1950’s that the 
condition has progressed from obscurity, behind a number of other better known 
conditions such as typhoid fever, also caused by gram-negative pathogens, to 
become one of the most studied and money-invested areas in medical research 
today. Unfortunately, the treatment of septic shock in humans is not straight 
forward as it is commonly contracted during surgery when bacteria are able to 
enter the body unimpeded by the ususal barriers. Therefore septic shock is often 
the cause of death in patients being treated for conditions which may not at first 
be considered life-threatening.
The clinical hallmarks of septic shock are peripheral arteriolar vasodilation, 
resulting in low systemic vascular resistance, high cardiac output, hypotension 
and inadequate tissue perfusion. The mechanisms underlying these symptoms 
are not fully understood, although many of the pathophysiological reactions 
occuring in septic shock patients can be mimicked and studied in laboratory 
animals by infusion of live bacteria or endotoxin (Suffredini et al., 1989; 
Kilbourn & Billiar, 1996). Endotoxin is the lipopolysaccharide (LPS) component 
of the bacterial cell walls and is the prime initiator of gram-negative bacterial 
septic shock (Glauser et al., 1991). From studies such as these the role of some 
potential mediators of endotoxic shock is gradually emerging and animals pre­
treated with anti-tumour necrosis factor antibodies (Kilbourn et al., 1990a),
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platelet activating factor receptor antagonists (Doebber et al., 1985) and 
prostacyclin inhibitors (Halushka et al., 1983) are significantly protected against 
septic shock. However, the relative importance of these mediators in the 
pathophysiology of septic shock remains unclear.
Increasing evidence from more recent studies suggests that NO is at least 
partially responsible for the sepsis syndrome (Stoclet et al., 1993). Indeed, the 
afore-mentioned factors and others, including the monocyte/macrophage-derived 
cytokines, interleukin 1 and 2 (IL -1, IL-2) are now thought to be involved in 
regulating NO production (Thiermermann et al., 1993; Szabd et al., 1993; 
Salvemini etal., 1995;Beasley, 1990;Kilboum etal., 1994).
As outlined in section 1.13.3, NO is synthesised from the substrate L-arginine by 
a group of isoenzymes, NOSs, which are specifically inhibited by L-arginine 
analogues such as Nw-nitro-L-arginine methyl ester (L-NAME) and NG- 
monomethyl-L-arginine (L-NMMA). LPS is known to induce a calcium- 
independent NOS (iNOS) resulting in overproduction of NO as part of the host- 
defense mechanism (see chapter 3). Unfortunately, high levels of NO not only 
have a cytotoxic effect on bacteria and tumour cells but can also be cytotoxic to 
host cells as well and this is thought to be responsible for the severe hypotension 
associated with endotoxic shock. This is certainly the case in animal models, as 
initially indicated from studies showing that the diminished pressor response to 
catecholamines in aortas from endotoxin-treated rats could be reversed by 
L-NMMA (Julou-Schaeffer et al., 1990) or L-NAME (Schott et al., 1993). These 
findings were further confirmed by similar studies carried out in vivo (Gray et 
al., 1991; Thiermermann & Vane, 1990).
With the purpose of investigating the clinical potential for targeting NO in 
humans, recent research has focused on using L-NMMA or L-NAME to treat the 
condition. Results have been mixed, with L-NMMA able to reverse the 
hypotension in septic shock both in animal models (Kilboum et al., 1990b) and
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humans (Petros et al., 1994; Lin et al., 1994), but only at the expense of other 
haemodynamic parameters which are altered and may ultimately be just as 
harmful. In a canine model of endotoxic shock, for instance, L-NMMA causes a 
large decrease in cardiac output for up to 2hrs after administration (Klabunde & 
Ritger, 1991). This will obviously impair regional blood flow and is therefore of 
limited clinical worth. Similar detrimental effects accompany L-NAME 
administration, most noteably pulmonary hypertension (Robertson et al., 1994) 
and in one study, using female Swiss-webster mice, L-NAME was found to 
increase fatality by 87.5% (Minnard et al., 1994).
The factors governing whether L-NMMA and L-NAME have a beneficial or 
adverse effect on blood pressure may include the dose and method of 
administration and/or the resulting increase in tumour necrosis factor (TNF) and 
interleukin-6 (IL-6) (Nava et al., 1991; Tiao et al., 1994). Nava et al (1991) 
using anaesthetised rats found that a high dose of L-NMMA (300mg/Kg, i.v.) 
potentiated the LPS-induced hypotension while an intermediate dose of 
30mg/Kg, i.v. was sufficient to prevent it, resulting in a 100% survival. Tiao et 
al (1994) concluded from their rat studies that NO inhibition was detrimental 
due to the loss of NO-mediated suppression of TNF and IL-6 levels. Hepatotoxic 
levels of IL-6 following treatment with a NOS inhibitor have previously been 
observed (Frederick et al., 1993). The idea that NO does not mediate the toxic 
effects of TNF contradicts several studies which suggest that it does (Estrada et 
al., 1992; Drapier et al., 1988). Cytotoxic levels of superoxide anion following 
NO inhibition may also be involved.
Detrimental effects most likely arise because these inhibitors do not discriminate 
between cNOS and the inducible isoform. By inhibiting cNOS, a basal release of 
NO is prevented and numerous physiological functions will be affected, 
including vasomodulatory activity in the lungs. Increasing evidence suggests that 
non-specific inhibition may not explain the increased mortality as cNOS activity
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is down-regulated in aortic rings isolated from guinea pigs (Parker & Adams, 
1993), but whether this also occurs in vivo remains to be elucidated. It was 
recently shown using a porcine model of endotoxic shock that some of the 
detrimental haemodynamic effects caused by L-NMMA can be prevented by 
combined inhalation of NO (Klemm et al., 1995).
A specific inhibitor to iNOS may prove to be more valuable as therapy for septic 
shock and recent studies using a compound called aminoguanidine (AG) in the 
rat have shown partial reversal of LPS-induced vascular hyporeactivity in vitro 
(Joly et al., 1994) and ex vivo (Wu et al., 1995b), with improved survival 
following LPS treatment (lOmg/Kg, i.v.) in vivo ( Wu et al., 1995b). Although 
AG inhibits iNOS more potently than eNOS (Misko et al., 1993), it also inhibits 
copper-containing diamine oxidases, which may ultimately affect vascular tone 
(Bieganski et al., 1983). Several other compounds are thought to inhibit iNOS 
although, the majority of these are not selective and their mechanism of 
inhibition has yet to be clearly defined (see Fig. 1.7).
Other methods of manipulating NO production and/or levels may include agents 
which inhibit essential cofactors like BH4 or L-arginine transport (see Part A, 
section 1.12.2).
A different approach to the same problem is being exploited by chemists and 
biochemists using compounds which selectively and irreversibly bind NO, so 
removing the influence of excess NO, without compromising the activity of 
eNOS. A team from Johnson Matthey Technology Centre in Reading, England 
have synthesised a number of ruthenium-based NO binding compounds. The 
leading compound to date is called JM1226, a polyaminocarboxylate complex. 
JM1226 (lOOmg.Kg, i.p.) has been shown to fully reverse the LPS-induced 
(4mg/Kg, i.p.) hypotension (-30% decrease in mean arterial blood pressure) in 
unanaesthetised Wistar rats over a period of 4-19hrs (Flicker et al., 1995).
82
Chapter I - Introduction
Scavengers of NO will also have the added advantage of removing NO produced 
non-enzymatically although, it is unclear whether or not this mode of NO 
production is increased during septic shock.
Sepsis and endotoxaemia are associated with increased production of NO as 
evident by the elevated circulating levels of nitrite and nitrate. Nitrite and nitrate 
are the stable end products of NO’s oxidation by haemoglobin (See section 
1.3.4). In vivo this conversion usually occurs fairly rapidly (3-5 seconds) which 
suggests that NO is not wholly responsible for the sustained haemodynamic 
alterations associated with sepsis. The role of iNOS-derived NO in LPS- 
mediated mortality has been studied using mice which lack the gene for iNOS 
(Wei et al., 1995; Laubach et al., 1995). It appears that resistance to LPS- 
induced mortality is dependent on the type of LPS used, with those derived from 
E. coli causing death independently of iNOS.
1.15.1 LPS LPS from the cell wall of gram -ve bacteria consists of a 
polysaccharide and lipid domain (Hitchcock et al., 1986). From the lipid layer in 
the cell wall the polysaccharide domain projects out into the extracellular 
environment and is thought to be responsible for the differences in serotype 
amongst gram -ve bacteria. Exposure to LPS results in a wide spectrum of 
physiological effects associated with the immune response, not least of all septic 
shock. LPS injectioned intraperitoneally into a rat is cleared from the circulation 
via the portal vein into the liver. Clearance is usually complete within 72hrs 
(Freudenberg et al., 1984), which is in accordance with the time course of nitrite 
and nitrate accumulation, which generally returns to control levels 72hrs after 
LPS exposure (this study; Tracey et al., 1995).
Macrophages are an important component of the immune system and have a role 
in receptor-mediated LPS detoxification (Hampton et al., 1991). In vitro studies 
implicate other receptors on macrophages, not involved with LPS detoxification, 
that provide a specific interaction with cell-free LPS and may instead be
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involved with tumouricidal activity (Chen et al., 1990). The receptor-mediated 
activation of macrophages by LPS may therefore initiate the sequence of events 
(ie. second-messenger systems) which culminate in altered gene expression and 
the subsequent release of various inflammatory mediators, including NO, certain 
ILs and TNF-ot (Rees et al., 1990; Libby et al., 1986; Zuckerman et al., 1989). 
Altered gene expression will also change the expression of cell surface 
molecules on a number of cell types, most notably endothelial cells. LPS 
increases T-cell (Yu et al., 1986), leukocyte (Bevilacqua et al., 1987) and 
granulocyte (Yamada et al., 1981) adhesion to vascular endothelial cells with 
deleterious effects. The perturbed endothelial lining may become increasingly 
permeable (Hutcheson et al., 1990) and promote easy access for inflammatory 
mediators going to the subjacent VSM. It is clear, therefore, that LPS-induced 
endothelial cell injury is important in the pathogenesis of septic shock.
Many of the pathophysiologic features resulting from exposure to LPS in vivo 
can be attributed to NO. Several studies using the rat model of endotoxic shock 
have shown that LPS induces high levels of iNOS in many tissues including, 
lung, liver, spleen, kidney, heart, brain and skeletal muscle (Hom et al., 1995; 
Liu et al., 1993; Buttery et al., 1994). Significant discrepancies are evident when 
comparing these studies and may relate to the different serotypes of LPS used. 
For instance, the expression of iNOS mRNA induced by Samonella enteritidis is 
sensitive to the glucocorticoid, dexamethasone (Liu et al., 1993), while that 
induced by Escherichia coli is not (Hom et al., 1995).
Subsequent chapters report on the findings of this study, comparing some of the 
physiological characteristics of vessels which previously supplied solid tumours 
and vessels isolated from rats in endotoxic shock.
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NAME OF COMPOUND INHIBITORY ACTION REFERENCE(S)
NG-nitro-L-arginine methyl
ester
Replaces L-arginine substrate; inhibits
activity of NOS in vascular tissues and 
macrophages.
Ayotunde S.O. etal 1993
NG-mono-methyl-L-arginine Replaces L-arginine substrate; inhibits
activity of NOS in vascular tissues and 
macrophages.
Gross S.S. et al 1990, 
Julou-Schaeffer G. et al
1990, Kilbourn R.G. et al 
1990.
Aminoguanidine Replaces L-arginine substrate; inhibits
activity of iNOS in vascular tissues.
Misko T.P. et al 1993,
Griffiths M.J.D. et al 1993, 
Joly G.A. et al 1994.
L-canavanine Replaces L-arginine substrate; inhibits
Induction / Activity of iNOS in vascular 
tissues.
Umans J.G. et al 1992
Dexamethasone Inhibits the induction of iNOS at a
transcriptional level in vascular tissues 
and macrophages.
Rees D.D. et al 1990, Smith
R.E.A. et al 1991.
Diphenyleneiodonium (and its
analogues).
Acts by inhibiting NADPH-dependent
flavoproteins, which are required for
NO synthase activity in macrophages.
Stuehr D.J. et al 1991.
Nicotinamide Inhibits the induction of iNOS at a 
transcriptional level in activated 
macrophages. May act by inhibiting 
poly(ADP-ribosyl)- ation.
Pellat-Deceunynck C. et al 
1994.
TGF-pi,PDGFAB, PDGFbb Inhibits the induction of iNOS inVSMC.
Schini V.B. et al 1992.
Thaliporphine Inhibits the induction of iNOS in
activated macrophages via a mechanism 
that may involve its inhibitory effect on 
IL-Ip.
Yu S.M. 1994.
Macrophage-stimulating
protein
Inhibits the induction of iNOS Wang M-H. et al 1994.
Glibenclamide Inhibits the induction of iNOS in
cultured macrophages.
Wu C-C. et al 1995.
Phorbol esters Inhibits the induction of iNOS at the
transcriptional level in VSMC1 but not 
macrophages2, via a mechanism that 
may be governed by activation of 
protein kinase C.
!Geng Y. and Hansson
G.K. 1994, 2Sevem A. et 
al 1992.
Colchicine Inhibits the induction of iNOS in
VSMC, suggesting that microtubules 
may be involved in regulating this 
enzyme.
Marczin N. et al Mar. 1993.
Cycloheximide Inhibits the synthesis of the iNOS
protein in VSMC1, but potentiates the 
expression of the iNOS mRNA.2
lKoide M. et al 1993,
2Sirsjo A et al 1994.
Angiotensin II Inhibits the induction of iNOS through
the activation of the ATI receptor in 
VSMC.
Nakayama I. et al 1994.
Thrombin Inhibits the induction of iNOS in
VSMC.
Schini V.B. et al 1993.
Tyrosine Kinase inhibitors Inhibits the induction of iNOS in
VSMC.
Marczin N. et al Sept.
1993.
Curcumin Inhibits the induction of iNOS in 
activated macrophages via a mechanism 
that may involve its inhibitory action on 
several transcription factors or PKC and 
TPK.
Brouet I. and Ohshima 
H.,1995.
Abbreviations: iNOS = inducible nitric oxide synthase, VSMC = vascular smooth muscle cells, TPK = 
Tyrosine protein kinase, PKC = protein kinase C.
Fig. 1.7 Table of compounds which are known to inhibit iNOS.
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Chapter 2
Scope of the Present Study
The present study follows on from that of Kennovin et al. (1993, 1994) and 
examines the role of nitric oxide in the unusual hyporesponsiveness to 
vasoconstrictors (ie. phenylephrine; PE) displayed by vessels isolated from 
animals in endotoxic shock as compared to those which formerly supplied solid 
tumours (Stoclet et al., 1993; Kennovin et al., 1993). It was postulated at the 
outset that the former might serve as a suitable model for predicting the 
therapeutic potential of novel drugs to retard solid tumour growth: agents which 
most effectively reverse the hyporesponsiveness associated with endotoxaemia 
may sufficiently constrict tumour-supply vessels so as to reduce blood flow into 
the tumour and thereby limit its growth (Andrade et al., 1992).
A single injection of bacterial lipopolysaccharide (LPS) induced a form of 
endotoxaemia in the rat, as defined by five separate parameters (see Chapter 3). 
A novel NO scavenging compound was found to alleviate the severe 
hypotension resulting from LPS treatment, highlighting NO as the primary 
mediator of this effect (see Chapter 6). Using this model, experiments were 
conducted ex vivo with NOS inhibitors to confirm the involvement of the L- 
arginine/NO pathway in the hyporesponsiveness of vessels to PE. Parallel 
experiments were conducted on isolated epigastric arteries which previously 
supplied a solid tumour (see Chapter 7). It is clearly of more therapeutic value 
for an inhibitor to selectively constrict vessels which supply nutrients to a 
tumour without unduly compromising the function of normal (non-tumour 
associated) vessels in the host. With this in mind, experiments were performed 
using a selective NOS inhibitor aminoguanidine, and the results were compared 
with those obtained for L-NMMA and L-NAME, and also for a number of novel 
NO scavenging drugs (see Chapters 4 & 6).
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Kennovin et al. (1994), also showed that cycloheximide administered on its own 
could reverse the hyporesponsiveness associated with isolated tumour-supply 
vessels and they postulated that this effect was due to inhibition of iNOS. 
Similar experiments were therefore performed using vessels isolated from LPS- 
treated animals. However, because cycloheximide indiscriminately inhibits 
protein synthesis, its effects can seldom be attributed to a single mediator. For 
this reason, indomethacin was used to see if vasoactive products derived from 
the cyclooxygenase pathway are also involved (see Chapter 5).
Intermittent blood flow into the tumour has been suggested to occur as a 
consequence of vasomotion in feeding vessels (Intaglietta et al., 1977) 
Increasing this intermittent flow could sufficiently augment the fraction of 
hypoxic tumour cells as to significantly improve the efficacy of bioreductive 
agents (Chaplin et al., 1987). The present study (Chapter 7) looks at the effects 
of NOS inhibitors and L-arginine on spontaneous pulsatile pressures in isolated 
supply arteries and raises the possibility that NO is involved in this phenomenon.
Finally, having established that these NOS inhibitors have a greater constricting 
effect on tumour-associated vessels as compared to normal (control) vessels, 
studies were then conducted in vivo to confirm their ability to suppress tumour 
growth (see Chapter 8). The effects on tumour growth of LPS on its own, or in 
combination with a NOS inhibitor, were also addressed. A discussion of the 
results is included at the end of each Chapter and the overall conclusions are 
considered in the final Chapter (Chapter 9).
87
chapter 3- Results
Chapter 3 
Part A
A Model of Endotoxic Shock in the Male Wistar Rat
3.1 Introduction
The most obvious similarity between vessels which previously supplied solid 
tumours and those removed from animals in endotoxic shock is their marked 
hyporesponsiveness to vasconstrictor agents, like phenylephrine (PE; Kennovin 
et al., 1994; Julou-Schaeffer et al., 1990; Schott et al., 1993). The underlying 
factor which appears to be common to both and is likely be responsible for this 
phenomenon is iNOS. This study was undertaken to investigate whether the 
expression of iNOS in vessels from endotoxic animals and tumour supply 
vessels and their relative insensitivity to PE is sufficient to justify using one as a 
model of the other. The inherent technical difficulties associated with isolating 
tumour-associated vessels, their susceptibility to damage during the experimental 
procedure and the fact that only one tumour vessel is obtained from each animal, 
all conspire to compromise the acquisition of reliable data. A relatively straight 
forward surgical dissection of the rat tail artery (RTA) that provides 3-4 
preparations per animal per day is clearly of more value. It was therefore 
postulated that this model could provide a more reliable alternative for studying 
the potential of NOS inhibitors to selectively abolish this abnormal 
hyporesponsive effect.
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Materials & Methods
3.2 Methods
3.2.1 Preparation of Isolated Rat tail Artery. Male Wistar rats (350-500g) 
were killed by cervical dislocation and their tails amputated by cutting through 
the intervertebral disc. The skin was reflected around the proximal 2 -7 cms of 
the tail and a longitudinal incision made through the midline of the fascia on the 
underside of the tail. The tail artery was exposed using blunt forceps and cleaned 
of fat and connective tissue. Following insertion of a polyethylene cannula, 
arteries were mounted in a perfusion apparatus, schematically shown in fig. 3.1. 
Vessels were incubated at 37°C (ambient temperature was -20-21 °C) in the 
organ bath, perfused internally (flow rate; 2mls.min-1 driven by a Gilson 
minipuls 3) and superfused (flow rate; -Smls.mnr1 driven by a flow inducer, 
Watson-Marlow LTD, England) with prewarmed, oxygenated Krebs solution 
(composition (mM); NaCl 118, KC1 4.7, NaHCO3, 25, NaH2PO4 1.15, CaCl2 
2.5, MgCl2 1.1, glucose 5.6, gassed with 95% 02 I 5% CO2 to maintain pH at 
7.4). The internal perfusion rate was gradually increased over lhr to allow the 
arteries to adjust and stabilize to the new perfusion pressure. Once a stable 
passive pressure had been attained drugs (ie. PE or SNAP) were injected (lOptl, 
bolus) through a resealable rubber septum directly into the path of the internal 
perfusate just proximal to the cannula. A differential pressure transducer (P; 
Sensym type SCX 150NC, Farnell Electronic Components, Leeds) detected 
perfusion pressure determined by arterial tone. Changes in perfusion pressure 
reflected changes in the resistance to flow: vasoconstriction of the arteries 
resulted in an increased perfusion pressure and vasodilation caused a decrease in 
pressure.
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Fig. 3.1 The apparatus used for perfusing isolated vessels.
3.3 Evaluation of a rat model of endotoxic shock. Male Wistar rats were given 
a single injection of bacterial lipolysaccharide (4mg/Kg; i.p.; E. coli serotype 
055:B5; Sigma Ltd). Similar doses of LPS have been shown to induce iNOS 
activity in the rat (Knowles et al., 1990). In order to characterise this model, five 
parameters were monitored to indicate the extent of endotoxaemia.
3.3.1 Measuring Blood Pressure. Haemodynamic parameters in unrestrained, 
unanaesthetised animals were measured using the tail cuff method (Model 179 
Blood Pressure Analyzer; IITC Life Science, Calif., USA.). Animals were 
familiarised to the procedure by a ‘training’ regimen (daily for 3 to 4 weeks) 
before commencing an experiment so as to avoid undue stress. Recordings of 
systolic (S.b.p.), mean (M.b.p.) and diastolic (D.b.p.) arterial pressures were 
made at the following times relative to the time at which animals were injected 
with LPS (t=Ohr) : t= -96, -48, 0, 6, 12, 18 & 24hrs. Before each reading, the
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animals were placed in a warmed environment (26-29°C) for 15 mins after 
which time they were cradled under one arm and comforted. The cuff was 
carefully placed on the tail about 2-3 cm from the body and pressure pulses were 
monitored on an oscilloscope as the cuff was inflated. Handling proved to be far 
less stressful to the animals than the perspex holders, with consistent readings 
usually attained within 5 mins. Analysis of digital traces (as outlined by Mr. 
Tom Delahanty, Model 179 Engineer, personal commun.), showing the tail 
pulses on one channel and corresponding cuff pressure on the other (see fig. 3.2), 
was carried out manually to avoid false readings which often occured as the 
computer detected movements of the animal causing artifacts on the trace.
ATYPICAL TRACE PRODUCED BY THE IITC BLOOD PRESSURE 
MONITOR
e...
Fig. 3.2 A trace of arterial pulse pressure obtained using the tail cuff method. 
The pulse pressure returns when the cuff pressure is equal to systolic b.p. (S b.p; 
indicated by a tall tick mark above the cuff pressure trace baseline). The point at 
which the pulse amplitude is maximal represents the mean b.p. (M b.p; small 
ticks above the cuff pressure trace baseline indicate updates throughout the 
reading cycle), and diastolic b.p. is calculated using the equation below:
Diastolic b.p. = Mean b.p.-1/2 (Systolic b.p. - Mean b.p.)
The heart rate was estimated from the pulse trace by measuring the time (each 
grid spacing = Is) from the first of a series of sixteen small ticks to a final taller 
tick (ie. seventeen ticks in all) as shown above the pulse pressure baseline (see 
fig. 3.2). This value was multiplied by 60 to estimate beats /min. Ticks appearing
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below either trace after this series of seventeen ticks indicated an interruption in 
the automatic reading cycle and the computer generated results were ignored.
3.3.2 Measuring Nitrate and Nitrite levels in blood samples The second 
parameter involved monitoring accumulated plasma nitrate and nitrite levels 
(=NOX) at various times (6, 12, 18, 24, 48 & 72hrs) after LPS injection. Animals 
were sacrificed by cervical dislocation and exsanguinated. A modified assay was 
employed, since the main oxidation product of NO in blood is nitrate 
(Wennmalm etal., 1993) and this must be quantitatively reduced to nitrite before 
performing the Griess test (see Section 1.4.1 and Appendix 3.5).
Blood samples (5-8mls) were obtained from the thoracic cavity of each animal 
and immediately centrifuged at 15,000g for 10-15mins at room temperature to 
separate out the plasma, which was then freeze-dried overnight. Thereafter, 
plasma was kept frozen (-20°C) in small vials until use. Samples containing low 
NOxs (from control animals and LPS-treated animals at t= 6, 12 & 72 hrs were 
re-constituted in 0.5ml de-ionised water (4 x concentration) and those with high 
NOxs (t= 18, 24 and 48hrs) were re-constituted in 8ml of de-ionised water (4 x 
dilution; deionised water: Milli-Q+ deionised water filtered through a 0.2pm 
pore membrane; Millipore Bedford, MA., USA.).
Test solutions, containing blood plasma, were spiked with known dilutions 
(mM) of nitrate (TNO3-) or nitrite (TNO2') and standard (control) solutions, 
containing de-ionised water instead of plasma were also spiked with nitrate 
(CNO3") or nitrite (CNO2'; see fig. 3.3). Two sets of five tubes containing test 
solution (sets 1&2: TNO3" & TNO2-) and two sets of five tubes containing 
standard solution (sets 3&4: CNO3" & CNO2“) were used, each of which 
contained either plasma (127pl; sets 1&2) or de-ionised water (127gl; sets 3&4), 
to which the following were added (final concentrations): FAD (48.2pM), 
NADPH (482pM), phosphate buffer (pH 7.4; 40mM), nitrate reductase enzyme 
isolated from Aspergillus species (70mU; added to all of the solutions containing
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nitrate; from Boehringer Mannheim GmbH, Germany) and, in tubes 1-5 
respectively, the following quantities (nmoles) of Analar grade authentic NO2“ 
or NO3" as ‘internal’ standards: 45, 22.5, 15.75, 11.25 and 2.25 nmoles.). Tubes 
were incubated at 37°C for 2hrs before the Griess test was performed. 
Absorbance was read at 540 nm and a linear graph of the results plotted with 
absorbance (Y axis) against [nitrate/nitrite] (X axis; see fig. 3.3). The intercept 
along the X axis represents nanomoles of nitrate/nitrite in the serum sample, (for 
control, t= 6, 12, & 72 hr samples this value was divided by four and for t= 18, 
24 and 48 hr samples this value was multiplied by four). A correction was made 
to allow for the efficiency of enzymatic reduction of NO3“ to NO2" (average 
conversion -93%) and the results expressed in pmoles/1 plasma.
TNO3-
TNO2"
cno3-
cno2-
Fig. 3.3 An example of a graph used to calculate to the levels of nitrate and 
nitrite in blood plasma. NOX = TNO3- (closed squares) and total nitrite - TNO2'
(open squaresfThe gradients for CN03‘ (closed circles)and CNO2' (open 
circles) are used to calculate the % conversion of nitrate to nitrite by NR (for 
explanation see text).
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3.3.3 The hyporesponsiveness to PE of isolated, internally-perfused tail 
arteries (see Section 3.2.1) from LPS-treated rats. PE (10_5M-10_2M) was 
injected into internally-perfused RTAs taken from animals treated with LPS {viz'. 
at t= 6, 12, 18, 24, 48 & 72hrs). PE produced transient vasoconstrictor responses 
(see fig. 3.4). Peak pressures were recorded on a computer and a print out was 
obtained at the end of the experiment. These values were used to construct log 
dose-response (D.R.) curves.
Fig. 3.4 Pressure recording of RTA to bolus injections (10pl) of PE (lO^M- 
The pressure induced by the internal perfusate alone is called ‘passive 
pressure’ (PP) while that induced by PE is 'active pressure’ (AP). Passive
pressure was restored before subsequent injections of PE were administered.
3.3.4 The hyporesponsiveness of pre-contracted, internally-perfused tail 
arteries to bolus (10gl) injections of SNAP. Control and LPS-treated (t= 24hrs) 
RTAs were precontracted to -lOOmmHg perfusion pressure with PE (2-5pM - 
10-12pM respectively) and exposed to increasing concentrations of the
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endothelium-independent vasodilator, SNAP (10_7M-10'3M). The responses to 
SNAP are expressed as a percentage of the active perfusion pressure (mmHg) 
and plotted as a function of log[SNAP] (see fig. 3.8).
3.3.5 The expression of NOS Antibodies specific to eNOS (# 2361) and iNOS 
(# 2464) were used for immunohistochemical analysis in various tissues 
including, lung, liver, heart, RTA, tumour-supply arteries and tumour tissue. A 
number of methods were employed to indicate the expression of NOS: NADPH 
diaphorase staining, indirect immunofluorescence, avidin-biotin- 
immunoperoxidase complex (ABC) method and Western blot analysis. The 
protocol for Western blotting is briefly oulined below with a more detailed 
account given in Appendix 3.1. Essentially, Western blots were made from 
extracts of lung, heart, liver and RTAs taken post mortem from animals 
sacrificed at different times after LPS injection (t= 4, 6, 12, 24, & 72hrs).Tissues 
were weighed and homogenised for 3-5 mins at 24,000rpm (Ultraturrax T25 
homogeniser) in 5 volumes ice cold buffer (see Appendix 3.1.2 for composition). 
The resulting lysate was centrifuged (100,000g, lhr at 4°C) and the protein 
content of the supernatent estimated using the Bradford assay. Samples 
containing 2mg protein/ml (lung, liver and heart) or lmg protein/ml (RTAs) 
were mixed with 0.5x volume of laemmli buffer (see Appendix 3.1.5) (3x 
strength) and p-mercaptoethanol added to a final concentration (v/v) of 15%. 
Samples were boiled and then subjected to SDS-PAG electrophoresis ( 15jlx1 per 
well; 7.5% SDS). Proteins were transferred onto a nitrocellulose membrane, 
probed overnight with a rabbit polyclonal antibody (#2464; 1:1000 dilution) and 
then treated with goat anti-rabbit IgG-horseradish peroxidase secondary antibody 
(GARP; 1:3000 dilution). Finally, the secondary antibody was detected by 
enhanced chemiluminescence (ECL). Molecular weight markers (ca. 26- 
170KDa) were used to estimate apparent molecular weights of iNOS-positive 
bands.
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3.4 Materials
3.4.1 Drugs In general these were prepared immediately before each 
experiment.
Lipopolysaccharide purified from Escherichia coli serotype 055:B5, (dissolved 
in 0.9% sterile saline (NaCl) solution), Nvv-nitro-L-arginine methyl ester 
hydrochloride (L-NAME hydrochloride; Mr 269.7), L-Phenylephrine 
hydrochloride (PE; Mr 203.7), aminoguanidine hemisulfate salt (AG; Mr 
123.1), L-arginine hydrochloride (L-Arg; Mr 210.7), cycloheximide from 
Streptomyces griseus (Mr 281.4) and indomethacin (Mr 357.8); 10_3M stock 
solution (dissolved in 5% sodium carbonate), were all obtained from Sigma Ltd 
and added to the internal perfusate at the appropriate concentration.
L-NG-monomethyl-L-arginine hydrochloride (L-NMMA hydrochloride; Mr 
266) was a gift from Dr. H. Hodson, Wellcome Res. Labs., Kent.
S-nitroso-N-acetylpenicillamine (SNAP; Mr 220) prepared by Dr. A.R. Butler, 
Dept. of Chemistry, St. Andrews University. Solutions were kept on ice during 
the experiment and administered as a bolus injection (10(il) into the internal 
perfusate at concentrations of 10"7M-10_3M.
3.4.2 Antibodies All primary antibodies are diluted and then stored at -20°C in 
aliquots of 2-5pl. Dilutions were made in PBSC (complete phosphate buffered 
saline) containing bovine serum albumin (BSA; 0.1% (v/v). See Appendix 
Section 3.2.3). Further dilutions made before Western blot analysis were made in 
1% skimmed milk (Boots PLC).
Primary antibodies. Specific to iNOS - # 2464 (Rabbit polyclonal raised 
against a murine macrophage iNOS polypeptide). Stored at 1:10 dilution and 
used at 1:200 for indirect immunofluorescence (IF), 1:750-1:1000 for avidin- 
biotin-complex-immunoperoxidase (ABC-IP) method and 1:1000-1:2500 for
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Western blot analysis. Specific to eNOS - # 2361 (Mouse monoclonal raised 
against bovine aortic cell extract). Stored at 1:100 dilution and used at 1:1000 for 
IF, 1:10,000 for ABC-IP and 1:10,000 for Western blot analysis. Both were a 
gift from Dr. Lee Buttery, RPMS, Hammersmith Hospital, London.
Conjugated Secondary antibodies. Goat anti-mouse IgG conjugated to 
fluorescein isothiocyanate (FITC; GAMF, diluted to 1:200 for IF on histological 
sections), goat anti-rabbit IgG conjugated to either fluorescein isothiocyanate 
(FITC; GARF, diluted to 1:200 for IF on histological sections), or 
tetramethylrhodamine isothiocyanate (TRITC; GARR, diluted to 1:80 for IF on 
histological sections) were obtained from Sigma Ltd. Donkey anti-rabbit IgG 
conjugated to horseradish peroxidase (HRP; DARP, diluted to 1:1000 for 
Western blot analysis using enhanced chemiluminescence detection) and sheep 
anti-mouse IgG conjugated to horseradish peroxidase (HRP; SAMP, diluted to 
1:1000 for Western blot analysis using enhanced chemiluminescence detection) 
were obtained from SAPU (Scottish Antibody Production Unit), Lanarkshire, 
Scotland. All secondary antibodies were stored neat in lOpl aliquots at -20°C 
before use.
3.4.3 Anaesthetic
A general anaesthesia (90mgKg_l Ketamine, lOmgKg-1 Xylazine; i.p.) was 
administered during tumour implantation and excision of inferior epigastric 
arteries.
3.4.4 Animals
Male Wistar rats (35O-55Og; John Tuck Ltd) were used for the model of 
endotoxic shock and all RTA experiments. Male, isogeneic BD9 rats (350~450g; 
from the CRC Gray Lab., Mount Vernon Hospital, Middlesex, England) were 
used for all tumour experiments.
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3.5 Results
3.5.1 The Time course of LPS-induced hypotension. Four haemodynamic 
parameters were measured using the tail-cuff method; systolic, mean and 
diastolic b.p’s (mmHg) and heart rate (beats/min). A group of ten rats was 
trained for approximately 1 month and b.p. was monitored at 4 and 2 days 
(-96hrs, -48hrs; see fig. 3.5) prior to a single bolus injection of LPS (4mg/Kg; 
i.p.) at t =0. Thereafter, b.p. and heart rate were monitored every 6hrs for a total 
of 24hrs with an average of four readings recorded per animal at each time point 
to improve accuracy and ensure that the results were consistent.
TIME BEFORE(-) or AFTER (+) 
LPS INJECTION (HRS)
Fig. 3.5 A graph showing the effect of LPS treatment on systolic (stippled 
column), mean (light grey column) and diastolic (dark grey column) b.p. 
recorded using the tail-cuff method, where (*) indicates a significant (p< 0.05) 
drop in b.p. compared to t- Ohrs. Filled circles denote meaned heart rate.
Animals were observed throughout the experiment and visual symptoms of LPS 
treatment were noted in conjunction with b.p. measurements. Within 30-60mins. 
after LPS injection, animals exhibited erectae pilae, reddening of the eyes, cold 
feet and became very sluggish. Rectal temperatures varied from 36.5-37°C.
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These symptoms were thought to reflect the onset of fever characteristic of 
endotoxic shock. During this period animals were kept warm by increasing R.T. 
from 21°C to 25°C. At t= 6hrs animals displayed no obvious symptoms of fever, 
although a marked darkening of faeces was noted. Haemodynamic parameters 
were not significantly altered from t= Ohrs (see fig. 3.5 & appendix table 3.1). At 
t=12hrs the symptoms of fever had returned in a few animals despite having 
been kept at a R.T. of 25°C. Systolic b.p. decreased from 150.3 ±3.59mmHg to
140.3 ±4mmHg and diastolic was significantly reduced from 89 ±4.09mmHg to 
73 ±3.6mmHg. Wanning the animals immediately prior to measuring b.p. 
consistently reversed the obvious symptoms of fever at every time point. At t= 
18 and 24hrs more than half of the animals appeared to be dehydrated, although 
they remained active and alert. All three parameters of b.p. were significantly 
reduced by t=24hrs with a noteable 23.5 ±6.2% drop in systolic b.p. from 150.30 
to 115.5 ±5.76mmHg.
3.5.2 The Time Course of Enhanced Nitrite and Nitrate accumulation 
following LPS exposure. The levels of nitrite and nitrate in blood plasma were 
measured using the Griess reaction after conversion of nitrate to nitrite using the 
enzyme nitrate reductase. Nitrite and nitrate represent the main oxidative 
products of NO metabolism and can therefore be used to indicate the 
accumulated NO levels within the bloodstream at any given instant in time. In 
order to monitor the levels of NO being produced in vivo following LPS 
treatment, blood samples were collected from animals sacrificed at t= 6, 12, 18, 
24, 48 & 72hrs after LPS injection (control animals (Ohrs) received 0.9% sterile 
saline solution and samples were taken at t= 24hrs). Results are expressed as 
mean (±SEM) of the combined amounts of nitrite and nitrate; (NOX: //moles/1) 
plotted as a function of time post-LPS injection (hrs; see fig. 3.6 & appendix 
table 3.2).
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Fig. 3.6 Time-dependent increase in NOX levels at depicted timepoints post- 
LPS treatment. NOX levels are also shown for control animals (Ohr).
Student’s t-test analysis found levels of NOX in blood plasma significantly 
increased from 26.35 ±6 pmoles/l to 81.8 ±27.9 pmoles/l by t= 12hrs as 
compared to controls, rising to a maximum of 463.1 ±50.3 pmoles/l by 24hrs 
(~18 fold increase) and returning to control levels by 72hrs (19.7 ±6.28pmoles/l; 
see appendix table 3.2).
3.5.3 LPS-induced Hyporesponsiveness of RTAs to PE. Administration of 
E. coli LPS to rats caused a time-dependent hyporesponsiveness to PE. This 
effect has previously been attributed to LPS-induced activation of the inducible 
NOS and the subsequent high levels of NO produced (Schott et al., 1993). Fig. 
3.7 shows dose response curves to PE for RTAs from animals receiving 0.9% 
saline injection (controls) compared to those obtained using vessels isolated 
from animals sacrificed at 6, 12, 18, 24, 72 hrs post-LPS injection.
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Group Control 6hr 12hr 18hr 24hr 48hr 72hr
% Con at 100.0 112.8 89.1 83.1 56.9 101.4 107.0
(5xl(t3M) ±4.4 ±7.8 ±7.7 ±9.4 ±8.1 ±11.7 ±15.2
Table 3.1 Shows the perfusion pressures produced by 5xlO~3M PE in control 
and LPS treated RTAs (removed 6, 12,18, 24, 48 and 72hrs after LPS treatment) 
expressed as a % of that for controls. [PE]~ 5xlO~3M was chosen as a maximum 
so as to include all the data.
The LPS-induced hyporesponsiveness in RTAs becomes apparent at t=12hrs 
with -11% decrease in sensitivity compared to the control at 5xlO_3M [PE] (see 
table 3.1). However, the curve is not significantly different from the control 
curve (2 way ANOVA; F= 0.56, df= 9, 183e, p= 0.827). At t= 18hrs the 
contractile responses are significantly diminished compared to the control (2 
way ANOVA; F= 2.29, df= 9, 256e, p= 0.017) and the response at 5xlO'3M[PE] 
is reduced by -17%. The hyporesponsiveness to PE is further accentuated by 
t=24hrs with responses now highly significantly as compared to controls (2 way 
ANOVA; F= 15.74, df= 9, 289e, p <0.001) with -43% decrease in sensitivity at 
5x10_3M[PE]. At 48hrs (not shown in Fig. 3.7) and 72hrs post-LPS treatment, 
the contractile responses are no longer reduced and now resemble those obtained 
with control vessels. Neither are significantly different from the control (see 
appendix table 3.3).
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Fig. 3.7 Shows the contractile responses for RTAs from control animals (dotted 
line; n= 18 RTAs), LPS treated animals after 6hrs (open triangles; n=16 RTAs), 
12hrs (open squares; n-4 RTAs), 18hrs (closed circles; n- 13 RTAs), 24hrs 
(open circles; n- 15 RTAs) and 72hrs (closed diamonds).
These results confirm that LPS treatment results in a transient decrease in 
sensitivity to PE with time after treatment.
3.5.4 Diminished Sensitivity to Bolus Injections of SNAP.
Fig. 3.8 Dose-response curves to increasing concentrations of SNAP for 
control (closed circles, n= 8) and LPS-treated (24hrs; open circles, n= 4) RTAs. 
Asterisks^ unpaired t-test.
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Pre-contracted, LPS-treated vessels displayed a highly significant 
hyporesponsiveness to SNAP at concentrations < 10~3M (see fig. 3.8 & 
Appendix table 3.4). The ED50 values reveal a 26.7 fold rightward shift in 
[SNAP] for LPS-treated responses compared to their respective control values. 
At 10_3M [SNAP] both groups displayed similar vasodilator responses to SNAP 
(-70%).
3.5.5 Time Course of iNOS Expression after LPS Treatment. The 
expression of iNOS protein was detected by Western blotting in extracts of lung, 
heart, liver and RTAs from post-mortem control and LPS-treated animals (t= 4, 
6, 12, 24, 72hrs; see Appendix 3.1). Fig. 3.9 shows lung extract from t= 24hr 
LPS-treated rats expressing high levels of iNOS as evident by the densely 
staining band at 130KDa. Lung extract from t= 24hr LPS-treated rats was used 
as a positive control for iNOS expression until the commercially available 
positive cell lysate arrived. The validity of the lung extract was confirmed with 
both bands detected at 130KDa (see fig. 3.10). Fig. 3.10 also reveals a time 
course of iNOS expression in LPS-treated RTAs, with a maximum at t= 4-6hrs, 
gradually declining until it was barely detectable by t= 24hrs and undetectable 
by t= 72hrs. Dot blot analysis further revealed that liver extracts from t= 24hr 
LPS-treated rats also expressed iNOS (see fig. 3.11).
Several histochemical and immunohistochemical techniques were used to detect 
eNOS and iNOS expression in tissue sections (see figs. 3.12-3.18 and Appendix 
3.2). Immunoflourescent labelling revealed intensely stained macrophage-like 
cells scattered throughout the lung tissue of t= 24hr LPS-treated rats (fig. 3.12). 
Intensely fluorescent cells were often seen in lung tissue from control animals 
but not to the same extent.
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Fig 3.9 Western blot analysis using a specific antibody to iNOS enzyme of lung 
extract from t= 24hr LPS-treated rat reveals an intensely staining band at 130 
KDa, suggesting that iNOS is being expressed.
130 Kl);i
12 3 4 5 6 7
Fig. 3.10 Western blot analysis using a specific antibody to iNOS of LPS- 
treated RTAs at t= 4hrs (lane 1), 6hrs (lane 2) 12hrs (lane 3) 24hrs (lane 4) and 
72hrs (lane 5). Lung extract from t= 24hr LPS-treated rats and activated- 
macrophage lysate are used as positive controls (lanes 6 & 7 respectively). iNOS 
expression is visibly reduced at t= 24hrs after LPS treatment.
Fig. 3.11 shows a dot blot of lung and liver extracts from t= 24hr LPS-treated 
rats demonstrating a more intense signal for iNOS with increasing protein
concentration.
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Fig. 3.11 Dot blot analysis with anti-serum to iNOS on lung ([proteinjs, 1.7, 
6.6, 7.6g/l; Nos 1-3 respectively) and liver ([proteinjs, 1, 7.6 and 30g/l; Nos 6-4 
respectively) extracts from t- 24hr LPS-treated rats.
Fig. 3.12 Cryostat section (5-7pm) of lung tissue from a t= 24hr LPS-treated 
rat immunostained with fluorescently-labelled (TRITC) 2° antibody. Intensely 
stained macrophage-like cells are scattered throughout the lung tissue (x400).
Fig. 3.13 shows that iNOS positive cells were not seen within bronchioles or 
their associated epithelial lining but were instead interposed between the alveolar 
network in the surrounding visceral pleura.
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Fig. 3.13 TRITC-labelled cryostat section of lung from t= 24hr LPS-treated rat 
showing the intensely fluorecent cells in the visceral pleura (A) but absent from 
the nearby bronchiole (B; x400).
Fig. 3.14 Similarly, immunostaining by the ABC method on sectioned lung 
tissue from a t-24hr LPS-treated rat showed iNOS positive cells (M) as large 
rounded black dots within the visceral pleura (x400).
Cryostat sections of the same area in the lung as shown in fig. 3.14 were also 
stained for NADPH-diaphorase activity (see Appendix 3.4) and resulted in a 
large number darkly stained cells within the visceral pleura and attached to the 
epithelial lining of a bronchiole (B; fig. 3.15).
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Fig. 3.15 Cells within lung tissue from t= 24hr LPS-treated rat stain intensely 
for NADPH-diaphorase. NADPH-diaphorase-Positive cells are also evident on 
the epithelial lining of a bronchiole (B; x400).
LPS-treated RTAs at t= 6, 24 and 72hrs were immunostained with anti-serum to 
eNOS to determine whether eNOS expression persisted throughout the LPS- 
mediated induction of iNOS (see figs. 3.16-3.18). Fig. 3.16 shows an LPS- 
treated RTA at t= 6hrs immunostained using the ABC method. iNOS is highly 
expressed at t= 4-6hrs and it is clear from fig. 3.16 that eNOS is also present at 
this time.
Fig. 3.16 Paraffin-sectioned (5-7pm) RTA from an LPS-treated rat at t- 6hrs 
immunostained with anti-serum to eNOS using the ABC method. Endothelial 
cells (E) which express eNOS are seen here as a thin, darkly stained layer facing 
towards the lumen of the vessel (L; xlOOO).
107
chapter 3- Results
Fig. 3.17 Paraffin-sectioned (5-7pm) RTA from an LPS-treated rat at t- 24hrs 
immunostained with anti-serum to eNOS and detected using a fluorescently- 
labelled (FITC) 2° antibody. Endothelial cells (E) which express eNOS are seen 
here as a thin, brightly stained layer facing towards the lumen of the vessel (L;
Fig. 3.18 Paraffin-sectioned (5-7pm) RTA from an LPS-treated rat at t- 72hrs 
immunostained with anti-serum to eNOS and detected using a fluorescently- 
labelled (FITC) 2° antibody. Endothelial cells (E) which express eNOS are seen 
here as a thin, brightly stained layer facing towards the lumen of the vessel (L; 
xlOOO).
It is important to realise that little quantitative information regarding the relative 
expression of eNOS at t= 6, 24 and 72hrs post-LPS is provided by these sections 
as staining will depend very much on a) the type of detection method used b) 
the condition of the RTA, which will vary from one preparation to the next; and 
finally c) the quality of the photograph. It can however be concluded that eNOS 
is expressed in RTAs at t= 6, 24 and 72hrs post LPS.
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Part B
3.6 Quantitative analysis of hyporesponsive vessels isolated from 
animals in endotoxic shock.
It will be seen later (Chapter 7) that isolated vessels that previously supplied a 
solid tumour exhibit a similar diminished sensitivity to PE when compared to 
their respective controls: superficially, at least, the hyporesponsiveness shown by 
LPS-treated vessels and tumour supply vessels appears very similar. However, a 
more detailed analysis (below) suggests that there may be qualitative differences 
between the two, a point which is discussed again later (Chapter 9).
3.6.1 Theory.
The diminished sensitivity to PE shown by LPS-treated vessels and tumour 
supply vessels could in theory take one of two forms: (a) one resembling a 
competitive-type of inhibition, where the log dose response curve is simply 
shifted to the right along the abscissa, with no change in the maximum response 
attainable at the higher doses; or (b) one resembling a non-competitive type of 
inhibition, where there is a decrease in the maximum response even at the 
highest doses. Of course, in practise, a given set of experimental results may 
only permit a restricted part of each curve to be constructed and this makes it 
difficult to decide to which type of inhibition the data belongs.
The two situations outlined above are illustrated diagramatically in Figure 3.19 
using simulated data. The analysis proceeds as follows. First, the ‘test’ values are 
expressed as a fraction of the corresponding ‘control’ values. The results 
obtained (b/a = f) are then plotted as a function of logioEPE]. Theoretically, if 
the response to PE were not altered the log dose response curves would be 
identical and all f values = 1.0. Plotting the latter as a function of [PE] would 
therefore yield a horizontal line with a slope (m ) of zero. Similarly, a horizontal
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line would also be obtained if all points on the curve were reduced by the same 
fraction (/< 1.0) at each [PE]. Fig 3.19 (lb & 2b) show that the simulated data, 
representing the two types of inhibition, give qualitatively different results.
Fig. 3.19 The difference in sensitivity to PE shown by LPS-treated RTAs and 
tumour supply vessels (line a; open circles) compared to their respective control 
(line b; closed circles) can theoretically resemble a non-competitive-type (fig.la)
or competitive-type (fig. 2a) shift with f values (h+ a; open squares) resulting in 
a negative slope (m; fig. lb) and a positive slope (fig. 2b) respectively.
3.6.2 Results of analysis. Fig 3.20 shows the results obtained by applying this 
method of analysis using the actual experimental data obtained with vessels 
taken from animals previously treated with LPS, presented earlier (t = 18, 24 and 
72 hr; Fig. 3.7). The values for f vary approximately linearly with the [PE], 
revealing a progressive increase in the relative sensitivity of LPS-treated vessels
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with increasing [PE]s: in other words, the administration of a sufficient [PE] is 
able to counteract, to some extent, the effects of LPS treatment.
Significantly, the slopes of the lines, m, derived by linear regression analysis, 
vary with time after LPS treatment. Table 3.2 shows a gradual reduction in the 
value of m between t = 6 - 24hr (from 0.29-0.10), falling to 0 at t = 48 and 72hr. 
The values of f obtained for the latter two time points approximate to 1.0: the 
means (+/- SEM) were found to be 0.96 ±0.18 and 1.00 ±0.20 respectively. The 
72hrs data is shown in Fig 3.20 (open circles).
Group Control 6hr 12hr 18hr 24hr 48hr 72hr
m 0.00 0.29 0.10 0.18 0.10 0.00 0.00
1/m 0.00 3.44 5.13 5.71 10.41 0.00 0.00
r2 - 0.879 0.851 0.960 0.887 - -
Table 3.2 Showing the 'm ' values and the respective r2 coefficients for the 
linear curve fit.
Fig. 3.20 Shows the LPS log D.R.s at 18hrs (closed triangles), 24hrs (closed 
circles) and 72hrs (open circles) expressed as a fraction (f) of control values 
plotted against log [PE]. The dashed line represents the theoretical result for 
values identical to the control (see text for further details).
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The hyporesponsiveness to PE clearly varies with time after LPS, increasing up 
to t = 24 hr and then decreasing thereafter. The time course of the development 
of the hyporesponsive state is therefore better described by plotting the 
reciprocal of m as a function of time after LPS treatment. The result of doing 
this using the values shown in Table 3.2 appears in Figure 3.21. This shows that 
the extent to which responses are impaired in LPS treated vessels rises to a 
maximum at t = 24 hr and then declines, so that by t = 48 and 72 hr, vessels 
show the same sensitivity to PE as control vessels. This compares closely with 
the time course for the increased accumulation of plasma NOX levels, shown in 
Figure 3.7.
Fig. 3.21 Shows the relative hyporesponsiveness increasing with time after LPS 
treatment.
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3.7 Discussion
3.7.1 Endotoxic Shock Model
Several studies have now reported on the effects of Escherichia coli LPS 
administration to rats in vivo (Wakabayashi et al., 1987) and the resultant 
hyporesponiveness to the pressor effects of catecholamines in vitro and ex vivo 
(Fleming et al., 1990; Julou-Schaeffer et al., 1990, see discussion table 3.3).
REF STIMULANT HOURS 
(Post LPS)
PREPARATION INHIBITORS EFFECTS MEDIATOR/
CONCLUSIONS
1 LPS (026:116, E. coli)
lOmg/kg i.p.
6 Aortic rings (Wistar) - | M.A.P. - in vivo
I contractility - ex vivo
Disorder of Ca2+ utilisation
2 LPS (S. typhosa) 
lOOng/m! i.v.
8 Aortic rings Dcxnmethasoue, 
Cyclohcximidc, L-NMMA, 
L-NIO, Polymyxin B
1 contractility - et vivo Induction of NOS (VSM)
3 LPS (055:B5. E. coli)
20mg/kg i.p. (infused i.v. 
Smg/kg/h)
4 Aortic rings (Wistar) L-NMMA, MEB | M.A.P. - in vivo 
i contractility - ex vivo
( NO production (VSM)
4 LPS (S. lyphimurium)
dnig/kg i.p.
6 Lung, liver and aorta tissue 
extracts (Wistar)
Dexamethasone Induction of NOS hi vivo Similar to iNOS in 
macrophages in vitro
5 LPS (055:B5) lOmg/kg i.v.
(E. coli).
4 Aortic rings 
(Spraguc-Dawlcy)
L-Canavnninc,
N^-nitro-L-arg
J contractility - et vivo t NO production (VSM)
6 LPS (0I27:B8) 2ntg/kgi.v. 3 Aortic rings (Wistar) TNFab (16 hrs prior to 
LPS), L-NAME
1 M.A.P.- in vivo
J contractility - et vivo
TNFcontributes to induction 
of NOS in vivo
7 LPS (011LB4) 3mg/kg i.v. 
(F. coli)
5 Jejunal & colonic tissue 
extracts (Wistar)
Dcxainctliasone (2 lirs prior 
to LPS). L-NMMA
1 in vascular permeability 
laE 3hr
t NO production by iNOS
8 LPS (S. Enterilidis) 
3mg/kg i.p.
4 Brain, lung, liver, spleen, 
kidney & skeletal muscle 
extracts (Wistar)
Dexamethasone (40 min 
prior to LPS)
mRNA iNOS expression Induces a tvidewpread tissue 
expression of iNOS mRNA
In vivo
9 LPS (0111:B4.F.co/»). r Aortic rings (Wistar) NG-nitro-L-nrg, L-NMMA,
anti noguanidine bicarbonate
| contractility - ex vivo selective inhibition of iNOS 
by aminoguanidine
10 LPS (055:D5) 4mg/kg i.p. 
(£. coli).
6-72 Perfused tail artery (Wistar) L-NAME. L-NMMA, 
aminogunnidinc 
hemisulfate
( M.A.P. - in vivo 
Hyporesponsivc - ex vivo
iNOS expression in vascular 
tissue. Hypotension 
correlates with 
hyporesponsiveness - 
maximal at 24 hrs
Abbreviations; N-iminoclhyl-Vomilhine (L-NIO), Tumour necrosis factor (TNF-a), TNF-a-antibody (rNFab), methylene blue (MEB)
References; 'Wakabayashi 1. el al., 1987, 2Rccj D.D. el al., 1990, 3Julou-Schacffcr O. cl al., 1990, “'Knowles R.G. el al., 1990, 5Unrans J.G. & Snniscl R.W., 1992, 
^Thicmcrmanu C. el al., 1993, 7Broughlon-Smith N.K., el al., 1993, ®Liu S. el al., 1993?Joly G.A. el al., 1994, '®Bisland S.K. el al., unpublished.
Discussion table 3.3 Showing some recent studies on the effects of LPS 
treatment in the rat.
Reversal of the hyporeactivity to PE by stereospecific inhibitors of NO 
production clearly implicates NO as the major mediator of this effect. Some 
studies have been made comparing the effects of LPS in vivo and ex vivo, yet in 
the majority of instances the properties of the isolated vessel ex vivo is not 
consistent with what occurs in vivo. This is perhaps not surprising when one 
considers that many different homeostatic mechanisms will be operating in vivo 
at any given time. Furthermore, it is becoming clear that different signalling 
mechanisms exist for the induction of iNOS mRNA in culture and in vitro
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(Sirsjo et al., 1994). Thus it is unlikely that the situation in vivo will ever be fully 
emulated outside the body.
The model of endotoxic shock described here is unusual in that the ex vivo 
experiments employed isolated, endothelium-intact vessels which are constantly 
perfused. Most previous studies did not use intraluminal perfusion, which is 
surprising, since this more closely replicates the situation in vivo, where blood is 
constantly flowing through the vessels. Similarly, using lengths of artery and 
rather than rings contracting isometrically is more physiologically relevant. This 
model also emcompasses a pharmacological examination of LPS-induced 
hypotension and vascular hyporeactivity in combination with analysis of iNOS 
protein expression (ie. Western Blot). The dose and mode of administration of 
LPS was designed to ensure 100% survival of the animals.
3.7.2 Hyporesponsiveness of LPS-treated RTAs to PE. These experiments 
were carried out in a darkened laboratory to minimize the influence of artificial 
light on NO release during prolonged experiments (Megson et al., 1995). The 
results from isolated segments of RTA ex vivo reveal that contractile responses 
to bolus injections of PE diminish with increasing time after LPS exposure. The 
effect is transient, lasting up to ~48hrs, and is maximal after ~18-24hrs. These 
results are completely consistent with the LPS-induced increase in blood plasma 
NOX levels, indicative of NO levels, which increased steadily from t= 6hrs until 
24hrs, by which time they were ~ 18 fold greater than controls, then subsequently 
returned to control levels over the next 48hrs. These results are also in agreement 
with a subsequent study by Tracey et al., (1995), who showed that NOX levels 
peak 20hrs after LPS.
L-arginine does not appear to be limiting the production of NO at t= 24hrs as 
added substrate did not alter responses to PE (data not shown). Equally, the 
apparent disparity at 6hrs, with high iNOS expression, but relatively low levels 
of circulating NOX and the lack of hyporesponsiveness to PE, may be due to
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insufficient substrate availability, limiting NO production. L-arginine has been 
shown to limit the diminished response to noradrenaline in endothelium-denuded 
aortic rings exposed to LPS in vitro (Schott et al., 1993) and as the only 
physiological substrate for the NOS reaction and the high NO production 
associated with iNOS activation, arginine is likely to be in high demand 
following LPS treatment. Studies have shown that LPS upregulates L-arginine 
transport into activated smooth muscle cells (Stoclet et al., 1994) as well as 
inducing the necessary enzymes involved in the regeneration of arginine from 
citrulline (Hattori et al., 1993 &1995). However, neither of these mechanisms 
are operating by 6hrs-post LPS and only appear after a lag of ~8hrs, peaking by 
24hrs and receding thereafter (Hattori et al., 1994). With sufficient substrate to 
sustain iNOS-derived NO production it is perhaps not surprising that after 12hrs 
vessels begin to show a reduced sensitivity to PE. The increase in substrate 
availability may also partly explain why after 24hrs NO production remains high 
while iNOS expression is declining. It is perhaps necessary for future studies to 
more fully consider the turnover of L-arginine during high level NO production 
in vessels, in order to better appreciate its time-course in relation to iNOS 
expression.
3.7.3 Diminished sensitivity to SNAP It is well documented that vessels 
isolated from LPS-treated animals are hyporesponsive to endothelium-dependent 
vasodilators (Julou-Schaeffer et al., 1990) but not to certain endothelium- 
independent agents like sodium nitroprusside (SNP; Parker & Adams, 1993). 
SNP undergoes tissue-catalysed reduction yielding NO. The tissue-dependent 
nature of SNP is thought to reflect the presence or absence of a membrane bound 
protein which is required to actively ‘strip’ NO off NP (Kowaluk et al., 1992). 
Furthermore, there is controversy as to whether NO is actually responsible for 
the vasodilator properties of SNP, as responses are not always attenuated by 
inhibitors of guanylate cyclase (Diamond & Chu, 1983). In this respect SNP is 
generally not considered to be a ‘typical’ NO donor drug.
115
chapter 3- Results
This study, using the more conventional NO donor drug, S-Nitroso-N-acetyl- 
DL-penicillamine (SNAP), showed that vasodilator responses were significantly 
reduced in LPS-treated vessels as compared to controls (these experiments were 
carried out in the dark to prevent photolysis). This result might be explained by 
the fact that LPS treated vessels are producing high levels of NO prior to 
injection with SNAP, so guanylate cyclase will be activated and may therefore 
be less sensitive to the additional NO release by SNAP.
3.7.4 iNOS Expression iNOS is maximally expressed in LPS-treated RTAs 
within 4-6hrs, some 6-8hrs before NOX levels are significantly increased and 
before vessels become hyporesponsive to PE. Even more conspicuous is the lag 
between iNOS expression in RTAs and the resultant in vivo hypotension which 
is maximal after ~24hrs-post LPS. This was accompanied by a slight bradycardia 
which is consistent with myocardial depression observed in conditions of shock 
(Hom et al., 1995). By 24hrs the expression of iNOS protein is considerably 
reduced and falls below the limit of detection by 72hrs.
It is important when comparing the in vivo response to LPS with that of the ex 
vivo response produced by the isolated RTA to bear in mind that the latter is only 
representative of one vessel, and with so many other vessels contributing to the 
cardiovascular system, it is inevitable that one will express iNOS after a lag 
period which differs from another. One must therefore appreciate that the same 
lag time separating iNOS expression and hypotension in this case may not be 
applicable had another vessel been used. This is exemplified by lung tissue 
which is shown using immunofluorescence to contain large numbers of activated 
macrophages expressing high levels of iNOS at t= 24hrs.
Other immunohistochemical techniques reveal that iNOS is also expressed in the 
vascular smooth muscle of LPS treated RTAs (t= 6hrs) but not controls, and is 
often seen in large (macrophage-like) cells attached to the endothelial layer of 
LPS RTAs.
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3.7.5 eNOS Expression eNOS is strongly expressed both at t= 6hrs, 24 and 
72hrs post-LPS with no apparent decrease due to increased iNOS expression. 
The evidence concerning whether or not constitutive NOS activity in endothelial 
cells (ie. eNOS) is reduced upon activation of iNOS remains ambiguous (Walter 
et al., 1994; Yen et al., 1993). Diminshed eNOS activity has been suggested by 
studies using endothelium-dependent agonists (Parker & Adams, 1993). It is 
conceivable that eNOS is indeed unaffected by LPS but that the transduction 
pathway involved in agonist-mediated NO synthesis in endothelial cells is 
disrupted. This hypothesis is borne out by the results of this study showing L- 
NMMA augmenting responses in t= 18hr LPS RTAs beyond that of AG. 
Assuming that AG inhibits iNOS and not eNOS activity, it is likely that the 
effect of L-NMMA is due to inhibition of eNOS activity.
3.7.6 Conclusion From this study it is clear that exposure to a single bolus 
injection of LPS (serotype 055:B5; 4mg/Kg, i.p.) is sufficient to induce 
endotoxic shock in the rat. The criteria chosen to reflect endotoxaemia are 
consistent with each other and clearly identify the time-course of LPS-induced 
NO production over 72hrs. NOX levels, hyporesponsiveness to PE and the severe 
hypotension which occur in vivo all follow a similar time-course, with maximal 
effects seen at t= 24hrs and a subsequent return to control values over the next 
48hrs. This establishes the validity of the model for studying the properties of 
blood vessels from animals in endotoxic shock.
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Chapter 4
Effects of NOS inhibitors and L-arginine on 
responses of control and LPS-treated RTAs to PE
4.1 Introduction
It will be seen later (see Chapter 9) that the physiological basis for the 
hyporesponsiveness to PE of vessels isolated from LPS-treated rats (RTAs) and 
those which formerly supplied a solid tumour (TEAs) may not be identical. 
However, they appear sufficiently similar in some aspects to make it worthwhile 
trying to identify inhibitors which can most effecively reverse the condition in ex 
vivo experiments using RTAs from LPS-treated animals. The outcome of such 
experiments could ultimately provide a rational basis for predicting which 
compounds are most likely to selectively constrict tumour supply vessels in vivo, 
and thus compromise the delivery of oxygen and essential nutrients to the 
growing tumour.
This chapter deals with the effects of several NOS inhibitors on the senitivity to 
PE of RTAs taken post mortem from LPS-treated rats: two relatively non­
specific NOS inhibitors, L-NMMA and L-NAME (Hibbs et al,, 1987) and one 
which reportedly (Misko et al,, 1993; see Section 1.13.3) displays some 
selectivity towards the inducible isoform of NOS, aminoguanidine (AG). The 
results will show that L-NMMA was most effective at reversing the 
hyporesponsiveness associated with LPS-treated RTAs, although AG selectively 
reversed the hyporesponsiveness without altering control RTA responses to PE.
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4.2 Materials & Methods
4.2.1 Methods
Segments of RTAs from control and LPS-treated rats were isolated and perfused 
internally and externally with Krebs solution as described earlier (chapter 3). The 
following protocol was used:
1. An initial series of injections of PE was administered in the presence of Krebs 
solution only.
2. NOS inhibitors (L-NMMA, L-NAME or AG; all at [80pM]) were added to the 
internal perfusate for 30 mins before making a second series of injections.
3. The inhibitors were washed out with Krebs solution (10 mins) and then 
L-arginine (ImM) was added to the internal perfusate. Vessels were perfused 
with Krebs solution + L-arginine for 45mins and a third series of injections was 
made.
Peak perfusion pressures were measured and used to construct log dose-response 
(D.R.) curves (1st, 2nd and 3rd, respectively). Statistical significance of 
differences between D.R. curves was evaluated by two way analysis of variance 
(ANOVA). Student’s paired or unpaired t-tests determined the significance of 
any difference between data recorded at a given [PE] with a probability (P) value 
of 0.05 considered as statistically significant (p < 0.05*; p < 0.01**, p < 
0.001***).
4.2.2 Materials
L-NMMA, L-NAME, AG and L-arginine were all obtained from Sigma Ltd.
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4.3 Results
4.3.1 Comparing PE Responses in Proximal and Distal Segments of RTA.
In order to ensure that segments of RTA produced similar responses to PE 
irrespective of their position along the length of the tail, D.R. curves for 
proximal segments (l-4cm; n= 29) were compared with those more distal (< 
4cm, n= 27).
Fig. 4.1 Comparing initial D.R.s to PE in RTAs from proximal (open circles, n- 
29) and distal (closed circles, n-27) portions of the tail.
The results are shown in fig. 4.1. Contractile responses from distal and proximal 
segments were not significantly different (student’s unpaired t-test; see 
Appendix table 4.6) and therefore results for all of these preparations were 
pooled.
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4.3.2 Effects of L-NMMA on responses to PE of RTAs from control and 
LPS-treated rats: reversal by L-arginine. The effects of L-NMMA and the 
ability of L-arginine to reverse its action were studied in both control (t= 0) and 
LPS-treated RTAs (t= 6, 18, 24).
The results are shown in figs. 4.2-4.5. L-NMMA enhanced responses to PE in 
both control and LPS-treated RTAs, producing a leftward and upward 
displacement of the D.R. curve. The effect was significant (Student’s paired t- 
test) for all groups, with the exception of vessels from LPS-treated animals 
sacrificed at t= 6hrs.
L-arginine completely blocked the effects of L-NMMA at all time points, but did 
so to differing extents. Interestingly, L-arginine more than reversed the effect of 
L-NMMA on t= 18hr RTAs, displacing the curve downwards and to the right, 
beyond the initial D.R. curve recorded in the presence of Krebs solution alone 
(fig. 4.4, filled triangles). This particular effect of L-arginine is considered again 
later (see 4.5, Discussion). Statistical analyses for the data presented in figs. 4.2­
4.5 appear in Appendix tables 4.1 .
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Log [PE] (M)
Figs. 4.2-4.5 The D.R.s for control (fig. 4.2) and LPS-treated (t= 6, 18 and 24; 
figs. 4.3-4.5 respectively) RTAs before (open circles) and after treatment with 
L-NMMA (open squares; 80pM) and L-arginine (ImM; closed triangles).
4.3.3 Effects of L-NAME on responses to PE of RTAs from control and 
LPS-treated rats: reversal by L-arginine. The effects of L-NAME and of 
subsequent treatment with L-arginine were studied in both control (t=Ohrs) and 
LPS-treated RTAs (t= 6, 18, 24 and 72hr). The results are shown in figs. 4.6­
4.10.
As with L-NMMA, L-NAME also enhanced responses to PE in both control and 
LPS-treated RTAs displacing the D.R curve upwards and to the left. The effect 
was statistically significant for t= 18 and 24hr LPS-treated arteries but not for the 
control or vessels sacrificed at t= 6 and 72hrs.
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Figs. 4.6-4.10 Showing the D.R.s for control (fig. 4.6) and LPS RTAs at t= 6 
(fig. 4.7), 18 (fig. 4.8), 24 (fig. 4.9) and 72hrs (fig. 4.10) before and after 
treatment with L-NAME and L-arginine.
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Treatment with L-arginine completely reversed the effect of L-NAME and in this 
respect resembled results obtained with L-NMMA. Statistical analyses for these 
data appear in Appendix table 4.2.
4.3.4 Effects of aminoguanidine alone and of aminoguanidine followed by 
L-NAME on responses to PE of RTAs from control and LPS-treated (t= 
18hr) rats. Experiments were made to test the effect of aminoguanidine (AG), a 
selective iNOS inhibitor, and of aminoguanidine followed by L-NAME, a 
relatively non-selective NOS inhibitor, on PE responses of both control RTAs 
and RTAs from LPS-treated (t= 18hr) animals. The protocol was as follows. 
First, isolated segments of RTA from control and LPS-treated animals were 
injected with PE in the presence of Krebs solution only. Second, vessels were 
perfused with Krebs solution containing AG (ImM) for lhr before a second 
sequence of PE injections was given. Finally, following a 10 min washout with 
Krebs solution, L-NAME (80//M) was added to the internal perfusate before 
performing a third sequence of PE injections.
Fig. 4.11 shows the effect on control arteries. Contrary to what was seen with 
L-NMMA and L-NAME, AG produced a small rightward shift in the D.R. curve, 
but this was not statistically significant (2-way ANOVA, F= 0.58, df= 9, 118e, 
p= 0.810). This effect was fully reversed by replacing AG with L-NAME. 
However, neither of the curves obtained with AG or with L-NAME was 
statistically different from that obtained in the presence of Krebs solution only.
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Log [PE] (M)
Fig. 4.11 A graph showing the D.R.s for controls (n-5-8) initially perfused 
with Krebs (dotted line, open circles) then after lhr AG (ImM; open squares) 
and 30mins L-NAME (80pM; closed circles).
Fig. 4.12 shows the results obtained from a similar series of experiments, this 
time using RTAs from animals sacrificed at t= 18 hrs after LPS treatment. RTAs 
from LPS-treated rats (open circles) were significantly less responsive to PE 
compared to control vessels (dotted line), as determined by 2-way ANOVA (F= 
2.51, df= 8, 153e, p= 0.014). This difference was completely abolished by AG, 
which displaced the curve for LPS-treated vessels to the left and upward, so that 
it almost exactly coincided with that obtained for control (ie. non LPS-treated) 
vessels (2-way ANOVA, F= 3.04, df= 9, 19le, p=0.002). Removal of AG 
followed by replacement with L-NAME further shifted the D.R. curve upward 
and to the left (2-way ANOVA, F= 2.10, df= 8,143e, p= 0.041). This difference 
is attributed (see Discussion) to the differential effect of the two NOS inhibitors 
on the constitutive and inducible NOS isoenzymes. Statistical (Student’s t-test) 
analyses for these data appear in Appendix table 4.3.
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Fig. 4.12 D.R.s for LPS treated RTAs (t- 18hrs, n= 7-11) perfused with Krebs 
(open circles), AG (ImM; open squares) and L-NAME (80pM; closed circles). 
The 1st D.R. curve for controls is included for comparison (dotted line). 
Asterisks indicate significant difference between the Krebs D.R. and the AG D.R. 
using t-test analysis.
Log [PE] (M)
Finally, experiments were also made using vessels taken from animals at t= 
72hrs after injection with LPS (data not shown). Results presented earlier 
(Chapter 3, section), clearly showed that such vessels do not display a 
hyporesponsiveness to PE and this was confirmed in this series of experiments. 
The results were comparable to those obtained for control (ie. non-LPS-treated) 
vessels ie. the log D.R. curve for vessels perfused with Krebs solution alone was 
not significantly different from that obtained with Krebs + AG (2-way ANOVA, 
f= 1.01, df= 9, 50e, p= 0.445). Although, the log D.R. curve for Krebs + 
L-NAME was significantly shifted to the left (2-way ANOVA, F= 2.57, df= 9, 
47e,p<0.01).
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4.4 Quantitative analysis of the effect of NOS inhibitors on PE-induced 
responses. For clarity and some measure of quantification, experiments 
involving drugs which altered PE-induced contractile responses (ie. NOS 
inhibitors) are analysed with reference to 2 parameters (refer to fig.4.13): 
a) the contractile response to a PE injection of 5xlO"3M (P),
and
b) the [PE] required to produce an active perfusion pressure of ISOmmHg 
(EDiso).
The largest effect on both parameters when tested on the most hyporesponsive 
vessels (t= 24hrs) was seen with L-NMMA. For this reason the effects of 
L-NAME and AG are expressed as a % of the changes seen with L-NMMA (ie. 
% AED150 and % AP.This is shown diagrammatically in fig. 4.13 where:
AED150 for L-NMMA = A - B= 100%
and
AP for L-NMMA = B’ - A’ = 100%
150mmHg
Fig. 4.13 The relative effects of a NOS inhibitor are expressed as a % of the
AED150 and AP between the D.R. curves for LPS-treated (t- 24hr) vessels in the 
presence of Krebs solution alone (1) and in the presence of L-NMMA (2).
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Fig 4.14- 4.16 show results for control and LPS-treated vessels exposed to 
L-NMMA (fig. 4.14), L-NAME (fig. 4.15) and AG (fig. 4.16). The effect of 
L-NMMA on both AP and AEDjsq increases progressively with time after LPS 
treatment, by definition reaching 100% at t= 24hrs. Responses to L-NAME, on 
the other hand rise to maximum at ~18hrs, increasing AP by -50-60% and 
AED150 by -40% of the maximum effect seen with L-NMMA.
The results obtained with AG refer only to control arteries and arteries from 
animals sacrificed t= 18hrs. Since AG caused a slight (not statistically 
significant) rightward and downward shift of the log D.R. curve when tested on 
control arteries ( see fig. 4.11) the changes in the ED 150 and P are negative. The 
effect of AG on the ED 150 value for LPS-treated vessels (t= 18hrs) was -20% of 
that produced by L-NMMA, but on the P value it produced an effect -80% of 
that seen with L-NMMA. Generally, in terms of their potency, the three NOS 
inhibitors can be ranked as follows: L-NMMA > L-NAME > AG. The one 
exception to this is the effect of AG on P which is greater than that of L-NMMA 
and L-NAME at t= 18hrs.
y= 9.803x; 0.991
0 6 18 24 72
% Effect 60-; 
of L-NMMA I
Time (Hrs)
Fig. 4.14 Shows the effect of L-NMMA on P (dark columns) and ED150 (striped 
columns). Results are expressed as % of LPS D.R. values (t~ 24hrs).
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% Effect 
of L-NAME
Fig. 4.15 A graph showing the effects of L-NAME on ED 150 (striped columns) 
and P (dark columns) expressed as a percentage of LPS, t- 24hr L-NMMA 
treated data.
Figs. 4.16 A graph showing the effects of AG on ED] 50 (striped columns) and P 
(dark columns) expressed as a percentage of LPS, t- 24hr L-NMMA treated 
data.
The time-dependent increase in the effect of L-NMMA on ED 150 from t= 6 - 
24hrs is consistent with the increasing hyporesponsiveness and when the values 
for LPS RTAs (t= 6, 18, 24hrs) are plotted against 1/m a linear relation is 
obtained (see fig. 4.14i). This implies that L-NMMA is equally effective at
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reversing the LPS-induced hyporesponsiveness at all time-points. A linear 
relation is not obtained if the same procedure is applied to L-NAME.
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4.5 Discussion
The results presented in this chapter confirm the results of chapter 3 in showing 
that RTAs taken from LPS-treated rats are hyporesponsive to PE. Both 
L-NMMA and L-NAME increased the sensitivity to PE of control and LPS- 
treated vessels and thus abolished their hyporesponsiveness. Indeed, there was 
no difference in sensitivity in control and LPS-treated vessels in the presence of 
either NOS inhibitor. The effects of AG, widely acknowledged to be a more 
selective inhibitor preferentially blocking the inducible isoform (Joly et al., 
1994; Wu et al., 1995; Griffiths et al., 1993), were somewhat different. First, AG 
had no effect on responses of control arteries to PE. Second, AG fully restored 
the sensitivity of LPS-treated (t= 18hr) vessels to control values, but it did not 
further increase their sensitivity as did L-NMMA and L-NAME (see fig. 4.12). 
The differing effects of AG on the one hand and L-NMMA and L-NAME on the 
other can be explained if a) the hyporesponsiveness of LPS-treated vessels to PE 
is due to enhanced NO production via the action of the inducible isoenzyme, b) 
AG does not significantly effect NO production via the constitutive isoform. The 
increased sensitivity of vessels treated with L-NMMA and L-NAME, over and 
above control sensitivities, can equally be explained if both drugs inhibit the 
constitutive as well as the inducible NOS isoforms. The additional effects of 
L-NMMA and L-NAME over those seen with AG is presumably entirely due to 
blockade of eNOS. This is consistent with the fact that administering L-NAME 
to control and LPS-treated vessels after treatment with with AG produced an 
additional increase to PE.
The fact that a high dose of L-arginine (ImM), the natural substrate for all NOS 
isoforms, could fully reverse the effects of both L-NMMA and L-NAME 
confirms that both inhibitors increase the sensitivity to PE by inhibiting NO 
production.
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Qualitatively similar results to those presented here were obtained when 
studying the effects of NOS inhibitors on arteries which previously supplied 
solid tumours and contralateral (control) arteries as will be seen in Chapter 7. 
Finally, the differential effects of non-selective and isoform selective NOS 
inhibitors might be usefully exploited in studies of the role of NO in solid 
tumour growth. This is considered in Chapter 8.
Although, L-NAME and L-NMMA are shown to reverse the LPS-induced 
hyporeactivity to PE, this does not rule out the possibility that other mediators 
other than NO are involved in this effect. A recent study suggests that NOS 
inhibitors can also inhibit cyclooxygenase activity (Salvemini et al., 1995). The 
implications of this become apparent in experiments shown in the next chapter.
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Chapter 5
Effects of Indomethacin, Cycloheximide and 
L-NMMA on Contractility of Rat tail Artery.
5.1 Introduction
Kennovin et al., (1994) showed that constant perfusion for 2hrs with the protein 
synthesis inhibitor cycloheximide (IOjiM) abolished the initial difference in 
sensitivity to PE between TEAs and CEAs. Furthermore, a time-dependent 
decrease in responsiveness of CEAs, occasioned by prolonged perfusion (up to 
9hrs) with Krebs solution only, was also prevented by cycloheximide. A similar 
observation was reported by Rees et al., (1990), using rat aortic rings, in which 
cycloheximide (10|iM) abolished the gradual loss of tone of preparations 
incubated in Krebs for up to 8hrs. The time-course of the phenomenon and its 
prevention by both cycloheximide and inhibitors of NOS (Kennovin et al., 1994; 
Rees et al., 1990), led to the conclusion that this effect was mediated by 
increased NO synthesis by iNOS within the vascular smooth muscle of these 
preparations. It was also found that the expression of iNOS and the ensuing loss 
of tone began after a lag period of ~2hrs, and although LPS hastened and 
potentiated this effect, the time of onset remained the same.
Experiments were conducted to see whether control and LPS-treated RTAs 
behaved in a similar manner to CEAs and TEAs following treatment with 
cycloheximide. Indomethacin, the preferential inhibitor of the cyclooxygenase 
pathway involved in arachidonic acid metabolism, was also used to determine 
whether the hyporesponsiveness of LPS-treated arteries could be attributed to the 
inducible cyclooxygenase (iCOX), known to be co-induced with iNOS both in 
vitro and in vivo (Salvemini et al., 1993). Cyclooxygenases are thought to be 
responsible, at least in part, for the symptoms associated with endotoxaemia 
(Salvemini et al., 1995) and since they have the potential to synthesise both
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vasoconstrictors (eg. thromboxane A2) and vasodilators (eg. prostacyclin), this 
pathway is likely to be of importance when considering the properties of isolated 
blood vessels. Their possible role in the time-dependent desensitization was not 
addressed in the study by Rees et al., (1990) since these authors used the 
synthetic glucocorticoid, dexamethasone, which inhibits both iNOS and iCOX. 
As a result, their experiments were unable to distinguish which enzyme system 
was responsible for the effect.
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5.2 Materials & Methods
5.2.1 Methods
Isolated segments of RTA from control and LPS-treated (t= 18hrs) Wistar rats 
were perfused both internally and externally with pre-warmed Krebs solution as 
decribed earlier (chapter 3). The following protocol was adopted:
1. Control and LPS-treated RTAs were divided into two groups: after 45 mins, 
perfusion, indomethacin (final concentration of lOpM) was added to the internal 
perfusate of group 1 (n= 6-8 for LPS and control RTAs), while group 2 
continued to be perfused with Krebs only (n= 5-6 for both). After a further 
30mins, both groups were given an initial (Ohrs) series of bolus injections of 
increasing [PE]s (10“5-10~2M).
2. Cycloheximide was added to the internal perfusate of both groups (final 
concentration of lOpM) and lhr later another series of injections was performed 
and repeated hourly for 4hrs (l-4hrs).
3. Finally, L-NMMA (80pM) was added to the internal perfusate of both groups 
and after 30-45mins a final series of PE injections was given.
Peak perfusion pressures were measured and used to construct log dose-response 
(D.R.). Statistical analysis was similar to that described earlier in chapter 4.
5.2.2 Materials
Cycloheximide, indomethacin and L-NMMA were all obtained from Sigma Ltd.
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5.3 Results
5.3.1 Effects of cycloheximide alone and cycloheximide + L-NMMA on PE- 
induced responses in control and LPS-treated RTAs. LPS-treated arteries 
were hyporesponsive to PE as compared to control arteries (as shown previously 
in Chapter 4).
Fig. 5.1 shows that the addition of cycloheximide alone to control vessels had no 
significant effect (2-way ANOVA, F= 0.38, df= 9, 85e, p= 0.94). Subsequent 
addition of L-NMMA to the internal perfusate (= Krebs + cycloheximide + 
L-NMMA) shifted the log D.R. curve to the left, but the effect was not as great 
as that produced by L-NMMA on control RTAs not previously exposed to 
cycloheximide (Fig. 5.2; Student’s t-test analysis, see Appendix Table 5.5), i.e. 
cycloheximide significantly reduced the effect of L-NMMA.
Figs. 5.1 & 5.2 Showing the D.R. curves for control RTAs perfused with Krebs 
(open circles, n= 5-6; Figs. 5.1 & 5.2), after 4hrs perfusion with cycloheximide 
alone (closed circles; Fig. 5.1) and following the addition of L-NMMA (closed 
triangles; Fig. 5.2). The D.R. curve for control RTAs not previously treated with 
cycloheximide is also shown in rig. 5.2 (close squares, n-l^) anJ tue asterisks 
show a significant difference between the data represented by closed triangles 
and closed squares.
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In contrast, responses to PE of LPS-treated arteries were significantly enhanced 
by cycloheximide (see Fig. 5.3; Asterisks represent p values < 0.05 *, Student’s 
paired t-test; see Appendix table 5.3). A similar effect has previously been 
shown for tumour-associated vessels (Kennovin et al., 1994). Indeed, the 
potentiation was as great as that seen after exposing LPS-treated vessels to 
L-NMMA only (i.e. without prior treatment with cycloheximide), so that 
responses were enhanced as compared to even untreated control vessels. Thus, 
the subsequent addition of L-NMMA (= Krebs + cycloheximide + L-NMMA) 
had no further potentiating action (see Fig. 5.4).
LOG [PE] (M) LOG [PE] (M)
Figs. 5.3 & 5.4. Showing the D.R. curves for LPS RTAs (t= 18hrs) perfused with 
Krebs (open circles, n~ 5-6; Figs. 5.3 & 5.4), after 3hrs perfusion with 
cycloheximide alone (closed circles; Fig. 5.3) and following the addition of L- 
NMMA (closed triangles; Fig. 5.4). The D.R. curve for LPS RTAs not previously 
treated with cycloheximide is also shown in Fig. 5.4 (open squares, n-9).
5.3.2 Effects of indomethacin and indomethacin + cycloheximide on 
PE-induced responses in control and LPS-treated RTAs. The addition of 
indomethacin to the internal perfusate of control RTAs (i.e. = Krebs + 
indomethacin) had no significant effect (not shown) and neither did the 
subsequent addition of cycloheximide (= Krebs + indomethacin +
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cycloheximide; see Fig. 5.5 & Appendix table 5.4 for Student’s t-test analysis). 
However, when L-NMMA was later added (= Krebs + indomethacin + 
cycloheximide + L-NMMA; Fig. 5.6, closed triangles), it produced a leftward 
shift of the curve approaching that seen in LPS-treated vessels not previously 
exposed to indomethacin or cycloheximide (Fig. 5.6; open squares).
LOG [PE] (M) LOG [PE] (M)
Figs. 5.5 & 5.6 Showing the D.R. curves for control RTAs perfused with Krebs 
(open circles, n~ 6-8; Figs. 5.5 & 5.6), after 4hrs perfusion with indomethacin + 
cycloheximide (closed circles; Fig. 5.5) and following the addition of L-NMMA 
(closed triangles; Fig. 5.6). The D.R. curve for control RTAs not previously 
treated with cycloheximide or indomethacin is also shown in Fig. 5.6 (open 
squares, n=10).
Treatment of LPS-treated RTAs with indomethacin alone (= Krebs + 
indomethacin) had no effect on responses to PE (not shown), and the subsequent 
addition of cycloheximide to the internal perfusate also had no effect (= Krebs + 
indomethacin + cycloheximide, see Fig. 5.7; closed circles & Appendix table 
5.4). This is marked contrast to the effect of cycloheximide alone (see section 
5.3.1), which greatly potentiated responses of LPS-treated vessels, i.e. prior 
treatment with indomethacin abolished the potentiating effect of cycloheximide. 
When L-NMMA was later added (= Krebs + indomethacin + cycloheximide + 
L-NMMA; see Fig. 5.8, closed triangles), responses to PE were enhanced in the 
normal way i.e. although indomethacin inhibited the potentiating effect of
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cycloheximide, it did not alter the effect of L-NMMA. See Appendix tables 5.5
LOG [PE] (M) LOG [PE] (M)
Fig. 5.7 & 5.8 Showing the D.R. curves for LPS RTAs (t- 18hrs) perfused with 
Krebs (open circles, n- 6-8; Figs. 5.7 & 5.8), after 3hrs perfusion with 
indomethacin + cycloheximide closed circles; Fig. 5.7) and following the 
addition of L-NMMA (closed triangles; Fig. 5.8). The D.R. curve for LPS RTAs 
not previously treated with cycloheximide or indomethacin is also shown in Fig. 
5.8 (open squares, n=9).
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5.4 Discussion
These experiments were designed to show whether a similar poteniating effect of 
cycloheximide as that described by Kennovin et al. (1994) in isolated tumour- 
supply vessels, was also seen in vessels taken from animals which had 
previously received an injection of LPS (t= 18hrs). The role of cyclooxygenase 
enzymes in this effect was also explored using the specific cyclooxygenase 
inhibitor, indomethacin.
5.4.1 Effects of cycloheximide and cycloheximide + L-NMMA on control 
and LPS-treated RTA responses to PE. A constant 4hr internal perfusion with 
the protein synthesis inhibitor cycloheximide (10|iM) alone did not significantly 
alter control RTA responses to PE. Furthermore, when L-NMMA was 
subsequently added to the internal perfusate, the characteristic leftward shift 
caused by L-NMMA in untreated control RTAs (i.e. not previously exposed to 
cycloheximide) was not seen. Cycloheximide therefore abolished the 
potentiating effect of L-NMMA in control RTAs.
In contrast to control RTAs, the sensitivity to PE of LPS-treated (t= 18hrs) RTAs 
was significantly enhanced after 3hrs of perfusion with cycloheximide, such that 
the D.R. curve was shifted beyond that of untreated control RTAs, to lie almost 
exactly on the curve produced by L-NMMA in untreated LPS-treated vessels 
(i.e. vessels which had not previously been exposed to cycloheximide). 
Moreover, the subsequent addition of L-NMMA did not further enhance 
responses to PE.
From this evidence it would appear that the hyporesponsiveness to PE associated 
with LPS-treated RTAs requires de novo protein synthesis and is consequently 
abolished by cycloheximide. Furthermore, the diminished effect of L-NMMA 
after cycloheximide treatment in control RTAs suggests that de novo synthesis
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may also be required for constitutive NO production by eNOS, although further 
work is needed to confirm this.
As a protein synthesis inhibitor, cycloheximide could potentially inhibit a 
number of enzymes thought to be stimulated by LPS, it is therefore unlikely that 
disruption of iNOS activity is solely responsible for the effects on LPS-treated 
vessels, if at all. Other factors which regulate iNOS activity could also be 
affected by cycloheximide, including interferon regulatory factor-1 (Kamijo et 
ah, 1994), nuclear factor-AB (Schreck et al., 1992), transforming growth factor 
(Vodovitz et al., 1993) and a number of other transcriptional factors (Gross et 
al., 1994). However, the role of many of these factors in iNOS expression is 
dependent on whether cells are in culture or as part of an isolated vessel (Sirsjo 
et al., 1994). Sirsjo et al., (1994) found that in culture cycloheximide potentiated 
the induction of iNOS expression by LPS but in aortic tissue strips 
cycloheximide attentuated iNOS expression. This indicates that the induction of 
iNOS ex vivo requires de novo protein synthesis and strengthens the idea that 
inhibition of iNOS by cycloheximide explains the effect on LPS-treated vessels.
The production of NO from L-arginine requires several different cofactors, 
including tetrahydrobiopterin (BH4), NADPH and flavins, all of which may be 
influenced by cycloheximide (see Section 1.12). De novo synthesis of BH4 is an 
absolute requirement for full NOS activation (Baek et al., 1993; Gross et al., 
1994) and may become limiting during cytokine-mediated activation of iNOS in 
VSM cells (Gross & Levi, 1992). It is clear therefore that cycloheximide could 
inhibit BH4 synthesis and so prevent NO production without disrupting iNOS 
expression. Furthermore, most BH4 (-90%) is produced by the endothelium and 
is then directed towards the VSM (Schoedon et al., 1993). This stresses the 
importance of using endothelium-intact vessels for studying iNOS-derived NO 
production ex vivo.
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In order that iNOS can produce high levels of NO there also has to be sufficent 
L-arginine substrate to satisfy demand. L-arginine is synthesised endogenously 
as part of the urea cycle (Meijer et al., 1990), although it can also be recycled 
from L-citrulline by an LPS-inducible enzyme, argininosuccinate synthetase 
(iAS) within the vasculature (Morris et al., 1994; see Section 1.13). 
Cycloheximide has been shown to attenuate the induction of iAS mRNA in 
cultured aortic smooth muscle cells (Hattori et al., 1994). Whether the same also 
occurs in tissue preparations is not clear. If cycloheximide does inhibit the 
expression of iAS in isolated vessels then L-arginine may become limiting to NO 
production in LPS-treated RTAs, with the result that responses to PE are 
potentiated.
It is clear that cycloheximide could reduce NO production via a number of ways, 
many of which do not involve the NOS enzyme. Whatever the mechanism, it’s 
potentiating effect was exclusive to vessels isolated from LPS-injected animals 
(t= 18hrs) and produced a leftward shift in their D.R. curve. This may imply that 
a) a vasodilator had been inhibited b) that a vasoconstrictor had been activated.
Further evidence that iNOS may be involved stems from two sources; a) 
Western Blot analysis shows that iNOS continues to be expressed beyond t= 
24hrs and will therefore also be expressed at t= 18hrs. b) aminoguanidine was 
able to abolish the hyporesponsiveness to PE displayed by LPS-treated vessels 
(t= 18hrs). However, it is worth noting that unlike cycloheximide, 
aminoguanidine did not potentiate the responses beyond those of control RTAs.
5.4.2 Effects of indomethacin, indomethacin + cycloheximide and 
indomethacin + cycloheximide + L-NMMA on control and LPS-treated 
RTA responses to PE. Indomethacin did not have a significant effect on the 1st 
D.R. curves (= Krebs + indomethacin) for either control or LPS-treated vessels 
(data not shown). After 4hrs perfusion with indomethacin + cycloheximide (both 
at concentrations = 10pM) the control responses to PE were not significantly
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altered. The addition of L-NMMA (= Krebs + indomethacin + cycloheximide + 
L-NMMA) produced a leftward shift comparable to that for untreated, control 
vessels.
As with control RTAs, indomethacin on its own did not influence responses to 
PE in LPS-treated vessels. However, the potentiating effect of cycloheximide 
seen when used on its own, was completely abolished when it was added after 
indomethacin (= Krebs + indomethacin + cycloheximide), the result of which 
was to reveal a large leftward shift when L-NMMA was later added (= Krebs + 
indomethacin + cycloheximide + L-NMMA). This shift was comparable to that 
produced by L-NMMA in untreated LPS-treated vessels.
These results suggest that LPS treatment induces the expression of 
cyclooxygenases in isolated RTA, and that the potentiating effect of 
cycloheximide in these vessels reflects the inhibition of vasoactive products 
synthesised by these enzymes. Furthermore, the effect of L-NMMA added after 
cycloheximide (= Krebs + indomethacin + cycloheximide + L-NMMA) appears 
to be enhanced in control RTAs as compared to its effect after cycloheximide 
treatment alone (= Krebs + cycloheximide; see Section 5.4.1), i.e. indomethacin 
prevents the inhibitory action of cycloheximide on the L-NMMA-mediated shift 
in control RTAs, and thereby exposes the synergism between NO and 
cyclooxygenase-derived products. This, together with the fact that in LPS-treated 
vessels L-NMMA (i.e. = Krebs + indomethacin + cycloheximide + L-NMMA) 
produced a shift similar to that in untreated LPS-treated vessels (i.e. not 
previously exposed to indomethacin or cycloheximide), implies that 
indomethacin does not inhibit cNOS-derived basal NO production in control 
RTAs or the upregulated NO production by iNOS in LPS-treated vessels.
Indomethacin inhibits the cyclooxygenase pathway and by doing so, may 
influence vascular tone by inhibiting vasoconstrictors (eg. thromboxane A2) or 
vasodilators (eg. prostacyclin). Two forms of cyclooxygenase have been
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identified, a constitutive isoform and an LPS/cytokine-inducible isoform 
(iCOX). iCOX is induced by endotoxin which can result in an upregulated 
thromboxane A2 or prostacyclin synthesis (Salvemini et al., 1993; Wu et al., 
1994). Therefore, the ability of indomethacin to abolish the potentiating effect of 
cycloheximide in LPS-treated RTA responses to PE suggests that vasoactive 
products such as these are synthesised and can modify responses to PE. These 
results also indicate that the effect of cycloheximide on its own reflects an 
inhibition of de novo synthesis of one or more of these products.
5.4.3 Conclusion
Cycloheximide selectively augments responses to PE in LPS-treated vessels. 
This effect was sensitive to indomethacin, indicating the involvement of 
vasoactive products of the cyclooxygenase pathway. The syngergistic 
relationship between the NOS and COX pathways has been thoroughly studied 
(Salvemini et al., 1993, 1995; Vane et al., 1994; Swierkosz et al., 1994). Both 
enzymes can be induced by cytokines to produce high levels of vasodilator and 
in the case of COX, vasoconstrictor products, which influence the size of 
contraction produced in response to PE by an LPS/cytokine-activated vessel (Wu 
et al., 1994). The fact that cycloheximide caused a leftward shift of LPS-treated 
RTA responses to PE suggests that production of an enzyme-derived vasodilator, 
synthesised de novo within the vessel wall, was inhibited. Further studies will 
have to be performed to determine the identity of these. The two most likely 
candidates are NO and/or prostacyclin. Prostacyclin is the main product of 
arachidonic acid metabolism in isolated vascular tissues (Honn et al., 1983).
The fact that NOS inhibitors were shown to fully reverse the hyporesponsiveness 
to PE in LPS-treated vessels (see chapter 4) does not rule out the involvement of 
prostaglandins in this effect as a recent publication by Salvemini et al., (1995), 
suggests that analogue inhibitors of NOS, including L-NAME, may also inhibit 
prostaglandin production. Whether this is due to a direct inhibition of the
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enzymes synthesising the prostaglandins (ie. cyclooxygenases) or an indirect 
result of reduced NO production is not clear.
It could be argued that LPS-treated vessels did not show an altered respones to 
PE in the presence of indomethacin only since both vasodilator and 
vasoconstrictor products of the cyclooxygenase pathway are being produced and 
therefore counteract each other. The effect of cycloheximide may suggest that 
only the vasodilator product requires de novo synthesis. This explanation is 
speculative and further studies will have to be conducted to confirm or dismiss 
it.
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Chapter 6
Ruthenium complexes as nitric oxide scavengers: 
therapeutic potential in nitric oxide-mediated 
disease.
6.1 Introduction
As already outlined in Part D of the Introduction and in Chapter 3, mounting 
evidence supports the view that iNOS-generated NO is an important causal 
factor in septic shock syndrome. The ability of NOS inhibitors to alleviate some 
of the haemodynamic manifestations of septic shock has focused attention on 
their therapeutic potential. The outcome thus far has been equivocal, with reports 
of adverse cardiovascular consequences, for example, pulmonary hypertension 
(Robertson et al., 1994) and ultimately, increased mortality in animal models 
(Minnard et al., 1994; Tracey et al., 1995). It is becoming increasingly apparent 
that the capacity to discriminate between iNOS and cNOS is crucially important 
in this context and increasing effort is now devoted to finding more isoenzyme- 
selective inhibitors of NOS. To date, the most promising compound displaying a 
greater specificity for iNOS than for cNOS is aminoguanidine (Griffiths et al., 
1993) which has been shown to cause partial reversal of vascular hyporeactivity 
ex vivo (Joly et al., 1994) and improved survival in endotoxic animals in vivo 
(Wu et al., 1995). Certain isothioureas also show some selectivity for the 
inducible isoform (Southan et al., 1995).
The present study addresses an alternative strategy to treating NO-mediated 
disease with the use of drugs which specifically scavenge and remove 
pathophysiological quantities of NO, rather than block its synthesis. The 
potential of a range of ruthenium compounds has been explored with this in 
mind and this study reports on the pharmacological properties of three ruthenium 
(III) complexes: penta-aminechloro-ruthenium-3-dichloride (or JM1006),
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potassium chloro [hydrogen(ethylenedinitrilo)tetraacetato]ruthenate (or JM1226) 
and aqua[hydrogen(ethylenedinitrilo)tetraacetato]ruthenium (or JM6245).
6.1.1 Summary of findings.
Experiments conducted in collaboration with Dr. Simon Flicker (Johnson 
Matthey Technonology Centre, Reading, England), have established that:
1) Many ruthenium(III) complexes react readily with NO to form stable 
ruthenium(II) mononitrosyls. A range of Ru(III) complexes was synthesised and 
a study made of the ability of each to bind NO, both in vitro and in vivo and also 
in the model of endotoxic shock in the rat (see Chapter 3).
2) Binding of authenic NO gas by aqueous solutions of JM1226 was studied 
manometrically by Dr. Simon Fricker. Reaction with NO gave a product with an 
infra red (IR) spectrum having a peak absorbance at 1897 cm“l, characteristic of 
an Ru(II)-NO adduct. Reaction of JM1226 with the NO donor drug S-nitroso-N- 
acetylpenicillamine (SNAP) yielded a compound with a similar IR spectrum.
3) Fricker et al., (m press), showed that the considerable increased accumulation 
of NO2“ in growth media from cultures of LPS/interferon-gamma-treated RAW 
264 macrophages was abolished in the presence of JM6245 or JM1226. 
Furthermore, the reduction in NO2" levels was comparable following treatment 
with L-NMMA and with all three compound, NO2" levels were similar to those 
obtained in media from wrcactivated macrophages.
4) Addition of JM1226 or JM6245 (both lOOjlM) to the culture medium of 
stimulated RAW 264 macrophages significantly increased the cell viability of 
co-cultured P815 murine mastocytoma cells. The degree of protection afforded 
by JM compounds was the same as that seen after blockade of NO production by 
the NOS inhibitor, L-NMMA (Fricker et al., in press).
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5) Male Wistar rats were injected with bacterial LPS (4mg/Kg; i.p.) to induce 
endotoxic shock (see Chapter 3). JM1006, 1226 and 6245 (both lOOgM) fully 
reversed the hyporesponsiveness to PE of internally-perfused RTAs isolated 
from animals injected with LPS 24hrs previously (ie. t= 24hrs). Furthermore, a 
single injection of JM1226 (lOOmg/Kg; i.p.) administered 20hr after an LPS 
injection (4mg/Kg; i.p.) reversed the hypotension associated with endotoxic 
shock within ca 9hrs.
6) These results show that JM1006, 1226 and 6245 are able to scavenge NO in 
biological systems and suggest a role for these ruthenium complexes in novel 
therapeutic strategies aimed at alleviating NO-mediated disease states.
I presented an account of some aspects of this work at the Fifth International 
Meeting on the Biology of Nitric Oxide held on Amelia Island, Florida (Flicker 
etal., 1996).
6.1.2 Theory
Ruthenium forms more nitrosyl complexes than any other metal (Bottomley, 
1978). Ru(II) reacts with NO to form six co-ordinate Ru(II) mononitrosyls 
containing a linear Ru-NO bond. The latter is very stable, able to resist a variety 
of redox and substitution reactions, and consequently the nitrosyl moiety is not 
easily displaced. Chelation of the metal with a suitable ligand can be employed 
to confer water solubility, facilitating rapid in vivo clearance and low toxicity, 
whilst providing an available binding site for NO. The polyaminocarboxylates, 
such as ethylenediaminetetraacetic acid (edta), satisfy these requirements as 
ligands. In all three complexes mentioned here edta is pentadentate so that one 
co-ordination position is available for NO binding.
Reaction of JM1226 with NO in aqueous solution (see fig. 6.1) involves 
formation of the aqua derivative, JM6245, followed by a rapid substitution of 
H2O for NO. The ligand around ruthenium(III) is kinetically inert and formation
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of the linear Ru-NO bond further stabilises the trans position in the resulting 
ruthenium(II) adduct (Fricker et al., in press').
JM 1226 JM 6245 I
NO f«t
Fig. 6.1 Equilibrium diagram of the reaction between JM1226 and NO in 
aqueous solution. Reaction between the aqua derivative, JM6245, and NO is 
rapid and proceeds via a seven co-ordinate intermediate. The resulting stable 
adduct contains a linear Ru(II)-NO bond (see fig. 6.2).
149
Chapter 6- Results
6.2 Materials and Methods
6.2.1 Methods
Binding of NO by aqueous solutions of JM1226. Two experiments were 
conducted (Fricker et al., 1995 and in press}. First, a known volume of authenic 
NO gas (3cm3; 1.3 x 10"4 moles) was introduced into the headspace above a 
stirred aqueous solution of JM1226 (25cm^; 1.3 x 10"4 moles) in a closed 
apparatus under an argon atmosphere. Temperature was maintained at 22-24°C. 
NO absorption was measured using a manometer. After complete absorption of 
NO (generally, ca 20 mins) the reaction mixture was freeze dried and the product 
examined by infra-red (IR) spectroscopy using a Perkin Elmer 1720X FT-IR 
spectrometer. Second, equimolar amounts (9 x 10'5M) of JM1226 and the NO 
donor SNAP were dissolved in water and allowed to react for 24hrs. The 
resulting compound was freeze-dried and its IR spectrum recorded later.
Isolated rat tail artery preparation. Segments of of RTAs from control and 
LPS-treated (t= 24hrs) Wistar rats were isolated and perfused internally and 
externally with Krebs solution as described earlier (Chapter 3). The following 
protocol was used:
1. An initial series of bolus (10p,l) injections of PE (10'5-10-2M) was 
administered in the presence of Krebs solution only.
2. JM1226, JM6245 and JM1006 (lOOpM) were added to the internal perfusate 
for 30 mins before making a second series of injections.
3. JM compounds were washed out for 2hrs, after which time a third series of 
injections of PE was administered.
4. Finally, L-NMMA (lOOjlM) was added into the internal perfusate for 30 mins 
before a final series of PE injections was administered.
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Evaluation of the ability of JM1226 to reverse the hypotension in LPS- 
treated rats. Using the well established model of endotoxic shock in male 
Wistar rats (see Chapter 3), two experiments were conducted to examine the 
ability of JM1226 to reverse the ensuing hypotension following LPS treatment. 
Blood pressure measurements were made in thirteen conscious rats (250 - 340g) 
at various times after a single injection of LPS (4mg/Kg; i.p.), followed later (at 
t= 20hrs) by a second injection of either (a) sterile saline (grp. 1) or (b) a sterile 
solution (lOOmg/Kg) of JM1226 (grp. 2). In the first experiment, blood pressures 
were measured at t= 0, 20 and 24hrs. In the second experiment recordings were 
made at t= 0, 20, 24, 29 and 32hrs. All blood pressure measurements were made 
using the tail cuff method (see Chapter 3, Section 3.5.1) and animals were 
familiarised to the procedure by a ‘training’ regimen (daily, for 1 or 4 weeks) 
before commencing an experiment so as to avoid undue stress. Recordings of 
systolic (S.b.p), mean (M.b.p.) and diastolic (Db.p.) arterial pressures were made 
at the following times relative to the time (t= Ohr) at which animals were injected 
with LPS: t= 0, 20, 24, 29 & 32hrs. Experiments 1& 2 followed exactly the same 
protocol and because blood pressure readings were made in the morning and 
afternoon a study was carried out on a group of rats (n= 8)to determine if this 
influenced the results. Blood pressure (b.p.) readings made in the morning were 
not significantly different from those made in the afternoon (results not shown).
6.2.2 Materials
L-NMMA and LPS (£. coli serotype 055:B5) were obtained from Sigma Ltd. 
JM1226, JM6245 and JM1006 were supplied by Johnson Matthey Technology 
Centre, Reading, England. Male Wistar rats (260-340gr. wt.) were bought from 
John Tuck Suppliers and the tail cuff apparatus (Model 179 Blood Pressure 
Analyzer) from IITC Life Science, Calif. USA.
151
Chapter 6- Results
6.3 Results
6.3.1 JM1226 binds NO to form a ruthenium(II) mononitrosyl. Fig. 6.2 
shows FT-IR spectra for JM1226 alone (A) and for JM1226 after reacting it with 
authenic NO in aqueous solution (B; see methods). The sharp absorbance peak at 
1897cm-1 in spectrum B (arrow) identifies a linear Ru(II)-NO bond in the 
resulting compound (Bottomley, 1978) and provides confirmation of the 
formation of a ruthenium(II) mononitrosyl. A similar result (spectrum not 
shown) was obtained after reacting JM1226 with the NO donor SNAP.
Fig. 6.2 Infra-red spectra of JM1226 (spectrum A) and JM1226 after reaction 
with NO (spectrum B). The product has a sharp absorbance peak at 1897cm'1 
(arrow), characteristic of a linear Ru(II)-NO adduct.
6.3.2 Time course of LPS-induced endotoxaemia in an experimental rat 
model. LPS induced a marked hypotensive response (Table 1): at t= 20hrs, 
SAPs, MAPs and DAPs had fallen by 32%, 28.5% and 25.1% respectively. 
Systemic pressures spontaneously returned to pre-injection values over the 
ensuing 24-28hrs (t= 44-48hrs). LPS also induced a modest (ca 10%) but 
statistically significant tachycardia.
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Time after injection t=Ohr t= 20hr p value*
SAP 166.4 ±8.8 113.2 ±5.2 0.028
MAP 110.6 ±4.9 79.1 ±6.4 0.000
DAP 82.8 ±4.9 62.0 ±7.8 0.000
HR 376.6 ±9.4 411.1 ±11.7 0.017
Table 1 Systemic blood pressure (mmHg) and heart rates (HR; beats/min) 
recorded with the rat tail cuff apparatus immediately before and 20hrs after 
injecting animals (n= 13) with bacterial LPS (4mgfKg). Student’s paired t-test (p 
values to the nearest 3rd decimal point).
6.3.3 JM1006, JM1226 and JM6245 reverse the hyporeactivity to PE of 
RTAs from LPS-treated rats. Fig. 6.3a & 6.3b show that the addition of 
JM1006 (100/<M) to the internal perfusate completely abolished the diminished 
sensitivity (2-way ANOVA, F= 6.78, df= 9, 136e, p= <0.001) to PE of isolated, 
internally-perfused RTAs from LPS-treated animals (t= 24hrs; closed circles; 
controls, open circles; n= 7) . Statistically, there was no significant difference 
between JM1006- (closed squares) and L-NMMA-treated (open triangles) 
arteries from LPS-treated rats (2-way ANOVA, F= 0.98, df= 9, 234e, p= 0.362). 
Similarly, the difference in sensitivity to PE ( 2-way ANOVA, F= 7.39, df= 9, 
155e, p < 0.001) between vessels from control (open circles) and LPS-treated (t= 
24hrs; closed circles, fig. 6.4a; n= 9) rats was reversed by JM1226 (100//M; 
closed squares, fig. 6.4b; 2-way ANOVA, F= 3.61, df= 9, 151e, p < 0.001). The 
effect of JM1226 (and of JM6245; data not shown) on vessels from LPS-treated 
rats was closely comparable to that seen after blocking NO synthesis with L- 
NMMA (100//M; open triangles; fig. 6.4b). Statistically, there was no significant 
difference between JM1226- and L-NMMA-treated arteries from LPS-treated 
rats (2-way ANOVA, F= 0.46, df= 9, 189e, p= 0.901). Meaned results are shown 
in Appendix tables 6.1 & 6.2.
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Fig. 6.3 a Log D.R. curves showing the vasoconstrictor effect of bolus injections 
of PE on arteries isolated from animals previuosly injected with LPS 24hrs prior 
to sacrifice (open circles) compared to vessels from animals injected with sterile 
saline only (controls; closed circles). Mean ±S.E.M. shown, b Log D.R. curves to 
PE of vessels from LPS-treated rats (t= 24hrs) before (open circles; same data 
as fig. 6a) and after the addition of either JM1006 (closed squares) or L-NMMA 
(open triangles) to the internal perfusate. The sensitivity to PE of L-NMMA- and 
JM1006-treated vessels were not statistically different and both were 
significantly greater than that for LPS-treated arteries (see text).
Fig. 6.4a Log D.R. curves showing the vasoconstrictor effect of bolus injections 
of PE on arteries isolated from animals previuosly injected with. LPS 24hrs prior 
to sacrifice (open circles) compared to vessels from animals injected with sterile 
saline only (controls; closed circles). Mean ±S.E.M. shown, b Log D.R. curves to 
PE of vessels from LPS-treated rats (t~ 24hrs) before (open circles; same data 
as fig. 6a) and. after the addition of either JM1226 (closed squares) or L-NMMA 
(open triangles) to the internal perfusate. The sensitivity to PE of L-NMMA- and 
JM1226-treated vessels were not statistically different and both were 
significantly greater than that for LPS-treated arteries (see text).
■6 -5 -4 -3
Log[PE] (M)
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6.3.4 JM1226 accelerates recovery of arterial blood pressures in LPS- 
treated (hypotensive) rats. Fig. 6.5 summarises the results in the form of a 
histogram in which the data from experiments 1&2 are combined for time points 
t= 0, 20, 24hrs, but for time points t= 29 and 32hrs the data is from experiment 2 
only. The are results also shown in Appendix table 6.3.
Time (hrs)
Fig. 6.5 Blood pressure measurements for rats immediately before (t= ohr; first 
block) and 20hrs after (second block) a single i.p. injection (4mg/Kg) of 
bacterial LPS (data also in Table 1). Animals in group I (stippled columns) 
received an injection of saline only and those in group 2 (blank columns) 
received JM1226 (i.p.; lOOmg/Kg) at t= 20hrs. Blood pressure recovered more 
rapidly in animals treated with JM1226 and was essentially complete after ca. 
9hrs. See text for details.
Each of the 5 grouped vertical columns in the histogram represents (from left to 
right) S.b.p.s, M.b.p.s, and D.b.p.s. Both groups of LPS-treated animals were 
markedly hypotensive by t= 20hrs (see Table 1 which shows combined data ie.
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experiments 1&2, n=13 animals) and shows some recovery thereafter. However, 
the recovery of saline-injected animals (stipplied columns) was incomplete even 
after 12hrs (t= 32hrs), whereas the rate of recovery of animals that received 
JM1226 (open columns) was enhanced and essentially complete within ca. 9hrs 
(t= 29hrs).
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6.4 Discussion
From these results it is clear that ruthenium-based scavengers could offer an 
alternative therapeutic strategy to the use of NOS inhibitors for alleviating the 
symptoms of septic shock, and possibly other mediated diseases too. Two 
chemically-related polyaminocarboxylate-ruthenium(III) complexes - JM1226 
and its aqua derivative JM6245 - were found to react with either authentic NO or 
with an NO donor (SNAP) in aqueous solution to yield the corresponding Ru(II) 
mononitrosyl adduct (Fig. 2; Flicker et al., 1995 and in press). This has yet to be 
confirmed for JM1006. Their ability to react with NO in several biological 
systems of increasing complexity (from cultured cells to whole animals) was 
therefore explored, following induction of the iNOS-driven, ‘high-ouput’ 
pathway for NO synthesis, using either LPS alone (whole animals) or combined 
LPS + interferon-gamma treatment (cell cultures; Flicker et al., 1995). It has 
been shown that ruthenium complexes reduced NO2" accumulation by cultured 
macrophages and afforded a significant degree of protection against the 
tumouricidal action of these macrophages (Flicker etal., in press).
The results of in vivo experiments using the rat model of endotoxic shock are 
clearly more relevant when evaluating the therapeutic potential of these 
compounds. The effects of LPS treatment (4mg/Kg; i.p.) have been defined 
according to five separate parameters all of which are consistent with the 
principal physiological manifestations of septic shock (Glauser et al., 1991) and 
therefore, establish the LPS-treated rat as a valid paradigm for testing the ability 
of JM compounds to scavenge pathophysiological quantities of NO under both 
ex vivo (isolated RTAs) and in vivo conditions.
The hyporesponsiveness to PE displayed by internally-perfused RTAs isolated 
from LPS-treated animals was maximal at t= 24hrs (see Chapter 3, fig. 3.7). The 
addition of JM1006, JM1226 and JM6245 (results not shown) to the internal
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perfusate of such vessels enhanced their sensitivity to PE: indeed, the effect was 
indistinguishable from that seen after blockade of NO synthesis at source using 
the NOS inhibitor, L-NMMA.
Treatment with LPS produced a profound but transient hypotensive response in 
laboratory animals. As it will be seen in Chapter 8, S.b.p.s, M.b.p.s amd M.b.p.s 
fall to a minimum around t= 20 - 24hrs and gradually recover over the ensuing 
24- 28hrs (t= 44 - 48hrs). Fig. 6.5 shows that some spontaneous recovery of 
blood pressures was seen in the saline-injected (control) group of LPS-treated 
rats but this was clearly incomplete after 12hrs (t= 32hrs). In contrast, the 
recovery of the LPS-treated group that received a single i.p. injection of JM1226 
given at t= 20hr was accelerated and complete after a further ca. 9hrs (t= 29hrs).
These results and those of Fricker et al., (1995) show that JM1226, 6245 and 
1006 are effective scavengers of NO in a variety of biological systems and they 
establish these complexes as potentially useful alternatives to NOS inhibitors for 
alleviating some of the symptoms of endotoxic shock. It has previously been 
shown, and is further confirmed in this study (see Chapter 7, Section 7.4.1), that 
tumour-supply vessels are remarkably unresponsive to vasoactive agents (Hirst 
& Wood, 1989; Kennovin et al., 1993) and in this respect they strongly resemble 
RTAs from LPS-treated rats. It is also shown in Chapter 7 (Section 7.4.2) that 
the sensitivity to PE of isolated, internally perfused epigastric arteries which 
previously supplied an inguinal tumour implant, can be fully restored using the 
non-selective NOS inhibitors L-NMMA or L-NAME. Moreover, chronic oral 
administration of L-NAME, via the drinking water, significantly retarded solid 
tumour growth (Chapter 8, Section 8.3.5). Based on the data presented here it is 
likely that JM1226, 6245 and/or 1006, could have similarly benefical effects to 
L-NAME.
Further studies will have to be conducted detailing the toxicological and 
pharmacokinetic properties of these JM compounds. However, preliminary
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toxicity tests in vivo have shown that Wistar rats can tolerate maximum doses of 
JM1226 some 2-4 times greater than those used here (200 - 400mg/Kg; i.p.) and 
pilot pharmacokinetic experiments indicate rapid plasma clearance times (Dr. 
Simon Fricker; personal commun.). Studies will also have to be conducted to 
optimize the dosing schedule of these drugs.
6.4.1 Conclusions. In conclusion, the results of this study demonstrate that by 
efficiently scavenging NO, ruthenium(III) complexes JM1006, 1226 and its aqua 
derivative, 6245, might be usefully exploited in new therapeutic strategies aimed 
at combating NO mediated disease.
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Chapter 7
Vasoconstrictor Properties of Tumour-Supply 
Arteries
7.1 Introduction
Experiments were carried out to establish whether isolated arteries which had 
previously supplied a solid tumour (ie. TEAs) displayed altered vasocontractile 
responses to PE when compared to non-tumour associated arteries (ie. CEAs), 
and if so, whether their responsiveness could be restored using specific inhibitors 
of NOS. Kennovin et al., (1994) first showed that TEAs were hyporesponsive to 
PE as compared to CEAs and the results of their study suggested that the reason 
for the difference was an upregulated NO production in TEAs. This hypothesis 
was borne out by their subsequent findings that inhibitors of NOS could abolish 
their their diminished hyporesponsiveness to PE. These inhibitors are specific for 
NOS but not selective for one or other of the different NOS isoforms. This study 
follows on from that of of Kennovin et al. and uses the selective iNOS inhibitor, 
aminoguanidine (AG), in addition to the non-selective NOS inhibitors, L-NMMA 
and L-NAME, to ascertain whether indeed increased iNOS-derived NO production 
is responsible for the hyporeactivity of TEAs to PE.
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Materials & Methods
7.2 Methods
7.2.1 Preparation of Isolated Tumour Supply Artery
Preparing the Tumour Tissue (step 1). Pieces of a spontaneous P22 
carcinosarcoma tumour found in a BD9 rat were taken and stored in vials 
containing minimum essential medium (MEM). In preparation for implantation, 
pieces were incubated at 37°C in fresh MEM for 20 mins, and minced using sterile 
scissors. To obtain sufficient tissue, tumours were initially grown subdermally on 
the backs of isogeneic female BD9 rats until they were of suitable size (8-10g), 
after which they were removed, minced and re-implanted into isogeneic males. 
Third generation (T3) tumour tissue was used for all experiments. Sterile 
technique was applied at all times when handling tumour samples.
Tumour Implantation (step 2). Small pieces of P22 carcinosarcoma tumour 
tissue (T3) were finely chopped into a slurry and injected (0.05mls; using a sterile 
19G1.5 needle) into the right inguinal fat pads of male isogeneic BD9 rats under 
general anaesthesia (90mg/Kg Ketamine: lOmg.Kg Xylazine; i.p.), close to the 
first bifurcation between the right inferior epigastric and femoral arteries. The 
developing tumour therefore derived its blood supply primarily through the right 
inferior epigastric artery (TEA). The left inferior epigastric artery (CEA) from the 
same animal did not supply a tumour and was used as a control (see fig. 7.1). 
This model is very similar to the isolated tumour model devised by Gullino & 
Grantham, (1961) and subsequently modified by Tozer et al., (1995) and others.
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INFERIOR
EPIGASTRIC
ARTERY
Fig. 7.1 A diagram of the vascular supply to the implanted tumour in the rat 
hindlimb (refer to text for details).
Isolation of TEA and CEA (step 3). The side branches along the femoral 
artery were ligated and a perfusion canula (Portex; with green mount) containing 
Krebs solution (see below) was fed into the femoral artery until the tip was 
adjacent to the junction with the epigastric artery (see fig. 7.2). Once the TEA and 
CEA had been removed (ie. a section of the femoral artery and the complete length 
of the epigastric artery), the animals were killed by anaesthetic overdose.
NEHUE
HRTERY
UEIN
SREINE FILLED
CHNNIIIH INSERTING INTO SYRINGE^ 
RRIERY -
CUE RRIERY
Fig. 7.2 A diagram showing the right inferior epigastric artery feeding into the 
developed tumour.
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7.2.2 Experimental Protocol. Isolated segments of TEA and CEA were 
mounted in a perfusion apparatus (similar to the one described in chapter 3). 
Vessels were allowed to acclimatise for -lhr during which time the internal 
perfusion rate was gradually increased from 0.05 to 0.6mls/min. TEAs and CEAs 
were subjected to a similar set of experiments as RTAs (outlined in chapter 4).
7.3 Materials
Isogeneic male BD9 rats and tumour tissue originated from the CRC Gray lab., 
Mount Vernon Hospital, England. Minimum essential medium was obtained from 
GibcoBRL Ltd.(cat. No. 11700). Arteries were perfused using a constant flow 
pump; Harvard Apparatus, South Natick., Massach. USA.
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7.4 Results
7.4.1 The hyporesponsiveness of isolated TEAs. Responses to PE are 
expressed as mean (± S.E.M) perfusion pressure (mmHg) and plotted as a 
function of logio phenylephrine (PE) concentration (M). In agreement with 
findings by Kennovin et al., (1994), vasoconstrictor responses to increasing 
concentrations of PE were significantly attenuated in TEAs (2 way ANOVA; F= 
7.80, df= 9, 445e p < 0.001) compared to CEAs (see fig. 7.4 below and 
Appendix table 7.1).
Fig. 7.4 A graph comparing the initial D.R. to PE concentration (M) in TEAs 
(n~28; open circles) and CEAs (n~29; closed circles) perfused with Krebs only. 
Asterisks indicate a significant difference between using a student’s unpaired t- 
test.
7.4.2 The Effect of NOS Inhibitiors on PE-Induced Vasocontractile 
Responses: Effects of L-NMMA or L-NAME. The effect of a number of 
NOS inhibitors was tested, in order to determine whether the difference between 
TEAs and CEAs is due to upregulated NOS activity. Exposure to L-NMMA or L- 
NAME (80pM) for 20-30 mins did not affect passive perfusion pressures but 
augmented the responses to PE and completely abolished the difference between 
TEAs and CEAs (figs.7.5 & 7.6 respectively).
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Figs. 7.5 & 7.6 (LHS and RHS respectively). Graphs of log dose response 
curves for CEAs (n=14; closed symbols) and TEAs (n=15; open symbols) in 
Krebs solution (circles), in the presence of L-NMMA (80pM; squares; n= 6 &7, 
respectively, fig. 7.5), or L-NAME (80pM; triangles; n- 10; fig. 7.6). Asterisks 
represent a significant difference between CEAs and TEAs (unpaired student’s t- 
test, p< 0.05*).
Initial responses to PE for CEAs and TEAs were statistically significantly different 
(2 way ANOVA; F= 2.85, df= 8,230e, p= 0.005**). however, their responses to 
PE were not significantly different from each other after treatment with L-NMMA 
(2 way ANOVA; F= 0.96, df= 8,83e, p= 0.471) or L-NAME (2 way ANOVA; 
F= 0.32, df= 6,85e, p= 0.927) showing that both NOS inhibitors abolished the 
TEA- associated hyporesponsiveness to PE (see figs.7.5 & 7.6). Furthermore, 
student’s unpaired t-test analysis did not reveal a statistically significant difference 
between TEA curves after treatment with L-NMMA or L-NAME. The same was 
also true for CEAs (see Appendix table 7.3).
The effects of L-arginine after 30-60 mins internal perfusion are shown in Figs. 
7.7 & 7.8. L-arginine completely reversed the shift produced by L-NMMA or L- 
NAME in CEAs (see figs. 7.7 & 7.8 respectively), such that the initial D.R. curve 
in the presence of Krebs solution alone (ie. 1st D.R.) did not differ significantly 
from that after treatment with L-arginine (3rd D.R.; 2 way ANOVAs; F= 0.87, 
df= 8,95e, p= 0.546 & F= 0.15, df= 8,9 le, p= 0.996, respectively). The
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potentiating effect of L-NAME to PE-induced responses in TEAs was also 
reversed in the presence of L-arginine. This is shown by the fact that the 1st D.R. 
curve did not significantly differ from the 3rd D.R. curve (2 way ANOVA; F= 
0.71, df= 8,124e, p= 0.681; see fig. 7.8). In contrast however, L-arginine was 
somewhat less effective at reversing the potentiating effect of L-NMMA in TEAs, 
such that the 1st and 3rd D.R. curves remained significantly different (2 way 
ANOVA; F= 3.94, df= 7,78e, p= 0.001***; see fig.7.7).
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Figs. 7.7 & 7.8 (LHS and RHS respectively). CEAs (closed symbols, n= 5) 
and TEAs (open symbols, n- 4-8) comparing the initial D.R. curves (Krebs only; 
circles) with those in the presence of L-arginine (diamonds) after L-NMMA (fig. 
7.7) or L-NAME (fig. 7.8) treatment.
7.4.3 The Effect of a selective NOS Inhibitor on PE-Induced
Vasocontractile Responses: Effects of Aminoguanidine.
Aminoguanidine (AG) is a relatively selective inhibitor of inducible NOS activity.
Joly et al., (1994) found that AG had no effect on the responses evoked by PE in
rat aortic rings. However exposure to LPS (5hrs incubation; 200ng/ml) induced a
significant hyporeactivity to PE which could subsequently be reversed after lhr
treatment with AG (100^M). To test whether AG had any effect on the PE-
induced responses of TEAs and CEAs, an a sequence of injections to PE was
followed by a lhr perfusion with Krebs + AG (ImM), before a second series of 
166
Chapter 7- Results
PE injections was given. Experiments were carried out on CEAs (n=6) and TEAs 
(n=5) and the results plotted in figs. 7.9 & 7.10 respectively.
It is clear from fig. 7.9 that AG does not significantly alter CEAs responses to PE. 
This was confirmed by comparing the 1st D.R. curve (in the presence of Krebs) 
and the 2nd D.R. curve (Krebs + AG) using 2 way ANOVA (F= 0.91, df= 9, 
89e, p= 0.347) and a student’s paired t-test (see Appendix table 7.4).
log [PE] (M)
Fig. 7.9 A graph of the D.R. curves to PE for CEAs (n=6) in the presence of 
Krebs only (closed circles) and Krebs + amino guanidine (ImM; lhr, semi-closed 
squares).
Fig. 7.10 shows that TEA responses to PE were, in contrast to CEAs, 
significantly shifted to the left by AG (2 way ANOVA; F= 2.20, df= 9,66e, p= 
0.033). Furthermore, a Student’s unpaired t- test revealed that AG-treated TEA 
responses (Fig. 7.10, squares) were not significantly different from those of 
CEAs in the presence of Krebs only (Fig. 7.9, closed circles). In other words, 
AG completely abolished the TEA-associated hyporesponsiveness to PE.
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Fig. 7.10 A graph comparing the D.R. curves to PE for TEAs (n=5) in the 
presence of Krebs only (open circles) and Krebs + amino guanidine (ImM; lhr, 
semi-closed squares).
7.4.4 Immunohistochemistry of CEAs and TEAs. The above results 
suggest that the hyporesponsivness of TEAs to PE is attributable to iNOS-derived 
NO. Immunohistochemically staining with an antiserum specific to iNOS (see 
Material and Methods in chapter 3) revealed intense staining in the vascular 
smooth muscle layer of TEAs and little or no staining in CEAs (see figs. 7.11 and 
7.12 respectively). It can also be seen in Fig. 7.11 that endothelial cells or cells 
attaching to the endothelial layer are also positive for iNOS.
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Fig. 7.11 Cryostat section through a TEA immunostained with antiserum to 
iNOS (xlOOO).
Fig 7.12 Cryostat section of a CEA immunostained with antiserum to iNOS 
(xlOOO).
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7.4.5 The Effect of cyclooxygenase Inhibition on PE-Induced 
Vasocontractile Responses: Effects of Indomethacin. NO activates the 
vasomodulating family of cyclooxygenases (COX) and LPS has been shown to 
induce a novel isoform of COX in vivo and in vitro (iCOX; Wu et al., 1993; 
Salvemini et al., 1993). This experiment aimed to establish whether or not COXs 
were involved in regulating the responses to PE of TEAs and CEAs.
Indomethacin is a selective inhibitor of COX and has been shown to increase 
metastasis of certain cancers (Honn et al., 1983) and suppress growth in 
prostaglandin-producing solid tumours (Milas et al., 1991). It was of interest 
therefore, to see what role COXs may have in regulating tumour blood flow 
through arterial-supply vessels.
After an initial sequence of PE injections in the presence of Krebs only, 
indomethacin was dissolved and added into the internal perfusate to give a final 
concentration of 10^M. 30mins later a second series of PE injections was 
performed. Indomethacin significantly supressed the responses to PE of both 
CEAs and TEAs (2-way ANOVA, p < 0.001 for both groups) and although this 
effect appeared to be greater in TEAs as compared to CEAs, (with a reduction in 
contractile pressure at the highest [PE] of 64.17 ±5.23% for TEAs and 45.30 
±8.11% for CEAs), it was not statistically significant according to 2 way ANOVA 
analysis (F= 1.69, df= 9, 90e, p= 0.103).
The diminished responsiveness in the presence of of indomethacin suggests that a 
COX-derived vasoconstrictor is being inhibited. Therefore, indomethacin may 
potentiate the TEA-associated hyporesponsiveness to PE.
7.4.6 Spontaneous Pressure Oscillations in Isolated TEAs
Spontaneous rythmic oscillations in perfusion pressure were seen in approx. 20%
of all the TEAs isolated from solid, inguinal tumours. Kennovin et al., (1994)
reported similar oscillations in ~60% of TEAs. Oscillations were more commonly
seen in TEAs isolated from large (>8g) tumours, however they were never 
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observed in CEAs. This unusual characteristic of tumour vasculature is thought to 
reflect the irregular, intermittent blood flow through these vessels, although the 
exact nature of the factors or mechanisms involved remains ill-defined (see p74 of 
Introduction for more details).
Oscillations were often observed in TEAs perfused with Krebs solution only. 
Their amplitude and frequency varied considerably. They were initially small and 
infrequent (9-18mmHg; every 20-40mins), but increased in both size (up to 
60mmHg) and frequency (every 8-10mins) with longer term (>120mins) 
perfusions of Krebs (see fig. 7.13). They were also enhanced (amplitude and 
frequency) after vessels were injected with PE.
SOmmHg
TEA
5 mins
CEA
Fig. 7.13 A trace showing spontaneous pulsatile pressures (18-60mmHg; 
every 8mins) in a TEA being perfused with Krebs (t> 200mins). The bottom trace 
shows the baseline pressure in the respective CEA also being perfused with 
Krebs. The BD9 rat was 397g in body weight with an inguinal solid tumour of 
11.65g).
Perfusion with AG (ImM) also potentiated their amplitude and frequency (40-
136mmHg; every 15 mins; see figs. 7.14 & 7.15). The time of onset of this effect
was rapid -lOmins after the initial addition of AG. In order to see if the effects of
AG could be reversed or influenced by excess L-arginine (ImM), a TEA
preparation which had been treated with AG were then perfused through with
Krebs + L-arginine. L-arginine dramatically altered both the frequency and
amplitude, such that they now resembled oscillations prior to AG treatment (see
fig. 7.15). If L-arginine was then removed from the internal perfusate the
oscillations again increased in size (see fig. 7.16).
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Fig. 7.14 A trace showing the effects of amino guanidine (AG; ImM) and AG + 
L-NAME (80pM & 250pM) on the spontaneous pulsatile pressures in a TEA. AG 
potentiates the frequency and amplitude of the pulses. Oscillations in pressure in 
the presence of AG were not inhibited by L-NAME.
Fig. 7.14 also shows that the addition of L-NAME to the Krebs + AG solution for 
an extended period of time (~2hrs) had no clear cut effect on the rythmic 
oscillations in TEAs.
Krebs A.G +L-ARG
100 mmHg
x A
j> ! i
A A
40 mins
Fig. 7.15 A trace showing the potentiating effect of AG (ImM) on rythmic 
oscillations in a TEA preparation and the subsequent reversal of this by excess 
L-arginine (ImM).
L-arginine reduced the size of the oscillations from approx. 40mmHg (in the 
presence of AG) to approx. lOmmHg. The removal of L-arginine from the internal 
perfusate augmented the contractions back to approx. 30mmHg (see fig. 7.16).
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Krebs AG +L-ARG Krebs
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lOOmmHg
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1
Fig. 7.16 A trace of spontaneous oscillations in pressure in a TEA initially 
perfused with Krebs only, then AG (ImM) and AG + L-arginine f+L-arginine 
ImM). On washout; when the excess L-arginine is removed from the internal 
perfusate, the inhibitory effect of L-arginine is apparently lost and oscillations 
again increase in size.
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7.5 Quantitative analysis concerning hyporesponsiveness of TEAs 
to PE and the effects of NOS inhibitors.
7.5.1 TEA-associated Hyporesponsiveness to PE. The
hyporesponsiveness of TEAs was quantified according to the protocols outlined in 
chapter 3, section 3.6 and chapter 4, section 4.7 for the effects of a drug on PE- 
induced responses. Fig. 7.17 shows factor (/) plotted against [PE] and reveals a 
negative slope (z7i) = -0.048. It will be recalled that a positive slope tending 
towards a maximum value off= 1.0 indicates that hyporesponsiveness of TEAs 
could in theory be overcome at higher [PE]s.
Fig. 7.17 A graph showing TEA responses plotted as a fraction (f) of CEA 
responses, with the resultant linear curve fit revealing a negative gradient.
It is clear from Fig. 7.17 that this not likely to be the case for TEAs and moreover 
suggests an underlying difference in the hyporesponsive nature of TEAs and 
RTAs.
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7.5.2 Quantitative analysis (ED150) of the effects of L-NMMA and 
L-NAME on PE-induced contractile responses are shown in tables 7.1 &
7.2 below. See Chapter 4, section 4.3.5 for details of quantiative analysis.
CURVE
(A-C)
Krebs L-NMMA
(80p.M)
L-Arg
(ImM)
AED150
L-NMMA
AED150
L-ARG
%
AED150
%
reversal
Group A (x10’4m) B (xI0’4m) C(x10‘4M) a(A-B) b(B-C) %(A-B) %(b+a)
CEAs 7.07 2.39 6.92 4.68 -4.53 20.18 96.79
TEAs 24.50 1.32 3.89 23.18 -2.57 100 11.08
Table 7.1 Showing the ED 150 values for TEAs and CEAs treated with L-NMMA
CURVE
(A-C)
Krebs L-NAME
(80pM)
L-Arg
(ImM)
AED15«
L-NAME
AED150
L-ARG
%
AED150
%
reversal
Group A (xI0'4M) B (xiO"4M) C(x10’4M) a(A-B) b(B-C) %(A-B) %(b-*-a)
CEAs 6.67 1.26 6.43 5.50 -5.17 23.73 94.00
TEAs 14.16 1.28 10.23 12.88 -8.95 55.56 69.48
Table 7.2 Showing the ED 150 values for TEAs and CEAs treated with L-NAME
Using a concentration that exceeds that required to inhibit cNOS and iNOS activity 
(Rees et al., 1990) L-NMMA shifted the TEA D.R. curve -5 times further to the 
left than the corresponding curve for CEAs (%AEDi5o = 100 and -20% 
respectively; see table 7.1). The %AP by L-NMMA was similarly greater for 
TEAs (%AP in TEAs= -57% & -14% in CEAs; results not shown). A similar 
dose of L-NAME (ie. 80jiM) caused a comparable leftward shift in the CEA D.R. 
curve to that caused by L-NMMA (%AEDi5o= -24%). However, the %AEDi5o in 
L-NAME-treated TEAs, although more than twice that for CEAs (%AEDi5o = 
55.56%), was nearly half that caused by L-NMMA (-44% less). If we assume 
that the AED 150 caused by L-NMMA in TEAs represents the inhibition of all the 
NO being produced within these vessels (derived from iNOS and eNOS), and the 
%AED 150 caused by L-NMMA and L-NAME in CEAs (average = -22%) 
represents basal NO production (derived from eNOS) it can be concluded that 
nearly 80% (100% - 22%) of the total AED150 is due to the production of NO 
from iNOS (see tables 7.1 & 7.2).
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The AED150 by L-NMMA was reversed by -11% in TEAs and almost fully 
reversed in CEAs (-97%; see table 7.1). The % reversal by L-arginine of the 
leftward shift caused by L-NAME of the TEA D.R. curve was considerably 
greater than that after L-NMMA treatment (-70%). Similarly, L-arginine almost 
fully reversed the effects of L-NAME (% reversal= 94%). AP tables are not 
shown as most vessels were not viable at 5xl0'3M [PE] after treatment with an 
inhibitor.
This data shows that the potentiating effect of L-NMMA on the TEA D.R. curve 
(ie. %AEDi5o ) was considerably greater than that by L-NAME, whereas the 
effect of L-NMMA on the CEA D.R. curve was similar to that by L-NAME, with 
only a marginally greater %AEDi5o caused by L-NAME. Similarly in CEAs, the 
% reversal by L-arginine (in terms of ED 150) was nearing 100% after treatment 
with L-NMMA or L-NAME. In contrast, the % reversal by L-arginine in TEAs 
was almost a 60% ( %AEDi5os of 69-11%) greater after treatment with L-NAME. 
The results in tables 7.1 & 7.2 are shown graphically in fig. 7.18.
TEAs CEAs
Groups
Fig. 7.18 Showing the %AED]so produced by L-NMMA and L-NAME 
(stippled columns) and the % reversal by L-arginine (open columns) in TEAs 
(columns 1 & 2 respectively) and CEAs (columns 3 & 4 respectively).
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The results of this analysis indicate that L-NMMA has a greater effect on the 
ED 150 TEA responses as compared to those of CEAs. Furthermore, with the 
ability of L-arginine to reverse the effects of L-NMMA in CEAs but, only partially 
reverse the effects in TEAs, there is perhaps therapeutic potential for using 
L-NMMA in combination with L-arginine to facilitate prolonged vasoconstriction 
in tumour supply vessels without unduly compromising the function of normal 
host vessels.
7.5.3 The effects of Aminoguandine. AG shifted the TEA D.R. curve to 
PE significantly to the left, (%AEDi5o = ~35%; 2 way ANOVA; F= 2.20, df= 
9,66e, p= 0.033; see appendix table 7.3 for Student’s t-test analysis & table 7.3 
below) although, the maximal contraction at lOmM [PE] was only increased from 
268 ±18.7mmHg to 298.2 ±14.1mmHg. On the contrary, CEAs responses to PE 
were not significantly enhanced by AG (%AEDi5o = 7.67%; see fig. 7.19). AG 
therefore offers some measure of selectivity for reversing the TEA-associated 
hyporesponsiveness to PE and provides further evidence that iNOS-derived NO 
production is responsible for this anomaly.
CURVE
(A-B)
Krebs
EDISO
AG
EDI50
Krebs
Pmax
AG
Pmax APmax aed150
%
AED1S0
Group A (xio*4M) B (x10 4m) A(mmHg) B(mmHg) (mmHg) [PE]x10-4M %
CEA 5.62 3.84 301.00 310.00 9 1.78 7.67
TEA 11.2 3.23 245.00 312.00 67 7.99 34.47
Table 7.3 Showing the App and AED150 values for TEAs and CEAs treated 
with AG.
For a comparison of the %AEDi5o caused by L-NMMA, L-NAME or AG, the 
results have been plotted together and are shown in Fig.7.19.
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Fig. 7.19 Compares the % AED 150 in TEA and CEA D.R. curves caused by L- 
NMMA (columns 1 & 4 respectively), L-NAME (columns 2 & 5 respectively) or 
AG (columns 3 & 6 respectively).
It is also clear from Fig. 7.19 that AG is not as effective as L-NMMA or L-NAME 
at shifting the TEA curve to the left with -65% greater %AEDi5o after L-NMMA 
compared to that by AG. The rank order of potency for the effect of NOS 
inhibitors on ED 150 is therefore L-NMMA > L-NAME > AG for TEA responses to 
PE and L-NAME > L-NMMA > AG for CEA responses to PE.
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7.5 Discussion
7.5.1 TEA-associated Hyporesponsiveness These results establish a 
difference in PE-induced responses for TEAs and CEAs and provide evidence that 
iNOS-derived NO production in TEAs may be partly responsible for this. 
However, the effects of indomethacin indicate that COX-derived vasoconstrictors 
are also active in TEAs and CEAs. A similar suppressor effect by indomethacin 
has been reported in aortic rings isolated from LPS-treated animals (Wu et al., 
1994). Quantitative analysis of TEA-associated hyporesponsiveness reveals an 
inverse relation between f and [PE], indicating that the extent of 
hyporesponsiveness is greater at higher [PE]s and is unlikely to be overcome at 
[PE]s greater than lOmM. This contrasts with the RTA-associated
J
hyporesponsiveness, point which is further discussed in chapter 9.
7.5.2 The effects of NOS inhibitors and cycloheximide on PE- 
induced responses. Competitive inhibitors of the constitutive and inducible 
NOS isoforms, L-NAME and L-NMMA, potentiated responses to PE in CEAs and 
TEAs and completely abolished the TEA-associated hyporesponsiveness to PE. 
Quantitative analysis indicates that L-NMMA had ~2 fold greater effect on the 
ED 150 for TEA responses as compared to L-NAME, while the effects of L-NMMA 
and L-NAME were similar for CEAs, with only a marginally greater AED 150 with 
L-NAME. The AED150 caused by L-NMMA and L-NAME was ~5 fold and ~2 
fold greater in TEAs than CEAs respectively, indicating enhanced NOS-derived 
NO production in TEAs. Moreover, this also shows that L-NMMA is more potent 
at inhibiting iNOS-derived NO production than L-NAME. This agrees with 
previous findings (Moncada et al., 1991).
L-arginine reversed the effects of both inhibitors in CEAs and the effect of L- 
NAME on TEA responses. However, the effects of L-NMMA in TEAs were not 
fully reversed by L-arginine and the 1st D.R. curve differed significantly from the 
3rd D.R. curve after 30-45 mins, perfusion. The inability of L-arginine to fully
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reverse the effects of L-NMMA in TEAs may prove to be of considerable 
therapeutic value. The ability to reduce blood flow into solid tumours without 
compromising host vessel function is clearly desirable. If arterial-supply vessels in 
vivo show a similar response to L-NMMA and L-arginine treatment it may be 
possible to reduce blood flowing into a solid tumour using L-NMMA (Andrade et 
al., 1992) and then selectively reverse the NOS inhibition in non-tumour 
associated host vessels and therefore reduce the risk of detrimental side effects eg. 
hypertension.
A time-dependent decrease in CEA responses has been reported (Kennovin et al., 
1994), such that after 400mins perfusion with Krebs there was no longer any 
significant difference between CEA and TEA responses. The time-dependent 
desensitisation of CEA was reversed by L-NMMA (40//M) and prevented by 
cycloheximide (10^M), implicating the expression of iNOS in this effect. They 
also showed that the TEA-associated hyporesponsiveness could be reversed after 
-2hrs incubation with cycloheximide but were unable to clarify the involvement of 
iNOS. Experiments were conducted to resolve whether iNOS is expressed in 
TEAs and if so, whether it is responsible for their diminished senitivity to PE. The 
selective iNOS inhibitor, AG was found to significantly augment TEA responses 
to PE with the result that they came to resemble those of CEAs. This was not due 
to the inhibition of eNOS-derived NO as AG did not alter CEA responses to PE. 
Furthermore, immunohistochemical staining with antiserum to iNOS revealed 
positive staining in TEAs but not in CEAs. These results confirm that TEAs 
express iNOS and CEAs do not. Moreover, the effects of AG indicate that iNOS- 
derived NO production is responsible for hyporesponsiveness to PE exhibited by 
TEAs.
7.5.3 Spontaneous Vasomotion Spontaneous rythmic oscillations in
perfusion pressure were seen in a number of TEAs (-20%) isolated from large
tumours, but never in CEAs. Kennovin et al., (1991), reported an even larger
proportion, as much as 60%. This characteristic of tumour associated vasculature 
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is thought to reflect spontaneous vasoconstriction within these vessels and may be 
responsible for the intermittent blood flow through them (Peters et al., 1980; 
Intaglietta et al., 1977). It is probable that this phenomenon is exacerbated in 
larger tumours, due to increased interstitial pressures elevating resistance to flow 
through the tumour vasculature. Oscillations were potentiated following exposure 
to phenylephrine, which suggests that irregular Ca2+ flux is involved, although 
nicotinamide which has been shown to reduce the amplitude and frequency of 
these oscillations (Hirst et al., 1995) has not been reported to affect [Ca2+]j levels 
and may act via an alternative, as yet unidentified mechanism. This study 
addresses the possibility that NO is involved: a transient down-regulation of the 
high output NO production in TEAs may result in vasoconstriction.
Perfusion with the selective iNOS inhibitor AG potentiated spontaneous 
contractions to more than twice their original amplitude and frequency, an effect 
which was not further enhanced when L-NAME was added in combination with 
AG. This suggests that L-arginine-derived NO release acts to supress spontaneous 
vasomotion, with by far the greatest influence attributed to iNOS-derived NO 
production. AG is an analogue-inhibitor and as such is reversible in the presence 
of excess L-arginine (Griffiths et al., 1993). Consistent with this, the addition of 
L-arginine dramatically reduced both the amplitude and frequency of contractions, 
which then resembled those prior to treatment with AG. Furthermore, contractions 
increased in size when L-arginine was subsequently removed from the internal 
perfusate. This evidence establishes NO as a mediator of spontaneous pulsatile 
vasoactivity in TEAs and points to a mechanism involving L-arginine substrate.
It is possible that with increased NO production by iNOS, L-arginine eventually 
becomes limiting. Thereafter, NO production is regulated by L-arginine and may 
fluctuate depending on its availability, increasing momentarily as more L-arginine 
becomes available, and subsequently decreasing as it is used up. This might 
explain the pulsatile nature of these contractions. Moreover, the inhibitory effect of 
nicotinamide on spontaneous vasoactivity may also reflect increased NO
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production, as nicotinamide is required for the production of NADPH which in 
turn is necessary for the formation of NO from L-arginine and molecular oxygen 
(Sagar et al., 1995). However, nicotinamide may also cause vasodilatation 
independently of NO, since its actions are not blocked by the NOS inhibitor, L- 
NAME (Hirst et al., 1994).
Spontaneous vasomotion is not seen in LPS-treated RTAs which implies that it 
probably relates to the presence of the tumour per se and not merely to iNOS 
activity and associated NO production within the vasculature.
7.5.4 Conclusion The main findings of this chapter are that TEAs express 
high levels of iNOS and are significantly hyporesponsive to bolus injections of 
PE. The hyporesponsiveness is abolished by specific NOS inhibitors and 
quantitative analysis reveals a rank order of potency as L-NMMA > L-NAME > 
AG. However, if these inhibitors are to be used to treat clinical disease they must 
be not compromise the constitutive NO production (ie. eNOS in blood vessels) 
which is essential for normal physiological function. Analysis of the AED 150 
reveals a rank order of potency in CEAs as L-NAME > L-NMMA > AG 
suggesting that L-NAME inhibits eNOS the most, while AG inhibits it the least. 
This confirms AG as a relatively selective inhibitor for iNOS and therefore of 
greater clinical value than non-selective inhibitors. However, it was also shown 
that the effects of L-NMMA in CEAs were reversed completely in the presence of 
excess L-arginine, while its effects in TEAs were more resistant to reversal. This 
suggests that L-NMMA may be of clinical use for treating NO-mediated disease 
when used in combination with L-arginine.
The potentiating effect of AG on spontaneous oscillations in TEAs indicates that 
iNOS-derived NO production normally suppresses this phenomenon and that AG 
may consequently reduce blood flow into a solid tumour in vivo by enhancing 
spontaneous vasomotion of supplying vessels. The effect of AG on the growth 
of solid tumours is addressed in chapter 8.
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Chapter 8
NO and Solid Tumour Growth: effect of LPS and 
NOS inhibitors
8.1 Introduction
Kennovin et al., (1993) showed that the relatively non-selective inhibitors of 
NOS, L-NMMA and L-NAME, enhance the sensitivity to a vasoconstrictor agent 
of arteries which previously supplied a solid tumour. This is confirmed in the 
present study (Chapter 7). Another vasoconstrictor, serotonin, has also been 
shown to have a greater effect on arteries supplying subcutaneously grown 
tumours in mice as compared to non-tumour associated arteries (Stiicker et al., 
1991). Furthermore, Stiicker et al., (1991) found that serotonin significantly 
suppressed the rate of growth of these tumours.
These findings raise the possibility that NOS inhibitors could also delay tumour 
growth in vivo. This was confirmed by Kennovin et al., (1994), who first showed 
that chronic administration of L-NAME significantly retarded growth of solid 
tumours in BD-9 rats. To date, the effects of more isoform-selective NOS 
inhibitors, such as aminoguanidine (AG), have not been studied and this and 
related questions are addressed in the present chapter.
8.1.1 Enhanced NO production and tumour growth: effects of bacterial
lipopolysaccharide. It has been known for more than a hundred years that
tumour growth is delayed by bacterial infection (Coley, 1893). The mechanism
for this effect is not understood, but presumably involves the immune response.
More recent experiments have used purified components of the bacterial cell
wall (lipopolysaccharide; LPS) to mimick the effects of bacterial infection. This
chapter also deals with the effects on tumour growth of LPS treatment alone and
in combination with AG or L-NAME. LPS is known to induce NOS activity,
resulting in potentially harmful levels of NO within the vascular system (Stoclet
et al., 1993, Hom et al., 1995). The role of NO in relation to the growth of solid 
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tumours remains unclear. Reports that it helps to improve tumour blood supply, 
and so promote growth, is contested by others showing that it is involved in 
killing tumour cells and would therefore act to inhibit tumour growth (see Part C 
of Introduction). By stimulating high levels of NO production with LPS 
administered on its own, or in combination with the NOS inhibitors, L-NAME or 
AG, the following experiments were designed to see whether LPS promotes or 
inhibits solid tumour growth and if so to what extent NO is involved in this 
effect. Having characterised the time-course of iNOS expression and enhanced 
NO production associated with LPS exposure in the rat (see Chapter 3), it was 
hoped to correlate the LPS-induced NO production with any effects on tumour 
growth.
8.1.2 Effects of NOS inhibitors on tumour growth. L-NAME and AG, were 
also administered on their own to determine the role of NO in tumour bearing 
animals which had not been exposed to LPS. L-NAME is a non-selective 
inhibitor of NOS and as such inhibits both cNOS and iNOS (Rees et al., 1990). 
Vasoconstrictor agents are generally associated with decreased blood flow in 
experimental tumours (Peterson 1991). L-NAME has also been shown to cause a 
decrease in solid tumour blood flow in the rat (Anrade et al., 1992; Wood et al., 
1993). However, the vasoconstrictor, angiotensin II reportedly increases blood 
flow in solid tumours (Chan et al., 1984). It is clear that the effects of 
vasoconstrictor agents on tumour blood flow are not consistent (Suzuki et al., 
1981, Jirtle, 1978) and the mechanism is poorly understood.
8.1.3 Altered haemodynamics and tumour growth. It has long been known 
that vasodilators which j b.p. can reduce blood flow through tumours (Algire et 
al., 1951). This effect is often referred to as the ‘steal effect’ and describes the 
decrease in blood flow in concert with the fall in local or systemic blood 
pressure (Hirst et al., 1991). Tumour vasculature is widely regarded as being 
poorly differentiated, generally lacking smooth muscle cells (Chan et al., 1984; 
Jain, 1988) and existing in a state of near maximal dilatation. For this reason it is
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usually less sensitive to vasodilators than normal vasculature (Peterson et al., 
1991). However, since NOS inhibitors can effectively constrict these vessels it 
seems likely that NO or some other endothelium-derived vasodilator (Salvemini 
et al., 1995) is mediating this effect. This is supported by the results of the 
present study, showing that LPS-treated vessels which release high levels of NO 
are also less sensitive to the vasodilator, SNAP (see chapter 3, Section 3.5.4).
It is possible then, that an altered haemodynamic state in the host, whether 
severe hypotension caused by vasodilators, or hypertension caused by 
vasoconstrictors, is a major determinant of tumour growth. A comparison of the 
effects of AG and L-NAME provides us with the means for testing whether 
inhibition of eNOS and the subsequent systemic hypertension contributes to their 
antitumour. AG does not inhibit eNOS activity and therefore does not result in 
hypertension.
8.1.4 Blood flow and pattern of solid tumour growth. Recent literature on 
subcutaneous solid tumours grown in rodents support the hypothesis that they 
conform to a distinct pattern of growth, governed by a number of fundamental 
processes ultimately determining the survival of tumour cells within the tumour 
mass (Thomas et al., 1986; Kennovin et al., 1994; Lepoivre et al., 1989; Jain, 
1988; Buttery et al., 1993). From these studies a pattern of growth is proposed 
which may prove to be of value when trying to interpret the effects of drugs on 
the tumour. Three separate stages have been defined:
stage 1, Angiogenic phase:- -Days 1-7. An initial slow period of growth during 
which time there is intensive angiogenesis (Jain, 1988). iNOS activity is not 
expressed in the tumour vasculature at this stage (Buttery et al., 1993).
stage 2, Growth phase:- -Days 7-14. The vascular supply is firmly established 
and tumour growth increases exponentially. iNOS is detectable in the tumour 
neovasculature (Buttery etal., 1993).
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stage 3, Necrotic phase:- -Days > 14. There is an increasing incidence of central 
necrosis as elevated interstitial pressures within the tumour compress thin walled 
vessels in the centre and the tumour begins to outgrow its vasculature. This stage 
also sees a pronounced expression of iNOS in the tumour vasculature (Buttery et 
al., 1993) and it has been suggested that this is the best time to deliver drugs 
which inhibit iNOS activity (Kennovin et al., 1994). This is indeed a critical 
stage when the tumour can no longer sustain exponential growth and growth rate 
plateaus due to inadequate nutritional supply. This may also prove to be the most 
likely period for enhanced metastases, with new cells starved of blood migrating 
away from the primary tumour to reach more suitable environments elsewhere.
8.1.5 Scope of the present study: This chapter addresses the following 
questions.
1) Is iNOS expressed in well established (23-27 day old) subcutaneously grown 
solid tumours ?
2) Does a single bolus injection of LPS significantly influence solid tumour 
growth and if so is the effect due to upregulated NO production?
3) Are the effects of LPS on solid tumour growth dependent on when LPS 
treatment is administered relative to the time of implantation?
4) Does AG influence solid tumour growth ?
The results will show:
First, LPS administration delays tumour growth. The effect is maximal on day 
11 post-implantation ie. the greatest inhibition is seen close to the critical 
transition between the rapid phase of growth and the necrotic phase. 
Furthermore, the resulting delay in growth (4-6 days) compares favourably with 
the time-course of enhanced NO production initiated by LPS.
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Second, chronic administration of L-NAME alone (via the drinking water) also 
suppresses tumour growth and its effects are potentiated when LPS is 
administered one day after treatment with L-NAME commences. AG on its own 
also delays tumour growth, but to a lesser extent than L-NAME. However, in 
contrast to L-NAME, the administration of LPS one day after AG, completely 
abolishes the growth retarding effect of the latter.
Third, iNOS expression in solid tumours is confirmed by immunohistochemical 
and Western blot analysis.
Finally, LPS treatment enhances the expression of iNOS in vessels and activates 
macrophage-like cells resident within the tumour. Furthermore, LPS also 
increases the incidence of lung metastases in tumour bearing rats.
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8.2 Materials & Methods
8.2.1 Methods
Isogeneic male BD9 rats were anaesthetised and shaved along their backs. 
Tumour slurry (from third generation tumour tissue; T3) was injected (0.05mls) 
subdermally at four specific sites on the back of each animal (see fig. 8.1 below).
Fig. 8.1 Photograph showing a rat with four tumours on its back.
The surgical protocol for tumour implantation was outlined earlier in Chapter 7. 
Tumours were measured throughout the course of their growth (3-4 weeks) using 
hand-held, skin-fold calipers. The long (Y) and short (X) axis measurements 
were used to calculate tumour volume using the hemiellipsoid formula (Heitjan, 
et al., 1993; see below):
Tumour volume = fl (Y H X) 6.
-<■
Y
-►
S3 Centre of the tumour.
SS Adjacent edge to centre.
A B Peripheral section.
Fig. 8.2 A diagram showing the different areas within a tumour.
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During the study, animals were divided into 12 groups, each fed ad libitum, with 
the mean daily ingested dose (mg/Kg/day) of a particular drug defined as:
Dose (mg/Kg/day) = (water drunk (mlVday) K (drug!;(lmg/ml) 
weight of rat (Kg)
Four separate experiments were conducted to determine the effect of L-NAME 
and AG on tumour growth, either administered singly or in combination with 
LPS treatment. A similar protocol was adopted for each experiment. AG or 
L-NAME was added to the drinking water at a concentration of lmg/ml, along
with lOmg/ml of sucrose to disguise the taste of the drug. According to a
f,
previous study, lmg/ml of AG of L-NAME provides an ingested dose of 
~100mg/Kg/day (Kennovin et al. 1994). Animals not treated with a drug also 
received lOmg/ml sucrose in their drinking water. LPS was administered via 
single bolus injection (4mg/Kg; i.p.) with control rats receiving an equivalent 
volume (v/v) of 0.9% sterile saline (i.p.).
1) Protocol for LPS or LPS + AG treatment. In two separate experiments (1&
2) rats were grouped and LPS administered at 24hrs prior to tumour implantation 
(exp. 2, grp. 2a; n=4 rats), 5 days post-implantation (exp. 1, grp. 2b; n= 3 rats) 
and 11 days post-implantation (exp. 1, grp. 2c; n= 4 rats). Control animals for 
each experiment (grp la, exp.l; n= 3 rats & grp. lb, exp. 2; n= 4 rats) received 
equivalent saline (0.9%) injections 5 days post- and 24 hrs prior to implantation 
respectively. AG was also continuously fed from day 10 to rats which had not 
been injected with LPS (grp. 3a, exp. 2; n= 4) and from day 4 to rats which were 
subsequently injected with LPS on day 5 (exp. 3b, exp. 1; n=5).
Sucrose was added to the drinking water (all groups) on day 4.
2) Protocol for LPS or LPS + L-NAME treatment. In a further two 
experiments (3 & 4) the separate effects of LPS (grp. 4a, exp. 4; n=5 rats) and L-
NAME (grp. 4b, exp.3, n= 3 rats) treatment were compared with those seen 
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when both were administered together (grp. 4c, exp. 4; n= 5). The blood 
pressures of rats used in exp. 4 were recorded every 1-2 days throughout the 
growth study (from days 5-21 post-implantation) using the tail cuff method, as 
outlined in Chapter 3, Section 3.3.1.
Grp 4a animals were injected with LPS on day 11 post-implantation while Grp 
4c animals were fed L-NAME from day 10 post-implantation and subsequently 
injected with LPS on day 11 (sucrose was added to the drinking water on day 4). 
Grp. 4b received L-NAME from day 0 (sucrose was added to the drinking water 
on day 0). Control grps lc & Id were included for exps. 3 & 4 respectively, with 
grp. Id receiving a saline injection on day 11.
Histochemical and immunohistochemical analysis was used to detect iNOS 
expression and the extent of necrosis within the tumour tissue (see Appendices
3.1 & 3.2). Sections of lung and liver from tumour bearing animals were also 
examined for evidence of metastases. Tumours were cut into blocks in 
preparation for sectioning, each block representing a different area in the tumour, 
as shown in Fig. 8.2.
Mean tumour volumes (mm3) were used to construct graphs of tumour growth 
against time (days post-implantantion). Student’s paired or unpaired t-tests 
determined the statistical differences between data on a given day post­
implantation.
For clarity, the experiments performed in this chapter are shown schematically in 
Fig. 8A over the page. Steps in a line indicates a single injection of LPS 
(4mg.Kg; i.p.; solid lines) or when the NOS inhibitors were added to the 
drinking water (lmg/ml; broken lines). The lines are drawn to correlate with the 
scale bar labelled ‘Real days’. N.B. Although Grps 2a, 2b and 2c are drawn on 
the same line, rat received a single injection of LPS on either day -1, or day 5, or 
day 11.
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Fig. 8A Schematic representation of the protocols and groups used in this study.
8.2.2 Materials
Male isogeneic BD9 rats (300-450g) and P22 carcinosarcoma (Tj) were obtained 
from the CRC Gray Lab., Mount Vernon Hospital, Middlesex. LPS (serotype 
055:B5). L-NAME and aminoguanidine (hemisulfate) were bought from Sigma 
Ltd. Sucrose and sodium chloride were obtained from BDH (AnalaR grade).
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8.3 Results
8.3.1 Histomorphology Microscopic examination of haematoxylin & eosin 
(H&E)-stained tumour sections from control animals at day 27 post-implantation 
revealed distinct layering from the centre to the periphery of the tumours. The 
border between concentric layers was often dramatic, with more intense staining 
in peripheral layers and a distinct lack of staining in the centre. H&E staining 
exposed the chaotic arrangement of tumour cells within the tumour mass. Cells 
were often seen as streams or chords radiating in a disorderly fashion throughout 
the stroma matrix, as is characteristic of carcinosarcomas (see fig. 8.3).
Fig. 8.3 A frozen section (~7pm thickness) through the centre of a solid tumour 
stained with H&E illustrates the chaotic arrangement of tumour cells within the 
tumour and the distinct areas of less intensely stained cells indicating necrotic 
foci. (obj. mag. x40).
. >/**!;< -
8.3.2 iNOS expression in solid tumours. Immunofluorescence was used to 
detect iNOS in sections of tumour removed (day 27) from tumour-bearing 
control animals (grps. la - Id). Intense staining was seen in -75% of tumours 
and appeared as discretely dispersed areas within the tumour mass (see fig. 8.4). 
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The presence of iNOS within solid tumours was confirmed using dot blot and 
Western blot analysis (see figs. 8.5a & 8.5b). Staining by the ABC method 
revealed darkly stained macrophage-like cells in the centre of 17-day old 
tumours removed from animals which had been injected with LPS on day 11 
(grp. 4a animals; see fig. 8.6). Similarly, capillaries at the periphery of the 
tumour showed intense staining for iNOS following LPS treatment (see fig. 8.7).
Fig. 8.4 Cryostat section through the centre of a 27-day old tumour 
immunostained with antiserum to iNOS and labelled with TRITC. Staining was 
confined to discrete areas within the tumour mass. (obj. mag. xlOO).
A B
Fig. 8.5a Dot blot of homogenised tumours (1 fll; [protein = 5mg/ml]) from four 
individual rats (A-D) immunostained with antiserum to iNOS and detected by the 
ABC method.
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Fig. 8.5b Western blot of tumour extracts (A-D) with lung extract from an LPS- 
treated rat at t= 24hrs as a positive control (E). This clearly shows that 27-day 
old tumours express iNOS, although levels of expression vary.
Fig. 8.6 Cryostat section through a 17-day old tumour removed from an LPS- 
treated rat immunostained with antiserum to iNOS and detected using the ABC 
method. Large macrophage-like cells were seen within the necrotic foci and 
displayed intense staining for iNOS. (obj. mag. xlOO).
Figs. 8.7 Cryostat sections through 17-day old tumours removed from LPS- 
treated rats immunostained with antiserum to iNOS and detected using the ABC 
method. Staining was evident in capillaries around the periphery of the tumour 
removed six days after LPS treatment.
8.3.3 Evidence of metastases. Cryostat sections of lung tissue removed on day 
27 post-implantation from tumour-bearing control animals and tumour-bearing 
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animals which had previously been treated with LPS on days 5 and 11 post­
implantation were stained with H&E. Staining revealed that -30% of all the lung 
samples examined from LPS-treated animals (3 out of 10) showed considerable 
secondary tumour invasion. Metastases were not seen in lung tissue from 
tumour-bearing control animals. Fig. 8.8 shows a cryostat section of lung tissue 
removed from a tumour-bearing animal which had been injected with LPS on 
day 11 post-implantantion. Staining with H&E clearly shows the interface 
between the densely packed area of the invading tumour and the less densely 
packed area of the surrounding lung tissue.
Fig. 8.8 H&E stained cryostat section of lung tissue removed from a tumour­
bearing animal 16 days after a single LPS injection. The lung tissue is seen as 
the paler, less densely packed area with the adjacent, darker staining tumour 
cells tightly packed together to form a compact solid mass. (obj. mag. x40).
Large, densely packed balls of tumour cells within the lung tissue were also
observed (see fig. 8.9). These balls of cells, often referred to as ‘canon-ball
tumours’, were situated within the visceral matrix of the lung and could
undoubtedly have the potential to form solid tumours depending on their ability
to establish an adequate vascular supply.
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Fig. 8.9 A cryostat section stained with H&E showing a canon-ball tumour 
within lung tissue taken from a rat 22 days after being injected with LPS. (obj. 
mag. x40).
8.3.4 Time-dependent suppression of solid tumour growth by LPS. LPS
suppressed the growth of solid tumours to differing degrees depending on when 
it was administered. Administering LPS 24hrs prior to tumour implantantion (ie. 
grp. 2a) had a no effect on tumour growth (see fig. 8.10). This represents one 
stage of the growth pattern. Delaying the LPS treatment until day 5 post- 
implantantion (ie. grp. 2b) resulted in a significant, albeit transient, effect on 
tumour growth (see fig. 8.11 & Appendix tables 8.1 - 8.2).
Day No (post-implantantion)
Fig. 8.10 Showing that a single LPS injection had no effect when given 24hrs 
prior to tumour implantation (grp. lb; closed circles, n= 16) as compared to 
controls (grp. 2a; open cirlces, n= 16).
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This effect on tumour growth lasted for up to 10 - 11 days after treatment 
(growth delay of -4 days). The initial effect was evident after 24hrs with 
maximal suppression occurring 6-10 days post-LPS injection. According to the 
proposed pattern of growth, tumours more than 7 days old are in the second 
stage of growth, a period of prolific cell division.
Fig. 8.11 Comparing the growth curves for control (grp. la; open circles, n- 
12) and day 5 LPS-treated animals (grp. 2b; closed circles, n= 12).
The greatest inhibition of tumour growth was seen when LPS was injected 11 
days post-implantation (see fig. 8.12). In this experiment the growth of tumours 
on LPS-treated animals was significantly suppressed within 12hrs of treatment 
(2-way ANOVA, F= 2.44, df= 7,183e> p= 0.02). The effect was less transient 
than that produced when LPS was injected on day 5 post-implantation, lasting up 
to 3-4 days longer, until -day 14 post-LPS treatment.
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Fig. 8.12 Comparing the growth curves for control (grp. la; open circles, n- 
12) and day 11 LPS-treated animals (grp. 2c; closed circles, n= 14).
This period extends into the last stage of growth, ‘the necrotic stage’, when 
tumours begin to outstrip their vascular supply and the rate of growth decreases. 
Fig. 8.12 shows that the growth rate of tumours in control animals began to 
decline at -day 20-23 post-implantation, while the tumours in LPS-treated rats 
continued to increase exponentially.
Figs. 8.13-8.15 are photographs of tumour-bearing rats on day 15 post­
implantation, representing controls (grp. la), day 5 LPS-treated (grp. 2b) and day 
11 LPS-treated animals (grp. 2c) respectively. These picture show visually the 
difference in tumour size in animals treated with on day 5 and day 11 post­
implantation. It is clear that tumours in the latter group are considerably smaller 
than those of the former.
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Fig. 8.13 A photograph of a tumour-bearing rat from control grp. la 15 days 
post-tumour implantation.
Fig. 8.14 A photograph of a tumour-bearing rat from LPS-treated grp. 2b 15 
days post-tumour implantation.
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Fig. 8.15 A photograph of a tumour-bearing rat from control grp. 2c 15 days 
post-tumour implantation.
8.3.5 The effect of NOS inhibitors on the growth of solid tumours.
Kennovin et al., (1994), showed that feeding L-NAME (lmg/ml) caused a 
marked reduction in tumour growth rate and that this effect was near maximal 
and not significantly enhanced with a six fold increase in [L-NAME].
In the present study, L-NAME (lmg/ml) significantly inhibited tumour growth 
when added to the drinking water of grp. 4b rats on the same day as tumour 
implantation (day 0; 2-way ANOVA, F= 7.73, df= 4, 130e, p < 0.001). The same 
concentration of AG on its own (grp. 3a rats) also suppressed tumour growth 
although the effect was less than that of L-NAME (still revealed that its effect 
was highly statistically significant, 2-way ANOVA, F= 15.26, df= 8,252e, p= < 
0.001). The reduction in growth rate only became statistically significant 5 days 
after AG was added to the drinking water (see Appendix tables 8.2 & 8.3 for 
meaned data). Assuming that the growth profile for each group can be drawn 
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linearly, the difference in growth rates (mm3/day) of tumours for each group can 
be estimated. According to this criteria, tumours in L-NAME-treated animals 
grew at a rate of ~0.1mm3/day and those in AG-treated animals at 
~0.19mm3/day.
8.3.6 The combined effects of LPS + L-NAME and LPS + AG on the 
growth of solid tumours. The effects of LPS injection on day 11 post­
implantation (ie. grp. 4a) were compared with the combined effect of LPS 
(injected on day 11) + L-NAME (ie. grp. 4c) and the effects of LPS injection on 
day 5 (ie. grp. 2b) were compared with the combined effect of AG + LPS (on 
days 4 & 5 respectively; grp. 3b). The results are shown in Appendix tables 8.1 
& 8.4. As with exp. 1, grp. 2c animals, LPS significantly suppressed tumour 
growth (2-way ANOVA, F-= 3.15, df= 8,29l4e, p=0.002). Moreover, the 
inhibitory effect of L-NAME in combination with LPS was statistically 
significantly greater than that by LPS alone (2-way ANOVA, F= 2.30, df= 
8,318e, p= 0.0021; see fig. 8.16a).
Fig. 8.16a Comparing the growth of tumours in control (grp. Id; open circles, 
n- 16), LPS-treated (grp. 4a; closed circles, n=16-20) and LPS + L-NAME- 
treated animals (grp. 4c; closed squares, n- 16-20). Asterisks indicate a 
significant difference between control and LPS-treated animals.
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the growth rate of tumours in control animals (~0.44mm3/day) was ~1.6x that of 
the LPS-treated group (~0.27mm3/day) and ~3.3x that of the LPS + L-NAME- 
treated group (0.13mm3/day). In other words, the rate of tumour growth in the 
LPS + L-NAME-treated group was reduced by -1/2 compared to that of the 
LPS-treated group. Students’ t-test analysis is shown in Appendix table 8.5.
Fig. 8.16b shows that in contrast to the enhanced suppression seen with LPS + 
L-NAME, treatment of LPS to animals being fed AG, completely abolished the 
retarding effects of AG (2-way ANOVA F= 0.76, df= 10, 245e, p= 0.851; see 
fig. 8.11).
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Fig. 8.16b Comparing the growth of tumours in control (grp. la; open circles) 
and AG + LPS-treated (on days 4 & 5 respectively) animals (grp. 3b; closed 
squares). LPS abolishes the inhibitory effects of AG alone on tumour growth.
To confirm that the inhibitory action of L-NAME is reversible (Kennovin et al., 
1994), L-NAME was removed from the drinking water of grp. 4c rats on day 21 
and tumour volume was measure over the subsequent 4 days. The removal of L- 
NAME resulted in a dramatic increase in growth rate (> 6 fold, from -0.078 to 
~0.52mm3/day) which exceeded that of controls (see Table 8.1)
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Fig. 8.17 The inhibitory effect of L-NAME on grp. 4c tumours was reversed 
when L-NAME was removed from the drinking water on day 21. The rate of 
tumour growth increased over the subsequent 4 days to that of controls.
Table 8.1 shows the changes in tumour growth rate (mm3/day) for groups Id, 4a 
and 4c. The rate of tumour growth was initially similar for all groups (days 7 
-10). It increased in control animals (grp. Id) by -2.5 fold from the early growth 
phase (days 7-10) to the late growth phase (days 11-14), then over the 
subsequent 4-5 days (during the necrotic phase; days 16-21), the growth rate 
decreased by -12%. The relative increase in growth rate between the early and 
late growth phases was less for tumours in LPS-treated rats compared to those of 
control rats, however, the growth rate increased by -20% during the necrotic 
phase. In contrast to tumours in either the control group or the LPS-treated 
group, those in L-NAME + LPS-treated animals showed a significant decrease 
(-46%) in growth rate from the early to the late growth phase.
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Growth rate
(mm3/dav)
Group
Days 7-10 
(early growth 
phase)
Days 11-14 
(late growth 
phase)
Days 16-21 
(necrotic phase)
Days 23-25
(necrotic phase)
- L-NAME
Control (Id) 0.16 0.40 0.35 - <
LPS
treated(4a)
0.10 0.20 0.24
LPS+L-NAME
(4c)
0.13 eft0.07 **0.14 0.52
Table 8.1 Showing the tumour growth rates for each experimental group. 
Asterisks indicate a significant difference compared to the control group.
8.3.7 Haemodynamic effects of LPS alone and LPS + L-NAME treatment.
In order to determine whether the growth of tumours influenced haemodynamic 
parameters and assess the effects of LPS and LPS + L-NAME, systolic, mean 
and diastolic blood pressures of two rats from each group were recorded using 
the tail-cuff method. Control tumour bearing rats did not show any significant 
decrease in blood pressure throughout the experiment (see fig. 8.18).
Fig. 8.18 Systolic (open squares), mean (closed circles) and diastolic (open 
triangles) blood pressures for control, tumour bearing rats (n- 2).
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It is clear from fig. 8.18 that systolic blood pressure fluctuated around 
160mmHg, mean blood pressure around 105mmHg and diastolic around 80­
85mmHg. Furthermore, the injection of sterile saline did not appear to have any 
effect on blood pressure.
However, a single injection of LPS on day 11 post-implantation resulted in a 
considerable hypotension within 24hrs. This was manifested as a decrease in 
systolic blood pressure of -42% from -162 to 94mmHg. Within 48hrs after LPS 
treatment (day 13) the blood pressure had returned to pre-injection levels (see 
fig. 8.19).
Fig. 8.19 Systolic (open squares), mean (closed circles) and diastolic (open 
triangles) blood pressures for LPS-treated, tumour bearing rats (grp. 4a;n~ 2).
A decrease in blood pressure was also seen in animals treated with LPS + 
L-NAME, but the hypotensive effect of LPS was attenuated in animals treated 
with L-NAME. Thus, 24hrs after LPS was injected, systolic blood pressure had 
dropped by -26% from -153 to 112mmHg (see fig. 8.20). According to Glauser 
et al., (1991), a decrease in systolic blood pressure of > 40mmHg indicates a 
state of haemodynamic shock associated with bacterial infection. Therefore, the
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administration of L-NAME 1 day prior to LPS treatment did not prevent the 
subsequent LPS-induced hypotension.
Day No (post-implantation)
Fig. 8.20 Systolic (open squares), mean (closed circles) and diastolic (open 
triangles) blood pressures for LPS + L-NAME-treated, tumour bearing rats (grp. 
4c;n= 2).
The hypotensive effect of LPS was followed by a ‘rebound’ hypertension in 
animals also receiving L-NAME. Thus, 72hrs following LPS treatment (at day 
14) the systolic blood pressure was increased by ~25mmHg above control levels 
before LPS treatment (from -153 up to 178mmHg). The L-NAME-induced 
hypertension continued to increase until a plateau was reached at -day 17, at 
which point the systolic blood pressure had risen to ~194mmHg. The results are 
shown in Appendix table 8.6.
8.3.8. Drinking rates and weights of experimental animals. Generally, LPS- 
treated animals showed a transient (lasting up to ~24hrs) decrease in drinking 
rate. Fig. 8.21a shows the decrease (-53%) in animals treated with LPS on day 
11 (grp. 4a). The transient reduction in drinking rates was greater in animals 
receiving LPS + L-NAME (grp. 4c; -62%) and resulted in an initially low 
ingested dose of L-NAME which subsequently increased to reach ~0.9mg/Kg
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(see fig. 8.21b). The data for drinking rates and weights are shown in Appendix 
Tables 8.7-8.15.
Figs. 8.21a & b Showing the effects of LPS (closed circles) and LPS + L-NAME 
(open diamonds) treatment on the amount of water consumed per day as 
compared to controls (open circles; fig. 8.21a, n= 4-5 rats for each group). The 
dose of L-NAME ingested is shown in fig. 8.21b.
It has been shown that the anti-tumour effects of L-canavanine, also known to 
inhibit NOS, may be attributed to its inherent toxicity, resulting in caloric 
deprivation and a subsequent loss in body weight (Thomas et al., 1986). None of
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the animals in this study suffered any permanent loss in body weight (see figs. 
8.22a-f).
Fig. 8.22b
J---- 1—-J—i i i
Fig. 8.22d 
J----- 1----- 1 i L
Day No (post-implantation)
Fig. 8.22a-f Showing the change in body weight for control (la- Id; open 
circles) and treated (closed circles) animals. LPS-treated (on day -1 fig. 8.22b; 
grp 2a), day 5 (fig. 8.22a) or day ll(closed squares; fig. 8.22a), L-NAME- 
treated (fro day 0; fig. 8.22c) AG-treated (from day 10; fig. 8.22d), L-NAME +/b
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LPS treated (fig. 8.22e; grp. 4c) and AG + LPS treated (fig. 8.22f; grp. 3b). 
Refer to text for an explanation of the different groups in each graph.
However, LPS treatment alone (on day 11; grps. 2c & 4a) or in combination with 
L-NAME, caused a small decrease in body weight (~5 & 11% respectively).
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8.4 Discussion
8.4.1 LPS-induced delay of tumour growth is dependent on the time of 
administration. A single intraperitoneal injection of LPS significantly 
suppressed tumour growth when administered on day 11 and to a lesser extent 
day 5 post-implantation. No effect was seen when LPS was administered 24hrs 
prior to tumour implantation. LPS induces an immune response: specifically, it 
induces the expression of the inducible isoform of NOS and generally increases 
NO production as evidenced by the enhanced accumulation of nitric oxide 
oxidation products (>18 fold above control levels; see chapter 3, Section 3.5.2). 
One consequence of this is a transient hypotensive effect lasting for at least 48­
72hrs, presumably due to the NO-induced hyporeactivity which occurs in the 
blood vessels. Normally this would be expected to decrease the driving force of 
blood entering the tumour and also increase the tumouricidal potential of 
macrophages resident in the tumour. The combined effect would be to decrease 
the flow of nutrients and oxygen into the tumour and increase cell killing for a 
period of at least 2-3 days. This time scale compares favourably with the delay in 
tumour growth (-4-5 days).
8.4.2 The effects of L-NAME or AG on solid tumour growth. Chronic oral 
administration of L-NAME or AG delayed tumour growth, the effect of the 
former being greater than that of the latter. Previous studies have attributed the 
effect of L-NAME to constricting tumour-supply vessels (Kennovin et al., 1993), 
effectively starving the growing tumour of nutrients and oxygen (Wood et al., 
1993). This interpretation is supported by the fact that tumour growth resumes at 
control rates when L-NAME is removed from the drinking water, first shown by 
Kennovin et al., (1994) and confirmed in the present study (Section 8.3.6, fig. 
8.19). Presumably, AG also constricts tumour-supply vessels, but unlike 
L-NAME, will not inhibit eNOS and therefore will not have a generalised 
hypertensive effect. This is borne out by physiological experiments which show
that AG reverses LPS-induced hyporesponsiveness and hypotension without 
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causing hypertension (Wu et al., 1995b). Physiologically therefore, the only 
difference between the L-NAME treated group (grp. 4b) and the AG treated 
group (grp. 3a) is the sustained hypertension in animals treated with L-NAME. 
Although there is no direct evidence given in the present study, L-NAME and 
AG would inhibit macrophage NO production as well as that from vascular 
smooth muscle cells.
8.4.3 The effects of combined treatment with NOS inhibitors and LPS. The
effect of LPS on tumour growth in animals chronically fed with L-NAME was 
completely different from that of animals fed with AG. In the former case an 
LPS injection given on day 11 potentiated the growth retarding effect of 
L-NAME, whereas a similar injection of LPS given on day 5 abolished the 
effects of AG. The only physiological difference between these two groups of 
animals is the fact that one remains normotensive (grp. 3b) while the other first 
experiences a transient hypotension (1-2 days), and then encounters a sustained 
hypertension lasting for 10-11 days. This is presumably due to the non-selective 
nature of L-NAME, inhibiting both eNOS and iNOS (Rees et al., 1990). 
Significantly, removal of L-NAME, which probably restores animals to the 
normotensive state, correlates with the resumption of normal tumour growth also 
seen at this time.
8.4.4 iNOS expression in solid tumours. It is likely that much of the iNOS 
being expressed within the tumour is derived from tumour cells. Indeed it is 
possible that iNOS-derived NO actually assistes in growth as evidenced by the 
retarding effect of NOS inhibitors. This is presumably due to the vasodilator 
effect of NO, facilitating blood flow into the tumour. The poor immune reponse 
by the host, conspicuous by the relative lack of iNOS-expressing macrophages 
within the tumour, may be attributed to the origins of the tumour implant since 
this is derived from a spontaneous tumour which arose in an isogeneic rat.
The immune response triggered by a single injection of LPS was sufficient to
significantly delay tumour growth with the maximum effect occuring during the 
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latter stages of growth (ie. the necrotic phase). This was presumably mediated by 
LPS-induced activation of macrophages and the subsequent release of cytotoxic 
levels of NO within the tumour (see fig. 8.6). However, the LPS-induced 
increase in tumour vascular resistance is not inhibited by scavengers of NO 
(Tozer et al., 1995), indicating that NO may not be responsible for all of the anti­
tumour effects associated with LPS treatment.
8.4.5 Conclusions. The factor which determines whether blood flow through a 
solid tumour is increased or decreased by vasoconstrictors appears to be the 
presence or lack of VSM in the tumour vasculature. Tumour vessels with VSM 
will constrict and blood flow through the tumour will consequently decrease 
(Jirtle, 1978), while those without VSM will not and blood flow will instead be 
determined by the elevated systemic blood pressure and associated increase in 
interstitial fluid pressure within the tumour (Suzuki et al., 1981). In the present 
study tumour growth was retarded in hypertensive (ie. L-NAME-treated) and 
hypotensive (ie. LPS-treated) rats, with a greater effect seen in tumours which 
were beginning to outgrow their vascular supply. These could conceivably have 
a higher proportion of vessels, either recruited from the host or neovasculature, 
which contain smooth muscle. These results suggest that an altered 
haemodynamic state per se has a major influence on the growth of solid 
tumours, although further studies are needed in order to resolve whether this is 
true in animals which have not been subjected to agents which modify NO levels 
(eg. spontaneous hypertensive rats).
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Chapter 9 
Discussion
9.1 Background to the present study. Our understanding of NO and its 
implications in clinical disease has progressed considerably since its discovery 
as an endothelium-derived relaxing factor and mediator of the 
proinflammatory/cytotoxic response in immune-activated macrophages 
(Furchgott and Zawadki, 1980; Hibbs Jr. et al., 1988). As a result, NO has been 
established as a pervasive physiological mediator of health and disease: in its 
capacity as a vasodilator, the small amounts of NO produced by the 
constitutively active NOS isoform (eNOS) are essential for normal physiological 
function, while the high levels of NO produced by the inducible isoenzyme 
(iNOS) under pathophysiological conditions, make it a very important part of the 
host’s non-specifc immune system. However, it has recently been shown that the 
amount of NO produced during an immune response is often so great as to 
actually supress the specific T-cell-mediated immune system and even kill the 
activated macrophages responsible for the anti-tumourogenic response. 
(Lepoivre et al., 1995; Orucevic & Lala, 1995; Drapier & Hibbs Jr., 1988). This 
paradoxical lymphoid immunosuppression in animals with enhanced nonspecific 
resistance to tumour development (mediated in pail by increased NO production) 
further emphasises the ‘double-edged sword’ nature of NO and ultimately makes 
it difficult to predict the outcome of an immune-mediated upregulation of NO 
synthesis in vivo. In this respect, the role(s) of NO in cancer, and in particular its 
influence on the growth of solid tumours, is unclear, although it is largely 
governed by the quantities of NO being produced: large amounts of NO can have 
an anti-tumourigenic effect (Hibbs, Jr., 1988), while smaller amounts can favour
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the development of solid tumours by improving their blood flow. Evidence 
supporting the latter is briefly outlined below.
Solid tumours derive their blood supply from the host and via the induction of 
an angiogenic stimulus which facilitates the development of neovasculature, 
without which the tumour would not grow beyond ~2-3mm in diameter 
(Folkman, 1972). Angiogenically-derived blood vessels possess a number of 
characteristics that distinguish them from normal vessels, in particular their 
frailty, tortuosity, arteriovenous anastomoses, lack of innervation and 
susceptibility to collapse (Jain, 1988; Baillie et al., 1995). In addition to 
structural abnormalities, in many solid tumours the apparent lack of a lymphatic 
system to assist interstitial fluid drainage results in abnormally high interstitial 
fluid pressures (Jain, 1994). Since these pressures often exceed intravascular 
pressures blood vessel patency can be compromised. The majority of vessels 
within a tumour lack smooth muscle (Chan et al., 1984) and the high interstitial 
pressures within experimental tumours predispose tumour blood flow to being 
critically dependent on the systemic blood pressure of the host animal.
Initial research focused on identifying chemical agents which improve blood 
flow into the tumour to allow enhanced uptake of anti-cancer drugs. However, it 
has recently become evident that agents which can selectively reduce blood flow 
also have a strategic therapeutic role.
Reports that iNOS is expressed in solid tumour vasculature (Buttery et al., 1993) 
and that host vessels which had previously supplied a solid tumour (ie. TEAs) 
display a diminished sensitivity to vasoconstrictor agents which can be abolished 
by specific inhibitors of NOS (Kennovin et al., 1993), indicate that NO has a 
role in modulating blood flow through the solid tumour. This is confirmed by in 
vivo studies which show that specific, non-selective inhibitors of NOS (ie. L- 
NMMA and L-NAME) can reduce blood flow in experimental solid tumours 
(Andrade et al., 1992; Meyer et al., 1995) by increasing vascular resistance (ie.
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vasoconstriction; Tozer et al., 1995). Kennovin et al., (1994), were first to report 
that chronic oral administration of L-NAME in the drinking water significantly 
retards the growth of subcutaneously transplanted tumours in the rat and, 
furthermore, that this effect only persists for as long as the drug is administered. 
Removal of L-NAME from the drinking water returns the growth rate of tumours 
back to those on control animals (ie. animals which had not been fed with 
L-NAME). It is clear that agents such as NOS inhibitors which constrict 
arteriole-supply vessels can effectively starve the tumour of its vital nutrients, 
thereby inhibiting its growth (Hirst & Wood, 1989; Wood et al., 1993; Peterson, 
1991).
It is well established that exposure to bacterial lipopolysaccharide (LPS) can 
induce a state of endotoxic shock in laboratory animals similar to that (ie. septic 
shock) seen in humans (Suffredini et al., 1989; Kilbourn & Billiar, 1996). 
Furthermore, arteries removed from animals in endotoxic shock (ie. LPS-treated 
animals) display a diminished pressor response to catecholamines, similar to that 
seen with tumour-supply vessels, and like them, the hyporesponsiveness can be 
reversed with NOS inhibitors (Julou-Schaeffer et al., 1990; Schott et al., 1993; 
Joly et al., 1994).
The inherent difficulties associated with propagating tumours and isolating their 
supply arteries compromises the collection of consistent results and reliable data. 
It is conceivable that vessels isolated from LPS-treated animals will provide a 
more reliable alternative for studying the potential of NOS inhibitors to 
selectively abolish this abnormal hyporesponsive effect and thereby ultimately 
provide valuable infoimation regarding the potential for a given NOS inhibitor to 
suppress tumour growth. Using an established model of endotoxic shock in the 
rat (see Chapter 3), this study therefore, offers a comparative look at some of the 
physiological properties of tumour-supply arteries and arteries isolated from LPS
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treated rats and also assesses the potential for various inhibitors, administered 
alone or in combination with LPS, to retard the growth of solid tumours.
9.2 The effects of LPS treatment in the rat. A single bolus injection of 
bacterial LPS (£. coli serotype 055 :B5; 4mg/Kg; i.p.) was sufficient to induce 
~18 fold increase in the accumulated levels of nitrate and nitrite in rat blood 
plasma within 24hrs of the injection. This effect was transient and within a 
further 48hrs (at t= 72hrs) nitrate and nitrite had returned to control levels. The 
increase in circulating nitrate and nitrite (maximal at ~t= 20-24hrs) was evident 
after a lag time of ~6-8hrs in relation to iNOS expression in RTAs (maximal 
expression at ~t= 6hrs). Moreover, iNOS expression was almost undetectable at 
t= 24hrs. A similar lag was also seen for the transient LPS-induced 
hyporesponsiveness to phenylephrine in perfused segments of RTA, which 
increased with time after LPS exposure, becoming maximal after ~18-24hrs and 
disappearing within 72hrs. Thus, the time-course for LPS-induced 
hyporesponsiveness to PE closely resembles that for the LPS-induced increase in 
blood plasma nitrate and nitrite levels. Furthermore, both of these parameters 
parallel the LPS-induced systemic hypotension in vivo which is also maximal 
after ~24hrs and recedes within ~44-48hrs after treatment. In summary, the 
inducible isoform of NOS is expressed for ~20-24hrs in RTAs following a single 
bolus injection of LPS and the symptoms of the ensuing increased NO 
production persist for up to another 48hrs after this.
9.3 Hyporesponsiveness to PE of vessels isolated from LPS-injected rats 
and those which formerly supplied a solid tumour. The accumulated data for 
the initial D.R. curves to PE revealed a highly significant difference between 
control RTA responses (n= 56) and LPS-treated RTA responses (at t= 24hrs, 
n=29; see fig. 9.1 and Appendix table 9.1). Similarly, TEAs were found to be 
significantly less responsive to PE as compared to CEAs (see fig. 7.4). 
Interestingly, 2 way ANOVA reveals no significant difference between LPS
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RTAs (at t=24hrs) and TEAs (F=1.60, df= 9, 513e, p= 0.113) nor control RTAs 
and CEAs (F= 0.89, df= 9, 735e, p= 0.538; see fig. 9.2). It must be assumed that 
this is purely coincidental since each type of artery is exposed to a different 
internal perfusion rate which will ultimately determine their contractile response.
Fig. 9.1 Represents the initial D.R. to PE data for accumulated control (closed 
circles, n~56) and LPS-treated (t- 24hrs; open circles, n-29) RTAs.
Fig. 9.2 Compares the initial D.R. to PE for TEAs (open squares, n-29) /CEAs 
(closed squares, n=28) and LPS-treated (open circles) and control (closed 
circles) RTAs.
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From this evidence, it could be suggested that LPS-treated RTAs and TEAs 
display a similar hyporesponsiveness. However, on closer examination they 
appear to differ: TEAs have a comparatively greater hyporesponsiveness at 
higher concentrations of PE and as a result a more defined ‘plateau’ is seen at the 
top of the D.R. curve. A plot of f values produced a negative slope (see fig. 
7.17). In contrast, LPS-treated RTAs proved to be more hyporesponsive at lower 
concentrations of PE and as a result, when the/values were plotted with a linear 
curve fit, a positive slope was obtained (see Fig. 3.20). It can therefore be 
concluded that the TEA-associated hyporesponsiveness conforms to the 
theoretical non-competitive-type of shift relative to CEAs, while that associated 
with LPS-treated RTAs more closely resembles a competitive shift (see Chapter 
3, Section 3.6.1). This indicates a fundamental difference in the types 
hyporesponsiveness exhibited by these two types of vessel. This is perhaps not 
surprising when we consider that LPS and tumour growth result in the synthesis 
& release of a large number of different chemicals. LPS stimulates a cascade of 
various types of cytokine and inflammatory mediators, including iNOS, while 
growing tumour releases a concoction of chemicals into its surrounding 
enviroment to stimulate angiogenesis and generally promote growth (Klagsbrun 
& D’Amore, 1991; Rees et al., 1990; Zuckerman et al., 1989; Kilbourn & 
Billiar, 1996).
9.4 NOS inhibitors abolish the Hyporesponsiveness to PE of vessels isolated 
from LPS-injected rats and those which formerly supplied a solid tumour.
NO-induced insensitivity to a-adrenergic agents is thought to explain the failure 
of vasopressor agents in some patients with septic shock. In the present study 
two relatively non-selective NOS inhibitors, L-NMMA, L-NAME and the more 
isoform selective inhibitor, AG, were found to fully reverse the diminished 
sensitivity to PE in LPS-treated RTAs and TEAs with a general rank order of 
potency L-NMMA > L-NAME > AG (see Chapters 4 & 7). However, unlike L- 
NMMA or L-NAME, AG did not further potentiate responses beyond the
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control groups (ie. control RTAs or CEAs), confirming its preferential inhibition 
of the inducible isoform (Griffiths et al., 1993; Joly et al., 1994; Wu et al., 
1995). In a separate set of experiments (see Chapter 6) a number of novel NO 
scavengers (JM1006, 1226 and 6245) were also shown to reverse the LPS- 
induced hyporesponsiveness in RTAs. These results together show that the 
hyposensitivity of vessels taken from LPS treated rats and those which had 
previously supplied a solid tumour is mediated at least in part by NO derived 
from the inducible isoenzyme of NOS.
9.5 De Novo Protein Synthesis in TEAs and LPS-Treated RTAs in vitro. It 
has previously been shown that arteries supplying a solid tumour are sensitive to 
the protein synthesis inhibitor, cycloheximide (Kennovin et al., 1994), whereby 
the hyposensitivity associated with these vessels is abolished within ~2hrs of 
initiating treatment. This suggests that TEAs contain vasoactive proteins which 
are rapidly synthesised and are involved in sustaining the hyporeactive effect. 
The study by Kennovin et al. (1994), also found that CEAs undergoing 
prolonged perfusions (> 7hrs) developed a similar cycloheximide-sensitive 
hyporeactivity to PE as that seen in TEAs. Prolonged exposure to bacterial 
contamination within the ex vivo apparatus is thought to be responsible for 
inducing iNOS in these vessels and may explain this effect.
A comparable time-dependent hyporesponsiveness was not seen in control RTAs 
after 9hrs perfusion (results not shown). The reason for this is not clear, although 
it is conceivable that the considerably larger diameter of RTAs compared with 
EAs (~150-200p,m and 40-70p,m respectively) may mean that more NO must be 
produced in RTAs than in EAs for a comparable effect to be seen. These results 
do not contradict those of Rees et al., (1990), who showed that rat aortic rings 
developed a cycloheximide-sensitive hyporesponsiveness after 8hrs using the 
organ bath technique, as a non-perfusion setup will undoubtedly favour the
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tendency for bacterial comtamination to accumulate around the vessel and 
thereby increase the likelihood of inducing iNOS activity.
Indomethacin on its own caused a marked suppression of contractile responses 
in TEAs and CEAs, with a slightly greater effect in TEAs compared to CEAs 
(although not significant with n=5; see fig. 7.), suggesting that under normal 
conditions cyclooxygenase enzymes are responsible for producing a 
vasoconstrictor ( eg. thromboxane A2) in these vessels. A similar enhanced 
production of thromboxane A2 or endoperoxides is thought to explain the 
augmented suppression of noradrenaline-induced contractions in rings from 
LPS-treated rats (Wu et al., 1994). Further experiments with TEAs are required 
to identify the mediator involved in this effect. However, since cycloheximide 
was reported to have no effect on CEAs within 2hrs of treatment (Kennovin et 
al., 1994) it must be concluded that the potentiating effect of cycloheximide, 
which is similar to that for AG, is not due to inhibition of cyclooxygenase 
protein synthesis, but more likely to inhibition of iNOS synthesis.
Responses to PE were similarly enhanced by cycloheximide in LPS-treated 
(24hrs) RTAs but not in controls. They were significantly increased by 2hrs and 
maximally so by 3hrs. After 4hrs perfusion with cycloheximide alone the 
subsequent addition of L-NMMA did not significantly potentiate the responses 
in either control or LPS-treated RTAs.
Indomethacin on its own did not alter responses in these vessels, however, it did 
completely abolish the cycloheximide-mediated augmentation of responses in 
LPS RTAs (see fig. 5.). The LPS-induced activation of iNOS and the subsequent /\ 
release of NO is known to stimulate iCOX activity (Salvemini et al., 1993). By 
inhibiting cyclooxygenase activity (iCOX), indomethacin may remove the 
influence of vasodilators (eg. prostacyclin) as well as vasoconstrictors (eg. 
thromboxane A2/B2). If both catergories are active in RTAs it is likely that 
treatment with indomethacin would not cause any visible alteration to PE-
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induced contractile responses. This may explain why indomethacin abolished the 
effects of cycloheximide in RTAs, without having any apparent effect when 
added on its own. A similar case may also be true for rat aorta (Wu et al., 1994). 
This could suggest that like iNOS, vasoactive products of the iCOX are rapidly 
turned over (ie. continously synthesised) during the LPS-induced immune 
response and therefore the effect of cycloheximide is a composite one inhibiting 
both iNOS and iCOX activity.
Assuming that cycloheximide inhibits iNOS activity in LPS-treated RTAs, the 
subsequent effect of L-NMMA presumably reflects the inhibition of eNOS 
activity. The effect of L-NMMA is masked by the shift caused by cycloheximide
alone (see fig. 5.), although basal NO production may actually be reduced in
A
these vessels. In the presence of cycloheximide + indomethacin, L-NMMA 
causes a considerable shift similar to that for untreated LPS RTAs (see fig. 5.), 
suggesting that eNOS-derived NO production is upregulated and does not rely 
on de novo protein synthesis for sustained activation. The presence of 
indomethacin therefore appears to enhance basal NO production in LPS-treated 
RTAs. The relative lack of effect by cycloheximide alone or in combination with 
indomethacin in control RTAs implies that iNOS or iCOX are not actively 
expressed in these vessels.
It can be concluded therefore, that the vasoactivity of rat epigastric arteries 
(EAs), whether they be associated with a tumour or not (ie. TEAs and CEAs 
respectively), is to some extent regulated by vasoactive products of the 
cyclooxygenase pathway. The ability of indomethacin to suppress EA responses 
to PE suggest that the predominant product is a vasoconstrictor. Similarly, RTA 
responses are also influenced by products of the COX pathway, although in 
contrast to EAs, this only applies to RTAs isolated from LPS-treated rats 
(synonymous with TEAs). This suggests the involvement of the inducible 
isoform of COX. Furthermore, the ability of indomethacin to abolish the
222
Chapter 9 - Discussion
vasoconstricor effect of cycloheximide implies that a vasodilator is being 
inhibited and not a vasoconstrictor, as in the case of EAs. LPS-induced NO 
production can increase prostaglandin synthesis (Salvemini et al., 1993). The 
fact that NOS inhibitors can fully reverse the LPS-induced hyporesponsiveness 
in isolated RTAs, does not identify NO as the sole mediator of this effect since 
recent evidence shows that NOS inhibitors, including L-NAME, can also inhibit 
prostaglandin production (Salvemini et al., 1995).
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9.6 Perturbation of Endothelial Lining. Several TEAs and LPS-treated RTAs 
were found to be structurally different from their respective controls by having 
deformed endothelial lining (see Figs. 93-9.6). Transmission electron 
microscopy revealed disruption of the endothelial cells in a few TEAs and LPS- 
treated RTAs with small cellular processes extending out from their surface.
fig 9.4
Figs. 93-9.6 are photographs (E.M. tnagn., xl5,000) of endothelial cells from a 
control and an LPS-treated RTA (Figs. 9.3 & 9.4 respectively, above) and a CEA 
and a TEA (Figs. 9.5 & 9.6 respectively, opposite). Endothelial cells on the LPS- 
treated RTA and TEA commonly showed signs of abnormality with tiny cellular 
processes extending out from their endothelial surface. Their respective controls 
on the other hand showed no signs of endothelial perturbation.
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Perturbed endothelial lining has been reported previously following LPS 
exposure and is thought to be responsible for the accompanying increased 
vascular permeability to proteins. (Hutcheson et al., 1990). Furthermore, a more 
recent study implicates iNOS in this effect (Boughton-Smith et al., 1993). 
Enhanced permeability is also a characteristic of tumour vasculature (Jain, 1994) 
and may reflect the expression of iNOS and/or vascular permeability factor in 
these vessels (Dvorak et al., 1991; Maeda et al., 1994). It has yet to be shown 
whether host vessels recruited into a solid tumour also exhibit hypermeability. 
Evidence here, although not conclusive, does raise the possibility that arteries 
recruited into a tumour are modified morphogically as well as physiologically 
and furthermore, that these properties are linked by the same common mediator, 
iNOS-derived NO production.
9.7 NOS expression in TEAs, their associated tumours and RTAs isolated 
form LPS-treated animals. Western blot analyses revealed that RTAs isolated 
from rats 6hrs after an injection with LPS expressed high levels of iNOS, while 
control {untreated) animals did not. iNOS expression diminished with time after 
LPS treatment and was absent by 72hrs. The enzyme was also highly expressed 
in lung tissue removed from LPS-treated animals 24hrs after being treated with 
LPS. Immunohistochemical analyses revealed that it was localised to 
macrophage-like cells and was generally not seen in the epithelial lining of 
major airways. iNOS was also weakly expressed in heart and liver extracts (not 
shown). Staining with antiserum specific to eNOS (see chapter 3, section 3.4.2) 
in RTAs at t= 6,24 and 72hrs after LPS treatment confirmed the expression of 
eNOS in the endothelial lining of these vessels. The expression of eNOS 
therefore persists throughout the LPS-mediated induction of iNOS.
TEAs also expressed eNOS as well as iNOS. iNOS expression was generally 
localised to their smooth muscle layer, although some sections revealed intensely 
staining cells on the endothelial layer. In contrast, CEAs did not express iNOS
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(see Figs. 7.11 & 7.12). Tumours grown on the back of isogeneic BD-9 rats for 
23-27 days also expressed iNOS. iNOS expression was greatest at the periphery 
of tumours (see Fig. 8.3), with little or no staining nearer their necrotic centres.
9.8 The effects of LPS and NOS inhibitors administered singly or in 
combination on the growth of solid tumours. A single injection of LPS 
(4mg/Kg, i.p.) significantly retarded tumour growth when administered 5 days or 
11 days after tumour implantation. The maximum delay of growth was ~5 days 
after which the rate of growth returned to control levels. Interestingly, no effect 
was seen when LPS was given 24hrs prior to implantation suggesting that the 
transplantation of tumour cells into the host was not impeded by the LPS- 
induced immune response. Chronic oral administration of either L-NAME or AG 
in the drinking water of rats (concentration = lmg/ml) significantly delayed 
tumour growth, although the inhibitory effect of L-NAME was considerably 
greater than that of AG. Growth rates returned to control levels when L-NAME 
was removed from the drinking water. A single injection of LPS to animals 
being fed L-NAME potentiated the growth retarding effects of L-NAME but 
inhibited those of AG. The precise reason for this difference is not clear, but it is 
conceivable that the hypertension caused by L-NAME after the effect of LPS 
had worn off may further act to suppress tumour growth. Presumably, the 
preferential inhibition of iNOS by AG would mean that these animals would not 
experience hypertension. This supports the view that altered haemodynamic state 
in the host per se is a prime determinant of solid tumour growth.
Bacterial endotoxin is currently undergoing clinical trials as a potential therapy 
against cancer (Engelhardt et al., 1991) and interleukin-2 (IL-2), which also 
mimics the haemodynamic changes which occur in septic shock (Ognibene et 
al., 1986), has been shown to have considerable anti-cancer properties 
(Rosenberg et al., 1989). The results of the present study indicate that LPS 
adminstered on its own, although able to significantly retard tumour growth,
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unfortunately also increases the incidence of lung metastases. Further studies are 
needed to confirm this.
9.9 The effects of NOS inhibitors on spontaneous vasoactivity in isolated 
TEAs. Spontaneous rythmic fluctuations in perfusion pressure are a unique 
characteristic of some isolated TEAs (-20% in the present study). They were 
never seen in CEAs. The rythmical increases in perfusion pressue are thought to 
reflect spontaneous vasoconstriction in TEAs and in vivo may be responsible for 
the intermittent blood flow through tumours in animals (Intaglietta et al., 1977; 
Peters et al., 1980) and/or humans (Chaplin &Trotter, 1992). Indeed, studies on 
the temporal and spatial changes in tumur blood flow at the microregional level 
have shown that blood vessels in experimental tumours can experience periods 
of non-perfusion lasting several minutes (Trotter et al., 1989; Jirtle, 1988) which 
may ultimately lead to acute hypoxia within these tumours (Chaplin et al., 1987). 
The present study shows that aminoguanidine (AG; ImM) potentiates the 
frequency and amplitude of TEA-associated oscillations and this effect can be 
reversed with L-arginine. Moreover, the effect of AG was not further potentiated 
when L-NAME (80-250pM) was added to the Krebs + AG solution. These 
results show that the L-arginine/NO pathway is involved in this phenomenon and 
that NO probably acts to suppress spontaneous vasomotor activity.
Because NOS inhibitors increase the pulsatile vasoconstriction of feeding vessels 
and reduce blood flow into a solid tumour, areas within the tumour not receiving 
adequate nutrients will increase considerably and as a result the number of 
acutely hypoxic tumour cells will also increase. It is therefore likely that there 
exists a potentially important therapeutic advantage to using NOS inhibitors in 
combination with bioreductive agents which specifically target hypoxic cells.
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10. Conclusions. The inherently inadequate blood supply into solid tumours 
was initially seen as an obstacle to the delivery of anti-cancer drugs. Increasing 
opinion and overwhelming evidence now see it as a remarkable therapeutic 
window through which tumours may be starved to death with agents which act to 
reduce tumour blood flow. It is unlikely that constriction of feeding arterioles is 
sufficent on its own to facilitate tumour regression. It is more likely that a 
combination of vasoconstrictor and bioreductive agents will prove to be more 
effective.
The present study has confirmed much of the work by Kennovin et al., (1993, 
1994) and provided immunohistochemical evidence that solid tumours and their 
host-derived supply vessels express iNOS. It also shows that inhibition of iNOS 
significantly retards tumour growth, indicating the pro-tumourogenic role of NO 
in the absence of any artificial stimulation of the immune response.
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Appendix 3.1
Estimating NOS activity using Western Blot Analysis.
3.1.1 Preparation of tissue extracts (ie. Heart, liver, lung, tail artery and 
tumour)
Tissue was dissected out from the rat, wearing gloves and using sterile forceps 
/scalpel, placed into small universal containers and immediately frozen in liquid 
nitrogen until homogenizing. An estimate of total tissue volume was made.
N. B. Sterile technique was maintained throughout the procedure.
3.1.2 Tissue Homogenization
Lysis buffer- (TE buffer):- 0.05M Tris(hydroxymethyl)methylamine (Tris; 
F.W.= 121.14, BDH, AnalaR) = 6.05g, 0.001M Ethylenediaminetetraacetic acid 
(EDTA; Disodium, F.W.= 372.24, BDH AnalaR) = 0.372g into a litre of distilled 
water (DH2O). Adjust pH to 7.4 using cone. HCL.
Immediately before use add protease inhibitors: -
O. 1M Dithiothreitol (DTT; SH reducing agent, prevents S-S polymers forming). 
MW= 154.3 ie 86mg/5.6mls DH2O.
0.1M Phenylmethylsulphonyl fluoride (PMSF) MW=174.2. ie 87mg/5mls 
(in either methanol or isopropanol).
Trypsin inhibitor(TI) (from Sigma) (lmg/ml DH2O). This has been previously 
aliquoted and stored at -20°C.
Antipain (from Sigma; lmg/mlDH2O). This is aliquoted into 50/ds and stored at 
-20°C.
Pepstatin A (500/<g/ml). Dissolve 5mg/10mls of 1% Acetic acid. This is stored at 
-20°C until use.
Final Cone.
To lOmls of TE buffer add 100/d of 0.1M DTT 0.001M
100/d of lmg/ml TI 10^g/ml
100/d of 0.1M PMSF 0.001M
10/4 of lmg/ml Antipain l^g/ml
20/4 of 500/^g/ml Pepstatin A l/<g/ml
Tissue extracts were removed from their universal containers and placed into ready 
cooled beakers with 5x vol. of ice cold TE buffer to tissue vol. The tissue was 
then diced up using sterilized scissors and homogenized over ice with an Ultra- 
turrax T25 (Janke & Kunkel; IKA) for 3-5mins at a speed of 24,000 revs./min.
3.1.3 Ultracentrifuging tissue homogenate
The tissue homogenate was then pipetted from the beaker into ice cold Beckman 
ultracentrifuge tubes (1/2” x 2” approx, vol. = 5mls) and immediately 
ultracentrifuged at 100,000 xG for lhr (at 4°C; Using the SW55Ti Beckman 
rotars, a rotor speed of approx. 23,000 rpm. = relative centrifugal field (xg) of 
100,000 at rmax).
It was important when doing this that the centrifuge tubes were filled almost to the 
brim and were balanced on the rotar. The outsides of the tubes must by dry before 
being placed into the rotor buckets.
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After centrifugation the supernatant was carefully pipetted into clean vials and 
stored at -80°C.
3.1.4 Protein estimation of tissue extracts.
Protein contents of tissue samples were estimated using the Bradford method 
(Merck), measuring range 0.1-1.4 mg/ml and the Biuret method (Merck) for 
measuring over a range of l-10mg/ml.
Spectrophotometric measurments were carried out using disposable plastic 
cuvettes (5mls) and gloves were worn at all times.
Bradford Method (measuring range 0.1-1.4mg/mi)
A stock of standard solution(10mg/ml) was prepared by adding lOOmg of bovine 
serum albumin; Sigma) (BSA) into lOmls of DH20 and is diluted over a range of 
0. lmg/ml to 1.4 mg/ml in steps of 0.2mg/ml. This standard solution was 
aliquotted and stored at -20°C.
Each cuvette contained 50/4 of sample solution (diluted into TE buffer in a ratio of 
1: 5, ie 10/4 into 40/4) or 50/4 of standard solution (0.1-1.4mg/ml) and 2.5 mis 
of Bradford reagent. The reference cell contained an equal volume of TE buffer + 
2.5mls of Bradford reagent. Solutions were left to sit for 2 minutes before 
readings were taken. Absorbance was measured at 595nm.
Biuret Method (measuring range l-10g/l)
A stock of standard solution was prepared by dissolving exactly lg of BSA into 
lOOmls of DH20. This was then diluted: 8g/l, 6g/l, 4g/l, 2g/l, lg/1. The stock was 
aliquotted and stored at -20°C.
Each cuvette contained 0.5mls of sample solution (diluted in TE buffer, 1: 5 ratio) 
or 0.5mls of standard solution (l-10g/l) and 2mls of Biuret reagent. The reference 
cell was similar to that for the Bradford method. The cuvetted solutions were 
allowed to sit at room temp, for 30 mins, before absorbance readings were taken. 
Absorbance was read at 546nm.
Evaluation of results
An estimation of protein concentrations in the tissues was made from a calibration 
curve: plotting the measured absorbance readings against the corresponding 
protein standards. A linear curve fit was applied to the graph and the gradient 
equation (Y=mX+c) and r2 value was noted. The Y value was be replaced for the 
absorbance readings obtained with the sample solution to calculate the X value. 
The approximate protein concentration in the tissue sample was estimated by 
multiplying the value of X by five, thus allowing for the previous dilution factor. 
(See above; The r2 value must > 0.995)
BSA has been suggested to result in a slight underestimation in protein 
concentration.
3.1.5 Preparing Samples
Lung, liver and heart samples were prepared at a protein concentration of 2mg/ml 
by diluting in TE buffer ; so if 20/4 of sample was loaded onto the gel then 40/<g 
of protein would theoretically be present. Artery samples were prepared as near to 
lmg/ml as is possible and tumour samples are prepared at 5mg/ml. The final 
protein concentration used depends on how much protein was estimated to be in 
the samples initially.
Once diluted, 2 volumes of a particular sample were added to 1 volume Laemmli 
sample buffer [x3] containing 15% b-mercaptoethanol (BME; Sigma). The BME
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was added immediately prior to use. The sample was then boiled in this solution 
for 5-10 mins to denature the proteins and break disulphide bonds.
Laemmli Buffer [x3]:
Glycerol 3ml
20% SDS 1.3ml
0.625MTris 3ml (pH=6.8)
0.1% Pyronin Y 0.9ml
DH2O 1.3ml
Samples were then either applied to the gel or stored at -20°C.
N.B. Samples were [2/3] at this stage : a sample diluted to lmg/ml was now 
2/3mg/ml; so 15pl of sample/gel lane = lOpg of protein.
3.1.6 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE)
3.1.6.1 Preparing Gels;- Running gel / Stacking gel. (Volumes are for two 
gels).
Using two clean (25ml) conical flasks into which prepare:-
Running gel (7.5%) Stacking gel (4%)
DH2O 15.7mls 5.9mls
acrylamide (29.2%)/
bis-acrylamide (0.8%) 8 mis 1.5 mis
1.5M Tris buffer (pH 8.8) 8 mis -
0.5M Tris buffer (pH 6.8) - 2.5 mis
10% SDS 0.32 mis 0.1ml
N.B. Sodium dodecylsulfate (Lauryl sulfate) electrophoresis reagent (Sigma, 
F.W. 288.4).
A loosely fitting lid was placed onto each flask and they were placed into a 
vacuum chamber for lhr (R.T.). This procedure removed the soluble oxygen from 
the solutions, thus inhibiting polymerization (This procedure may not be necessary 
with concentrations of ammonium persulfate; APS) >5%).
Polyacrylamide gels are composed of chains of polymerised acrylamide which 
become cross-linked by a bifunctional agent such as N,N’-methylene-bis- 
acrylamide. The separation of proteins onto the gel depends on the concentration 
of polyacrylamide and the amount of cross-linking.
A higher ratio of acrylamide monomer to N,N’- methylene-bis- acrylamide cross­
linker allows most proteins to migrate faster and will also promote easier transfer 
of immunoblots.
3.1.6.2 Preparation of gel plates
The glass gel plates were prepared while the gel solutions were being degassed.
1) The glass plate were washed in decon 90 (Decon lab. LTD, E. Sussex) and 
rinsed in DH20. This was followed by a further wash in 70% alcohol and a final 
rinse in DH20.
2) The plates were assembled vertically in the MV2-DC apparatus (Anachem LTD) 
with the large plate at the back. Side spacers were then placed between the plates 
and tightened together in the front of the rack, ensuring that the spacing card could 
easily fit into the gap between them. The side clamps were tightened, the sample 
combs (1mm width) placed between the plates and a mark* was made 1cm below 
the teeth level. The combs were then removed and the plates were placed to the 
back of the rack.
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3.1.6.3 Gels
Running gel: Pipette 2mls of running gel into a universal container and add 80/d 
of 10% APS followed by 8jwl of N,N,N’,N’-Tetramethylethylenediamine 
(TEMED).
lml of this was then pipetted into the comers of each gel, ensure that the bottom of 
each gel was covered. This sealed the bottom before the rest of the running gel 
was added.
To the rest of the running gel add 160/d of 10% APS and 15/d of TEMED. 
Polymerization starts within ~10 minutes during which time the gel was pipetted 
between the glass plates up to the level of the mark*. It is important not to aerate 
this gel. A thin layer of water-saturated isobutanol (10%) was carefully pipetted 
over the running gel to create a barrier to oxygen, inhibiting the polymerization of 
the acrylamide. Allow the gel to set for ~30minutes.
N.B. It is important to remove air bubbles from the bottom of the running gel to 
prevent the gel front from being distorted.
After the gel was set, the isobutanol solution was poured off and the top of the 
running gel was washed with DH20, drained and dried with blotting paper.
Stacking gel: To the flask containing the stacking gel add 130/d of 10% APS and 
20/d of TEMED. Using a lml pipette the remaining area between the plates was 
filled by pouring this gel solution directly onto the polymerized running gel and 
placing the appropriate comb (ie curtain or 24 tooth comb) into it without trapping 
air bubbles underneath any of the comb teeth. The stacking gel was allowed to set 
for ~ lOminutes.
During this time the samples, molecular weight markers (MrM) and electrode 
buffer (E.B.) were be prepared.
MrM: Calibration proteins for SDS gel electrophoresis were bought from 
combithek, Boehringer Mannheim Biochemica and Amersham, Life Science. The 
combithek contains eight calibration proteins [0. l-0.2/0.2ml buffer each with 50% 
glycerin (v/v)] over a Mr range of ~ 14,000 to 340,000. 10//1 of each protein was 
mixed together in 80/d of laemmli sample buffer. 5/ri of this mixture was applied 
per gel lane. This protein mixture is stable for 4months when stored at -20°C.
' Rainbow MrM from Amersham were bought ready mixed containing seven 
proteins [lmg/ml] over a Mr range of 14,300 to 220,000. This mixture was 
diluted before use in laemmli sample buffer, 1:1 with 20/d/gel lane for a large gel 
(16-20cm). •
E.B(pH8.3): (21itres)[xl0] 0.1% SDS 
0.025MTris
(require 20g) 
(require 60g) 
(require 288g)Glycine
Dissolved in 21 of DH20 and diluted 1:10 for use.
3.1.6.4 Preparing the gels for samples.
The gelled plates were lifted from the preparatory platform and placed into the 
electrophoresis chamber and clamped in. The combs were removed and E.B. was 
poured into the top reservoir between the gels, completely filling the reservoir and 
spilling over between the glass plates. The teeth of the stacking gel usually needed 
straightening at this stage and was carried out using a needled syringe and 
squirting E.B. into each well. The wells were washed thoroughly to remove any 
unpolymerised acrylamide. E.B. was also placed into the lower reservoir to cover
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the electrodes running along the bottom of the chamber and any air bubbles were 
removed from the bottom of the gel using the syringe.
3.1.6.5 Loading samples
Thawed samples were pipetted slowly into each gel lane (15/d-20/d) to ensure the 
sample was kept as a tight layer and a note was made of the sample order along the 
gel. A MpM was run with each gel. Care was taken not to spill samples into 
neighbouring lanes. Samples may sometimes need to be centrifuged at 13,000g 
for 5 minutes before loading.
3.1.6.6 Electrophoresis
Electrophoretic conditions vary depending on the size, thickness and number of 
gels being run. The current increases in proportion to the number of gels or gel 
thickness, eg. 2 gels require twice the current of 1 but the same voltage (V) . 
Longer gels require proportionally higher voltages or longer running time. During 
this procedure die gel plates are kept cool by water circulating around them.
Gels were usually run at 120-150V which allows ~ lhr for the dye front to reach 
the bottom of the gel. The power was then turned off and the plates were removed 
from the electrophoretic chamber.
3.1.6.7 Staining gels or Western blotting.
The plates were laid flat on a clean surface and carefully prised apart using a 
spatula. This usually meant removing the side spacers and levering from this gap. 
Once the plates were separated, the gel was nicked at one comer with a clean razor 
blade. This nick was closest to the 1st gel lane and is important when identifying 
proteins from the western blot.
Fixing and staining gels with coomassie brilliant blue
Coomassie brilliant blue R250 (Sigma, FW = 826) is a triphenylmethane textile 
dye which is suitable for detecting proteins on PA gels. A stock of 2 litres was 
made up as follows:- 1.5g of coomassie blue was dissolved into 900mls of 
methanol: DH20 (1:1 v/v) and 200mls of glacial acetic acid. This solution was 
then filtered through a No. 1 Whatman filter to remove any particulate matter.
The gel was immersed in at least 5 volumes of stain and agitated for a period of 
>4hrs. at R.T. The stain was then drained off, back into the stock, and the gel was 
destained.
The destain solution consists of exactly the same ingredients as the stain but lacks 
coomassie blue. The gel was soaked in destain overnight changing the solution at 
least 4 times.
After destaining the gel can be stored indefinitely in DH20 (containing 20% 
glycerol) in a sealed container. For a permanent record the stained gel can be 
photographed.
Western blotting. (Using the WB2 Western blotting unit from Anachem Origo) 
After the initial electrophoretic separation of the SDS-polyacrylamide complexed 
proteins in the running gel a further electrophoretic transfer of the proteins from 
the acrylamide gels to the transfer membranes is performed.
The plates were removed from the chamber and separated carefully using a 
spatula. A comer relating to the 1st gel lane was nicked off using a clean razor. 
The gels were then carefully lifted off the glass and soaked in transfer buffer for 
20 minutes.
Transfer buffer (10 litres)
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Tris (AnalaR grade, pH 7.5 - 8) 30g
Glycine (Electrophoresis grade, pH 8.3) 144g
Methanol (AnalaR grade) 21
(MilliQ DH20 make up to 101)
0.1% (w/v) SDS can also be added. This anionic detergent binds to the denatured 
proteins which then become negatively charged and are therefore more efficiently 
electrolysed across from the cathode (-ve) to the anode (+ve).
At this stage the area of the gel was measured and the equivalent area of Whatman 
chromatography paper (3mm) cut out (x4/gel). The same size of nitrocellulose 
transfer membrane (BDH) was prepared and together with the blotting paper was 
pre-soaked in transfer buffer for 15 minutes. The fibre pads of the transfer 
apparatus were also pre-soaked.
N.B. If only one gel was being blotted then the smaller pads were used and a pre­
cooled buffer saver block was placed into the transfer tank.
The transfer tank was half filled with transfer buffer and continually stirred to 
maintain uniform temp.
Once the gel had soaked for 20 minutes the half of the transfer cage corresponding 
to the cathode side was placed into a basin of transfer buffer and the following 
was placed on top of this pre-soaked fibre pad:
Two pre-soaked blotting papers.
The gel.
The pre-soaked transfer membrane.
Two pre-soaked blotting papers.
The other pre-soaked fibre pad.
The other half of the transfer cage corresponding to the +ve side.
It is important to roll out any air bubbles between the layers. This was done using 
a pre-wet glass rod.
The layers were then clamped together and placed into the transfer tank.The power 
was switched on and set to 200mA. Transfer was carried out over 2hrs.
3.1.6.8 Detecting proteins on Western blot membranes :- Using 
^Ponceau ‘S’ red stain (PonS), 3,3’ ^diaminobenzidine Tetrahydrochloride 
(DAB) or ^enhanced chemiluminescence (ECL).
1 Prewet membrane in PBSa.
2 Block overnight in 10% marvel (in PBS- 0.5%Triton X-100; PBS-0.5%T).
3 Wash (x3) briefly in PBS-0.5%T then for a further 15 mins.
4 Probe with 1° antibody. Make up in 1% marvel (PBS-0.5%T). Incubate on 
rotator for 2hrs at R.T.
5 Wash x4-x5 mins, in PBS-0.5%T.
6 Probe with 2° antibody in 1% marvel for 2-4hrs, R.T. on rotator.
7 Wash briefly in PBS-0.5%T (x2) then for 15mins., followed by a furhter 2 
washes for 5 mins.
8 Wash in PBSa
9 Visualise with 1 PonS, 2 DAB, or 3 ECL.
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10 Staining procedure^: PonS [xlO] stock
a) Trichloroacetic acid (TCA) AnalaR grade (BDH) 30g
5-Sulfosalicylic acid dihydrate (Sigma,F.W.254.2) 30g
Dissolve into lOOmls DH20 then add 2g of Ponceau S sodium salt (Sigma, 
practical grade F.W. 760.6) and dissolve.
b) Rinse blot in PonS solution for 2-10 mins, with agitation.
c) Wash off stain with DH20 and mark the postions of the MWM with a pencil 
and store damp wrapped in clingfilm at 4°C.
This procedure can be used to show the presence of proteins on the blot before 
immuno-probing for a particular protein.
Staining procedure^: Nickel enhanced DAB
a) A lOmg tablet of DAB (Sigma, stored at -20°C) was thawed to R.T. and 
dissolved into 15mls of Tris (50mM, pH 7.6).
b) Add 1.7mls of 0.3% nickel chloride (Sigma, NiCl2 Hexahydrate) and filter 
into a clean flask using Nol whatman.
c) Pipette in 16.7/ri of hydrogen peroxide (30%, Sigma) immediately before 
application to blot.
d) This solution was pipetted into the bag containing the blot and the bag was then 
sealed.
e) The solution was left for l-5mins. on the rotator.
f) Then rinse briefly in PBSa and allow the blot to air dry before being wrapped 
in clingfilm.
g) Blots were photographed within a few days as stain may fade.
Staining procedure^: ECL
ECL Western blotting is a light emiting non-radioactive method for detecting 
immobilized specific antigens, conjugated directly or indirectly with horseradish 
peroxidase(HRP)-labelled antibodies. Enhanced chemiluminescence is achieved 
by performing an HRP/hyrogen peroxide catalyzed oxidation of luminol in the 
presence of chemical enhancers such as phenols. The maximum light emission 
(l=428nm) can be detected by a short exposure to the blue-light sensitive 
autoradiography Film (Hyperfilm ECL).
3.1.6.9 Calculating the Molecular weight of Immunolabelled 
Proteins.
The logarithms of molecular weight (M.W., dal tons; Da) values of certain MrM 
(Boehringer CombitheK; Boehringer Mannheim Biochemica; see appendix section 
2.1.6.3) were plotted against Rf values; where Rf = Migration distance of the 
MrM sample, measured from the start of the running gel (mm), divided by the 
length of the entire gel; from the start of the running gel to the gel front (indicated 
by Pyronin Y; mm). If the procedure had been correctly carried out, a linear 
calibration curve (r2 0.995) was obtained from which the molecular weights of 
the samples were plotted.
Boehringer Combithek MrM;
Calibration Proteins M.W.
<X2-Macroglobulin 170,000
6-Galactosidase 116,353
vii
Appendices
Fructose-6-phosphate 85,204
Glutamate dehydrogenase 55,562
Aldolase 39,212
Triose phosphate isomerase 26,626
10/H of each of the above standards was added to a 1.5ml eppendorf tube 
containing; 42/d of sterile milli-Q-water, 53p\ of laemmli buffer [x3]. 5/d of 15% 
BME was then added and the samples were boiled for 2-10mins, cooled to R.T. 
and stored at -20°C. For use, 5p\ of MrM sample was applied per well.
From the gradient, Y=mX +c, of the plotted graph where X can be substitued for 
the Rf value of the unknown immunolabelled protein to give a value for Y. Y = the 
logarithmic M.W. of the unknown, so the anti-logarithimic value of Y - M.W. of 
the unknown immunolabelled protein. For iNOS the expected M.W. is ~ 
130,000Da.
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Appendix 3.2
Staining Histological sections using the 
Indirect Imunofluorescence Method
3.2.1 Tissue Preparation
1. Lung, liver, heart and tumour extracts were isolated from experimental animals 
and, either fixed by submersion in 1% paraformaldehyde (Fisons Lab. Reagent) 
overnight at 4°C or, dissected into small blocks and quick frozen in 
isopentane/liquid nitrogen or CO2 snow. All arterial preparations (ie. RTAs, TEAs 
and CEAs) were perfuse fixed (1% paraformaldehyde) for 10-15mins at37°C and 
then submersed for a further 4-6hrs at 4°C.
2 Fixed lung, liver, heart and tumour extracts were then dehydrated in 10% 
sucrose solution (made up in PBSC) overnight, before being embedded in 
paraffin. Arteries were also submersed in 10% sucrose (2-3hrs) before being 
embedded in paraffin. Frozen blocks were wrapped in clingfilm and tinfoil before 
being stored at -70°C.
3 5-7^m sections were cut from a cryostat and thaw-mounted onto polysine slides 
. N.B. Frozen sections were embedded in O.C.T-Tissue-Tek, BDH for 
sectioning.
4 Mounted frozen sections were stored in dry, air-tight container at 4°C until use. 
(Used within 7-10 days of mounting). Paraffin embedded sections were 
deparaffinized and hydrated through a series of alcohols. They were sat in PBSC 
immediately before use. A well was formed around the sections using bostik glue 
to contain the antibody solutions.
3.2.2 Staining Procedure
5 Rinsed briefly in fresh PBSC before being washed in 0.1% Nonidet P40 (NP- 
40; nonionic detergent, Sigma) in PBSC for lOmins at R.T.
6 Rinsed off NP-40 solution in PBSC (2mins (x2) and placed coverslips into 
0.02% sodium borohydride (NaBHzp F.W.= 37.83, Sigma) solution (made up in 
DH2O) for lOmins. and rinse with DH2O. This prevents binding of fluorescent 
label to aldehydes and alcohols within the tissues.
7 Blocked non-specific staining using an appropriate 5% serum solution (ie. 
serum derived from the same animal as the 2° antibody was raised in, diluted in 
PBSc). Alternatively used 0.1% PBSc/bovine serum albumin (BSA). Blocked for 
lhr at R.T.
8 Rinsed off blocking serum in PBSC for 2mins (x2).
9 Diluted the 1° antibody in 5% blocking solution and flash-spun the mixture in 
the centrifuge at 13,000 RPM. Applied 20/d of 1° antibody to each slide and 
incubated at 4°C in a moist chamber overnight, making sure they were kept level.
10 Washed in 5% blocking solution for 5mins (x3).
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11 Applied appropriate 29 antibody, (antibodies should be raised against animal in 
which 1° antibody was raised (eg. anti-rabbit for 1° rabbit polyclonal). Diluted 2° 
in blocking solution and flash-spun the mixture in the centrifuge at 13,(XX) RPM. 
50/d of the 2° antibody solution was applied to each slide and they were incubated 
for 30-45mins at 37°C in a closed, moist chamber.
12 Washed off 2° antibody with PBSa for 20mins. (x4-5).
13 Rinsed in DH2O.
14 Applied a small drop of mounting agent (gelvatol) to each slide and placed a 
coverslip onto each. Care was taken to remove any bubbles without pressing too 
hard onto the coverslips.
15 Slides were kept at 4°C in a sealed, dried container until the mounting agent 
had set before photos were taken.
3.2.3 Materials
PBSa (per litre; [X10]) = NaCl 
KC1
KH2PO4
Na2HPO4
80g
2g
2g,
21.6g Dissolved into 11 of DH2O.
PBSC = [lx] PBSa + ImM CaCl + 0.5mM MgCl.
Isopentane- BDH; GPR, F.W.= 72.15.
Gelvatol was prepared fresh every two or three days in the following way;
Add 25g of Airvol into lOOmls of 0.14M NaCl, 0.01M KH2PO4 / 
NaHPOzg pH, 7.2 solution.
Mix solution and add vinol (ploy vinyl alcohol resin) slowly. Continue to mix for 
16hrs at R.T. Add glycerol (AnalaR grade) and mix for a further 16hrs. 
Centrifuge at 12,(XX) rpm for 15mins at R.T. and then decant supernatant into air­
tight containers for storage at -20°C. Beofre use, thaw out and add lOOmg 1,4- 
diazabicyclo[2,2,2]octane (DABCO; F.W.= 112.2, Sigma)/ ml of gelvatol. Mix 
well and centrifuge (5mins at 3,000 rpm) before application to slides.
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Appendix 3.3
Staining sections using the ABC method
Slide-mounted tissue sections were prepared as above, see appendix section 
3.2.1.
3.3.1 Staining Procedure
X Frozen sections were air-dried and then fixed in 1% paraformaldehyde for 
5mins. Deparaffinized sections and frozen sections were then washed in PBSa 
before being incubated for 30mins in 0.3% hydrogen peroxide in methanol to 
reduce the high background staining which may occur due to endogenous 
peroxidase activity.
2 Rinsed off blocking serum in PBSC for 2mins (x2).
3 Blocked non-specific staining using 5% goat serum solution (ie. serum derived 
from the same animal as the 2° antibody was raised in, diluted in PBSC). Blocking 
was carried out for lhr at R.T.
4 Blotted excess blocking solution from the slides and pipetted 20/d of 1° 
antibody; 2464 (1:750-1:1000; diluted in 5% blocking solution and flash-spun the 
mixture in the centrifuge at 13,000 RPM.) on each section. Slides were incubated 
for lhr at R.T.
5 Rinsed off in PBSC for 2mins (x2).
6 Sections were then incubated in the dark for 30mins in biotinylated 2° antibody; 
goat anti-rabbit IgG, (50/d/section; pre-diluted in 5% blocking serum) at R.T.
7 Rinsed off in PBSC for 5mins (x2).
8 Incubated sections for a further 30mins in the dark with VECTASTAIN® Elite 
ABC Reagent; avidin-biotinylated horseradish peroxidase macromolecular 
complex.
9 Rinsed off in PBSC for 2mins (x2).
10 Sections were subsequently incubated for 2-5mins in peroxidase substrate 
solution:
A lOmg tablet of DAB (Sigma, stored at -20°C) was thawed to R.T. and 
dissolved into 15mls of Tris (50mM, pH 7.6).
b) 1.7mls of 0.3% nickel chloride (Sigma, NiCl2 Hexahydrate) was added to this 
and filtered into a clean flask using Nol whatman.
c) 16.7^1 of hydrogen peroxide (30%, Sigma) was pipetted into this immediately 
before application to the slides. N.B. All of the above solutions were made up in 
tinfoil-covered beakers.
11 Sections were rinsed carefully under the tap water and then counterstained with 
eosin (submersion l-2mins), before finally being dehydrated through a series of 
ethanol dilutions; 50%-100% (30sec -2mins in each), cleared using histoclear 
(3mins submersion) and mounted with coverslips using DPX solution.
xi
Appendices
3.3.2 Materials
3,3’ Diaminobenzedine tetrahydrochloride tablet- DAB; Sigma. 
Suspected carcinogen; gloves were worn during experiment.
DPX- lOg of distrene 80, 5ml of dibutylphalate and 35ml of xylol; BDH.
Vectastain® Elite ABC kit- Goat anti-rabbit IgG; Vector Labs, CA, USA.
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Appendix 3.4
Staining for NADPH-Diaphorase
Slide-mounted tissue sections were prepared as above, see appendix section 3.2.1 
although, 10-15/<m sections were used in this procedure.
3.4.1 Staining Procedure
Solutions of nitroblue tetrazolium (Sigma; 0.4mg/ml; [0.48mM]) and the reduced 
form of 8-nicotinamide adenine dinucleotide phosphate (8-NADPH) diaphorase 
(Sigma; 2mg/ml; [2.39mM]) were prepared separately in freshly made 0.1M PBS 
solution, pH 7.4. Solutions were made in tinfoil-covered beakers and when they 
had dissolved, following stirring with a glass rod, they were mixed together and 
applied to the sections. Sections were incubated for 20-35mins in the dark at 
37°C. The sections were then rinsed in PBS solution, dehydrated, cleared and 
mounted with coverslips as for appendix section 3.3.1 (No 11).
3.4.2 Materials
0.1M PBS solution, pH 7.4 (500mls); 6.8g disodium hydrogen 
orthophosphate dihydrate (BDH, AnalaR, F.W.= 177.99) was added with 1.25g 
sodium dihydrogen orthophosphate dihydrate (BDH, AnalaR, F.W.= 155.99) to 
500mls of DH2O and dissolved at R.T.
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Appendix 3.5
SPECTROPHOTOMETRIC DETERMINATION OF NITRITE AND 
NITRATE LEVELS USING NITRATE REDUCTASE ENZYME.
SOLUTIONS
Phosphate buffer solution pH 7.5 made up with :
1_ Potassium Dihydrogen Orthophosphate (AnalaR) M.W. = 136.09
2. DiPotassium Hydrogen Orthophosphate trihydrate (AnalaR) M.W. = 228.23
Make up 500mIs, [400mM] stock solution of each and from these make 
up lOOmls of buffer by mixing solution 1 with solution 2 in the ratio of 
2:8 respectively. Check that the pH is 7.3. The PBS is kept in the fridge 
until needed.
By adding 22.5/d of the mixed PBS to each tube a final concentration of 
40mMPBS (pH 7.3) is present.
Diazochromophore agents
Solution A is 1% sulfanilamide in 5% cone, phosphoric acid in distilled water.
Solution B is 0.1% N-(l-naphthyl)-ethylenediamine dihydrochloride in distilled water. 
Make up stock solutions of both (500mls), which can be kept separately in 
the fridge for up to 2months.
B- Nicotinamide Adenine Dinucleotide Phosphate, Reduced form (B-
NADPH)
M.W. = 833
NADPH is made up fresh before each experiment, by adding 4 mg of NADPH 
into 1 ml of
distilled water giving a solution of 4.8mM. By adding 22.5^1 of this into each test tube a 
final concentration of 480/*M NADPH is present.
Flavin adenine dinucleotide (FAD) solution
M.W. = 829.5
The FAD is made up to lOOx the final concentration. A final concentration of 4S.2pM is 
used.
The FAD can be kept frozen at -20°C.
Prepare 4mg of FAD in lOmls of distilled water, this gives a 482/<M 
solution.
22.5/d of this is then added into each test tube to give a final concentration 
of 48.2/*M.
Nitrate Reductase enzyme
Nitrate reductase(NR) from the Aspergillus species is in powder form. The 
batch size is 20Units and we require 70mU of NR per 127/d sample, so by diluting the 
20U into 2mls of distilled water it can be calculated that 7/d of this solution will contain 
70mU. This stock enzyme solution is kept frozen at -20°C.
Standards; No?- and N03- solutions
Using sodium nitrite (M.W.= 69) and Sodium nitrate (M.W. = 84.99) (both AnalaR) 
2mM stock solutions are made of each (in distilled water).
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PROTOCOL (1): To DETERMINE Nox“ LEVELS IN 18 hr and 
24 hr LPS SERUM SAMPLES.
Prepare 6 1ml tubes into which a final total of 0.672mls of solution is going to 
be added. Make up the NADPH solution fresh each day, and prepare serial 
dilutions of internal standard i.e. No3’ at 2mM, ImM, 0.7mM, 0.5mM , 
O.lmM from the stock solutions, (with > 2mls for each concentration).
Inorder to ensure that any precipitate in the serum sample 
is removed, it is centrifuged at 13,000 rpm for 15mins 
before use.
Into 5 of the tubes add the following:
127/4 of sample, (i.e. serum).
22.5/4 of 400mM mixed PBS (pH 7.3).
22.5/4 of NADPH solution
22.5/4 of FAD solution
Internal Standardization: Into each of the 5 tubes add the following:
22.5/d of N03“ of the previously made dilutions:- Amount Present
1 2mM 45nmoles
2 ImM 22.5nmoles
3 0.7mM 15.75nmoles
4 0.5mM 11.25nmoles
5 O.lmM 2.25nmoles
THEN ADD 7/4 of Nitrate Reductase enzyme TO EACH. 
Incubate aliquots for 2hrs at 37°C.
Then add 224/4 of Solution A and 224/4 of Solution B to 
each tube and incubate for a further 15mins at 37°C.
Read absorbances on the spectrophotometer at a 
wavelength of 540nm.
REFERENCE CELL
The reference cell for N0x" levels in serum should 
contain 127/4 of serum sample, 22.5/zl of NADPH 
solution, 22.5/4 of PBS solution, 224/4 of solution A, 
22.5/4 of 2mM NO3" internal standard and 253.5/4 of 
distilled water (which takes into account the 22.5/4 of 
FAD solution, 224/4 of solution B and 7/4 of N.R.).
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PROTOCOL (2): To DETERMINE No2’ LEVELS IN 18 hr and 
24 hr LPS SERUM SAMPLES.
Prepare 6 1ml tubes into which a final total of 0.672mls of solution is going to 
be added. Make up the NADPH solution fresh each day, and prepare serial 
dilutions of internal standard i.e. N02' at 2mM, ImM, 0.7mM, 0.5mM , 
O.lmM from the stock solutions, (with > 2mls for each concentration.)
Inorder to ensure that any precipitate in the serum sample 
is removed, it is centrifuged at 13,000 rpm for 15mins 
before being read.
Into 5 of the tubes add the following:
127/4 of sample, (i.e. serum).
22.5/4 of 400mM mixed PBS (pH 7.3).
52/4 of distilled water.
Internal Standardization: Into each of the 5 tubes add the following:
22.5pl of N02- of the previously made dilutions:- Amount Present
1 2mM 45nmoles
2 ImM 22.5nmoles
3 0.7mM 15.75nmoles
4 0.5mM 11.25nmoles
5 O.lmM 2.25nmoles
Incubate aliquots for 2hrs at 37°C.
Then add 224/4 of Solution A and 224/4 of Solution B to 
each tube and incubate for a further 15mins at 37°C.
Read absorbances on the spectrophotometer at a 
wavelength of 540nm.
REFERENCE CELL
The reference cell for N02" levels in serum should 
contain 127/4 of serum, 22.5/4 of PBS solution, 224/4 of 
solution A, 22.5/4 of 2mM N02- internal standard and 
276/4 of distilled water (which takes into account the 
224/4 of solution B) .
xvi
Appendices
PROTOCOL (3): THE STANDARD CURVE FOR N03- READINGS 
( FOR 18hr AND 24hr LPS SAMPLES ).
Prepare 6 lml tubes into which a final total of O.672mls of solution is going to 
be added. Prepare serial dilutions of internal standard i.e. N03" at 2raM, 
ImM, 0.7mM, 0.5mM , O.lmM from the stock solutions, (with > 2mls for 
each concentration.).
Into the 5 tubes add the following:
127/d of distilled water.
22.5/d of 400mM mixed PBS (pH 7.3).
22.5/d of NADPH solution
22.5/d of FAD solution
Internal Standardization; Into each of the 5 tubes add the following:
22.5/d of N03- of the previously made dilutions: Amount Present
1 2mM 45nmoles
2 ImM 22.5nmoles
3 0.7mM 15.75nmoles
4 0.5mM 11.25nmoles
5 O.lmM 2.25nmoles
THEN ADD 7/d of Nitrate Reductase enzyme TO EACH. 
Incubate aliquots for 2hrs at 37°C.
Then add 224/d of Solution A and 224/d of Solution B to 
each tube and incubate for a further 15mins at 37°C.
Read absorbances on the spectrophotometer at a 
wavelength of 540nm.
REFERENCE CELL
The reference cell for NO3" standards contains, 22.5/d of 
PBS solution, 224/d of solution A, 224/d of solution B, 
22.5/d of 2mM internal standard, 22.5/d of NADPH 
solution and 156.5/d of distilled water (which takes into 
account the 22.5/d of FAD and 7//1 of N.R. ) .
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PROTOCOL (4): THE STANDARD CURVE FOR No2“
READINGS (FOR 18hr AND 24hr LPS SAMPLES).
Prepare 6 1ml tubes into which a final total of 0.672mls of solution is going to 
be added. Prepare serial dilutions of internal standard i.e. No2‘ at 2mM, ImM, 
0.7mM, 0.5mM , O.lmM from the stock solutions, (with > 2mls for each 
concentration.).
Into the 5 tubes add the following:
179/d of distilled water
22.5/d of 400mM mixed PBS (pH 7.3).
Internal Standardization; Into each of the 5 tubes add the following:
22.5/zl of N02- of the previously made dilutions:- Amount Present
1 2mM 45nmoles
2 ImM 22.5nmoles
3 0.7mM 15.75nmoles
4 0.5mM 11.25nmoles
5 O.lmM 2.25nmoles
Incubate aliquots for 2hrs at 37°C.
Then add 224/d of Solution A and 224/ri of Solution B to 
each tube and incubate for a further 15mins at 37°C
Read absorbances on the spectrophotometer at a 
wavelength of 540nm.
REFERENCE CELL
The reference cell for N02“ levels in the standard should 
contain 22.5//1 of PBS solution , 224/d of solution A, 
22.5/d of 2mM internal standard and 403/d of distilled 
water (which takes into account the 224/d of solution B ).
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PROTOCOL (5): To DETERMINE Nox- LEVELS IN CONTROL 
SERUM AND 6hr / 12hr LPS SERUM SAMPLES.
Prepare 6 1ml tubes into which a final total of 0.672mls of solution is going to 
be added. Make up the NADPH solution fresh each day, and prepare serial 
dilutions of internal standard i.e. No3“ at 0.5mM, 0.4mM, 0.3mM,
O.lmM from the stock solutions, (with > 2mls for each concentration).
N.B. 2 mis of serum is freeze-dried and reconstituted into 0.5mls, 
so the final result has to be divided by 4 .
Inorder to ensure that any precipitate in the serum sample 
is removed, it is centrifuged at 13,000 rpm for 30 mins, 
precipiatate removed and then a further 10 mins; and 
precipitate removed again before use.
Into 5 of the tubes add the following:
100/4 of sample, (i.e. serum) + 27/4 of distilled water. 
22.5/il of 400mM mixed PBS (pH 7.3).
22.5/4 of NADPH solution
22.5/4 of FAD solution
Internal Standardization; Into each of the 5 tubes add the following:
22.Sfi\ of N03“ of the previously made dilutions:- Amount Present
1 0.5mM 11.25nmoles
2 0.4mM 9 nmoles
3 0.3mM 6.75 nmoles
4 O.lmM 2.25nmoles
THEN ADD 7/4 of Nitrate Reductase enzyme TO EACH. 
Incubate aliquots for 2hrs at 37°C.
Then add 224/4 of Solution A and 224/4 of Solution B to 
each tube and incubate for a further 15mins at 37°C
Read absorbances on the spectrophotometer at a 
wavelength of 540nm.
REFERENCE CELL
The reference cell for N03“ levels in serum should 
contain 100/4 of serum, 22.5/4 of PBS solution, 224/4 of 
solution A, 22.5/4 of 0.5mM N03" internal standard, 
22.5/4 of NADPH and 280.5/4 of distilled water ( which 
takes into account the 22.5/4 Of FAD, 7/zl of N.R. and 
224/4 of solution B).
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PROTOCOL (6): To DETERMINE No2‘ LEVELS IN CONTROL 
SERUM AND 6hr / 12hr LPS SERUM SAMPLES.
Prepare 5 lml tubes into which a final total of 0.672mls of solution is going to 
be added. Make up the NADPH solution fresh each day, and prepare serial 
dilutions of internal standard i.e. No 2' at 0.5mM, 0.4mM, 0.3mM,
O.lmM from the stock solutions, (with > 2mls for each concentration.)
N.B. 2 mis of the control serum is freeze-fried over-night, and is 
reconstituted into 0.5mls (ie 4x original concentration). So the final 
result has to be divided by 4.
Inorder to ensure that any precipitate in the serum sample 
is removed, it is centrifuged at 13,000 rpm for 30 mins, 
precipiatate removed and then a further 10 mins; and 
precipitate removed again before use.
Into 5 of the tubes add the following:
100/d of sample, (i.e. serum).
22.5/d of 400mM mixed PBS (pH 7.3).
79/d of distilled water.
Internal Standardization; Into each of the 5 tubes add the following:
22.5/d of NO2' of the previously made dilutions:- Amount Present
1 0.5mM 11.25nmoles
2 0.4mM 9nmoles
3 0.3mM 6.75nmoles
4 O.lmM 2.25nmoles
Incubate aliquots for 2hrs at 37°C.
Then add 224//l of Solution A and 224/d of Solution B to 
each tube and incubate for a further 15mins at 37°C.
Read absorbances on the spectrophotometer at a 
wavelength of 540nm.
REFERENCE CELL
The reference cell for N02" levels in serum should 
contain 100/d of serum, 22.5/d of PBS solution, 22.5/d of 
2mM NO2" internal standard, 224/d of solution A and 
303/d of distilled water ( which takes into account the 
224/d of solution B).
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PROTOCOL (7): THE STANDARD CURVE FOR N03- READINGS 
(for control and 6hr/12hr LPS samples).
Prepare 5 1ml tubes into which a final total of O.672mls of solution is going to 
be added. Prepare serial dilutions of internal standard i.e. N03’ at ,0,5mM,
0.4mM, 0.3mM, O.lmM from the stock solutions, (with > 2mls for each 
concentration.).
N.B. 2 mis of serum is freeze-dried and reconstituted into 0.5mls, 
so the final result has to be divided by 4 .
Inorder to ensure that any precipitate in the serum sample 
is removed, it is centrifuged at 13,000 rpm for 30 mins, 
precipiatate removed and then a further 10 mins; and 
precipitate removed again before use.
Into the 4 tubes add the following:
127/4 of distilled water.
22.5/4 of 400mM mixed PBS (pH 7.3).
22.5/4 of NADPH solution
22.5/4 of FAD solution
Internal Standardization; Into each of the 5 tubes add the following:
22.5/d of NO3" of the previously made dilutions: Amount Present
1 0.5mM 11.25nmoles
2 0.4mM 9nmoles
3 0.3mM 6.75nmoles
4 O.lmM 2.25nmoles
THEN ADD 7/zI of Nitrate Reductase enzyme TO EACH.
Incubate aliquots for 2hrs at 37°C.
Then add 224/4 of Solution A and 224/4 of Solution B to 
each tube and incubate for a further 15mins at 37°C.
Read absorbances on the spectrophotometer at a 
wavelength of 540nm.
REFERENCE CELL
The reference cell for N03’ standards contains, 22.5/4 of 
PBS solution, 224/4 of solution A, 224/4 of solution B, 
22.5/4 of 2mM internal standard, 22.5/4 of NADPH 
solution and 156.5/4 of distilled water (which takes into 
account the 22.5/4 of FAD and 7/zl of N.R.).
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PROTOCOL (8): THE STANDARD CURVE FOR N02"
READINGS (for control and 6hr/12hr LPS samples)
Prepare 5 1ml tubes into which a final total of 0.672inls of solution is going to 
be added. Prepare serial dilutions of internal standard i.e. N02’ at 0.5mM, 
0.4mM, 0.3mM, O.lmM from the stock solutions, (with > 2mls for each 
concentration.).
Into the 4 tubes add the following:
179/4 of distilled water
22.5/4 of 400mM mixed PBS (pH 7.3).
Internal Standardization; Into each of the 5 tubes add the following:
22.5/d of NO2' of the previously made dilutions:- Amount Present
1 0.5mM 11.25nmoles
2 0.4mM 9nmoles
3 0.3mM 6.75nmoles
4 O.lmM 2.25nmoles
Incubate aliquots for 2hrs at 37°C.
Then add 224//1 of Solution A and 224/4 of Solution B to 
each tube and incubate for a further 15mins at 37°C
Read absorbances on the spectrophotometer at a 
wavelength of 540nm.
REFERENCE CELL
The reference cell for N02“ levels in the standard should 
contain 22.5/4 of PBS solution , 224/4 of solution A, 
22.5/4 of 2mM internal standard and 403/4 of distilled 
water (which takes into account the 224/4 of solution B ).
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Appendix tables
Appendix table (3.1) to Fig. 3.5.
Blood Pressure & Heart Rate before and after LPS injection
Time Systolic Diastolic Mean Heart Rate
(hrs) Mean S.E. n Mean S.E. n Mean S.E. n Mean S.E. n
-96 163.00 8.23 9 86.80 2.60 9 108.70 2.80 9 - - -
-48 152.00 10.60 9 89.70 2.30 9 111.50 2.90 9 - - -
0 150.30 3.59 5 89.00 4.09 5 109.56 4.38 5 313.90 31.00 6
6 156.90 7.27 10 75.70 4.38 10 102.80 2.88 10 299.30 13.50 10
12 140.30 4.00 10 73.00 3.60 10 91.50 3.46 10 275.20 11.60 10
18 129.30 5.88 9 76.90 4.40 9 97.90 3.90 9 251.30 15.90 9
24 115.50 5.76 10 71.90 2.78 10 86.90 3.13 10 283.40 16.70 10
Student’s unpaired t-test p values
t= 6hrs 0.480 10 0.062 10 0.339 10 0.505 10
t= 12hrs 0.108 9 0.009 8 0.076 10 0.358 10
t= 18hrs 0.019 8 0.064 9 0.198 9 0.011 9
t= 24hrs 0.000 10 0.005 10 0.016 10 0.646 10
Appendix table (3.2) to Fig. 3.6.
Nitrate and nitrite levels in blood plasma_________________
Time
post-LPS
NOX
(pmoles/l) S.E. n
Mean%
conversion
unpaired
t-test
(control) 0 26.4 6 6 88.7 from Ohr
6 50.6 18.67 4 93.6 0.182
12 81.8 27.9 2 93.1 0.018
18 384.8 97.7 4 90.9 0.002
24 463.1 50.3 10 93.1 0.000
48 247.0 41.6 4 93.1 0.000
72 19.7 6.28 4 91.2 0.284
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Appendix table (3.3) to Fig. 3.7
The time-dependent hyporesponsive effect of LPS.
[PE] Control 6hr 12 hr
(M) Mean S.E. n Mean S.E. n Mean S.E. n
lxlO'5 11.38 1.08 18 3.32 0.84 16 5.78 3.47 4
2x10-5 18.26 1.88 18 8.81 1.15 16 5.78 1.49 4
5x10-5 34.12 3.49 18 23.58 3.20 16 13.80 4.00 4
1x10-4 51.40 5.34 18 47.22 5.00 16 26.01 4.60 4
2x10-* 83.45 7.12 18 70.90 6.00 16 50.30 8.20 4
5xl0‘4 133.80 8.39 18 134.75 8.70 16 80.90 11.60 4
lxlO-3 182.00 10.30 18 182.56 8.12 16 154.30 16.50 4
2xl0-3 226.00 9.83 18 243.95 9.19 16 189.05 15.70 4
5x10-3 262.70 11.60 7 296.20 8.86 16 234.14 8.80 4
1x10-2 286.30 13.50 2 - - - 258.99 7.40 4
[PE] 18 hr 24 hr 72 hr
(M) Mean S.E. n Mean S.E. n Mean S.E. n
lxlO5 3.20 0.69 12 3.23 0.70 15 16.18 4.52 4
2x10-5 6.47 1.48 12 5.85 1.00 15 19.65 6.70 4
5x10-5 15.90 3.30 13 12.48 2.40 15 35.25 9.21 4
lxlO’4 26.49 5.90 13 22.65 3.00 15 53.17 10.55 4
2x10-4 41.60 9.80 13 34.37 3.81 15 69.36 17.37 4
5xl0-4 79.40 12.27 13 56.47 4.90 14 123.11 31.86 4
lxlO’3 123.00 11.87 13 75.47 5.00 14 179.11 23.32 4
2x10-3 165.70 13.30 13 111.47 6.35 14 232.93 25.35 4
5x10-3 218.30 12.99 12 149.35 9.60 15 281.15 28.20 4
lxlO-2 221.00 13.78 8 176.79 10.65 15 282.02 30.20 4
48 hr data
[PE] lxlO5 2xl0'5 5xl0-5 lxlO4 2x10-4 5x10-4 lxlO-3 2xl0-3 5xl0-3 lxlO'2
Mean 1.15 10.98 49.71 62.42 83.23 150.8 206.4 241.6 266.5 265.3
S.E. 0.66 1.73 6.08 9.85 7.49 16.16 11.91 12.32 19.12 12.39
n 4 4 4 4 4 4 4 4 4 4
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Appendix table (3.4) to Fig. 3.8
SNAP Control LPS (24 hr) t-test
(M) Mean S.E. n Mean S.E. n unpaired
lxlO-7 13.90 2.30 8 3.50 1.50 4 0.014
lxlO-6 23.80 4.35 7 5.30 1.70 4 0.013
1x10-5 40.35 5.56 8 11.10 1.70 4 0.005
lxlO-4 61.80 2.26 8 30.30 8.80 4 ' 0.001
lxlO-3 69.30 2.10 8 68.89 5.90 4 0.932
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L-NMMA & L-Arg Data Tables
Appendix tables (4.1) to Figs. 4.2-4.5
Control Table
[PE] Krebs L-NMMA (80 //M) L-Arg (1 mM)
(M) Mean S.E. n Mean S.E. n Mean S.E. n
lxlO-5 10.63 1.42 10 25.43 5.07 10 12.25 1.75 10
2x10-5 15.02 2.39 10 38.37 6.67 10 17.34 3.30 10
5xl0-5 26.82 5.68 10 67.27 8.79 10 40.60 5.40 10
lxlO-4 41.38 8.23 10 92.48 10.76 10 56.80 7.70 10
2X10-4 70.70 11.41 10 122.53 13.75 10 83.20 10.30 10
5x10-4 115.83 13.91 10 178.25 18.09 10 149.50 14.30 10
lxlO’3 156.06 14.13 10 215.47 16.02 10 186.80 13.40 10
2x10-3 209.00 14.95 10 249.69 18.80 10 234.20 13.40 10
5x10-3 246.61 14.09 10 254.00 0.00 10 240.40 25.40 10
lxlO'2 256.63 16.18 10 - - - 263.50 27.70 10
6 Hour Table
[PE] Krebs L-NMMA (80 pM) L-Arg (1 mM)
(M) Mean S.E. n Mean S.E. n Mean S.E. n
lxlO'5 20.49 6.70 7 33.04 8.35 7 18.17 4.29 7
2x10-5 22.80 7.81 7 33.37 6.71 7 17.51 3.53 7
5x10-5 33.05 10.80 7 55.51 8.47 7 30.07 5.14 7
lxlO-4 51.88 11.65 7 74.34 10.23 7 49.23 4.62 7
2x10-4 70.71 10.79 7 98.79 10.93 7 72.03 4.69 7
5x10-4 109.03 9.00 7 138.76 9.63 7 107.71 5.44 7
lxlO’3 137.70 8.47 7 182.70 11.51 7 139.75 6.90 7
2x10-3 179.10 13.16 7 210.12 14.40 7 175.43 10.50 7
5x10-3 219.70 24.20 7 233.58 18.56 7 194.93 12.29 7
1x10-2 - - - - - - - -
xxvi
Appendices
18 Hour Table
[PE] Krebs L-NMMA (80 pM) L-Arg (1 mM)
(M) Mean S.E. n Mean S.E. n Mean S.E. n
lxlO'5 6.50 3.20 5 21.65 6.90 5 8.50 2.20 5
2x10-5 12.02 4.35 5 30.50 6.50 5 13.40 4.20 5
5x10-5 19.80 7.00 5 45.70 7.70 5 20.30 6.50 5
lxlO-4 30.50 9.40 5 76.70 13.70 5 24.90 8.40 5
2xl0-4 41.60 11.60 5 114.20 17.10 5 44.80 12.80 5
5x10-4 78.10 18.40 5 174.30 17.20 5 63.30 18.20 5
lxlO-3 122.90 21.40 5 219.60 20.50 5 82.70 20.50 5
2x10-3 173.80 20.20 5 245.07 19.60 5 112.80 21.70 5
5x10-3 227.90 21.40 5 254.70 22.60 5 154.00 23.40 5
lxlO’2 228.40 15.60 5 242.10 27.90 5 154.90 20.90 5
24 Hour Table
[PE] Krebs L-NMMA (80 pM) L-Arg (1 mM)
(M) Mean S.E. n Mean S.E. n Mean S.E. n j
lxlO'5 6.60 1.35 9 17.90 3.70 9 8.00 2.50 9
2x10-5 11.04 1.70 9 24.40 3.80 9 11.00 2.27 9
5xl0-5 22.30 3.70 9 50.30 4.60 9 26.90 6.20 9
lxlO"4 32.30 4.60 9 74.70 7.60 9 42.10 6.60 9
2x10-4 52.40 7.50 9 103.70 16.02 9 65.70 9.40 9
5xl0-4 80.90 11.70 9 142.50 18.50 9 97.80 13.70 9
lxlO"3 106.80 1.40 9 175.00 16.90 9 125.90 17.00 9
2x10-3 142.00 15.80 9 211.60 18.00 9 159.00 20.00 9
5x10-3 172.30 14.40 9 244.00 13.70 9 201.60 17.70 9
lxlO'2 205.50 12.90 9 246.30 16.90 9 213.03 22.10 9
xxvii
Appendices
Statistical tables for Fig. 4.2-4.5
Group Control 6 Hr 18 Hr 24 Hr
[PE] (M) Student’s paired t-tests comparing Krebs and L-NMMA curves
1x10-5 0.022 0.014 1 0.078 0.005
2xl0-5 0.012 0.115 0.020 0.001 1
5x10-5 0.000 0.044 0.015 0.001 i
lxlO-4 0.000 0.099 0.036 0.000
2X10-4 0.000 0.094 0.008 0.003
5x10-4 0.006 0.112 0.008 0.001
1x10-3 0.010 0.005 0.015 0.000
2xl0-3 0.066 0.008 0.021 0.001
5x10-3 - 0.339 0.166 0.000
lxlO'2 - - 0.272 0.005
Group Control 6 Hr 18 Hr 24 Hr
[PE] (M) Student’s paired t-tests comparing Krebs and L-arginine curves
lxlO5 0.466 0.676 0.131 0.815
2x10-5 0.612 0.488 0.661 1.000
5x10-5 0.022 0.820 0.775 0.491
lxlO-4 0.028 0.816 0.606 0.196
2x10^ 0.115 0.910 0.680 0.137
5x10-4 0.025 0.918 0.919 0.221
lxlO’3 0.077 0.821 0.783 0.221
2x10-3 0.060 0.641 0.042 0.361
| 5x10-3 - 0.102 0.005 0.194
lxlO'2 - - 0.004 0.705
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Appendix tables (4.2) to Figs. 4.6-4.10
Control Table
[PE] Krebs L-NAME (80 ^M) L-Arg (1 mM)
(M) Mean S.E. n Mean S.E. n Mean S.E. n !
lxlO-5 11.70 1.63 9 29.89 1.50 9 23.15 3.98 9
2xl0-5 20.59 2.76 9 39.79 3.56 9 23.27 3.20 9
5xl0-5 39.21 3.33 9 60.30 7.23 9 39.47 4.45 9
1x10-4 58.88 5.52 9 80.93 10.85 9 58.00 6.48 9
2xl0-4 91.37 8.10 9 119.10 12.69 9 92.00 9.90 9
5xl0-4 143.85 10.57 9 178.40 17.09 9 162.50 14.50 9
lxlO'3 201.53 13.01 9 229.74 17.40 9 206.60 17.60 9
2x10-3 237.85 12.39 9 266.09 14.20 5 243.40 16.41 9
5x10-3 282.81 17.17 3 282.58 12.47 5 246.34 27.71 5
lxlO-2 299.82 0.00 3 - - - - - -
6 Hour Table
[PE] Krebs L-NAME (80 /zM)
(M) Mean S.E. n Mean S.E. n
lxlO-5 1.15 0.60 7 25.74 5.88 7
2x10‘5 8.66 2.56 7 30.03 6.74 7
5xl0-5 29.45 5.68 7 68.98 12.81 7
lxlO-4 60.63 7.20 7 86.47 16.49 7
2X10-4 86.62 5.20 7 123.78 14.64 7
5xl(B 156.50 8.18 7 193.40 13.12 7
1x10-3 195.70 2.56 7 243.29 11.16 7
2x10-3 251.70 7.48 7 268.92 13.56 3
5xl0-3 297.90 11.50 7 278.98 16.56 3
lxlO-2 - - - - - -
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18 Hour Table
[PE] Krebs L-NAME (80 yM) L-Arg (1 mM)
(M) Mean S.E. n Mean S.E. n Mean S.E. n
lxlO-5 6.08 2.53 9 25.69 9.29 9 16.55 6.24 9
2x10-5 10.68 3.40 9 30.88 8.36 9 18.94 5.91 9
5x10-5 18.90 3.89 9 50.13 12.86 9 32.98 8.53 9
lxlO-4 32.62 7.50 9 74.08 12.62 9 50.59 11.32 9
2X10-4 50.60 12.80 9 114.03 12.10 9 72.70 14.70 9
5x10‘4 95.93 13.70 9 177.30 13.20 9 120.60 18.10 9
1x10-3 141.49 9.79 9 234.18 11.90 9 158.12 19.60 9
2xl0-3 184.90 10.60 9 251.40 8.87 5 198.47 19.50 9
5x10-3 235.94 11.90 8 280.00 11.16 5 242.80 15.60 9
lxlO'2 247.95 14.00 4 - - - 233.38 25.40 4
24 Hour Table
[PE] Krebs L-NAME (80 /fM) L-Arg (1 mM)
(M) Mean S.E. n Mean S.E. n Mean S.E. n
lxlO'5 6.40 1.70 9 15.15 2.28 9 15.60 3.60 9
2x10-5 10.70 2.90 9 25.60 3.60 9 21.00 4.60 9
5x10-5 23.37 4.50 9 47.00 5.50 9 38.70 6.60 9
lxlO-4 36.20 7.10 9 66.50 6.30 9 53.90 8.70 9
2x10-4 52.10 10.70 9 105.30 9.00 9 75.00 11.40 9
5x1 O'4 95.00 16.30 9 152.60 11.90 9 107.80 13.60 9
lxlO’3 140.00 17.00 9 198.80 11.47 9 134.30 18.30 9
2x10-3 186.20 17.80 9 245.50 8.50 9 153.10 18.00 9
5x10-3 225.00 16.00 9 271.00 9.30 8 180.90 20.80 8
lxlO-2 251.70 12.40 9 276.00 14.80 5 195.60 14.80 8
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72 Hour Table
[PE] Krebs L-NAME (80 /iM) L-Arg (1 mM)
(M) Mean S.E. n Mean S.E. n Mean S.E. n
1x10-5 12.30 4.70 6 45.50 8.37 6 23.50 5.40 6
2xl0-5 28.90 9.60 6 45.50 8.90 6 35.40 6.20 6
5x10-5 40.10 8.49 6 74.00 11.20 6 46.20 7.90 6
lxlO-4 62.80 11.30 6 100.50 13.10 6 73.50 11.20 6
2xl0'4 98.30 15.40 6 128.00 18.10 6 104.80 17.50 6
5xl0-4 149.80 17.90 6 181.80 13.10 6 159.00 25.80 6
lxlO’3 194.50 18.00 6 227.70 12.20 6 189.00 17.50 6
2x10-3 232.60 18.50 5 278.90 12.20 6 214.00 14.80 6
5xl0-3 278.50 20.10 4 314.40 14.20 4 256.60 11.30 6
lxlO-2 292.50 14.60 4 312.80 10.19 3 266.30 11.60 5
Statistical tables for Fig. 4.6-4.10
Group 6 Hr 18 Hr 24 Hr 72Hr
[PE] (M) Student’s unpaired t-tests comparing Krebs curveswith control '
lxlO'5 0.001 0.08 0.045 0.888
2xl0-5 0.012 0.038 0.026 0.344
5xl05 0.063 0.001 0.013 0.916
lxlO-4 0.493 0.013 0.023 0.735
2x10^ 0.228 0.017 0.010 0.675
5x10-4 0.930 0.014 0.023 0.761
lxlO-3 0.734 0.002 0.011 0.753
2x10-3 0.175 0.005 0.030 0.811
5x10-3 0.202 0.108 0.14 0.902
lxlO'2 - - - -
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Group Control 6 Hr 18 Hr 24 Hr 72 Hr
[PE] (M) Student’s paired t-tests comparing Krebs and L-NAME curves
lxlO'5 0.000 0.008 0.048 0.001 0.019
2x10-5 0.001 0.012 0.034 0.018 0.155
5xl0-5 0.010 0.009 0.036 0.008 0.043
lxlO-4 0.029 0.131 0.020 0.002 0.030
' 2X10-4 0.012 0.040 0.014 0.000 0.093
5x10-4 0.009 0.073 0.013 0.000 0.071
lxlO-3 0.685 0.067 0.001 0.000 0.093
2xl0-3 0.009 0.447 0.051 0.001 0.103
5x10-3 0.500 0.207 0.253 0.01 0.262
lxlO’2 - - - 0.208 0.376
Group Control i 6 Hr 18 Hr 24 Hr 72 Hr
[PE] (M) Student’s paired t-tests comparing Krebs and L-arginine curves
1x10-5 0.008 0.082 0.004 0.113
2x10-5 0.466 - 0.103 0.077 0.416
5xl0-5 0.957 - 0.152 0.011 0.428 ‘
1x10-4 0.915 - 0.190 0.008 0.212
2x10-4 0.960 - 0.255 0.003 0.704
5x10-4 0.413 - 0.314 0.107 0.681
lxlO"3 0.869 - 0.334 0.586 0.798
2x10-3 0.806 - 0.370 0.034 0.663
5x10-3 - - 0.627 0.074 0.436
1x10-2 - - 0.659 0.016 0.143
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Appendix table (4.3) to Figs. 4.11 &4.12
Control Tables
[PE] Krebs AG (1 mM) L-NAME (80 ^M)
(M) Mean S.E. n Mean S.E. n Mean S.E. n
lxlO’5 9.80 2.38 8 19.26 8.80 6 36.10 9.00 5
2xl0-5 22.80 6.10 8 22.30 9.80 6 36.90 7.20 5
5xl0-5 41.30 11.40 8 38.10 15.70 6 64.20 11.00 5
lxlO-4 67.60 12.90 8 57.00 16.60 6 84.60 12.40 5
2x10-4 97.30 15.20 8 73.59 18.10 6 110.00 13.00 5
5x10-4 155.70 16.60 8 123.69 21.80 6 153.50 9.80 5
lxlO-3 196.80 16.70 8 158.40 20.70 6 214.00 14.30 5
2xl0-3 245.00 9.20 8 226.00 23.20 6 261.25 12.40 5
5x10-3 293.30 8.46 8 278.90 11.00 6 319.50 5.80 5
lxlO-2 313.60 9.00 6 309.80 7.00 6 332.90 17.70 4
18 hours
[PE] Krebs AG (1 mM) L-NAME (80 /zM)
(M) Mean S.E. n Mean S.E. n Mean S.E. n
lxlO’5 10.08 2.05 11 20.80 4.80 11 49.50 7.50 7
2x10-5 17.40 3.80 11 20.59 4.70 11 40.90 8.20 7
5xl0-s 27.70 3.90 11 47.29 5.11 11 83.89 8.40 7
lxlO-4 51.90 4.60 11 66.40 6.29 11 104.00 9.46 7
2x10-4 73.90 5.57 11 92.90 7.00 11 154.90 12.90 7
5xl0-4 111.60 8.35 11 146.28 10.10 11 206.40 16.60 7
1x10-3 154.06 8.50 11 193.70 9.70 11 249.70 18.16 7
2x10-3 199.25 9.50 11 248.00 11.30 11 314.70 18.20 7
5x10-3 237.90 7.80 11 299.00 11.00 11 319.40 11.90 7
lxlO"2 281.83 11.00 10 285.90 21.20 3 - - -
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72 hours
[PE] Krebs AG (1 mM) L-NAME (80 ^M)
(M) Mean S.E. n Mean S.E. n Mean S.E. n
lxlO’5 10.90 1.10 4 12.10 3.10 4 19.26 8.10 3
2xl0-5 13.80 2.10 4 15.60 2.50 4 29.30 4.68 4
5x10-5 23.80 6.00 3 25.40 6.10 3 56.30 9.47 3
lxlO’4 34.60 4.80 3 47.90 10.20 3 91.30 11.40 4
2x10-4 60.80 10.70 3 93.40 23.80 3 138.70 14.40 4
5x10-4 100.90 19.20 3 140.00 21.20 3 161.80 11.50 2
lxlO’3 156.40 20.40 3 195.00 17.40 3 223.00 23.00 4
2xl0-3 228.80 10.90 3 231.20 11.50 3 249.60 20.80 4
5x10-3 292.80 19.40 3 273.90 15.40 3 265.80 6.90 4
lxlO-2 312.10 21.40 3 307.50 4.60 3 263.50 11.00 4
Group Control 18 Hr 72 Hr Krebs 18Hr vs 
Con
18 hr(+AG) 
vs Con 
Krebs
[PE] (M) paired t-tests comparing Krebs and AG curves unpaired unpaired
lxlO-5 0.305 0.079 0.752 0.934 0.087
2xl0-5 0.800 0.510 0.547 0.440 0.773
5x10-5 0.804 0.016 0.840 0.220 0.607
lxlO-4 0.988 0.037 0.405 0.215 0.928
2x10-4 0.783 0.004 0.300 0.124 0.773
5x10-4 0.611 0.001 0.112 0.020 0.613
lxlO'3 0.529 0.001 0.060 0.025 0.870
2x10-3 0.665 0.000 0.695 0.004 0.851
5x10-3 0.280 0.000 0.760 0.000 0.705
lxlO’2 0.767 0.716 0.177 0.066 0.191
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Appendix Tables (5.1) for Figs.5.1-5.4
Cycloheximide raw meaned Data
Zero Hour Table
[PE] Control LPS (24 hr)
(M) Mean S.E. n Mean S.E. n
lxlO-5 7.32 2.63 6 6.93 1.19 6
2xl0-5 9.64 2.18 6 11.94 2.69 6
5x10-5 21.96 6.33 6 23.12 5.02 6
1x10-4 37.76 10.31 6 40.46 7.55 6
2X10-4 52.79 13.33 6 55.11 11.73 6
5x10-4 107.52 26.43 6 92.90 16.05 6
lxlO'3 135.66 25.48 6 127.57 19.17 6
2xl0-3 182.31 19.27 6 166.11 18.19 6
5xl0-3 209.54 13.05 5 207.70 17.19 6
1x10-2 218.30 16.80 3 198.92 11.87 4
1 Hour Table
[PE] Control LPS (24 hr)
(M) Mean S.E. n Mean S.E. n
lxlO’5 14.64 4.68 6 16.18 3.10 6
j 2xl0-5 15.80 5.70 6 14.79 4.65 6
5x10-5 34.68 8.56 6 31.44 4.36 6
lxlO-4 47.40 11.75 6 47.17 6.14 5
2x10-4 71.68 15.50 6 69.37 7.56 5
5x10-4 117.16 27.04 6 106.36 11.13 5
lxlO’3 163.02 28.67 6 151.69 10.70 5
2x10-3 202.33 15.08 4 194.20 13.76 6
5x10-3 234.97 6.33 5 205.05 13.07 3
lxlO’2 240.52 15.36 5 210.40 11.53 3
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2 Hour Table
[PE] Control LPS (24 hr)
(M) Mean S.E. n Mean S.E. n
lxlO'5 6.93 2.19 5 18.88 4.02 5
2x10-5 8.32 1.87 5 18.49 4.09 5
5xl0-5 17.11 5.30 5 32.75 7.19 5
lxlO-4 32.84 7.75 5 51.25 10.41 5
2X10-4 47.63 9.62 5 78.62 14.84 5
5x10-4 90.65 14.45 5 118.32 20.25 5
lxlO-3 129.04 20.21 5 176.65 19.90 5
2xl0’3 167.89 19.54 5 212.27 17.91 5
5xl0-3 236.49 14.42 4 199.48 13.46 4
lxlO-2 230.13 25.24 4 - - - 1
3 Hour Table
[PE] Control LPS (24 hr)
(M) Mean S.E. n Mean S.E. n
lxlO'5 5.55 1.38 5 32.83 6.67 5
2xl0-5 7.86 1.56 5 32.83 7.32 5
5x10-5 16.65 4.22 5 45.78 8.34 5
lxlO'4 29.13 5.30 5 78.29 11.86 5
2x10-4 45.32 7.43 5 110.97 15.76 4
5x10-4 85.10 16.46 5 143.82 17.79 5
lxlO'3 110.54 13.19 5 185.44 19.30 5
2xl0-3 153.56 18.12 5 215.50 25.67 5
5x10-3 200.74 15.62 5 205.85 11.46 4
' lxlO'2 229.89 11.77 5 - - -
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4 Hour Table
[PE] Control LPS (24 hr)
(M) Mean S.E. n Mean S.E. n
lxlO’5 8.78 4.92 5 15.26 4.65 6
2xl0-5 13.87 6.07 5 22.19 0.92 6
5x10-5 20.34 8.96 5 31.91 1.69 6
lxlO-4 31.44 11.52 5 55.95 5.50 6
2x10^ 43.01 12.02 5 80.46 5.33 6
5x10-4 76.30 20.70 5 135.96 10.98 6
lxlO-3 114.24 20.60 5 159.00 9.71 5
2x10-3 152.64 13.91 5 180.76 11.18 6
5x10-3 200.75 9.82 5 214.30 10.41 6
lxlO-2 221.47 14.32 4 235.87 15.50 5
L-NMMA
[PE] Control LPS (24 hr)
(M) Mean S.E. n Mean S.E. n
lxlO-5 16.64 3.53 5 22.66 4.16 5
2xl0-5 19.88 4.54 5 19.88 3.58 5
5x10-5 34.22 8.18 5 41.16 9.76 5
lxlO-4 58.72 6.64 5 60.58 14.10 5
2x10-4 80.45 9.43 5 104.53 17.14 5
5x10-4 124.38 12.65 5 143.38 16.25 5
lxlO'3 154.44 15.37 5 195.19 10.11 5
2x10-3 185.42 17.92 5 228.51 10.68 5
5x10-3 221.37 20.73 4 250.96 30.71 4
lxlO’2 250.85 30.27 4 - - -
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Appendix Tables (5.2) to Figs. 5.5-5.8 
Indomethacin & cycloheximide raw meaned Data
Combined data for control and LPS-treated RTAs.
[PE] Control LPS (18 hr) t-test
(M) Mean S.E. n Mean S.E. n unpaired
lxlO'5 8.82 1.83 12 5.25 1.03 11 0.147
2x10-5 12.86 2.41 12 9.04 1.93 11 0.264
5xl0-5 28.32 4.42 12 17.45 3.52 11 0.086
lxlO’4 46.10 6.81 12 29.22 5.34 11 0.082
2X10-4 66.62 8.68 12 46.25 6.98 11 0.102
5x10-4 122.26 15.22 12 77.24 10.05 10 0.042
lxlO'3 158.97 14.84 12 116.26 12.10 11 0.048
2x10-3 198.14 11.75 12 157.89 13.40 11 0.035
5xl0-3 212.08 8.26 10 190.27 12.45 11 0.169
1x10-2 223.39 12.09 7 189.08 9.34 8 0.040
1 Hour Table
[PE] Control LPS (18hr)
(M) Mean S.E. n Mean S.E. n |
lxlO’5 14.64 8.58 6 11.18 4.19 6
2x10-5 16.59 7.96 6 5.09 2.44 6
5xl0-5 23.12 10.33 6 20.04 3.61 6
1x10-4 37.37 14.21 6 31.22 5.87 6
2x10-4 57.41 18.30 6 48.95 8.85 6
5x10-4 99.80 25.15 6 80.56 13.81 6
lxlO’3 138.30 29.80 6 121.04 18.32 6
2x10-3 162.20 28.65 6 158.42 25.10 6
, 5x10-3 173.40 24.19 4 171.75 21.67 4
lxlO-2 184.96 23.59 4 176.37 19.97 4
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2 Hour Table
[PE] Control i LPS (18 hr)
(M) Mean S.E. n Mean S.E. n
lxlO-5 13.49 5.32 6 10.70 4.82 8
2x10-5 13.48 4.44 6 8.38 3.05 8
5x10-5 27.75 9.44 6 15.61 4.43 8
, lxlO"4 42.39 13.58 6 31.22 7.48 8
2x10-4 64.75 15.42 6 49.15 8.20 8
5x10^ 113.70 21.64 6 88.18 14.07 8
lxlO-3 168.44 21.63 6 131.26 18.49 8
2xl0-3 198.88 15.38 6 186.00 23.01 8
5x10-3 230.73 13.60 4 192.00 23.09 6
lxlO-2 241.13 12.65 4 - - -
3 Hour Table
[PE] Control LPS (18 hr)
(M) Mean S.E. n Mean S.E. n
lxlO-5 15.61 6.54 8 11.27 4.22 8
2x10-5 15.90 3.22 8 9.25 3.03 8
5x10-5 33.53 6.75 8 18.51 6.48 8
lxlO-4 48.56 8.66 8 30.36 7.66 8
2x10-4 70.24 10.15 8 48.87 8.79 8
5x10-4 108.10 11.73 8 79.22 12.10 8
lxlO’3 152.63 16.25 8 125.48 13.82 8
2x10-3 190.78 14.32 8 176.26 22.37 8
5x10-3 220.48 15.44 6 205.52 23.57 6
lxlO-2 244.38 17.35 6 - - -
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4 Hour Table
[PE] Control LPS (18 hr) '
(M) Mean S.E. n Mean S.E. n
lxlO-5 13.87 3.65 8 10.12 4.12 8
2x10-5 19.07 4.29 8 8.38 3.73 8
5xl0-5 31.79 5.90 8 14.16 3.69 8
lxlO-4 56.60 8.70 8 28.05 7.65 8
2x10-4 68.22 9.08 8 43.37 9.27 8
5x10^ 110.42 13.63 8 81.25 12.36 8
lxlO'3 148.87 15.19 8 128.08 14.60 8
2x10-3 180.95 11.45 8 184.75 19.24 8
5xl0-3 214.31 16.12 6 207.82 21.70 6
1x10-2 233.19 14.13 6 - - -
L-NMMA
[PE] Control LPS (18 hr)
(M) Mean S.E. n Mean S.E. n
lxlO’5 37.33 13.24 7 30.45 8.09 6
2x10-5 42.28 11.63 7 25.15 8.63 8
5x10-5 57.81 9.46 7 46.84 11.19 8
lxlO-4 82.58 13.15 7 66.49 15.21 8
2x10-4 106.37 14.28 7 94.54 18.25 8
5X10-4 140.39 14.05 7 151.77 21.18 8
lxlO'3 186.31 23.73 7 190.79 27.43 8
2x10-3 197.03 27.17 5 219.39 27.98 7
j 5x10-3 216.90 18.67 5 216.50 10.60 5
1x10-2 237.50 16.54 4 226.70 15.40 4
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Statistical Tables (5.3) to Figs. 5.1-5.4
Cycloheximide data. Student’s paired t-test analysis comparing the initial 
responses in the presence of Krebs only with responses after l-4hrs perfusion and 
in the presence of L-NMMA.
Groups Con LPS Con LPS
[PE] (M) t=l Hr t= 2 Hr
lxlO’5 0.311 0.006 0.665 0.008
2x10-5 0.330 0.087 0.587 0.010
5x10-5 0.022 0.007 0.815 0.019
1x10^ 0.052 0.019 0.388 0.020
2X10-4 0.013 0.020 0.119 0.029
5x10-4 0.118 0.078 0.546 0.032
lxlO-3 0.055 0.058 0.487 0.046
2xl0-3 0.610 0.057 0.963 0.029
5xl0-3 0.213 0.376 0.112 0.791
lxlO-2 0.586 0.558 0.766 0.854
Groups
[PE] (M)
Con | LPS 
t=3 Hr
Con | LPS 
t= 4 Hr
Con | LPS 
LNMMA
lxlO-5 0.495 0.011 0.938 0.670 0.164 0.013
2xl0-5 0.799 0.023 0.390 0.001 0.170 0.016
5x10-5 0.849 0.017 0.509 0.001 0.188 0.038
lxlO-4 0.766 0.013 0.775 0.001 0.032 0.026
2x10-4 0.392 0.007 0.916 0.001 0.042 0.008
5x10-4 0.562 0.011 0.681 0.003 0.477 0.003
lxlO"3 0.457 0.007 0.973 0.083 0.319 0.029
2x10-3 0.330 0.016 0.476 0.463 0.903 0.147
5x10-3 0.739 0.321 0.466 0.695 0.747 0.391
lxlO’2 0.205 0.559 0.681 0.639 0.109 0.471
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Statistical tables (5.4 ) for Figs.5.5-5.8
Indomethacin + cycloheximide Data. Student’s paired t-test analysis comparing the 
initial responses in the presence of Krebs only with responses after l-4hrs 
perfusion and in the presence of L-NMMA,
Groups Con LPS Con LPS
[PE] (M) t=l Hr t= 2 Hr
lxlO’5 0.379 0.087 0.352 0.221
2xl0-3 0.727 0.119 0.957 0.488
5x10-5 0.889 0.036 0.683 0.388
lxl(H 0.979 0.111 0.800 0.281
2x10^ 0.748 0.150 0.608 0.274
5x10^ 0.651 0.305 0.449 0.082
lxlO’3 0.897 0.607 0.344 0.064
2x10-3 0.681 0.710 0.493 0.202
5x10-3 0.329 0.601 0.706 0.689
lxlO-2 0.640 0.673 0.502 0.675
Groups
[PE] (M)
Con | LPS 
t=3 Hr
Con | LPS 
t= 4 Hr
Con | LPS 
LNMMA
: lxlO'5 0.316 0.076 0.080 0.100 0.101 0.018
2xl0-5 0.703 0.194 0.366 0.434 0.106 0.041
5x10-5 0.355 0.172 0.071 0.508 0.062 0.013
1x10-4 0.404 0.056 0.058 0.306 0.062 0.021
2x10-4 0.284 0.012 0.171 0.008 0.006 0.020
5x10-4 0.279 0.187 0.196 0.408 0.065 0.024
lxlO"3 0.368 0.144 0.416 0.084 0.192 0.017
2x10-3 0.470 0.086 0.671 0.032 0.509 0.050
5x10-3 0.967 0.108 0.989 0.090 0.532 0.157
lxlO-2 - - 0.125 0.416 0.304 -
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Student’s unpaired t-test analysis comparing the Krebs data (ie. t= Ohr) for control 
and LPS-treated RTAs which have not previously been exposed to cycloheximide 
(untreated) with those exposed to cycloheximide (cyclo) only or indomethacin +
cycloheximide (cyclo + indo). Reveals no significant difference between any of 
the groups.
Statistical Tables (5.5) for Figs.5.1-5.8
Groups
[PE] (M)
Con | LPS 
Krebs-untreated 
vs
t= Ohr (Cyclo)
Con | LPS 
Krebs-untreated 
vs
t= Ohr (Cyclo/Indo)
Con | LPS 
t= Ohr cyclo 
vs
t=Ohr cyclo/Indo
lxlO’5 0.246 0.896 0.111 0.096 0.900 0.063
2xl0’5 0.150 0.773 0.771 0.041 0.281 0.057
5xl0’5 0.592 0.902 0.572 0.066 0.970 0.085
lxlO*4 0.790 0.350 0.742 0.224 0.958 0.083
2X10-4 0.336 0.842 0.305 0.166 0.925 0,193
5x10-4 0.763 0.555 0.226 0.344 0.536 0.162
lxlO’3 0.458 0.396 0.422 0.961 0.962 0.383
2x10-3 0.293 0.344 0.243 0.485 0.853 0.760
5xl0-3 0.090 0.141 0.601 0.283 0.261 0.624
lxlO-2 0.221 - 0.151 - 0.950 0.901
Student’s unpaired t-test analysis Comparing the L-NMMA data for untreated 
control and LPS-treated RTAs with that vessels exposed to cycloheximide only
Groups
[PE] (M)
Con | LPS 
LNMMA-untreated
vs 1
LNMMA (Cyclo)
Con | LPS 
LNMMA-untreated 
vs
LNMMA (Cyclo/Indo)
lxlO'5 0.275 0.446 0.712 0.142
2xl0-5 0.090 0.454 0.307 0.935
5xl0-5 0.033 0.349 0.483 0.766
lxlO-4 0.008 0.350 0.568 0.623
2x10-4 0.065 0.975 0.440 0.710
5x10-4 0.072 0.977 0.147 0.747
lxlO’3 0.032 0.426 0.306 0.627
2x10-3 0.038 0.526 0.137 0.812
5x10-3 - 0.813 - 0.201
lxlO-2 - - - -
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Appendix table (6.1) to Figs. 6.3a/b
Data for control RTAs
[PE] Control Krebs JM10I)6 (10C>/iM) L-NMMA (100/zM)
(M) Mean S.E. n Mean S.E. n Mean S.E. n
lxlO"5 5.4 1.3 8 20.48 5.7 8 22.4 5.7 6
2x10-5 12.1 2.8 8 21.1 5.0 8 30.3 5.6 6
5x10-5 28.3 6.8 8 54.18 6.4 8 62.7 9.4 6
lxlO-4 47.7 7.7 8 85.2 9.0 8 91.7 9.5 6
2x10-4 74.0 9.6 8 116.9 13.5 8 127.9 15.3 6
5X10-4 115.0 9.9 8 180.0 12.8 8 185.0 11.2 6
lxlO'3 167.0 13.4 8 228.3 16.9 8 231.6 12.3 6
2xl0-3 213.0 14.3 8 276.8 17.6 7 289.0 16.8 6
5x10"3 270.0 14.3 8 306.0 12.1 4 328.0 17.4 6
1x10-2 297.0 19.2 8 331.1 19.2 4 343.6 21.2 5
Data for LPS-treated RTAs
[PE] LPS Krelt»s JM101)6 (10CIpM) L-NMMA (100/jM)
(M) Mean S.E. n Mean S.E. n Mean S.E. n
1x10-5 1.6 0.9 7 19.1 3.8 7 27.4 7.7 7
2x10-5 3.9 1.3 7 22.4 6.3 7 24.7 4.4 7
5x10-5 7.6 1.9 7 45.2 8.1 7 62.0 8.3 7
1x10-4 18.8 4.2 7 62.0 8.4 7 85.1 10.0 7
2x10-4 33.9 7.9 7 96.3 8.9 7 119.8 12.8 7
5x10-4 75.2 9.6 7 149.8 12.4 7 165.3 11.7 7
lx 10'3 113.5 13.3 7 186.0 16.4 7 205.6 10.3 7
2x10-3 147.8 8.7 7 210.6 24.6 7 250.8 12.0 7
5x10-3 194.7 16.5 7 242.0 10.7 7 301.4 16.4 7
1x10-2 216.2 10.8 7 263.0 8.5 7 299.4 17.7 7
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Appendix table (6.2) to Figs. 6.4a/b
Data for control RTAs
[PE] Control Krebs JM1226 (100/jM) L-NMMA (100 
/iM)
(M) Mean S.E. n Mean S.E. n Mean S.E. n
lxlO-5 4.8 1.7 9 36.9 6.5 9 25.43 3.3 8
2x10-5 14.1 3.2 9 43.4 5.29 9 30.0 3.7 8
5xl0-5 28.3 4.7 9 79.6 9.97 9 58.0 5.5 8
lxlO-4 45.5 4.7 9 117.9 15.17 9 84.4 7.0 8
2xl0-4 66.8 6.6 9 159.7 16.9 9 114.2 10.4 8
5X10-4 129.5 9.1 9 248.6 18.0 9 174.2 12.5 8
lxlO'3 191.1 10.1 9 288.7 17.7 5 213.38 14.4 8
2xl0-3 247.3 9.3 9 - - - 259.5 14.5 8
5x10-3 299.0 11.1 9 - - - 291.5 13.8 8
lxlO’2 297.6 7.8 9 - - - 294.7 15.5 7
Data for LPS-treated RTAs
[PE] LPS Krebs JM1226 (10C>/*M) L-NMMA (100/zM)
(M) Mean S.E. n ; Mean S.E. n Mean S.E. n i
lxlO’5 3.8 0.7 9 25.9 4.5 9 29.8 5.3 13
2x10-5 7.2 1.1 9 33.4 3.9 9 28.6 4.4 13
5xl0-5 21.1 3.3 9 56.2 6.0 9 64.2 6.3 13
lxlO-4 35.4 5.6 9 89.1 9.0 9 90.6 8.7 13
2x10-4 49.3 6.2 9 120.5 13.5 9 133.3 10.0 13
5x10-4 89.1 9.5 9 181.4 13.0 9 179.2 9.5 13
1x10-3 130.2 13.6 9 224.0 14.7 9 214.0 8.5 13
2xl0-3 167.2 13.4 9 260.0 15.0 8 248.0 8.8 13
5x10-3 223.7 12.7 9 286.3 19.5 6 293.0 11.0 12
lxlO’2 224.2 9.12 9 273.4 21.5 4 296.6 12.0 12
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Appendix Table (6.3) to Fig. 6.5
The effect of JM1226 on Blood pressure (mmHg)
Group ! t Systolic Mean Diastolic n
Conitrols
inject saline 0 162 ±9 109 ±4 83 ±6 7
inject JM1226 20 151 ±6 92 ±8 62 ±11 7
24 144 ±8 101 ±6 80 ±6 7
29 156 ±6 105 ±10 80 ±12 3
32 169 ±20 118 ±4 93 ±3 3
LPS-treated
inject LPS 0 169 ±13 105 ±8 73 ±7 7
inject saline 20 114 ±6 75 ±7 56 ±8 7
24 99 ±7 65 ±7 48 ±8 7
29 126 ±14 87 ±7 68 ±6 3
32 132 ±9 88 ±18 66 ±19 3
LPS + L-NAME
inject LPS 0 164 ±13 115 ±6 91 ±6 7
inject JM1226 20 112 ±9 83 ±11 68 ±13 7
24 149 ±8 104 ±10 83 ±11 7
29 191 ±9 135 ±5 106 ±3 3
32 183 ±19 122 ±15 106 ±5 3
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Appendix table (7.1) to fig. 7.1
The Krebs curves using the combined L-NMMA and L-NAME data.
[PE] ALL CEAs (Krebs) ALL TEAs (Krebs) t-Test
(M) Mean S.E. n Mean S.E. n unpaired
lxlO-5 8.36 1.05 14 7.47 0.68 15 0.470
2xl0-5 11.93 1.19 14 10.75 1.02 15 0.450
5x10-5 21.73 2.26 14 17.48 1.93 15 0.163
lxlO-4 37.43 4.50 13 30.13 4.01 15 0.236
2X10-4 71.57 9.58 13 48.12 6.07 15 0.043
5x10-4 125.13 16.31 13 83.43 8.55 15 0.026
lxlO’3 179.59 22.02 13 121.93 11.43 15 0.023
2xl0-3 221.98 17.75 13 165.54 15.31 14 0.023
5x10-3 253.88 15.61 11 202.32 15.94 11 0.032
Anova 2-way: F= 2.85 df= 8, 230e p= 0.005 **
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Appendix tables (7.2) to Figs. 7.5 & 7.6
Data for CEAs
[PE] Krebs L-NMMA (80 jzM) L-Arg (1 mM)
(M) Mean S.E. n Mean S.E. n Mean S.E. n
lxlO-5 9.08 1.93 7 16.43 2.53 6 8.36 0.85 5
2xl0-5 12.04 2.18 7 29.93 2.90 6 15.13 2.36 5
5xl0-5 22.07 4.27 7 51.01 11.06 5 31.06 5.95 6
lxlO-4 36.98 7.50 7 69.16 10.70 6 48.04 7.34 7
2X10-4 72.81 15.99 7 130.52 13.77 6 86.31 7.85 7
5x10-4 113.87 24.00 7 222.12 18.59 6 146.10 15.60 7
lxlO'3 167.70 32.20 7 282.64 17.30 5 176.02 11.70 7
2xl0-3 240.29 26.60 7 292.00 7.97 5 192.98 18.60 5
5x10-3 263.59 22.50 6 299.98 0.00 5 254.43 0.00 2
lxlO-2 - - - - - - - - -
Data for TEAs
[PE] Krebs L-NMMA (80 /zM) L-Arg (1 mM)
(M) Mean S.E. n Mean S.E. n Mean S.E. n
lxlO'5 8.37 0.44 7 13.33 1.60 7 6.61 1.74 4
2x10-5 11.19 0.98 7 25.52 5.46 7 11.75 2.17 6
5x10-5 15.75 1.88 7 48.65 10.70 7 25.50 7.53 6
1x10-4 24.12 3.86 7 89.10 14.90 7 45.62 13.72 6
2xl0-4 38.15 6.83 7 205.00 25.50 7 108.60 25.60 5
5xl0-4 68.03 11.70 7 251.01 26.60 6 172.58 27.15 5
lxlO'3 93.62 16.40 7 260.00 24.79 4 176.65 29.60 4
2x10-3 143.34 26.40 7 283.00 16.76 3 160.23 1.47 2
5x10-3 191.19 26.50 6 299.98 0.00 3 - - -
1x10-2 - - - - - - - - -
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Appendix Tables (7.3) to Figs. 7.7 & 7.8
Data for CEAs
[PE] Krebs L-NAME (80 ^M) L-Arg (1 mM)
(M) Mean S.E. n Mean S.E. n Mean S.E. n
lxlO-5 7.5 0.79 8 15.72 2.66 10 10.25 2.98 5
2x10-5 11.22 1.21 8 27.85 3.75 8 15.86 5.09 5
5xl0-5 20.28 2.05 7 59.57 6.36 8 28.96 8.36 5
1x10-4 35.00 5.16 7 123.44 19.64 8 46.89 10.60 5
2x10-4 66.31 9.96 7 193.53 28.29 8 77.23 18.53 5
5x10-4 127.60 21.83 7 238.73 27.55 4 132.06 25.42 5
lxlO'3 180.60 29.50 7 240.78 29.70 3 163.78 28.22 5
2xl0-3 214.81 23.20 7 - - - 233.17 38.32 4
5x10-3 251.70 20.32 6 - - - 246.63 32.26 5
lxlO-2 - - - - - - -
Data for TEAs
[PE] Krebs L-NAME (80 pM) L-Arg (1 mM)
(M) Mean S.E. n Mean S.E. n Mean S.E. n
lxlO'5 7.67 0.97 10 18.64 3.80 10 12.93 6.69 4
2x10-5 10.01 1.42 10 29.33 4.78 10 16.37 8.51 4
5x10-5 17.78 2.70 10 61.28 4.80 8 17.97 9.47 7
1x10-4 32.80 5.34 10 115.96 15.88 6 23.92 8.43 8
2x10-4 52.21 7.72 10 191.34 23.06 7 53.44 19.78 8
5x10-4 86.85 10.80 10 258.52 21.35 6 74.13 17.05 7
lxlO'3 130.49 13.40 10 276.13 23.84 4 148.55 24.09 6
2x10-3 169.16 15.40 9 272.81 27.16 3 198.99 13.32 7
5x10-3 200.38 14.98 7 - - 221.90 12.29 6
lxlO-2 - - - - - -
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Appendix Tables (7.4) to Fig. 7.9 &7.10
Data for CEAs A B
[PE] 1 Krebs AG (ImM) student’s student’s
(M) Mean S.E. n Mean S.E. n paired t-test unpaired test
lxlO’5 6.55 1.1 6 12.94 1.56 5 0.003 0.010
2xl0-5 14.60 1.9 6 21.4 1.9 6 0.014 0.088
5x10-5 26.90 2.1 6 41.61 5.9 6 0.035 0.742
lxlO-4 49.30 2.9 6 69.30 13.1 6 0.18 0.470
2x10-4 86.7 4.9 6 95.20 9.87 5 0.448 0.021
5x10-4 144.10 11.8 6 169.30 18.5 4 0.145 0.198
lxlO-3 194.04 12.8 6 234.00 8.8 4 0.056 0.517
2xl0-3 250.00 9.6 6 290.70 10.1 4 0.222 0.252
5x10-3 301.00 9.9 6 310.00 19.2 5 0.659 0.508
1x10-2 325.00 26.3 3 320.50 27.4 3 0.926 0.418
Column A shows the statistical significance between the CEA Krebs 
and CEA + AG values.
Column B shows the statistical significance between the CEA Krebs 
and TEA + AG values.
Data for TEAs C D
[PE] Krebs AG (ImM) student’s student’s
(M) Mean S.E. n Mean S.E. n paired t-test unpaired test
lxlO'5 4.60 1.0 5 19.4 2.7 5 0.014 0.24
2xl0-5 6.00 1.2 5 19.8 1.8 5 0.009 0.006
5x10-5 24.90 6 5 28.6 4.4 5 0.540 0.750
1x10-4 44.30 12.7 5 61.9 1.8 5 0.450 0.630
2x10-4 62.42 17.7 4 128.2 15.4 5 0.026 0.150
5x10-4 99.89 23.6 4 193.0 39.9 4 0.090 0.102
1x10-3 119.70 24.6 4 213.5 27.89 4 0.045 0.018
2x10-3 205.10 12.5 4 272.5 16.7 4 0.018 0.020
5x10-3 245.00 15.5 4 312.1 4.8 4 0.016 0.012
lxlO’2 268.90 18.7 3 298.2 14.1 3 0.190 0.010
Column C shows the statistical significance between the TEA Krebs 
and TEA + AG values.
Column D shows the statistical significance between the TEA Krebs 
and CEA Krebs values.
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Appendix Tables (8.1) to Figs. 8.11, 8.12 & 8.16b
Tumour Volume for Control group la and those injected with LPS on day 5 post­
implantation (ie. grp. 2b).
Grp Control (1) 2b
Day Mean S.E. n Mean S.E. n
5 0.13 0.03 12 0.10 0.03 12
7 0.18 0.03 12 0.08 0.02 12
9 0.33 0.05 12 0.19 0.03 12
11 0.73 0.10 12 0.25 0.04 12
13 0.92 0.15 12 0.32 0.05 12
15 1.49 0.26 12 0.62 0.14 12
17 2.12 0.35 12 1.03 0.20 12
19 3.08 0.56 12 1.88 0.35 12
f 21 4.64 0.81 12 1 3.48 0.40 12
23 5.80 0.85 9 4.33 0.79 8
25 7.40 1.15 10 5.04 0.60 10
27 8.12 1.13 10 5.04 0.61 9
Tumour Volume for those injected with LPS on day 11 post-implantation (ie. grp. 
2c) and those being fed AG from day 4 and subsequently injected on day 5 (ie. 
grp. 3b).
Grp 2c 3b
Day Mean S.E. n Mean S.E. n
5 0.02 0.01 . 14 0.01 0.00 18
7 0.10 0.03 14 0.03 0.01 18
9 0.20 0.04 14 0.09 0.02 18
11 0.35 0.04 14 0.29 0.05 18
13 0.41 0.05 14 0.66 0.10 18
15 0.60 0.08 14 1.31 0.20 18
17 0.85 0.13 14 2.07 0.31 18
19 1.33 0.17 14 3.30 0.60 18
21 2.10 0.28 12 4.70 0.60 18
23 3.03 0.32 13 5.67 0.50 10
25 I 4.65 0.52 13 6.23 0.82 8
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Appendix Tables (8.2) to Fig. 8.10
Tumour volumes for Control group lb and those injected with LS on day 11 post­
implantation (ie. grp. 2c).
Grp Control (2) 2a
Day Mean S.E. n Mean S.E. n :
7 0.01 0.00 16 0.01 0.00 16
9 0.04 0.01 16 0.05 0.01 16
11 0.24 0.06 16 0.51 0.11 16
13 0.85 0.15 16 0.88 0.13 16
15 1.72 0.28 16 1.33 0.22 16
17 2.13 0.29 16 1.60 0.25 16
19 2.68 0.32 16 2.40 0.48 16
21 3.43 0.56 16 4.00 0.63 16
23 4.08 0.63 16 5.30 1.04 16
Tumour volumes for animals fed with AG from day 10 (ie. grp. 3a)
Grp AG treated
Day Mean S.E. n
7 0.13 0.03 14
8 0.16 0.03 14
9 0.24 0.04 14
10 0.35 0.05 14
11 0.52 0.08 14
12 0.57 0.07 14
13 0.73 0.07 14
14 0.84 0.08 14
15 1.01 0.08 14
16 1.19 0.12 14
17 1.32 0.15 14
18 1.58 0.13 14
19 1.90 0.15 14
20 2.18 0.17 14
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Appendix table (8.3)
Tumour Volumes for Control group lc and those treated with L-NAME from day 
0 post-implantation (ie. grp. 4b).
Grp Control (3) L-NAME Treated
Day Mean S.E. n Mean S.E. n
7 0.28 0.05 12 0.08 0.01 16
9 0.75 0.12 12 0.31 0.05 16
11 1.38 0.31 12 0.43 0.07 16
13 2.22 0.42 12 0.72 0.14 16
15 3.32 0.62 12 0.95 0.12 16
Appendix Table (8.4) to Fig. 8.16a
Tumour Volumes for Control group Id and those injected with LPS on day 11 
post-implantation (ie. grp. 4a) and those receiving both LPS and L-NAME 
treatment
Grp Control 4) LPS LPS + L-NAME
Day Mean S.E. n Mean S.E. n Mean S.E. n
7 0.25 0.03 16 0.50 0.05 20 0.27 0.03 20
9 0.50 0.05 16 0.67 0.05 20 0.47 0.05 20
10 0.72 0.07 16 0.80 0.07 20 0.65 0.08 20
11 0.99 0.09 16 0.94 0.09 20 0.72 0.08 20
i 12 1.23 0.13 16 1.00 0.10 20 0.75 0.08 20
13 1.61 0.16 16 1.26 0.10 20 0.80 0.09 20
14 2.20 0.25 16 1.54 0.12 20 0.93 0.13 20
16 2.79 0.33 16 1.91 0.19 20 1.06 0.15 20
18 3.24 0.49 16 2.35 0.26 16 1.51 0.23 16
20 3.94 0.57 16 2.76 0.35 16 1.70 0.26 16
21 4.54 0.63 16 3.10 0.36 16 1.79 0.25 16
23 - - - - - - 2.50 0.31 16
24 - - - - - - 3.17 0.41 16
25 - - - - - - 3.54 0.44 16
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Appendix Tables (8.5) to Figs. 8.10-8.16b
Student’s unpaired t-test analysis comparing the tumour volumes on a particular 
day. Column G is the result of a comparison between grp. Id and grp. 4a. 
Column H is the result of a comparison between grp. Id and grp. 4c. Column I is 
the result of a comparison between grp. 4a and grp. 4c.
G H I
Day Control vs LPS
Control vs
LPS + L-NAM
E
LPS vs
LPS + L-NAM
E
10 0.580 0.598 0.144
11 0.154 0.038* 0.409
12 0.069 0.002** 0.117
13 0.002** 0.0001*** 0.137
14 0.001*** 0.0001*** 0.048*
16 0.001*** 0.0001*** 0.017*
j 18 0.018** 0.003** 0.196
20 0.017** 0.001*** 0.079
21 0.025* 0.0001*** 0.029*
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Appendix Tables (8.6) to Figs. 8.18-8.20.
Systolic, Mean and Diastolic Blood Pressure Measurements (mmHg) for the 
Control Group (ie. grp. Id).
Day Systolic Mean Diastolic
5 160.00 104.20 76.32
6 155.96 105.40 80.12
7 161.45 112.60 88.15
8 158.96 107.30 81.45
9 171.89 106.00 73.30
10 163.54 105.20 76.00
11 155.00 112.50 91.31
12 156.25 115.60 94.00
13 156.25 103.10 76.70
14 165.60 112.50 86.02
17 165.63 103.13 71.97
18 159.40 112.50 89.00
19 156.25 112.50 94.40
20 150.00 100.00 75.00
21 143.75 106.25 87.52
Systolic Mean and Diastolic Blood Pressure Measurements (mmHg) for the LPS 
Treated Group (ie. grp. 4a)
Day Systolic Mean Diastolic
5 156.25 106.25 81.23
6 159.40 103.13 73.50
7 165.63 109.40 81.23
8 153.13 112.50 92.30
9 168.75 100.00 65.63
10 165.37 112.50 85.93
11 162.50 109.38 82.84
12 93.75 65.63 51.56
13 162.50 115.63 92.14
14 165.60 109.40 81.26
17 159.38 109.40 84.37
18 162.50 115.63 92.25
19 156.25 109.40 86.06
20 165.63 103.13 71.86
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21 162.50 103.13 73.45
Systolic, Mean and Diastolic Blood Pressure Measurements (mmHg) for the LPS
+ L-NAME Treated Group (ie. grp. 4c)
Day Systolic Mean Diastolic
5 162.50 103.13 73.40
6 156.25 109.40 85.90
7 159.38 109.40 84.38
8 153.13 112.50 92.25
9 162.50 103.13 75.20
10 165.63 103.13 58.84
11 153.13 109.40 87.59
12 112.50 78.12 61.10
13 168.75 100.00 63.63
14 178.13 112.50 79.70
17 193.60 121.89 86.00
18 187.50 121.89 89.10
19 189.20 118.75 83.53
20 193.75 125.00 90.62
21 193.75 118.75 71.24
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Appendix Tables 8.7
The drinking rates for control group la and animals injected on day 5 (grp. 2b) 
and 11 (grp. 2c) post-implantation.
L<?e Control (10 2b 2c
Day Mean S.E. n Mean S.E. n Mean S.E. n
3-4 42.93 3.80 3 44.80 2.40 3 32.70 9.20 4
4-5 65.60 3.41 3 67.20 2.00 3 23.70 5.60 4
5-7 67.00 25.50 3 55.60 28.00 3 42.10 5.50 4
7-9 65.20 6.00 3 73.80 14.40 3 50.25 2.90 4
9-11 70.70 5.90 3 71.40 7.70 3 36.20 10.70 4
11-13 90.56 13.60 3 98.50 10.70 3 29.10 2.42 4
13-15 66.46 15.90 3 65.30 18.30 3 38.00 1.37 4
15-17 78.80 7.90 3 80.00 14.00 3 48.50 1.18 4
17-19 70.56 4.60 3 76.80 8.60 3 68.90 2.80 4
19-21 58.50 19.20 3 60.70 20.90 3 49.10 4.40 4
21-23 79.50 7.70 3 85.50 14.80 3 55.30 4.00 4
23-25 75.50 3.70 3 93.90 10.50 3 58.86 2.36 4
25-27 87.60 17.60 3 68.10 8.40 3 - - -
The drinking rate and injested dose of AG for animals fed on AG from day 4 post­
implantation and subsequently injected with LPS on day 5 (ie. grp. 3b).
Grp 3b 3b Doseage s
Day Mean S.E. n Mean S.E. n
3-4 14.60 0.10 5 -
4-5 30.60 0.60 5 0.08 0.006 5
5-7 41.80 4.90 5 0.145 0.018 5
7-9 41.90 4.10 5 0.140 0.017 5
9-11 46.50 2.40 5 0.158 0.010 5
11-13 43.90 1.80 5 0.140 0.009 5
13-15 47.30 2.10 5 0.149 0.007 5
15-17 51.80 2.00 5 0.150 0.009 5
17-19 68.40 2.00 5 0.200 0.007 5
19-21 49.30 3.50 5 0.140 0.011 5
21-23 48.90 2.70 5 0.140 0.150 5
23-25 47.60 2.30 5 0.130 0.012 5
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Appendix Tables 8.8
Drinking rates for Control group lb and animals injected with LPS one day prior 
to implantation (ie. grp. 2a).
Grp Control (2) 2a
Day Mean S.E. n Mean S.E. n
5-7 61.50 3.30 4 63.40 3.00 4
7-9 67.40 2.20 4 51.50 3.70 4
9-11 59.80 3.70 4 59.50 2.70 4
11-13 58.00 4.30 4 60.60 3.80 4
13-15 56.25 2.90 4 53.30 3.20 4
15-17 56.25 2.70 4 59.50 3.80 4
17-19 57.40 6.65 4 71.30 3.50 4
19-21 54.20 4.60 4 50.02 2.60 4
Drinking rates and injested dose of AG for animals fed AG from day 10 (ie. grp. 
3a).
Grp LG Treated AG Treated Doseage
Day Mean S.E. n Mean S.E. n
6-7 33.25 0.62 4 - -
7-8 39.15 1.49 4 - - -
8-9 36.50 1.80 4 -
9-10 41.60 1.60 4 - - ’
10-11 41.90 2.40 4 0.020 0.002 4
11-12 39.40 1.06 4 0.100 0.003 4
12-13 47.67 24.60 4 0.100 0.002 4
13-14 40.47 3.40 4 0.118 0.006 4
14-15 36.45 2.50 4 0.100 0.004 4
15-16 38.50 2.70 4 0.090 0.004 4
16-17 40.50 3.00 4 0.100 0.005 4
17-18 39.80 2.40 4 0.100 0.006 4
18-19 39.15 2.40 4 0.096 0.008 4
19-20 37.90 2.30 4 0.097 0.006 4
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Appendix Table 8.9
Drinking rates for Control group lc and animals fed with L-NAME from day 0 
(ie. grp. 4b).
Grp Control (3) L-NAME Treated L-NAME
Dose
Day Mean S.E. n Mean S.E. n Mean S.E.
0-2 67.20 3.47 3 48.12 2.90 4 0.078 0.008
2-4 53.90 2.70 3 29.90 2.50 4 0.069 0.012
4-6 63.50 6.30 3 38.70 6.21 4 0.101 0.026
6-11 127.80 9.00 3 79.60 4.04 4 0.076 0.007
11-13 67.30 1.60 3 44.00 4.10 4 0.067 0.005
13-15 61.40 6.20 3 38.70 6.00 4 0.067 0.061
15-17 70.20 5.90 3 41.70 6.30 4 0.058 0.010
17-19 67.80 5.30 3 45.40 6.40 4 0.081 0.008
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Appendix Table (8.10) to Fig. 8.21a.
Mean drinking rates, weights and effective dosage for control group Id. This 
group of animlas received water only.
Grp Weight (g) Intake (ml) Effective Dose
(ml/g)
Day Mean S.E. n Mean S.E. n Mean S.E. n
0 335.52 8.82 5 30.30 1.14 5 0.090 0.004 5
1 338.40 8.38 5 33.76 1.30 5 0.100 0.003 5
2 343.40 8.27 5 31.30 1.10 5 0.091 0.003 5
3 347.80 8.32 5 34.20 1.17 5 0.099 0.005 5
7 355.36 8.69 5 31.26 2.04 5 0.089 0.007 5
8 357.60 8.37 5 34.76 1.95 5 0.097 0.006 5
9 359.00 8.36 5 32.52 0.81 5 0.091 0.002 5
10 357.62 7.12 5 30.34 2.21 5 0.085 0.006 5
11 358.40 7.75 5 35.32 1.41 5 0.099 0.004 5
12 363.60 6.44 5 32.82 1.73 5 0.090 0.004 5
13 362.20 7.61 5 31.34 2.40 5 0.087 0.006 5
14 361.60 7.95 5 39.48 2.25 5 0.110 0.008 5
15 363.20 7.37 5 28.48 1.97 5 0.079 0.005 5
16 364.80 7.64 5 34.34 2.47 5 0.094 0.006 5
17 370.20 8.19 5 38.65 4.03 4 0.102 0.010 4
18 377.75 6.64 4 31.30 2.49 4 0.083 0.006 4
19 376.23 6.75 4 42.28 3.28 4 0.113 0.010 4
20 381.25 7.32 4 35.70 3.65 4 0.093 0.008 4
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Appendix Tables (8.11) to Fig. 8.21a
Mean drinking rates, weights and effective dosage in animals injected with LPS on 
day 11 (ie. grp. 4a).
Grp Weight (g) Intake (mi) Effective Dose
(ml/g)
Day Mean S.E. n Mean S.E. n Mean S.E. n
0 320.08 12.16 5 31.14 3.51 5 0.096 0.008 5
1 323.80 11.98 5 32.48 3.49 5 0.100 0.007 5
2 327.00 11.72 5 29.94 2.26 5 0.092 0.004 5
3 331.40 11.67 5 34.26 2.74 5 0.104 0.007 5
7 337.60 11.29 5 29.12 2.40 5 0.086 0.005 5
8 337.60 10.87 5 33.56 2.12 5 0.099 0.004 5
9 337.70 10.46 5 30.00 1.49 5 0.087 0.006 5
10 339.30 11.33 5 30.90 2.95 5 0.091 0.006 5
11 337.40 11.08 5 15.14 4.43 5 0.093 0.012 5
12 345.60 16.98 5 22.72 3.90 5 0.044 0.011 5
13 334.98 14.64 5 27.08 2.92 5 0.082 0.010 5
14 325.60 13.11 5 39.08 3.54 5 0.119 0.007 5
15 324.60 13.10 5 24.06 3.04 5 0.073 0.007 5
16 324.00 13.10 5 29.90 3.40 5 0.091 0.007 5
17 325.38 13.01 4 36.50 4.54 4 0.111 0.009 4
18 328.50 14.45 4 30.25 4.72 4 0.091 0.010 4
19 328.00 14.12 4 32.88 4.21 4 0.099 0.008 4
20 333.00 14.24 4 35.45 4.03 4 0.106 0.007 4
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Appendix Table (8.12) to Figs. 8.21a/b & 8.22e.
Mean drinking rates, weights and effective dosage in the animals receiving LPS + 
L-NAME (ie. group 4c).
Grp Weight (g) Intake (mi) Actual Dose (ml/g)
Day Mean S.E. n Mean S.E. n Mean S.E. n
0 335.96 7.84 5 33.36 3.69 5 - -
1 341.00 6.86 5 33.99 2.37 5 - - -
2 347.80 5.79 5 34.06 2.20 5 - - -
3 353.40 5.41 5 38.40 1.72 3 - - -
7 357.24 5.28 5 31.34 3.77 5 - - -
8 360.60 4.93 5 38.74 1.87 5 - - -
9 362.00 4.97 5 34.42 2.24 5 - - -
10 359.24 4.60 5 24.40 1.52 5 0.020 0.004 5
11 350.20 4.87 5 9.00 6.04 5 0.026 0.017 5
12 332.00 7.35 5 13.02 6.68 5 0.038 0.019 5
13 319.60 10.30 5 19.46 3.58 5 0.060 0.009 5
14 321.00 10.31 5 33.58 4.10 5 0.104 0.013 5
15 321.40 9.76 5 15.78 2.37 5 0.048 0.006 5
16 320.20 9.47 5 32.00 1.99 5 0.068 0.005 5
17 327.13 11.41 4 30.68 3.33 4 0.093 0.008 4
18 328.75 12.09 4 29.18 1.81 4 0.090 0.008 4
19 331.75 10.07 4 29.38 1.93 4 0.089 0.008 4
20 334.25 10.55 4 30.13 1.40 4 0.091 0.006 4
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Appendix Table (8.13) to Figs. 8.22a &8.22f
Meaned weights (g) of control animals (la) and animals injected with LPS on day 
5 post-implantation (ie. grp. 2b).
Grp Control (1) 2b
■ Day Mean S.E. n Mean S.E. n
4 397.70 34.40 3 389.10 49.00 3
5 398.60 32.16 3 388.70 43.60 3
7 405.00 32.97 3 373.10 52.10 3
9 408.00 27.40 3 379.50 48.10 3
11 411.70 28.50 3 377.30 46.00 3
13 416.30 26.00 3 381.80 45.20 3
15 409.70 35.70 3 389.00 44.40 3
17 420.30 29.40 3 395.40 42.40 3
19 428.00 26.40 3 399.30 40.10 3
21 431.10 27.50 3 413.30 32.10 3
23 456.60 22.30 3 410.00 38.00 3
25 463.50 28.50 3 432.00 11.00 3
27 469.00 26.00 3 458.50 11.50 3
Meaned weights of animals injected with LPS on day 11 (ie, grp. 2c) and fed with 
AG and subsequently injected with LPS on day 5 post-implantation.
Grp 2c 3b
Day Mean S.E. n Mean S.E. n
4 354.40 25.90 4 331.60 16.20 5
5 351.70 27.13 4 307.00 16.50 5
: 7 350.90 26.67 4 288.40 16.27 5
9 352.30 24.50 4 299.10 16.62 5
11 353.80 27.10 4 307.80 16.10 5 ?
13 339.90 25.90 4 312.20 15.40 5
15 332.30 25.50 4 320.30 14.08 5
17 335.80 23.80 4 324.50 15.70 5
19 341.70 23.50 4 327.80 15.60 5
21 358.00 29.60 4 343.10 14.10 5
23 367.00 27.50 4 325.26 25.58 5
25 373.00 23.17 4 358.90 22.90 5
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Appendix Table (8.14) to Figs. 8.22b & 8.22d.
Meaned weights of control animals (grp. lb) and animals injected with LPS one
day prior to implantation.
Grp Control (2) 2a
Day Mean S.E. n Mean S.E. n
7 403.10 18.60 4 366.60 12.30 4
9 402.10 16.53 4 376.30 13.40 4
11 404.60 17.69 4 378.40 13.60 4
13 402.70 16.69 4 384.70 12.60 4
15 403.70 16.89 4 388.40 11.40 4
17 402.80 14.50 4 391.50 11.80 4 :
19 408.90 13.30 4 400.00 11.70 4
21 408.20 13.05 4 408.60 8.40 4
23 406.30 10.50 4 410.50 8.70 4
Meaned weights of animals fed with AG from day 10 post-implantation.
Grp AG Treated
Day Mean S.E. n
5 368.70 12.20 4
7 389.60 10.50 4
8 393.60 9.80 4
9 394.00 9.70 4
10 391.00 6.70 4
11 398.80 8.36 4
12 395.50 8.25 4
13 394.20 8.75 4
14 394.70 9.19 4
15 399.20 9.36 4
16 399.20 9.50 4
17 399.90 10.00 4
18 398.50 10.90 4
19 399.30 11.20 4
20 400.60 10.60 4
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Appendix Tables (8.15) to Fig. 8.22c
Meaned weight of control animals (grp. lc) and those treated with L-NAME from 
day 0 (ie. grp. 4b).
Grp Control (3) L-NAME Treated
Day Mean S.E. n Mean S.E. n
0 354.60 39.60 3 300.20 20.70 4
4 355.00 33.10 3 298.00 19.60 4
6 358.90 32.70 3 296.00 13.70 4
11 361.70 30.90 3 303.30 15.20 4
13 368.80 33.10 3 305.00 13.00 4
15 374.20 32.80 3 303.00 13.10 4
17 383.00 32.30 3 305.00 9.90 4
19 385.00 31.16 3 300.00 7.50 4
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Appendix tables (9.1) to Figs.9.1 & 9.2
Comparing all the control and LPS-treated RTA data
[PE] Control LPS (24 hr) t-test
(M) Mean S.E. n Mean S.E. n unpaired
lxlO’5 10.57 1.19 56 8.13 1.62 25 0.248
2x10-5 10.25 1.64 56 11.87 1.84 29 0.102
5xl0-5 30.28 2.85 56 21.52 2.85 29 0.054
lxlO-4 45.91 3.65 55 30.53 3.27 29 0.007
2x10-4 69.97 4.66 56 45.36 4.21 29 0.001
5x10*4 115.34 6.41 56 71.67 6.31 28 0.000
lxlO-3 156.91 7.29 56 108.83 7.00 29 0.000
2xl0-3 198.28 7.48 56 148.46 7.57 29 0.000
5xl0-3 230.04 8.34 42 185.13 7.86 29 0.000
lxlO’2 236.66 9.53 30 214.12 7.66 28 0.073
Comparing all the CEA and TEA data
[PE] CEA TEA t-test
(M) Mean S.E. n Mean S.E. n unpaired
lxlO"5 9.20 0.70 28 7.60 0.70 29 0.210
2x10-5 12.85 1.00 28 10.56 1.00 27 0.135
5x10-5 26.10 2.80 28 21.20 2.10 29 0.175
lxlO-4 41.40 3.60 .27 37.70 3.90 29 0.500
2x10-4 72.88 6.80 27 56.80 5.20 29 0.067
5x10-4 114.00 8.90 27 92.40 7.50 28 0.059
lxlO'3 159.00 12.70 26 117.80 7.30 27 0.007
2x10-3 192.60 11.80 21 154.30 9.40 23 0.015
5xl0-3 254.00 10.40 14 179.40 9.80 18 0.000
1x10-2 286.40 6.70 5 195.10 15.80 8 0.001
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